MTOR (INHIBITOR | INHIBITORS | INHIBITION)

/ Uncategorized / By
  1. Immunoregulatory functions of mTOR inhibition
  2. Dissecting the role of mTOR: lessons from mTOR inhibitors
  3. Updates of mTOR inhibitors
  4. mTOR inhibitors: an overview
  5. The pharmacology of mTOR inhibition
  6. Current development of mTOR inhibitors as anticancer agents
  7. Functional consequences of mTOR inhibition
  8. mTOR inhibitors in the treatment of cancer
  9. Will mTOR inhibitors make it as cancer drugs?
  10. mTOR pathway and mTOR inhibitors as agents for cancer therapy
  11. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
  12. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
  13. The biology behind mTOR inhibition in sarcoma
  14. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
  15. Predicted mechanisms of resistance to mTOR inhibitors
  16. mToR inhibitors-induced proteinuria: mechanisms, significance, and management
  17. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
  18. The applicability of mTOR inhibition in solid tumors
  19. Enhanced radiation damage of tumor vasculature by mTOR inhibitors
  20. The potential role of mTOR inhibitors in non-small cell lung cancer
  21. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
  22. The role of mTOR inhibitors in the management of posttransplant malignancy
  23. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy
  24. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma
  25. mTOR inhibitor‐associated dermatologic and mucosal problems
  26. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
  27. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor
  28. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
  29. PI3K/AKT/mTOR inhibitors in ovarian cancer
  30. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.
  31. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
  32. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases
  33. PI3K and mTOR inhibitors—a new generation of targeted anticancer agents
  34. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
  35. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents
  36. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
  37. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
  38. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
  39. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)
  40. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
  41. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition
  42. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
  43. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
  44. mTOR inhibitors in polycystic kidney disease
  45. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
  46. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals
  47. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa
  48. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
  49. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
  50. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients
  51. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
  52. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies
  53. mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes
  54. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
  55. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
  56. The pleiotropic effects of mTor inhibitors.
  57. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression
  58. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line
  59. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
  60. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
  61. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
  62. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
  63. mTOR inhibition and its effect on cancer in transplantation
  64. Chemoprevention and treatment of experimental Cowden’s disease by mTOR inhibition with rapamycin
  65. mTOR inhibitors for hepatocellular cancer: a forward-moving target
  66. In vivo antitumor effect of the mTOR inhibitor CCI‐779 and gemcitabine in xenograft models of human pancreatic cancer
  67. Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer
  68. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia
  69. Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders
  70. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
  71. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver …
  72. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
  73. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin’s lymphoma
  74. mTOR inhibition induces endothelial progenitor cell death
  75. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics
  76. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis
  77. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
  78. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors
  79. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents
  80. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level?
  81. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors
  82. Replacing calcineurin inhibitors with mTOR inhibitors in children
  83. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved …
  84. In vitro release of the mTOR inhibitor rapamycin from poly (ethylene glycol)-b-poly (ε-caprolactone) micelles
  85. Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients
  86. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma
  87. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
  88. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy
  89. Augmentation of autophagy by mTOR-inhibition in myocardial infarction: when size matters
  90. Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma
  91. [18F] fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor …
  92. A Dual Phosphoinositide-3-Kinase α/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN-Mutant Glioma
  93. NCCN Task Force Report: mTOR inhibition in solid tumors
  94. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells
  95. A novel mTOR inhibitor is efficacious in a murine model of colitis
  96. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy
  97. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
  98. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute …
  99. mTOR inhibitors: do they help preserve renal function?
  100. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status
  101. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus
  102. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs
  103. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels
  104. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma
  105. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
  106. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
  107. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors
  108. The synthesis and anti-proliferative effects of β-elemene derivatives with mTOR inhibition activity
  109. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
  110. A novel dual PI3Kα/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells
  111. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors
  112. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition
  113. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
  114. The role of mTOR inhibitors for treatment of sarcomas
  115. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells
  116. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5‐fluorouracil in scirrhous gastric cancer
  117. The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms.
  118. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat
  119. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement
  120. mTOR inhibition: the learning curve in kidney transplantation
  121. IRS-1: auditing the effectiveness of mTOR inhibitors
  122. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process
  123. Mammalian target of rapamycin (mTOR) inhibitors
  124. The impact of mTOR inhibitors on the development of malignancy
  125. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
  126. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors
  127. Comprehensive lung injury pathology induced by mTOR inhibitors
  128. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
  129. BRAF mutation‐selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic‐potentiated synergism with the mTOR inhibitor …
  130. mTOR inhibitors in oncology
  131. Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs
  132. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast …
  133. … inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor …
  134. NVP‐BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells
  135. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
  136. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors
  137. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor
  138. Management of mTOR inhibitor side effects.
  139. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive …
  140. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
  141. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma
  142. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat
  143. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
  144. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas
  145. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Rα signaling
  146. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
  147. The role of mTOR inhibition in augmenting radiation induced autophagy
  148. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells
  149. Use of mTOR inhibitors in human organ transplantation
  150. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
  151. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway
  152. Can mTOR inhibitors reduce the risk of late kidney allograft failure?
  153. Enhancing mammalian target of rapamycin (mTOR)–targeted cancer therapy by preventing mTOR/Raptor inhibition-initiated, mTOR/Rictor-independent Akt activation
  154. FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
  155. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid …
  156. Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor
  157. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial
  158. Targeting endocrine resistance: is there a role for mTOR inhibition?
  159. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo
  160. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer
  161. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model
  162. Do mTOR inhibitors still have a future in ADPKD?
  163. 18F-FDG and 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model
  164. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal …
  165. Clinical development of mTOR inhibitors: a focus on lymphoma
  166. The dual PI3K/mTOR inhibitor PI‐103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib‐treated melanoma cells
  167. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal …
  168. Hypoxia‐inducible factor‐2α: effect on radiation sensitivity and differential regulation by an mTOR inhibitor
  169. … of (thienopyrimidin-2-yl) aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of …
  170. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma
  171. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model
  172. mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo
  173. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme
  174. Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 …
  175. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity
  176. Recent advances in the discovery of small molecule mTOR inhibitors
  177. Everolimus and mTOR inhibitors in liver transplantation: opening the “box”
  178. Sunitinib, sorafenib and mTOR inhibitors in renal cancer
  179. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells
  180. mTOR inhibitors in hematologic malignancies.
  181. … pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with …
  182. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom’s Macroglobulinemia
  183. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with …
  184. Anti-angiogenic/vascular effects of the mTOR inhibitor everolimus are not detectable by FDG/FLT-PET
  185. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma
  186. … a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition …
  187. mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours
  188. Rapamycin and mTOR kinase inhibitors
  189. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
  190. Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy
  191. Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers
  192. mTOR pathway and mTOR inhibitors in cancer therapy
  193. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease
  194. The rationale for mTOR inhibition in epithelial ovarian cancer
  195. Involvement of autophagy via mammalian target of rapamycin (mTOR) inhibition in tributyltin-induced neuronal cell death
  196. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
  197. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and …
  198. Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells
  199. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin
  200. … )phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of …
  201. Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors
  202. mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP
  203. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats
  204. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma
  205. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)
  206. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)
  207. Treatment options in metastatic renal cell carcinoma: focus on mTOR inhibitors
  208. Combination signal transduction inhibition: A phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with …
  209. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET
  210. mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001).
  211. Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibition
  212. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
  213. Time to rethink immunosuppression by mTOR inhibitors?
  214. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor, administered IV daily X 5 every other week in patients (pts) with …
  215. Inhibition of mTOR activates the MAPK pathway in glioblastoma multiforme
  216. mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells
  217. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas
  218. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option
  219. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
  220. Nephrotoxicity of calcineurin and mTOR inhibitors
  221. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS)
  222. Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway
  223. The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat
  224. mTOR inhibitors and their secondary effects in cardiac trasplant recipients: a descriptive study
  225. Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non–small cell lung cancer with the mTOR inhibitor everolimus
  226. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress
  227. A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).
  228. Synergistic activity of combinations of JAK2 kinase inhibitor with PI3K/mTOR, MEK or PIM kinase inhibitor against human myeloproliferative neoplasm cells expressing …
  229. mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma
  230. A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: study …
  231. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
  232. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
  233. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment
  234. Rapamycine and mTOR inhibitors: from bench to bedside
  235. Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors
  236. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent
  237. A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin’s …
  238. mTOR inhibition is a rational target for the treatment of endometrial cancer
  239. Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors
  240. A Phase Ib Trial of RAD001, an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer.
  241. Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with …
  242. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
  243. Changes in Magnesium and Potassium Homeostasis after Conversion from a Calcineurin Inhibitor Regimen to an mTOR Inhibitor–Based Regimen
  244. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature
  245. The potential role of mTOR inhibitors in the treatment of endocrine tumors
  246. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients
  247. Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).
  248. Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
  249. Expression and activation of mTOR in neuroendocrine tumors. Effects of mTOR inhibition by RAD001 upon growth, cell cycle regulation and signalling in …
  250. Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor
  251. Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea …
  252. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment
  253. A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and …
  254. Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase …
  255. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins
  256. Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is …
  257. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.
  258. N0377: Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma
  259. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2
  260. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma
  261. mTOR inhibitors and calcineurin inhibitors do not affect adhesion molecule expression of human macro-and microvascular endothelial cells
  262. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
  263. Construction of the 3D structure of the mTOR kinase-domain and discovery of novel mTOR inhibitors
  264. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies
  265. Drug evaluation: AP-23573–an mTOR inhibitor for the treatment of cancer.
  266. Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition
  267. Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: a phase II trial in the North Central Cancer Treatment Group
  268. PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to …
  269. Of mice and men: therapeutic mTOR inhibition in polycystic kidney disease
  270. D7-07: A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced …
  271. mTOR inhibition and adult T-cell leukemia
  272. The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.
  273. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
  274. … Inhibitor Temsirolimus (CCI-779) Induces Cell Cycle Arrest and Autophagy in Hodgkin Lymphoma (HL) Cell Lines and Enhances the Effect of the PI3-Kinase Inhibitor …
  275. mTOR inhibition leads to increased sensitivity to methotrexate
  276. A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies
  277. … effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor …
  278. Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients …
  279. A phase Ib study combining the mTOR inhibitor everolimus (RAD001) with low-dose cytarabine in untreated elderly AML
  280. Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia
  281. PP2AT61ɛ is an inhibitor of MAP4K3 in nutrient signaling to mTOR
  282. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells
  283. Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography …
  284. Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor
  285. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
  286. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies
  287. A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC)
  288. Dual inhibition of IGFR and mTOR pathways.
  289. Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A …
  290. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer’s disease
  291. Abstract B137: Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC‐0980: Initial phase I evaluation
  292. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model
  293. Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response.
  294. Effect of mTOR inhibition on sensitivity of triple-negative breast cancer cells to epidermal growth factor inhibition
  295. Structure of the human mTOR complex I and its implications for rapamycin inhibition
  296. mTOR inhibitors: pleiotropic antiproliferative drugs
  297. Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses
  298. Role of FK778 Alone or in Combination with Tacrolimus or mTOR Inhibitors as an Immunomodulator of Immunofunctions: In Vitro Evaluation of T Cell Proliferation and …
  299. PI3K-AKT-mTOR pathway inhibitors
  300. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis
  301. Sirolimus, the first mTOR inhibitor
  302. Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function
  303. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells
  304. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
  305. A Phase I Dose Escalation Study of the mTOR Inhibitor Sirolimus and MEC Chemotherapy Targeting Signal Transduction in Leukemic Stem Cells for Acute …
  306. Phase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine (CAPE)
  307. mTOR pathway inhibitors in cancer therapy: moving past rapamycin
  308. Inhibition of mTOR in kidney cancer
  309. Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer
  310. … mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR
  311. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR
  312. Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies.
  313. mTOR inhibition affects primary liver cancer
  314. Compensatory activation of Akt in response to mTOR and Raf inhibitors–a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
  315. A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer.
  316. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease
  317. Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases
  318. 2-Arylureidophenyl-4-(3-oxa-8-azabicyclo [3.2. 1] octan-8-yl) triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human …
  319. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom’s macroglobulinemia.
  320. Abstract S3-6: Combination therapy of the novel PI3K inhibitor GDC-0941 and dual PI3K/mTOR inhibitor GDC-0980 with trastuzumab-DM1 antibody drug conjugate …
  321. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
  322. Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma
  323. mTor inhibition in lymphoma: A rational and Promising Strategy
  324. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway
  325. mTOR inhibition as a potential treatment for progesterone refractory endometrial hyperplasia
  326. A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.
  327. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells
  328. … EFFECTS ON DOSE-DEPENDENT PK FOLLOWING DIFFERENT DOSING SCHEDULES IN TWO PHASE I TRIALS OF AP23573 (AP), AN mTOR INHIBITOR
  329. Rhinitis in Patients Treated with a Combination of an mTOR Inhibitor and an EGFR Inhibitor
  330. The potential of mTOR inhibitors for the treatment of human cancers
  331. Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines.
  332. A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma …
  333. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice
  334. RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF-κB–Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTEN
  335. Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.
  336. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
  337. Activation of the mTOR signalling pathway is required for pancreatic growth in protease‐inhibitor‐fed mice
  338. A phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results
  339. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
  340. High Overall Response Rate in Calcineurin Inhibitor-Free Treatment with the mTOR Inhibitor Everolimus in Advanced Extensive Chronic GvHD after …
  341. Regulation of D-cyclin translation inhibition in myeloma cells treated with mTOR inhibitors: rationale for combined treatment with ERK inhibitors and …
  342. Combination of a MEK inhibitor, AZD6244, and dual PI3K/mTOR inhibitor, NVP-BEZ235: an effective therapeutic strategy for acute myeloid leukemia
  343. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
  344. A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence
  345. The mTOR inhibitor CCI-779 (temsirolimus) downregulates p21 and induces cell cycle arrest and autophagy in mantle cell lymphoma (MCL)
  346. MTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature
  347. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy
  348. Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)
  349. The mTOR Inhibitor RAD001 (Everolimus) Improves Survival in Preclinical Models of Primary Human ALL.
  350. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38
  351. Genomic and pathway connectivity analyses identify novel strategies to overcome mTOR inhibitor resistance in DLBCL
  352. Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients …
  353. Temozolomide combined with the PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin inhibits melanoma cell growth, survival and invasion
  354. … LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND PROTEINURIA IN RENAL ALLOGRAFT RECIPIENTS TREATED WITH mTOR INHIBITORS …
  355. mTOR inhibitors for treatment of sclerodermatous chronic graft-versus-host disease following allogeneic stem cell transplantation
  356. Conversion from calcineurin inhibitors to mTOR inhibitors
  357. Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164–Driven Angiogenesis, in Part by Blocking S6Kinase
  358. Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma
  359. Activity of mTOR-inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines
  360. Effects of mTOR inhibitor rapamycin on Smad 3 protein and collagen type I expression in rat myocardial fibroblasts infected with coxsackie virus B 3
  361. Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia?
  362. … activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR
  363. mTOR inhibitors in ADPKD
  364. … analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) in human …
  365. A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination with Capecitabine for Metastatic Breast Cancer.
  366. The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma.
  367. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways
  368. Dual inhibition of PI3Kα and mTOR as an alternative treatment for Kaposi’s sarcoma
  369. mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals
  370. Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: a phase I study
  371. Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l-DOPA–Induced Dyskinesia
  372. Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.
  373. Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis
  374. Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic …
  375. … [2, 3-b] pyridin-3-yl) methylene-4-hydroxybenzofuran-3 (2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
  376. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells
  377. Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer
  378. … replacement in 6-aryl-1H-pyrazolo [3, 4-d] pyrimidines and 2-arylthieno [3, 2-d] pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
  379. Combination of the mTOR inhibitor Rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) inhibits proliferation and induces apoptosis …
  380. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
  381. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload
  382. Phase II study of the mTOR inhibitor sirolimus for nonprogressive NF1-associated plexiform neurofibromas: A Neurofibromatosis Consortium study.
  383. Construction of the Three-dimensional Structure of the MTor Kinase-domain and Discovery of Novel MTOR Inhibitors
  384. Phase 1b study defining the optimal dosing combinations of the mTOR inhibitor AP23573 and Paclitaxel (PTX)
  385. The FRB Domain of mTOR:  NMR Solution Structure and Inhibitor Design,
  386. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
  387. NVP-BEZ235, A novel dual PI3K/mTOR inhibitor, elicits multifaceted antitumor activities in human gliomas
  388. A dual PI3K α/mTOR inhibitor cooperates with blockade of EGFR in PTEN-mutant glioma
  389. Combination of carboplatin and the mTor inhibitor RAD001 is a new therapeutic approach for p53-mutated breast cancer.
  390. Dual proteasome and mTOR inhibition promotes apoptosis in non-Hodgkin lymphoma cell lines
  391. Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5)
  392. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells
  393. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt
  394. Discovery of 2-arylthieno [3, 2-d] pyrimidines containing 8-oxa-3-azabi-cyclo [3.2. 1] octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K
  395. The mTOR inhibitor rapamycin demonstrates activity against AML in combination with imatinib mesylate and with 5-azacytidine.
  396. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine
  397. Honokiol mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast and prostate carcinoma without …
  398. Response of a neuronal model of tuberous sclerosis to mTOR inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function
  399. Drug Essentials mTOR* Inhibitors
  400. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice
  401. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer
  402. Current status of mTOR inhibitors as novel therapeutic agents
  403. Safety and efficacy of the mTOR inhibitor everolimus as early interventional replacement for calcineurin inhibitors in graft-versus-host disease (GvHD) …
  404. Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.
  405. Anti-tumor activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in sarcoma and endometrial cancer models and exploration of molecular correlates of …
  406. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors
  407. Differential impact of mTOR inhibition on CD4+ CD25+ Foxp3+ regulatory T cells as compared to conventional CD4+ T cells
  408. The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition
  409. WJD008, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant
  410. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)–dependent inhibition of p53
  411. The use of mTOR inhibitors in kidney transplantation: who are the best patients and how should these inhibitors be used?
  412. Abstract B145: Highly selective pyrazolopyrimidine mTOR inhibitors with profound in vivo antitumor activity
  413. Integrative approaches to investigate the molecular basis of the in vivo activity of NVP-BEZ235, a dual pan-PI3K / mTOR inhibitor
  414. The mTOR Inhibitor RAD001 (Everolimus) Inhibits Myeloma Tumor Growth In Vivo and Enhances the Anti-MM Effects of Bortezomib and Arsenic Trioxide.
  415. The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition
  416. Synergistic Growth Inhibition with a PI3 Kinase/mTOR Inhibitor Plus Lapatinib.
  417. Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells
  418. A chemical genetic screen for mTOR pathway inhibitors based on 4E-BP-dependent nuclear accumulation of eIF4E
  419. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis
  420. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide
  421. 44: mTOR inhibitors (mTOR-I) and proteinuria after lung transplantation
  422. Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia
  423. … -6-aryl-1H-pyrazolo[3,4-d]pyrimidines as Highly Potent and Selective ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin (mTOR): Optimization of the …
  424. GSK-3b inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma
  425. mTOR Inhibitor Rapamycin Interacts Synergistically with Farnesyltransferase Inhibitor FTI-277 To Induce Growth Inhibition in Human Leukemia Cells.
  426. An exploratory biomarker trial of an mTOR inhibitor in subjects with newly diagnosed advanced stage squamous cell carcinoma of the head and neck
  427. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells
  428. Sera from Diabetics does not Alter the Effect of mTOR Inhibition on Smooth Muscle Cell Proliferation
  429. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells
  430. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase
  431. Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent or T315I-Mutated Cells.
  432. Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress
  433. Combined use of HDAC and mTOR inhibitors has synergistic effect on inhibiting B-cell tumor cell lines
  434. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
  435. Expression of mTOR pathway in human adrenocortical carcinomas and in vitro effects of mTOR inhibitors in human adrenocortical cell lines
  436. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence
  437. Combination therapy targeting hypoxia inducible factor-α (HIF-1 α) and tissue factor (TF) by the mTOR inhibitor rapamycin and the histone deacetylase inhibitor …
  438. Modulation of antifolate sensitivity in cancer chemotherapy using mTOR inhibitors
  439. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
  440. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer
  441. Effect of mTOR inhibitors on sorafenib-induced endoplasmic reticulum stress and apoptosis in melanoma cells.
  442. Another step in defining the role of mTOR inhibitors in kidney transplantation
  443. PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
  444. Abstract P6-15-07: A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic …
  445. In vitro evaluation of dual pan-PI3-kinase/mTOR inhibitor in HER2 overexpressing breast cancer cells
  446. PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical …
  447. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
  448. Anti-proliferative activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in combination with cytotoxic and targeted agents in sarcoma and endometrial cancer …
  449. Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin
  450. Comparison of radiosensitizing effects of the mTOR inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
  451. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models
  452. Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor.
  453. Targeted inhibition of mTORC1 and mTORC2 by the active-site mTOR inhibitors, PP-242 and OSI-027, has cytotoxic effects in T-cell acute lymphoblastic leukemia
  454. REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A–DDB1 ubiquitin ligase
  455. AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection
  456. A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P).
  457. PTEN expression in archival tumor samples in patients (pts) with advanced malignancies in two phase I studies of AP23573 (AP), an mTOR inhibitor
  458. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and …
  459. Abstract C65: Enhanced antitumor effect by the combination of a PI3K inhibitor ZSTK474 with an mTOR inhibitor rapamycin
  460. Combined Bcl-2/mTOR inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small-cell lung tumor xenograft model
  461. FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.
  462. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway
  463. Effective targeting of the PI3-K pathway in CLL with NVP-BEZ235, a novel orally available dual PI3K/mTOR inhibitor
  464. EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation
  465. Mtor and PI3K Inhibitors Block Myeloma Cell Growth in a Synergistic Manner.
  466. Clinical activity of Azacitidine in combination with the oral mTOR inhibitor everolimus (RAD001) in relapsed and refractory AML: interim analysis of a phase Ib …
  467. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells
  468. Temsirolimus, an mTOR inhibitor, in combination with low-dose clofarabine in older patients with advanced acute myeloid leukemia: results of a phase 2 …
  469. Molecular Mechanisms of the mTOR Inhibitor Temsirolimus (CCI-779) Antiproliferative Effects in Mantle Cell Lymphoma: Induction of Cell Cycle Arrest, Autophagy …
  470. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer
  471. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells
  472. Anti-Angiongenic Effects of mTOR-Inhibitors Is Regulated by AKT Activity in Multiple Myeloma Cells.
  473. Inhibition of mTOR suppresses experimental liver tumours
  474. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel
  475. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells
  476. Methylnaltrexone potentiates the antiangiogenic effects of the mTOR inhibitor, temsirolimus
  477. Combined Bcl2/mTOR Inhibition Leads to Enhanced Radiosensitization via Induction of Autophagy and Apoptosis in Non-small Lung Tumor Xenograft Model
  478. P1-084: Mammalian target of rapamycin (mTOR) inhibition by RAD001 in patients (pts) with reccurent non-small cell lung cancer (NSCLC): Use of 18F …
  479. The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line
  480. Mechanism by Which mTOR Inhibitors Sesitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis.
  481. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation
  482. The role of mTOR inhibition in the control of autosomal dominant polycystic kidney disease
  483. Pediatric Preclinical Testing Program (PPTP) evaluation of the mTOR inhibitor rapamycin
  484. Pharmacodynamic (PD) endpoints and cellular proliferation effects of NVP-BEZ235, a dual PI3K/mTOR inhibitor, in breast cancer cells and xenografts with wild-type …
  485. mTOR Inhibitors Are Safe and Effective Radiosensitizers in Glioblastoma Multiforme Pre-Clinical Models
  486. Brain-selective mTOR inhibitors as potential therapeutics for glioblastoma multiforme
  487. Enhancing mTOR-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
  488. Oncogenic Pim Kinase Activity Provides Resistance to Mtor Inhibition in Vitro and In Vivo.
  489. Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer
  490. Combining mTor inhibitors with rapa-resistant T cells: a two-pronged approach to tumor elimination
  491. Abstract B143: Distinct antitumor mechanisms of VEGFR inhibitor tivozanib (AV‐951) and mTOR inhibitor rapamycin support rational combination for solid tumors to …
  492. mTOR pathway inhibition attenuates skeletal muscle growth induced by stretching
  493. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways
  494. Molecular Inhibition of mTOR with Temsirolimus (TORISEL™, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.
  495. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes
  496. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling: role in FTI enhancement of taxane and …
  497. Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR
  498. Molecular analysis of hormone refractory prostate cancer biopsies supports the rationale of using mTOR inhibitors
  499. The PI3K/mTOR Inhibitor NVP-BEZ235 Is a Promising Pre-Clinical Candidate for Therapeutic Intervention in Acute Myeloid Leukemia.
  500. mTOR signal pathway and its inhibitors in antitumor therapy: A review
  501. Overcoming cisplatin resistance with mTOR inhibition in small cell lung cancer: A phase I-II trial design
  502. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs
  503. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
  504. The discovery and optimisation of pyrido [2, 3-d] pyrimidine-2, 4-diamines as potent and selective inhibitors of mTOR kinase
  505. … , mTOR, and Pharmacodynamic Strategies for a Targeted Cancer Therapy: Commentary re: JM Peralba et al., Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in …
  506. Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes
  507. Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative …
  508. Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension
  509. Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model
  510. Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor …
  511. Abstract C60: In vitro efficacy of the dual PI3‐kinase/mTOR inhibitor NVP‐BEZ235 in hepatocellular carcinoma
  512. Human Eukaryotic Release Factor 3a Depletion Causes Cell Cycle Arrest at G1 Phase through Inhibition of the mTOR Pathway
  513. Current perspectives in metastatic renal cell carcinoma treatment: the role of mammalian target of rapamycin (mTOR) inhibition
  514. Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells.
  515. The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.
  516. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kα
  517. Abstract P5-06-05: Catalytic mTOR Inhibition with pp242 but Not Allosteric Inhibition with Rapamycin RAD001 Enhances the Radiosensitivity of Inflammatory Breast …
  518. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells
  519. Melatonin represses oxidative stress‐induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibition of Ras
  520. Transcription inhibitors stimulate translation of 5′ TOP mRNAs through activation of S6 kinase and the mTOR/FRAP signalling pathway
  521. New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic …
  522. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
  523. Chemical genomic screening reveals that PI3K/mTOR inhibition enhances activity of the anti-leukemia stem cell compound parthenolide.
  524. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in …
  525. Inhibition of amino acid-mTOR signaling by a leucine derivative induces G1 arrest in Jurkat cells
  526. NVP-BEZ235 a dual PI3K/mTOR inhibitor destabilises Mycn in vitro and is growth inhibitory in the TH-MYCN murine neuroblastoma model
  527. Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro
  528. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
  529. The Efficacy of Dual PI3K and mTOR Inhibitor, NVP-BEZ235 against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Combination with …
  530. Combined mTOR and AKT inhibition in renal cell carcinoma (RCC).
  531. Antiproliferative effects of mTOR inhibition with rapamycin (RAP) either given as a single agent or in combination with carboplatin and paclitaxel in Human Head and …
  532. mTOR inhibitors for the treatment of lymphoma
  533. Of Mice and (Hu) man: Therapeutic mTOR Inhibition
  534. Direct inhibition of mTOR may be detrimental when combining mTOR inhibitors or dual PI3 kinase/mTOR inhibitors with paclitaxel
  535. Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support
  536. Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway
  537. Tuberous sclerosis complex tumor suppressor–mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent
  538. ATP depletion increases phosphorylation of elongation factor eEF2 in adult cardiomyocytes independently of inhibition of mTOR signalling
  539. … Inhibition of Growth of Tuberous Sclerosis Complex 2–Null Cells by Atorvastatin Is Associated with Impaired Rheb and Rho GTPase Function and Reduced mTOR …
  540. MTOR INHIBITORS (MTOR-I) AND LUNG TRANSPLANTATION: CAN ITS USE BE JUSTIFIED?: 364
  541. Evaluation of metabolic imaging for assessment of tumor response to mTOR inhibitors
  542. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor …
  543. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
  544. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
  545. Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis
  546. FDG-PET in mTOR inhibitor therapy (mTOR Rx): A study of the relationship between Akt/mTOR and glycolytic pathways
  547. MTOR INHIBITORS IN LIVER TRANSPLANTATION-THE BUDAPEST PRACTICE: 1237
  548. Inhibition von mTOR reduziert Tumorwachstum und Angiogenese des Magenkarzinoms in einem experimentellen Modell
  549. Biochemical determinants for mTOR inhibitor sensitivity in lung cancer cell lines
  550. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis
  551. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer: Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J …
  552. A Novel mTOR Inhibitor Is Efficacious in a Murine Model of Colitis: 1044
  553. New mTOR* Inhibitor for Renal Cell Cancer
  554. BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo
  555. PRONOSTIC FACTOR FOR MTOR INHIBITORS (MTOR-I) PROTEINURIA AFTER LUNG TRANSPLANTATION: 365
  556. Novel indole α-methylene-γ-lactones as potent inhibitors for AKT-mTOR signaling pathway kinases
  557. Antitumoral effect of farnesiltransferase and mtor inhibitors in hepatocellular carcinoma: in vitro studies
  558. Inhibition of human melanoma proliferation by combination treatment with ODC inhibitor and mTOR inhibitor
  559. SEQUENCING TKIs AND mTOR INHIBITORS IN RENAL CELL CARCINOMA
  560. The Dual PI3K and mTOR Kinase Inhibitor NVP-BEZ235 Induces Cell Cycle Arrest in Acute Lymphoblastic Leukemia Cells and Potentiates the Cytotoxicity of …
  561. Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway
  562. Serum glucose measurements as a pharmacodynamic biomarker for mTOR inhibition
  563. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway
  564. mTOR inhibitors in the treatment of advanced renal cell carcinoma
  565. Abstract C66: Development of mechanistic assays to differentiate PI3K and mTOR inhibitors
  566. Novel mTOR inhibitors with distinct anticancer profiles and favorable DMPK properties
  567. Synergistic effects of mTOR inhibitor on the growth of gastric cancer in combination with 5-Fluorouracil
  568. Tumorstammzell-gerichtete Therapie mit mTOR-inhibitor RAD001 und Hedgehog-signaling-inhibitor Cyclopamin sensitiviert chemotherapieresistente …
  569. mTOR Inhibitors in Kidney Cancer: Template for Personalized Therapy
  570. Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2
  571. Abstract 1308A: Novel antiinvasive and antiangiogenic mechanisms of mTOR inhibition in glioblastoma
  572. PI3-Kinase Inhibition Decreases the Proliferation of ALL Cells, Potentiates mTOR Inhibition, and Abrogates Growth Factor-Mediated Reversal of mTOR Inhibition.
  573. Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E …
  574. Administration of RAD001 in patients with metastasized renal cell carcinoma: Review of the clinical development of an oral mTOR inhibitor
  575. Abstract# 817: mTOR inhibitor temsirolimus (Torisel) overcomes adriamycin resistance in head and neck cancer
  576. mTOR inhibitor sensitizes chemo-cytotoxicity for hepatocellular carcinoma
  577. Abstract C55: Involvement of oxidative stress in the antitumor effect of mTOR inhibitors in mantle cell lymphoma
  578. Combination of HSP90 and mTOR inhibition promotes pancreatic cancer growth inhibition
  579. The Role of mTOR Inhibition in Augmenting Radiation Induced Autophagy
  580. The mTOR pathway and its inhibitors
  581. AKT Activity Regulates Sensitivity of Multiple Myeloma Cells to mTor Inhibitors.
  582. EFFECTS OF MTOR-INHIBITION ON HYPOXIC ADAPTATION BY HIF–PREFERENTIAL INFLUENCE ON ERYTHROPIETIN REGULATION: 540
  583. The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway
  584. XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR
  585. … HEPATOCELLULAR CARCINOMA WITH A DUAL TYROSINE KINASE RECEPTOR INHIBITOR (AEE788) AND AN MTOR INHIBITOR (RAD001, EVEROLIMUS): 121
  586. P52: In vivo anti-tumor effect of mTOR inhibitor RAD001 on xenograft tumor of human pancreatic cancer
  587. Abstract B147: Lack of an additive effect of radiation treatment on PI3K or mTOR inhibition in prostate cancer cell lines
  588. Differential regulation of cytokine expression determines the differential drug sensitivity between carcinomas and lymphomas towards mTOR inhibitor
  589. Interaction between the p53 genotype of lung cancer and response to mTOR inhibitor combined with irradiation therapy
  590. mTOR Inhibition and Diet Induced Obesity in a Mouse Model of Postmenopausal Breast Cancer.
  591. HORMONAL STATUS INFLUENCES ADAPTIVE AND MALADAPTIVE SIGNALING AFTER MTOR INHIBITION IN FEMALE CARDIOMYOCYTES: 1125
  592. … : The PI3K pathway inhibition in prostate cancer cells is enhanced by dual targeting with the mTOR inhibitor RAD001 and a mTOR/PI3K inhibitor leading to decreased …
  593. Cooperative induction of apoptosis through p53 signaling and mTOR inhibition in neuroblastoma
  594. Abstract #5239: Erlotinib enhances RAD001\#8217;s anticancer activity in vivo involving abrogation of mTOR inhibition-induced eIF4E phosphorylation
  595. The Combination of the mTOR Inhibitor Rapamycin and Protein Kinase C Inhibitors Produces Marked Synergistic Anti-Myeloma Effects.
  596. Effect of mTOR inhibition by rapamycin on promotion of skin tumors in BK5. Aktwt transgenic mice
  597. Nuclear PTEN-mediated autophagy is independent of mTOR inhibition in U251MG cells
  598. Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia
  599. The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
  600. A potential for combining the mTOR inhibitor RAD001 (everolimus) with the EGFR receptor tyrosine kinase inhibitor erlotinib.
  601. Mammalian target of rapamycin (mTOR) inhibitors with therapeutic potential for colitis
  602. MRI molecular imaging monitors downstream anti-angiogenic effects of mTOR inhibition
  603. Tumor FDG uptake as biomarker for defining the optimal biological dose of the mTOR inhibitor everolimus
  604. Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor …
  605. The anti-tumor activity of the mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma (NPC)
  606. mTOR Inhibitors Induce Apoptosis and Inhibit Growth of Primary Adult Human ALL in Xenograft and Tissue Culture Models.
  607. Response of extensive sclerodermatous chronic graft-versus-host disease to an mTOR inhibitor-based treatment
  608. MTOR (Mammalian Target of Rapamycin) Inhibition with RAD001 Induces Cell Cycle Arrest in Diffuse Large B Cell Lymphoma (DLBCL) Cells and Sensitizes DLBCL …
  609. Improvement of anti-hormone therapy of human breast cancer xenografts by combination with the mTor inhibitor RAD001
  610. Combination of the mTOR Inhibitor Rapamycin and Revlimid™(CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).
  611. EARLY VERSUS LATE CONVERSION TO MTOR-INHIBITORS IN LIVER TRANSPLANT RECIPIENTS WITH IMPAIRED RENAL FUNCTION AT THE TIME OF …
  612. TYROSINE KINASE AND MTOR INHIBITION IN RENAL CELL CARCINOMA SPHEROIDS: 79
  613. … Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.
  614. Abstract #2749: In vitro and in vivo efficacy of the dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in renal cell carcinoma (RCC)
  615. Tumor T1 is a non-invasive imaging marker of proliferation and response to the mTOR inhibitor everolimus
  616. Effects of a novel PI3 kinase/mTOR inhibitor on proliferation and pAKT signaling in canine lymphoma
  617. Limited Growth-suppressive effect of RAD001, an mTOR inhibitor, in hepatocellular carcinoma cells may be related to the compensatory activation of Akt
  618. Abstract# LB-215: Antiproliferative effects of a novel mTOR inhibitor (Temsirolimus) provide the prolonged survival in a pleural dissemination model using non-small …
  619. Contrast Enhanced Sonography shows Superior Microvascular Renal Allograft Perfusion in Patients Receiving mTOR-inhibitor Therapy
  620. Long Term Follow-up of Patients Treated with mTOR Inhibitors for Severe Chronic Gvhd Following Allogeneic Stem Cell Transplantation.
  621. Antiproliferative effect of a novel mTOR inhibitor (temsirolimus) in esophageal cancer cells
  622. Synergistic Antilymphoma Effect of Protein Kinase C Beta (PKCβ) and mTOR Inhibition in Mantle Cell Lymphoma.
  623. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists
  624. … /AKT/mTOR mediates resistance to MEK inhibition in preclinical model of Acute Myeloid Leukemia (AML): synergistic effect of combined MEK and mTOR inhibition.
  625. Targeting the Hypoxic Microenvironment by mTOR Inhibitors Sensitizes ALL Cells to Chemotherapy
  626. THERAPEUTIC MONITORING OF MTOR-INHIBITOR INDUCED IMMUNOSUPPRESSION BY PHOSPHO-FLOW CYTOMETRY: 2145
  627. Tolerability of the mTOR inhibitor rapamycin in cirrhotic patients with advanced hepatocellular carcinoma
  628. mTOR inhibition influences cell viability of medullary thyroid carcinoma primary cultures
  629. Expression of mTOR and IGF2 and in vitro effects of mTOR inhibitor drugs on cell proliferation and cortisol production in human adrenocortical cancer cells
  630. RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential …
  631. The mTOR inhibitor rapamycin inhibits proadhesive activity of arterial intimal smooth muscle cells
  632. Combinations of Cytotoxic Drugs, Ionizing Radiation, and Mammalian Target of Rapamycin (mTOR) Inhibitors
  633. Abstract# 2321: The mTOR inhibitor, temsirolimus, inhibits tumor growth, vascularization, and macrophage infiltration in a transgenic model of mammary carcinoma in …
  634. Rapamycin, mTOR inhibitor, a potent inhibitor for the cell growth and proliferation by p21-dependent mitotic arrest in human gastric cancers
  635. The contribution of antiangiogenic agents and mTOR inhibitors to the treatment of endocrine tumours of the gastro-intestinal tract
  636. Observational study evaluating resource utilization among metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based …
  637. DE NOVO USE OF MTOR INHIBITOR EVEROLIMUS IN COMBINATION WITH MYCOPHANOLATE SODIUM IN PATIENTS UNDERGONE ORTHOTOPIC LIVER …
  638. MTOR Inhibitors Activate the AKT Kinase in Multiple Myeloma Cells by Upregulating the IGF-1/IRS-1/PI-3 Kinase Cascade.
  639. … growth factor (IGF‐R) inhibitor (IMC‐A12) in combination with a mammalian target of rapamycin (mTOR) inhibitor (CCI‐779) to overcome resistance to mTOR inhibition
  640. Biomarkers In Cell Death of Imatinib-Resistant Ph-Leukemia Cells During Treatment with mTOR Inhibitor, Everolimus
  641. The PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin sensitize melanoma cells to cisplatin and temozolomide
  642. The dual PI3K/mTOR inhibitor BEZ235 impairs gastric cancer growth in vitro and in vivo
  643. mTOR and FTY 720 inhibitors
  644. Abstract# 3204: Effects of the novel PDK-1 inhibitor OSU-03012 and the dual PI3 kinase/mTOR inhibitor PI103 on neuroblastoma
  645. Inhibition of PI3K, but not mTOR inhibition sensitizes glioblastoma cells for death receptor-or chemotherapy-induced apoptosis
  646. Molecular combined therapy in hepatocellular carcinoma with an EGFR/Her2/VEGF RTK inhibitor (AEE788) and an mTOR inhibitor (RAD001, everolimus) results in …
  647. Cytostatic action of the dual PI3K/mTOR inhibitor NVP-BEZ235 in non-functioning pituitary adenomas
  648. Abstract# 1838: C/EBP\# 946; and MnSOD as targets of mTOR inhibitors in mantle cell lymphoma.
  649. … Role of AKT and ERK in Regulating D-Cyclin Translation Inhibition and G1 Arrest in Multiple Myeloma Cells Treated with mTOR Inhibitors: Rationale for Combination …
  650. Complete Responses in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) Using the mTOR Inhibitor Sirolimus (rapamycin)
  651. Abstract P6-15-19: PI3K-MTOR Inhibitor BEZ235 Shows Antitumor Activity Against a Panel of Basal-Like Cells and Potentiates the Antitumor Activity of Taxanes and …
  652. mTOR Inhibition and Alloantigen-Specific Regulatory T Cells Synergize to Promote Long-Term Graft Survival in Immunocompetent Recipients
  653. Activation of the AKT pathway in tumor cells following mTOR-raptor inhibition is dependent on the mTOR-rictor complex and does not define the antiproliferative …
  654. Combined mTOR inhibition and post-transplant infusion of alloantigen-specific Treg promotes long-term graft survival in otherwise unmanipulated hosts (141.42)
  655. 040 mTOR inhibition reverses alveolar epithelial neoplasia induced by oncogenic K-ras
  656. Targeting Tissue Factor-Factor VIIa Signaling Pathway to Enhance Activity of mTOR Inhibitors in the Treatment of Breast Cancer
  657. Cyclosporine, but Not mTOR Inhibitors, Hampers the Reconstitution of Bone Marrow-Derived Tregs in Long-Term Complete Donor chimeras.
  658. Impact of mTOR Inhibition on FoxP3+ Regulatory T Cells as Compared to Conventional T Cells after Allogeneic Bone Marrow Transplantation.
  659. Abstract# 2707: Design and synthesis of dual PI3K/mTor inhibitors
  660. Abstract# 5590: mTOR inhibitor CCI-779 enhances the efficacy of radiotherapy in a cisplatin-resistant HNSCC cell line
  661. Abstract B20: In vitro and in vivo antitumor activities of the dual PI3K/mTor inhibitor NVP‐BEZ235. Implications for patient stratification strategies
  662. The mTOR pathway in estrogen response: A potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara®) in breast …
  663. BEZ235, a dual PI3K/mTOR inhibitor, enhances the activity of the multikinase inhibitor sorafenib in acute myeloid leukemia (AML)
  664. Treatment of Retinal Degeneration by mTOR Inhibition in the T17M Mouse Model of Rhodopsin Retinitis Pigmentosa
  665. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
  666. PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
  667. Treatment of Retinal Degeneration by mTOR Inhibition in Mouse Model of Rhodopsin Retinitis Pigmentosa
  668. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene expression levels
  669. Phosphomimetic mutation of hnRNP A1 inhibits AKT-dependent IRES function and results in mTOR inhibitor sensitivity
  670. Pin1 as a Biomarker of ER+ Breast Cancers to Predict the Response to Tamoxifen and mTOR Inhibitors
  671. P2-110: Combined Caspase-3/mTOR inhibition Enhance Radiosensitization of Non-Small Cell Lung Cancer via Upregulation of Autophagy
  672. Rapamycine et inhibition de mTOR: des voies de signalisation aux applications cliniques
  673. Phase I and pharmacokinetic study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
  674. Pin1 as a Biomarker of ER+ Breast Cancers to Predict the Response to Tamoxifen and mTOR Inhibitors PRINCIPAL INVESTIGATOR
  675. EFFECT OF MTOR INHIBITOR ON DYSLIPIDEMIA IN HEART TRANSPLANT RECIPIENTS RECEIVING STATINS. IS THERE ANY DIFFERENCE BETWEEN …
  676. … -0941 synergizes with mTOR inhibitors by blocking negative feedback and causes distinct effects on signaling and apoptosis compared to a dual PI3K/mTOR inhibitor
  677. mTOR inhibitors rapamycin and RAD001 (Everolimus) induce antiproliferative effects in GH3 cell line and human pituitary adenomas
  678. Tumor stem cell targeted therapy with mTOR inhibitor RAD001 and hedgehog signalling inhibitor Cyclopamine reverts chemoresistance towards 5-Fluorouracil in …
  679. Abstract C249: Down‐regulation of the HIF pathway enhances anti‐tumor effects of the mTOR inhibitor ridaforolimus in the Her2/Neu mouse model of breast cancer
  680. mTOR INHIBITORS (MTI) ARE SYNERGISTIC WITH METHOTREXATE: AN EFFECTIVE COMBINATION TO BOTH PREVENT POST-HSCT RE-LAPSE OF ALL …
  681. Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone
  682. Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of …
  683. Abstract# 2017: Novel imidazolopyrimidines as dual PI3-kinase/mTor inhibitors
  684. Abstract C59: Discovery and characterization of selective PI3Kα and PI3Kα/mTOR‐dual inhibitors for targeting PI3Kα‐activated tumors
  685. Metformin augments rituximab and chemotherapeutic agents-induced apoptosis via mTOR inhibition in rituximab-resistant B lymphoma cell lines
  686. DE NOVO USE OF mTOR INHIBITOR EVEROLIMUS IN COMBINATION WITH MYCOPHANOLATE SODIUM OR MYCOPHENOLATE MOPHETIL AND EARLY …
  687. Abstract B142: PKI‐402, a dual PI3K/mTOR inhibitor
  688. A phase I study of the mTOR inhibitor sirolimus (rapamycin) in combination with nanoparticle albumin-bound paclitaxel (ABI-007, abraxane) in advanced solid cancers
  689. The mTOR inhibitor rapamycin inhibits p27 protein degradation by downregulating the expression of its ubiquitin ligase Skp2 in breast cancer
  690. Inhibition of the mTOR pathway enhances sensitivity of breast cancer triple negative cell lines to EGFR family inhibition.
  691. FLT3-ITD–, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment
  692. mTOR inhibition impairs proliferation of hepatocytes with DNA damage during chronic liver injury thereby delaying liver tumor development
  693. Preclinical investigation of MEK and mTOR inhibitors on human-derived Neurofibromatosis Type 1 malignant peripheral nerve sheath tumours
  694. Abstract #2901: FDG-PET uptake is a surrogate marker for defining the optimal biological dose of mTOR inhibitors in vivo
  695. 971 COMBINED TREATMENT WITH CISPLATIN AND DUAL PI3K-MTOR INHIBITOR NVP-BEZ235 CAN RESTORE CASPASE DEPENDENT APOPTOSIS IN …
  696. 58: mTOR inhibitors (MTI) are synergistic with methotrexate: An effective combination to both prevent post-HSCT relapse of all and prevent GVHD
  697. Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During a Clinical Trial Combining the mTOR Inhibitor Sirolimus with Mitoxantrone …
  698. IL-7 and Thymic Stromal Lymphopoietin (TSLP) Stimulate Proliferation of All Cells and Reverse mTOR Inhibitor-Induced Growth Inhibition, Suggesting a Role for IL …
  699. The mTOR inhibitor everolimus cooperates with the Toll-like receptor 9 (TLR9) agonist IMO in renal cell carcinoma by interfering with both tumor cells and …
  700. Abstract PD02-09: Effects of an mTOR Inhibitor RAD001 on Human Breast Cancer Stem Cells In Vitro
  701. The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and-resistant breast cancer xenografts
  702. Effect of EGFR and IGF1R on feedback activation of AKT arising from inhibition of mTOR in malignant pleural mesothelioma (MPM).
  703. 499: Acute Rejection and Survival Following Late Replacement of CNIs with an mTOR Inhibitor Plus MMF after Heart Transplantation
  704. COMBINED TREATMENT WITH CISPLATIN AND DUAL PI3K-MTOR INHIBITOR NVP-BEZ235 CAN RESTORE CASPASE DEPENDENT APOPTOSIS IN …
  705. Abstract# 1887: The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancer
  706. Beyond temsirolimus: Discovery of PKI-587 a highly efficacious dual PI3K/mTOR inhibitor
  707. Abstract LB-301: The impact of Abcb1 and Abcg2 on the brain penetration of PI3K-mTOR inhibitors
  708. Androgen receptor antagonist bicalutamide sensitizes androgen-independent prostate cancer cells to mTOR inhibitor rapamycin by regulating phosphorylation of …
  709. Genomic profiling of ovarian tumor cell lines provides a predictive signature of sensitivity to PF-4691502, a dual PI3kinase and mTOR inhibitor
  710. Study of mammalian target of rapamycin (mTOR) signaling and the effects of its specific inhibitors in hepatocellular carcinoma
  711. Abstract C62: Identification of GSK2126458, a highly potent inhibitor of phosphoinositide 3‐kinase (PI3K) and the mammalian target of rapamycin (mTOR)
  712. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel …
  713. PNEUMONITIS FROM INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (MTOR) IN PATIENTS WITH METASTATIC CANCER
  714. Abstract #2817: Ex vivo and in vivo effects of NVP-BEZ235, a dual pan-PI3K / mTOR inhibitor, on insulin signaling and metabolic regulation.
  715. Abstract# 2328: Preclinical testing of a vascular disrupting agent in combination to an mTOR inhibitor in renal cell carcinoma models.
  716. Abstract P2-19-01: Modulating Response to Phosphoinositol-3-Kinase/mTOR Inhibition in ER Positive Breast Cancer Cell Lines after Acquired Resistance to Estrogen …
  717. 298: Usefulness of mTOR Inhibitors for Treatment of Heart Transplant Patients with Non-Cutaneous Non-Lymphomatous Tumours: Data from the Spanish Post-Heart …
  718. Abstract LB-302: Activity of PF-04691502, A dual PI3K/mTOR inhibitor in breast cancer cell lines and models discriminates between ER, PR and HER2 positive and …
  719. Abstract #2301: Combined Bcl2 /mTOR inhibition leads to enhanced radiosensitization via autophagy and apoptosis in non-small lung numor nenograft model
  720. Neuroendocrine Tumors: RAD00l Inhibitor of mTOR Used with Octreotide Shows Activity
  721. 381: Immunosuppression after Post-Heart-Transplant Neoplasia with MMF and mTOR Inhibitors and Withdrawal of Calcineurin Inhibitors. Is It Safe Enough for …
  722. Topics in mTOR pathway and its inhibitors
  723. 39: Differential impact of mTOR inhibition on FoxP3+ regulatory T cells as compared to conventional T cells after allogeneic bone marrow transplantation
  724. … : A novel Bayesian dose-escalation Phase Ib study design investigating combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 with standard …
  725. Abstract LB-159: An orthotopic model of head and neck squamous carcinoma reveals that mTOR inhibition with rapamycin halts lymph node metastasis
  726. Abstract# 1071: Tumor stem cell targeted therapy with mTOR inhibitor RAD001 and hedgehog signalling inhibitor Cyclopamine reverts chemoresistance towards 5 …
  727. Abstract# 2816: Biologic effects of NVP-BEZ235, an orally available dual PI3K/mTOR inhibitor, in human breast, lung, colon, pancreas, and liver cancer cell lines in …
  728. Insights into the regulation of mTOR signaling and the consequences of pharmacological inhibition
  729. … signaling pathway constitutively activated in esophageal squamous cell carcinona cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR
  730. Abstract# 2809: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and …
  731. Influence of the genotype in the response of lung cancer cells to inhibitors of ampk and pik3/akt/mtor.
  732. A selective PIM kinase inhibitor is highly active in multiple myeloma: the biology of single agent and PI3K/AKT/mTOR combination activity
  733. PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia.
  734. Biomarker development for XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a Phase I clinical trial
  735. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II …
  736. Acetaldehyde promotes rapamycin-dependent activation of p70S6K and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human …
  737. 5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-α and mTOR for the treatment of breast cancer
  738. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies
  739. Combined MEK and mTOR suppression is synergistic in human NSCLC and is mediated via inhibition of protein translation
  740. Der mTOR-Inhibitor Sirolimus inhibiert die VEGF-C getriggerte physiologische Lymphangiogenese: Eine experimentelle Erklärung für frühe postoperative Probleme
  741. Insulin inhibition of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR signaling cascade but does not involve internal ribosomal entry site …
  742. Kombination von antiangiogener Therapie mit dem mTOR Inhibitor RAD001 und Strahlentherapie als neues Therapiekonzept in der Tumortherapie
  743. Inhibition of mammalian target of rapamycin (mTOR) induces phosphatidylinositol 3 kinase-dependent and Mnk-mediated eIF4E phosphorylation
  744. Inhibition of mTOR Induces Cumulus Expansion and Meiotic Maturation in Mouse Oocytes Without Gonadotropin Stimulation.
  745. Abstract P6-14-10: Treatment of Breast Cancer Using Multistage Delivery of PI3K/mTOR Inhibitors
  746. Verminderte Anfallsfrequenz unter mTOR-Inhibitor
  747. Das neue Wirkprinzip der mTOR-Inhibition
  748. … Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This …
  749. Inhibition of AKT/mTOR Signaling Pathway Induces Cell Cycle Arrest and Apoptosis in Acute Myelogenous Leukemia.
  750. Die Tyrosinkinasen-Inhibitoren Imatinib (Glivec) und NVP-AEE788 und der mTOR-Inhibitor Sirolimus hemmen das Wachstum von Gallengangskarzinomen in vitro …
  751. Antitumor effects of sorafenib, bevacizumab and cetuximab as single agents or in combination with an MEK, mTOR or bcl-2 inhibitor, in a SNU-398 human …
  752. Chronische Allograftdysfunktion nach Nierentransplantation-Rolle der mTOR-Inhibition und prädiktiver Wert der Proteinurie
  753. Abstract C8: Short‐chain fatty acids induce autophagy through inhibition of mTOR pathway
  754. Activation of mTOR by inhibitors of translation is dependent on PKC-delta.
  755. Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in …
  756. Abstract A225: The mTOR kinase inhibitor AZD8055 modulates 18F‐FDG uptake in vivo in the human glioma xenograft model U87‐MG
  757. Dual inhibition of Akt/mTOR pathway by nab-rapamycin and perifosine induces anti-tumor activity in multiple myeloma
  758. Inhibition of AKT/mTOR Signaling Induces Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma.
  759. Inhibitors of the Proteasome and mTOR
  760. Abstract B144: NVP‐BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2‐positive cells
  761. mTOR kinase inhibitors exhibit properties that distinguish them from Rapamycin
  762. Small-molecule inhibitors of mTOR and DNA-PK
  763. Effect of the farnesyl transferase inhibitor lonafarnib on sensitivity of melanoma cells to the multikinase inhibitor sorafenib and on Rheb farnesylation and mTOR …
  764. Research article Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
  765. Novel PI3K/mTOR dual inhibitor, NVP-BGT226, displays potent inhibitory activity against human head and neck cancer cell growth in vitro and in vivo
  766. Intravenöse mTOR-Inhibition auch in der Hämatologie erfolgreich
  767. Abstract C201: A novel potent and selective inhibitor of PI3K/mTOR, GDC‐0980, currently in phase I clinical trials
  768. … ) inhibition of mTOR in tamoxifen sensitive and resistant human breast cancer cells produces estrogen dependent growth inhibition but paradoxical induction of …
  769. Pharmacological studies of a novel inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway
  770. Inhibition of mTOR signaling by psoralidin in breast cancer
  771. AZD8055 is an effective inhibitor of mTOR kinase signaling and breast cancer growth while relieving feedback inhibition of HER-kinase signaling
  772. Inhibition of mTOR for the treatment and prevention of lung cancer
  773. Inhibition of mTOR Kinase Pathway Selectively Sensitizes Acute Myeloid Leukemia Cells to Cytarabine-Induced Apoptosis.
  774. MTOR as therapeutic target for T-cell leukemia: Synergism with conventional cytotoxic drugs and signaling inhibitors.
  775. A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?
  776. mTOR inhibitors: interest and development for oncology purpose
  777. Enhanced anti-tumor effect of combination therapy with anti-CD40 antibody and the mTOR kinase inhibitor AZD8055
  778. The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design
  779. Abstract B267: AR‐mTOR‐1: A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy
  780. Intra-Pathway Inhibition of Upstream (PI3K) and Downstream (mTOR) Kinases Synergistically Induces Apoptosis in AML.
  781. Chemosensitization by dual pharmacological inhibition of MEK and mTOR signaling pathways in human non-small cell lung cancer (NSCLC)
  782. Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole
  783. Methoxychalcone induces cell‐cycle arrest and apoptosis in human hormone‐resistant prostate cancer cells through PI 3‐kinase‐independent inhibition of mTOR …
  784. Abstract# 3710: Novel potent and selective mTOR/PI3K inhibitors that inhibit tumor growth in animal models through efficient and sustained shut down of the PI3K/Akt …
  785. … bei Lebertransplantierten nach Umsetzen einer Calcineurin-Inhibitor-basierten auf eine mTOR-Inhibitor-basierte immunsuppressive Therapie
  786. Anti-proliferative aminopeptidase inhibitors inhibit mTOR and alter expression of Noxa and Mlc-1 in leukemic cells via amino acid deprivation
  787. Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase
  788. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells
  789. Simultaneous inhibition of Hsp90 and mTOR synergistically reduces tumor growth and angiogenesis of hepatocellular cancer in an experimental model
  790. Inhibition of protein translation via mTOR signaling as a target in radiotherapy
  791. Abstract# LB-52: NVP-BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2 positive cells
  792. Inhibition of the mammalian target of rapamycin (MTOR) for the chemoprevention of tobacco-carcinogen induced lung tumorigenesis
  793. Dual Inhibition of mTOR and Pim Kinase Pathways Using Small Molecule Inhibitors Synergistically Kills Myeloid Leukemic Cells In Vitro and In Vivo.
  794. A Novel mTOR Kinase Inhibitor Causes Growth Inhibition, Cell Cycle Arrest, Apoptosis and Autophagic Cell Death in Mantle Cell Lymphoma Cell Lines: A Distinct …
  795. Abstract# 1683: mTOR pathway inhibition via folate receptor specific delivery of the folate-everolimus conjugate EC0565
  796. Disruption of DEPTOR/mTORC1/mTORC2 signaling cascade using a novel selective mtor kinase inhibitor azd8055 results in growth arrest and apoptosis in multiple …
  797. AMPK-Mediated Inhibition of mTOR Kinase
  798. Abstract B138: SB2312, a novel and potent dual inhibitor of mTOR and PI3K with high target inhibition and antitumor efficacy
  799. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function
  800. PI-103, a Novel Dual Inhibitor of PI3-Kinase and mTOR, Enhances the Activity of Imatinib Mesylate in BCR-ABL-Positive Acute Leukaemia Cells
  801. Inhibition of mTOR activity potentiates 2-DG-induced cell death in hypoxic cells via down-regulation of HIF-1α
  802. Rapamycin, Inhibitor of Mtor Kinase, Sensitizes Leukemia Cells to Fludarabine-Induced Apoptosis, but Protects Survival of Normal Lymphocytes.
  803. Inhibition of Human T-Cell Proliferation by mTOR antagonists requires Non-Coding RNA growth-arrest-specific transcript 5 (GAS5)
  804. FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in Hepatocellular Carcinoma
  805. Glucocorticoid Induction of Autophagy in Lymphocytes, Mediated by Dig2 and Inhibition of mTOR Signaling
  806. Abstract B15: Targeted inhibition of mTOR signaling attenuates the growth and progression of colorectal cancer
  807. Inhibition of PI3K/mTOR Pathways In Glioblastoma and Implications for Combination Therapy with Erlotinib, Temozolomide, and Radiation
  808. Interactions between inhibitors of mTOR and EGFR/ERK signaling in SiHa cervical carcinoma
  809. mTOR Inhibition vermindert die proinflammatorische und profibrogene Genexpression bei experimenteller NASH
  810. Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature
  811. DUAL INHIBITION OF CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE AND mTOR AS A NEW THERAPEUTIC OPTION FOR T-CELL ACUTE …
  812. Abstract A41: Combined inhibition of mTOR and MAPK signaling attenuates the growth and progression of colorectal cancer
  813. Fatty acid synthase (Fas) inhibitors modulate energy balance via Mtor complex 1 (Mtorc1) signaling in the central nervous system (Cns)
  814. Abstract B141: Effects of AZD8055, a novel mTOR kinase inhibitor, in human cancer cells developing resistance to rapamycin
  815. Inhibition of mTOR Reverses the Ability of c-MYC To Block the Differentiation of Murine Granulocytes.
  816. Inhibitors of mToR Mediate Anti-Myeloma Activity by Apoptosis through the Extrinsic Pathway.
  817. Inhibition of mTOR and targeting insulin-like growth factor I synergistically enhance taxol-induced cytotoxicity in estrogen receptor positive breast cancer cells.
  818. First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on …
  819. Targeted inhibition of mtor by azd8055 blocks protein translation and has anti-leukemic activity in acute myeloid leukemia
  820. Reduziertes Wachstum kolorektaler Karzinomzelllinien-Xenografts nach kombinierter EGF-Rezeptor-und PI3K/AKT/mTOR-Inhibition
  821. AR-mTOR-26–A Potent, Selective mTORC 1/2 Kinase Inhibitor for the Treatment of Malignancy
  822. mTOR pathway inhibition attenuates skeletal muscle growth induced by stretching
  823. The activity of novel, potent, selective PI3K/mTOR pathway inhibitors in B-cell malignancies
  824. Characterisation of a novel and highly selective kinase inhibitor of the mammalian target of rapamycin (mTOR)
  825. INCREASED FREQUENCY OF ANGIOEDEMA UNDER COMBINED TREATMENT WITH MTOR–AND ACE-INHIBITOR IN KIDNEY TRANSPLANTED PATIENTS: 1618
  826. p53-independent radiosensitization of lung cancer cells by inhibition of mTOR pathway
  827. Targeting mTORC1/2 by a mTOR kinase inhibitor (PP242) induces apoptosis in AML cells under conditions mimicking bone marrow microenvironment
  828. … -70: In vitro anti-cancer activity of PF-04691502, a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) in a panel …
  829. Pre-clinical treatment of adrenal cortical carcinoma with a combination of small molecule inhibitors to IGF-1R and mTOR
  830. A novel PI3K/mTOR dual inhibitor provides correlations of pharmacokinetic pharmacodynamic and tumor growth inhibition in a prostate PC3 xenograft model for …
  831. Dual targeting of PI3K and mTOR results in synergistic growth inhibition in NSCLC cells
  832. A small molecule inhibitor against kinase domain of mammalian target of rapamycin (mTOR) causes autophagic cell death in glioblastoma
  833. Investigation of the inhibition of the cell growth and down-regulation of mTOR in the cholangiocarcinoma QBC939 cells transfected with plasmid PTEN in vitro
  834. RAD001, An Inhibitor of mTOR, Enhances Monocytic Differentiation Induced by ATRA through Phosphorylation of C/EBPα In AML Cell Lines
  835. Inhibition of the mTOR/ p70 S6K pathway by FTI and the involvement of Rheb (Ras homologue enriched in brain)
  836. The inhibition of insulin stimulated proliferation of vascular smooth muscle cell by rosiglitazone is mediated by the Akt-mTOR-p70S6K pathway
  837. In vivo activity of combined PI3k/mTOR and MEK-inhibition in a K-RASG12D; PTEN deletion mouse model of ovarian cancer
  838. Transcription inhibitors stimulate translation of 5â ² TOP mRNAs through activation of S6 kinase and the mTOR/FRAP signalling pathway
  839. J013 Inhibition of mTOR survival pathway by an embryonic developmental Wnt pathway suppresses preconditioning induced cardioprotection
  840. Sweet gum extract inhibits proliferation of prostate cancer through dual inhibition of PI3K/Akt and mTOR pathways.
  841. Targeted therapy for osteosarcoma using 17AAG and rapamycin: Characterization of induced apoptosis and inhibition of mTOR and AKT/MAP kinase pathways
  842. Dual inhibition of PI3K/mTOR by PI-103 inhibits pancreatic cancer cell growth mediated via autophagy and cell cycle arrest
  843. INHIBITION OF MTOR SURVIVAL PATHWAY BY AN EMBRYONIC DEVELOPMENTAL WNT PATHWAY SUPPRESSES PRECONDITIONING INDUCED …
  844. Combined Inhibition of MEK and mTOR Prevents Proliferation of Glioblastoma Cell Lines by Abolishing Phosphorylation of Cyclin-Dependent Kinase 4
  845. Inhibition of the PI3K and mTOR survival pathways enhances apoptosis in human mesothelioma tumor fragment spheroids
  846. Inhibition of mTOR and the MEK/ERK pathway enhance paclitaxel-induced cytotoxicity in estrogen receptor-positive breast cancer cells.
  847. Multiple Strategies Based on MEK, mTOR and BCL-2 Signal Transduction Inhibition in Acute Lymphoblastic Leukemia (ALL)
  848. Eine mTOR Inhibition mittels Rapamycin vermindert die proinflammatorische und profibrogene Genexpression bei experimenteller NASH
  849. PF-04691502, a potent and selective mTOR/PI3K dual inhibitor, demonstrates in vitro and in vivo antitumor activity in non-small cell lung carcinoma cells
  850. Polyamine catabolism drug N1, N11-Diethylnorspermine caused cell death in glioblastoma cells via inhibition of mTOR-regulated protein initiation
  851. PI3K/Akt/mTOR activity is a major determinant for the sensitivity of NPM-ALK (+) anaplastic large cell lymphoma cells to ALK inhibition
  852. Reversion of the resistance to tamoxifen and cross-resistance to fulvestrant in a novel breast cancer cell line by inhibition of the PI3K/Akt/mTor signaling pathway
  853. Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.
  854. Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains
  855. Farnesyltransferase inhibitor (FTI) disruption of Rheb/FKBP38 association leads to FKBP38-mediated inactivation of mTOR
  856. AMPK activation vs. inhibition induces apoptosis in acute lymphoblastic leukemia cells by differentially altering PI3K/Akt/mTOR or RAS/cRAF/MEK/Erk signaling
  857. Abstract C63: Biological characterization of GSK2126458, a novel and potent inhibitor of phosphoinositide 3‐kinase and the mammalian target of rapamycin (mTOR)
  858. Inhibition of PI3 kinase by NVP-BEZ235 suppresses the PI3K/Akt/mTOR pathway and is growth inhibitory in human orthotopic primary pancreatic cancer xenografts
  859. Abstract# 5241: Effect of targeted inhibition of mTOR complexes on proliferation, apoptosis and cell cycle progression in colorectal carcinoma
  860. … # 2757: Combination therapy with inhibitors of mTOR and MEK1/2 (AZD6244) kinases, shows enhanced apoptosis and tumor growth inhibition in preclinical models
  861. Cyclosporin A and Cannabinoids induce autophagy-associated cell death in malignant glioma cells through inhibition of mTOR/S6K1 pathway
  862. Targeted Therapy: mTOR-Inhibition (Temsirolimus/CCI-779) in der Behandlung des metastasierten Mammakarzimons–Daten einer Phase II-Studie bei intensiv …
  863. Research article The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not …
  864. 2619: Inhibition Of mTOR or Apopotic Pathway Induces Autophagy and Radiosensitizes PTEN Null Prostate Cancer Cells
  865. Wirkung des Tyrosinkinase-Inhibitors Sunitinib und des mTOR-Inhibitors Rapamycin auf die Proliferation und Apoptose von Ewing-Sarkom-Zellen in vitro
  866. Induction of granzyme B expression in human regulatory T cells requires TCR and CD28 triggering but not IL-2 and is suppressed by inhibitors of the PI3K-mTOR …
  867. 548: Inhibition of the MTOR Pathway by Rapamycin Reverses Renal Cystogenesis in Polycystic Kidney Disease Models
  868. Palomid 529, An Inhibitor of the Akt/mTOR Pathway Reduces Photoreceptor Cell Death Following Experimental Retinal Detachment
  869. Abstract P2-19-02: mTOR Pathway Inhibitor Nanoparticles Beneficially Modulate Autophagy in Triple Negative Breast Cancer Cells
  870. Palomid 529, a PI3K/Akt/mTOR dual TORC1/2 inhibitor, is a radiosensitizer with effect in both subcutaneous and orthotopic U251 glioblastoma tumor xenograft models
  871. Preclinical PKPD modeling and human dose projection of PF-04691502, a PI3K/mTOR dual inhibitor
  872. Abstract# 3202: Dual inhibition of phosphoinositide-3-kinase (PI3K) and mTOR shows enhanced efficacy in human neuroblastomas (NBs)
  873. PF-04691502, a potent and selective PI3K/mTOR dual inhibitor with antitumor activity
  874. … ) induces caspase-independent autophagic cell death in human non-small cell lung cancer cell lines through the inhibition of akt/mtor signaling pathways and …
  875. … pathway in hepatocellular carcinoma: evidence of its blockade and antineoplastic effect with a novel dual tyrosine kinase inhibitor (aee788) and a mtor inhibitor  …
  876. … -negativen Mammakarzinomzellinien MDA-MB-231 und SKBr3 durch Behandlung mit GHRH-Rezeptor-Antagonist JMR-132 in Kombination mit mTOR-Inhibitor …
  877. Abstract# 2302: NVP-BEZ235 a dual inhibitor of phosphatidylinositol 3-Kinase (PI3 Kinase) and mammalian target of rapamycin (mTOR) potently enhances the effects …
  878. … -Studienprogramm zur Behandlung des HER2/neu-positiven (BOLERO 1/3) und ER-positiven (BOLERO 2) metastasierten Mammakarzinoms mit dem mTOR-Inhibitor …
  879. … Chemotactic Lipid S1P Regulates Hematopoietic Progenitor Cell Egress and Mobilization Via Its Major Receptor S1P1 and by SDF-1 Inhibition In a p38/Akt/mTOR …
  880. … tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor (TAE226) leads to apoptosis in esophageal cancer by inhibiting AKT-mTOR …
  881. MKC-1 significantly increases survival of mice bearing renal cell carcinoma CAKI-1 xenograft tumors through inhibition of the Akt/mTOR pathway
  882. Abstract# 2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with …
  883. … # 3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR …
  884. Abstract# LB-261: Combined inhibition of histone deacetylase and mTOR: A novel therapeutic approach for pancreatic cancer
  885. Abstract# 4405: Cytotoxic effects of simultaneous inhibition of AMPK/mTOR and IGF-1R signaling pathways on acute lymphoblastic leukemia
  886. Transduction of cells with adenovirus lacking early regions 1 and 3 overcomes hypoxia-induced inhibition of the mTOR pathway, and promotes the accumulation of …
  887. … ciblées dans le carcinome rénal: Description de la voie signalétique mTOR (mammalian target of rapamycin) et de l’importance de son inhibition dans le traitement du …
  888. … au tamoxifène et au fulvestrant dans le cancer du sein hormono-dépendant: stratégies de réversion par inhibition des voies PI3K/Akt/mTOR et MAPK: identification de …
  889. Inhibition of Amino Acid-mTOR Signaling by a Leucine Derivative Induces G1 Arrest in Jurkat Cells
  890. Präsidentenposter: Duale Inhibition der PI (3) K-Akt-mTOR und der Ras-Raf-MEK-Erk1/2 Signalkaskade in neuroendokrinen Tumorzelllinien pankreatischen-, midgut …
  891. P. 238 Inhibition de la voie de signalisation PI3K/mTOR dans les cellules endocrines tumorales STC-1: étude in vitro et in vivo
  892. mTOR inhibitors in cancer therapy
  893. mTOR signaling pathway and mTOR inhibitors in cancer therapy
  894. Rapamycin passes the torch: a new generation of mTOR inhibitors
  895. Mechanisms of mTOR inhibitor resistance in cancer therapy
  896. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
  897. mTOR inhibitors in renal cell carcinoma
  898. mTOR inhibitors in tuberous sclerosis complex
  899. mTOR inhibitors in advanced renal cell carcinoma
  900. mTOR drives its own activation via SCFβTrCP-dependent degradation of the mTOR inhibitor DEPTOR
  901. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
  902. Current development of the second generation of mTOR inhibitors as anticancer agents
  903. Clinical presentation and management of mTOR inhibitor-associated stomatitis
  904. Development of ATP-competitive mTOR inhibitors
  905. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
  906. mTOR inhibitor–associated proteinuria in kidney transplant recipients
  907. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates
  908. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
  909. Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model
  910. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
  911. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
  912. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
  913. The evolving role of mTOR inhibition in transplantation tolerance
  914. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas
  915. Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition
  916. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer
  917. miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1
  918. Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options
  919. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
  920. Updating progress in sarcoma therapy with mTOR inhibitors
  921. mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome
  922. Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK …
  923. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
  924. mTOR pathway and mTOR inhibitors in head and neck cancer
  925. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells
  926. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM-and DNA-PKCs-mediated DNA damage responses
  927. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis
  928. “Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?
  929. Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition
  930. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma
  931. mTOR inhibitors in breast cancer: a systematic review
  932. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis
  933. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma
  934. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer
  935. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials
  936. Utility of mTOR inhibition in hematologic malignancies
  937. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors
  938. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials
  939. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro
  940. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCFβTrCP E3 ubiquitin ligase and regulates survival and autophagy
  941. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis
  942. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats
  943. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor–based immunosuppression? A systematic review and meta-analysis
  944. mTOR signaling, function, novel inhibitors, and therapeutic targets
  945. Tuberous sclerosis complex–associated angiomyolipomas: focus on mTOR Inhibition
  946. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with …
  947. The promise of mTOR inhibitors in the treatment of colorectal cancer
  948. mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma
  949. Advancing age is associated with gene expression changes resembling mTOR inhibition: evidence from two human populations
  950. The mTOR inhibitor rapamycin suppresses DNA double-strand break repair
  951. The role of mTOR inhibitors for the treatment of B-cell lymphomas
  952. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors
  953. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
  954. A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models
  955. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor
  956. Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy
  957. MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
  958. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma
  959. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
  960. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination
  961. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
  962. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy
  963. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model
  964. Expanding human T regulatory cells with the mTOR-inhibitor rapamycin
  965. Combined therapeutic application of mTOR inhibitor and vitamin D3 for inflammatory bone destruction of rheumatoid arthritis
  966. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines
  967. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
  968. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury
  969. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells
  970. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors
  971. The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
  972. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis
  973. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy
  974. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
  975. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family …
  976. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model
  977. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP‐BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
  978. mTOR inhibition and erythropoiesis: microcytosis or anaemia?
  979. mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions
  980. mTOR inhibitor for the treatment of hepatocellular carcinoma
  981. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and …
  982. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics
  983. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast …
  984. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT …
  985. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations
  986. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment
  987. The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice
  988. Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects
  989. mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
  990. Discovery and assembly-line biosynthesis of the lymphostin pyrroloquinoline alkaloid family of mTOR inhibitors in Salinispora bacteria
  991. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma
  992. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo
  993. Levels of p27 sensitize to dual PI3K/mTOR inhibition
  994. Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors
  995. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
  996. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas
  997. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells
  998. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells
  999. Inflammation-Driven Reprogramming of CD4+Foxp3+ Regulatory T Cells into Pathogenic Th1/Th17 T Effectors Is Abrogated by mTOR Inhibition in vivo
  1000. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo
  1001. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models
  1002. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer
  1003. Costimulatory blockade with mTor inhibition abrogates effector T‐cell responses allowing regulatory T‐cell survival in renal transplantation
  1004. Pushing the envelope in the mTOR pathway: the second generation of inhibitors
  1005. ATP-competitive inhibitors of mTOR: an update
  1006. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC
  1007. Perspectives on mTOR inhibitors for castration-refractory prostate cancer
  1008. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review
  1009. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing
  1010. Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001
  1011. Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy
  1012. A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome
  1013. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines
  1014. Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II …
  1015. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients …
  1016. A decade of experience using mTor inhibitors in liver transplantation
  1017. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
  1018. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001
  1019. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
  1020. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy
  1021. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
  1022. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition
  1023. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy
  1024. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor
  1025. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation
  1026. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells
  1027. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced …
  1028. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
  1029. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells
  1030. Evidence for the involvement of mTOR inhibition and basal autophagy in familial Mediterranean fever phenotype
  1031. Successful outcome of ganciclovir‐resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors
  1032. Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin
  1033. The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy
  1034. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
  1035. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors
  1036. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
  1037. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line …
  1038. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor
  1039. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma
  1040. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma
  1041. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma
  1042. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of …
  1043. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under …
  1044. Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition
  1045. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR‐inhibitors in peripheral human blood
  1046. … -cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive …
  1047. Aging and cancer: can mTOR inhibitors kill two birds with one drug?
  1048. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines
  1049. mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
  1050. Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin
  1051. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens
  1052. Brief report: a phase II “window-of-opportunity” frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC …
  1053. Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
  1054. mTOR inhibitors: A novel class of anti-cancer agents
  1055. Quantitative visualization of autophagy induction by mTOR inhibitors
  1056. Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model
  1057. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction
  1058. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
  1059. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug
  1060. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice
  1061. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer
  1062. Resistance to the mTOR-inhibitor RAD001 elevates integrin α2-and β1-triggered motility, migration and invasion of prostate cancer cells
  1063. Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
  1064. Relief with rapamycin: mTOR inhibition protects against radiation-induced mucositis
  1065. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer
  1066. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
  1067. Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy
  1068. Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease–antiprotease system by the mTOR inhibitor rapamycin
  1069. … )phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of …
  1070. Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1, 3, 5-triazine sulfonamide scaffold
  1071. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer
  1072. MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition
  1073. mTOR inhibition, a potential novel approach for bronchial carcinoids
  1074. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled …
  1075. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs)
  1076. Inhibitors of PI3K/Akt and/or mTOR inhibit the growth of cells of myeloproliferative neoplasms and synergize with JAK2 inhibitor and interferon
  1077. Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor
  1078. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
  1079. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
  1080. mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation
  1081. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
  1082. mTOR inhibitors: facing new challenges ahead
  1083. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial
  1084. AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation
  1085. Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines
  1086. Effects of mTOR inhibitors on components of the Salvador-Warts-Hippo pathway
  1087. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors
  1088. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
  1089. The role of mTOR inhibitors in renal diseases
  1090. How to use mTOR inhibitors? The search goes on
  1091. The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer–a phase I trial
  1092. SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).
  1093. The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response
  1094. Prospective, multicenter study of the MTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom’s macroglobulinemia
  1095. mTOR inhibition in kidney transplant recipients
  1096. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro
  1097. Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go?
  1098. The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma
  1099. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors
  1100. Does the use of mTOR inhibitors increase long-term mortality in kidney recipients?
  1101. Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1
  1102. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
  1103. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors
  1104. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells
  1105. Inhibition of MTOR disrupts autophagic flux in podocytes
  1106. Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer …
  1107. Lymphedema of the breast as a symptom of internal diseases or side effect of mTor inhibitors
  1108. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
  1109. Rash to mTOR inhibitor everolimus: Systematic review and meta-analysis.
  1110. Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER−) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors
  1111. TNFα-mediated apoptosis in human osteoarthritic chondrocytes sensitized by PI3K-NF-κB inhibitor, not mTOR inhibitor
  1112. α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways
  1113. … -dimensional quantitative structure–activity relationship (3D-QSAR) analysis and molecular docking of ATP-competitive triazine analogs of human mTOR inhibitors
  1114. PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter
  1115. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy
  1116. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors
  1117. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance
  1118. Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma
  1119. EGFR-and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells
  1120. Impact of gender on clinical outcomes after mTOR-inhibitor drug-eluting stent implantation in patients with first manifestation of ischaemic heart disease
  1121. The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors.
  1122. Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability
  1123. Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition: myth or reality?
  1124. The role of mTOR inhibition in renal transplant immune suppression
  1125. mTOR kinase inhibition results in oocyte loss characterized by empty follicles in human ovarian cortical strips cultured in vitro
  1126. PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations.
  1127. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
  1128. The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
  1129. An evaluation tool for FKBP12-dependent and-independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR
  1130. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs
  1131. … of mTOR activation by an AKT-independent mechanism provides support for the combined treatment of PTEN-deficient prostate tumors with mTOR and AKT inhibitors
  1132. The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer.
  1133. Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models
  1134. Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors
  1135. Molecular imaging of therapy response with 18F-FLT and 18F-FDG following cyclophosphamide and mTOR inhibition
  1136. Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic …
  1137. mTOR kinase inhibitors as a treatment strategy in hematological malignancies
  1138. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors
  1139. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non–small-cell lung cancer
  1140. Antihormonal therapy in breast cancer and mTOR inhibitors
  1141. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment
  1142. Inhibition of mTOR by rapamycin in the amygdala or hippocampus impairs formation and reconsolidation of inhibitory avoidance memory
  1143. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors
  1144. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo
  1145. PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).
  1146. A review of research on mTOR inhibitors
  1147. Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors
  1148. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling
  1149. Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC).
  1150. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and …
  1151. A new clue to explain resistance to mTOR inhibitors
  1152. Combined mTOR inhibition and OX40 agonism enhances CD8+ T cell memory and protective immunity produced by recombinant adenovirus vaccines
  1153. Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition
  1154. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity
  1155. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
  1156. mTOR pathway and mTOR inhibitors in cancer therapy
  1157. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature
  1158. mTOR pathway inhibition in renal cell carcinoma
  1159. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor
  1160. mTOR inhibitors in sarcoma
  1161. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor
  1162. Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) …
  1163. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor–mediated PI3K feedback loop activation via ERK1/2 and …
  1164. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma
  1165. Potential therapeutic roles for inhibition of the PI3K/Akt/mTOR pathway in the pathophysiology of diabetic retinopathy
  1166. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
  1167. … cohort study of the safety, pharmacokinetics and pharmacodynamics of SAR245409 (S09), an orally administered PI3K/mTOR inhibitor, in patients with …
  1168. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway
  1169. Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition
  1170. mTOR inhibitor as a potential drug of age-related disease
  1171. The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes
  1172. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors
  1173. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis
  1174. EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
  1175. Everolimus, an mTOR inhibitor, in combination with docetaxel for second-or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.
  1176. A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R …
  1177. The mTOR inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B ALL
  1178. Impairment of object recognition memory by rapamycin inhibition of mTOR in the amygdala or hippocampus around the time of learning or reactivation
  1179. mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah …
  1180. Effects of an mTOR inhibitor RAD001 on human breast cancer stem cells in vitro and in vivo.
  1181. Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high …
  1182. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
  1183. Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?
  1184. In vivo antitumor activity of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and RAD001 (everolimus), an mTOR inhibitor, in endometrial cancer
  1185. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma
  1186. Phase I study of mTOR inhibitor everolimus plus CHOP in patients with advanced, aggressive T-cell lymphomas
  1187. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway
  1188. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
  1189. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing
  1190. Mtor inhibition and the tumor vasculature
  1191. Use of mTOR-inhibitors in solid tumors
  1192. The PI3K/mTOR inhibitor PWT33597 regresses 786-0 renal xenografts
  1193. Phase I trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies
  1194. Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors
  1195. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
  1196. mTOR Inhibition: a promise for a young heart
  1197. mTOR inhibitor therapy for patients with carcinoid
  1198. Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant …
  1199. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells
  1200. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype
  1201. Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition
  1202. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
  1203. The effect combining the KIT inhibitor Imatinib with the PI3K inhibitor BKM120 or the dual PI3K/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal …
  1204. Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?
  1205. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management
  1206. PI3K–AKT–mTOR inhibitors for the systemic treatment of endometrial cancer
  1207. Abstract P4-08-01: PI3K/mTOR inhibition overcomes in vitro and in vivo trastuzumab resistance independent of feedback activation of pAKT
  1208. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors
  1209. Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis
  1210. 3D-QSAR and docking studies of 4-morpholinopyrrolopyrimidine derivatives as potent mTOR inhibitors
  1211. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice
  1212. PD09-06: Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2− Negative Metastatic Breast Cancer …
  1213. Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone.
  1214. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors
  1215. Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibition
  1216. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy
  1217. Genetic determinants of mTOR inhibitor response in breast and endometrial cancer
  1218. Incidence and clinical features of mTOR inhibitor-induced interstitial lung disease
  1219. Combined mTOR inhibition and autophagy inhibition: phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors
  1220. Absence of mTOR inhibitor effect on hepatic cyst growth: a case report of a kidney transplant recipient with autosomal dominant polycystic kidney disease
  1221. Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity
  1222. Research progress of PI3K/Akt/mTOR signaling pathway and mTOR inhibitors in urologic malignancies
  1223. The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis
  1224. Discovery of triazine-benzimidazoles as selective inhibitors of mTOR
  1225. Use of proteomic analysis of LKB1/AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB1 loss or mTOR inhibition in NSCLC: Implications for …
  1226. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience
  1227. mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
  1228. … of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the …
  1229. Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival
  1230. Inhibition of mTOR in carcinoid tumors
  1231. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway
  1232. Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells
  1233. Targeted inhibition of mammalian target of rapamycin (mTOR) signaling pathway inhibits proliferation and induces apoptosis of laryngeal carcinoma cells in vitro
  1234. In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
  1235. Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells
  1236. mTOR inhibitors in ovarian cancer
  1237. The dual PI3K/mTOR inhibitor, PI-103, demonstrates therapeutic efficacy in undifferentiated pleomorphic sarcoma
  1238. Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus
  1239. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin …
  1240. Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA …
  1241. Evaluating the Therapeutic Potential of mTOR Inhibitors Using Mouse Genetics
  1242. mTOR inhibitors: a myth, a cure for cancer or something in between?
  1243. Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition.
  1244. A phase 1b study to evaluate the safety and pharmacology of the dual PI3K-mtor inhibitor GDC-0980 in combination with a fluoropyrimidine, oxaliplatin, and …
  1245. Identification and Optimization of Dual PI3K/mTOR Inhibitors
  1246. Effect of sequential docetaxel followed by mTOR inhibitor temsirolimus on suppression of PI3K overactivation resistance mechanism.
  1247. Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice
  1248. Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling
  1249. Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism
  1250. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62 …
  1251. mTOR inhibition in management of advanced breast cancer
  1252. Effect of PI3K-and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
  1253. Inhibition of autophagy as a strategy to augment radiosensitization by the dual PI3K/mTOR inhibitor NVP-BEZ235
  1254. Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake
  1255. mTOR targets its own inhibitor
  1256. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells
  1257. Suppression Of Lung Fibrosis By Dual MTOR Inhibitors
  1258. Abstract OT2-3-02: Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen …
  1259. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway
  1260. Preclinical assessment of the absorption and disposition of the PI3K/mTOR inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human
  1261. PI3K/AKT/mTOR signaling pathway inhibitors in proliferation of retinal pigment epithelial cells
  1262. A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with …
  1263. Inhibition of mTOR signaling by oleanolic acid contributes to its anti‐tumor activity in osteosarcoma cells
  1264. The Role of mTOR Inhibitors and P13K Pathway Blockade in RCC
  1265. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR
  1266. Azacitidine in combination with the mTOR inhibitor everolimus in relapsed and refractory AML
  1267. Oral toxicity with mTOR inhibitors in cancer therapy
  1268. Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235.
  1269. mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
  1270. The effect of mTOR inhibitors on the rabbit ovarian secretory activity
  1271. Abstract P5-19-02: Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models
  1272. Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer.
  1273. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055)
  1274. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine
  1275. Combining allografting with mTOR inhibitors for metastatic renal cell cancer
  1276. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells
  1277. What is the benfit of mTOR inhibitors (mTORi) rechallenge in metastatic renal clear cell carcinoma (mRCC) patients (pts) initially treated with TKI?
  1278. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats
  1279. Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling
  1280. LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain …
  1281. … cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent Inhibition of sirtuin 1
  1282. β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/mTOR signalling pathways
  1283. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells
  1284. 402 Reconstitution of CMV-Specific Immunity after Heart Transplantation Is Modulated by mTOR Inhibition, but Not by Antiviral Strategy
  1285. Cigarette smoke components induce matrix metalloproteinase-1 in aortic endothelial cells through inhibition of mTOR signaling
  1286. Abstract LB-7: HPV-associated HNSCC: widespread mTOR pathway activity and preclinical evaluation of mTOR inhibitors rapamycin and RAD-001
  1287. Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis
  1288. Biological Toxicity can be a Surrogate Marker of Efficacy in Patients (PTS) Treated with MTOR Inhibitors (MTORI) for MRCC
  1289. Abstract C69: Preliminary activity of temsirolimus, an mTOR inhibitor, in patients with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix …
  1290. A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR
  1291. Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy
  1292. Dehydrocostuslactone Suppresses Angiogenesis In Vitro and In Vivo through Inhibition of Akt/GSK-3β and mTOR Signaling Pathways
  1293. Efficacy of sunitinib rechallenge in kidney cancer: are mTOR inhibitors involved or is it only a matter of time?
  1294. Unique Role of mTOR Inhibitor, Everolimus in Inducible Regulatory T Cells
  1295. Subependymal giant cell astrocytoma: role of mTOR pathway and its inhibitors
  1296. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake
  1297. PDK1-driven Myc signaling regulates cellular response to mTOR inhibitors
  1298. Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2)
  1299. PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of …
  1300. Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor
  1301. Somatostatin analog and mTOR inhibitor treatment of Merkel cell tumor
  1302. Radiosensitization by the dual PI3K/mTOR inhibitor NVP-BEZ235
  1303. Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinoma
  1304. Sorafenib (Sor) and mTOR inhibitors (mTORinh) combination for hepatocarcinoma recurrence after liver transplantation.
  1305. Radiosensitization by the dual PI3K/mTOR inhibitor NVP-BEZ235
  1306. mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations
  1307. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent nonresectable chondrosarcomas.
  1308. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma
  1309. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and …
  1310. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
  1311. Effect of NVP-BEZ235, a dual PI3K/mTOR inhibitor, on chemotherapy and antiangiogenic response in pancreatic cancer.
  1312. … with HR+/HER2–locally advanced or metastatic breast cancer, treated with aromatase inhibitor, and progressed on or after mTOR inhibitor-based treatment–BELLE-3
  1313. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia
  1314. The dual PI3K/mTOR inhibitor NVP-BEZ235 has a potent antiproliferative action in human nonfunctioning pituitary adenomas
  1315. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex
  1316. mTOR inhibitors in cancer treatment
  1317. Fisetin, a dietary flavonoid and novel mTOR inhibitor for treatment and prevention of prostate cancer
  1318. AKT/mTOR as novel targets of polyphenol piceatannol possibly contributing to inhibition of proliferation of cultured prostate cancer cells
  1319. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development
  1320. Combination strategy of gemcitabine with the dual PI3K/mTOR inhibitor NVP-BEZ235 in pancreatic cancer cells.
  1321. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40
  1322. A phase I trial of the mTOR inhibitor temsirolimus (TEM) in combination with capecitabine (CAP) in patients with advanced malignancies.
  1323. Overview and mechanism of action of mTOR inhibitors
  1324. Inhibition of autophagy in combination with ponatinib or dual PI3K/mTOR inhibition to improve treatment response for both Bcr-Abl dependent and …
  1325. Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered …
  1326. Dual inhibition of PI3K/Akt/mTOR pathway and role of autophagy in non-small cell lung cancer cells
  1327. Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1, 4‐phenylenebis (methylene) selenocyanate in human prostate cancer cells
  1328. Dual PI3K/mTOR inhibitor NVP BEZ-235 suppresses translation of hypoxia-inducible factor (HIF)-1α and increases cell death under hypoxia
  1329. sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR
  1330. The effect of dual PI3K/mTOR inhibitor NVP-BGT226 on cell cycle and survivin and STAT3 gene expression in human pancreatic cancer cell lines.
  1331. Effect of the combination of mTOR inhibitor ridaforolimus and HDAC inhibitor vorinostat on in vitro synergism in synovial sarcoma, osteosarcoma, and a range of other …
  1332. mTOR inhibitors in breast cancer
  1333. Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors.
  1334. MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells
  1335. mTOR inhibitors in Hodgkin’s and non-Hodgkin’s lymphomas
  1336. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells
  1337. … -3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or …
  1338. Pml represses tumour progression through inhibition of mTOR
  1339. Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway
  1340. Utilizing mTOR inhibition to study the role of mTOR signal transduction in angiogenesis
  1341. Anti-tumor clinical research of mTOR inhibitor
  1342. mTOR inhibitors in renal cell carcinoma
  1343. Effects of an mTOR inhibitor on immune subpopulations
  1344. Bronchial carcinoid response to mTOR inhibitors depends on mTOR expression levels
  1345. DEPTOR is a regulator of response to mTOR kinase inhibitors in multiple myeloma
  1346. New developments in the therapy for NETs: new drugs including mTOR inhibitors
  1347. MTOR Inhibitors and Beyond: Targeting a Critical Pathway
  1348. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non‐small‐cell lung cancer cells
  1349. Abstract A52: Comparison of the efficacy of different mTOR inhibitors for the treatment of prostate cancer
  1350. Dual inhibition of PI3K/AKT and mTOR signaling in human non-small cell lung cancer cells by a dietary flavonoid fisetin
  1351. Identification and Optimization of Dual PI3K/mTOR Inhibitors
  1352. The mTOR inhibitor, RAD001, displays higher cytotoxicity in leukemias with hyperactivated PI3K/AKT/mTOR pathway
  1353. PI3K and/or MTOR Inhibitors: Current Status, Future Directions
  1354. A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways
  1355. Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
  1356. Investigation of the effects of different mTOR inhibitors on protein synthesis
  1357. mTor inhibition in RCC: proof of concept, clinical use, and future directions
  1358. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification
  1359. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors
  1360. Late Conversion Is a Risk Factor for mTOR Inhibitor Induced Proteinuria: 1616
  1361. Research Article A Decade of Experience Using mTor Inhibitors in Liver Transplantation
  1362. mTOR Drives Its Own Activation via SCFᵝᵀʳCᴾ-Dependent Degradation of the mTOR Inhibitor DEPTOR
  1363. GSK3 plays a crucial role in determining cell response to mTOR inhibitors
  1364. Inhibition of PI3K/mTOR leads to adaptive resistance in extracellular matrix attached cancer cells
  1365. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
  1366. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR
  1367. Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells
  1368. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors
  1369. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer
  1370. Enhancing anti cancer activity of PI103, a dual PI3K/mTOR inhibitor, by designing a self assembled Nanoformulation
  1371. Early switch from calcineurin inhibitors to mTOR inhibitors leads to improved renal graft function
  1372. UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma
  1373. mTOR inhibition in hormone-resistant breast cancer
  1374. mTOR inhibitors hamper cell viability in selected human medullary thyroid carcinoma primary cultures
  1375. Inhibition of Na/K-ATPase promotes myocardial tumor necrosis factor-alpha protein expression and cardiac dysfunction via calcium/mTOR signaling in endotoxemia
  1376. Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL
  1377. MTOR INHIBITORS REDUCES THE IN VITRO MINERALIZATION OF VASCULAR SMOOTH MUSCLE CELLS: PP. 33.125
  1378. Effects of mTOR inhibitors in the control of non functioning pituitary adenomas cell growth
  1379. PIK3CA Mutations Predict Response to PI3K/AKT/mTOR Inhibitors
  1380. GFR meets mTOR: value of different methods to measure and estimate GFR & (side) effects of mTOR inhibition in renal transplantation
  1381. mTOR Inhibition in Liver Transplantation: How to Dose for Effective/Safe CNI Reduction?: 1562
  1382. Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling
  1383. Genotype-dependent efficacy of a Dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas
  1384. The Effect of Mtor-Inhibition on Inflammation in Kidney Ischemia-Reperfusion Injury in Mice: 1124
  1385. Use of PTEN status to determine the functional outcome of combined MEK and mTOR inhibition.
  1386. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
  1387. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen …
  1388. Treatment of Patients with Metastatic Kidney Cancer During Haemodialysis with mTOR Inhibitors
  1389. Combined Effect of Mtor Inhibitors and FTI for the Growth Inhibition of T Cell Lymphoma-Involvement of Different Molecular Mechanisms According to the Lymphoma …
  1390. Design, Synthesis, Characterization and Pharmacological Evaluation of mTOR Inhibitors for Anticancer Activity.
  1391. Abstract B155: A phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K/mTOR inhibitor GSK2126458 (GSK458) in patients with …
  1392. Efficacy of the ATP-competitive mTOR inhibitor AZD8055 in PTEN-wild type cancer cells
  1393. Radiosensitizing Effects of mTOR Inhibitor (Temsirolimus) Under Normoxic/Hypoxic Conditions
  1394. Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors
  1395. Severe Cardiotoxicity in a Patient with Renal Cell Carcinoma Treated with MTOR Inhibitor: A case Report
  1396. Abstract PR4: Incomplete inhibition of phosphorylation of 4EBP1 is a mechanism for KRAS driven resistance to the ATP-competitive mTOR inhibitor PP242 in …
  1397. mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
  1398. The novel mTOR inhibitor RAD001 (Eeverolimus) induces antiproliferative effects in goat fetal fibroblasts
  1399. mTOR Inhibition Results in Oocyte Loss in Human Ovarian Cortex.
  1400. Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression
  1401. Understanding the mechanism of mTOR inhibition in Human Herpes Virus-8 associated malignancies
  1402. mTOR inhibitor Torin1 induces antiproliferative effects in MtT/E cell line and human pituitary tumors
  1403. Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
  1404. mTOR inhibition radiosensitizes bladder cancer tumor cells in vitro and in vivo: A novel strategy for treatment
  1405. PUK13 COST-EFFECTIVENESS ANALYSIS OF THE EARLY CONVERSION OF TACROLIMUS TO MTOR INHIBITORS IN PATIENTS WITH RENAL …
  1406. Early detection of cardiac dysfunction induced by the mTOR inhibitor temsirolimus.
  1407. Intrapatient correlation of clinical benefit from VEGF and mTOR inhibition in metastatic renal cell carcinoma.
  1408. Multimodal Imaging of a Dual PI3K/mTOR Inhibitor Demonstrates Strong Effects on Vascular Function
  1409. Identifying and Targeting Molecular Deregulations in Uterine Leiomyosarcoma: A Role for mTOR Inhibition-Based Combination Therapies
  1410. Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH …
  1411. Addition of the mTOR Inhibitor Rapamycin Deepens Response to HDAC Inhibition or Hypomethylating Therapy in Myelodysplastic Syndromes
  1412. Late Conversion from CNI to mTOR Inhibitors Rather Preserves than Improves Renal Function in Kidney Allograft Recipients: 2263
  1413. … Impairs Vascular Endothelial Recovery After Stent Placement In the Setting of Locally Eluted mTOR inhibitors via S6K Dependent Inhibition of Cell Proliferation
  1414. Prostate Cancer Stem Cells Display Lowered Activity of the mTOR Pathway and Resistance against mTOR Inhibition Caused by Elevated Hypoxic Signaling
  1415. Development of novel, potent and selective small molecular weight PI3K/mTOR inhibitors for the treatment of cancer
  1416. MEK and PI3K/mTOR Inhibition in RAS Mutant Colorectal Cancer
  1417. Loss of TSC2 function predicts optimal therapeutic response to combinations of MEK and mTOR inhibitors
  1418. Preclinical efficacy of the novel dual PI3K/mTOR inhibitor, BEZ235 compared with RAD001 in HER2+ breast tumors
  1419. mTOR inhibitor increases radiation sensitivity in a radiation-resistance cancer cells through induction of cellular senescence
  1420. Abstract P352: The Anticancer mTOR-Inhibitor Temsirolimus Produces Left Ventricular Dysfunction in Murine Hearts
  1421. The JAK1/2 Inhibitor Ruxolitinib Kills Malignant Plasma Cells and Is Synergistic with PI3K and mToR Inhibitors
  1422. … Of Mesenchymal Stromal Cell From Individual IPF Patients To MTOR Inhibitor Rapamycin And Its Correlation To Dysregulation In The PI3K/PTEN/Akt/mTOR Pathway
  1423. Radiosensitization by the mTOR inhibitor RAD001 involves the induction of autophagy in two cancer cell lines
  1424. Cell death induction end-points to identify new cancer indications with high likelihood of response to dual PI3K/mTOR inhibitors
  1425. Protein microarray analysis of aberrant signaling pathways in acute myeloid leukemia to predict the patients responsiveness to PI3K/akt/mtor inhibitors
  1426. mTOR Inhibition has Similar Effects to Treatment with Substance P in the Cornea of Pseudomonas aeruginosa-Infected BALB/c Mice
  1427. … of inhibitors specific for torc2 as strategy to overcome feedback erk activation in multiple myeloma cells when treated with second generation mtor inhibitors
  1428. Abstract P058: Necessity of mTOR Inhibition and Autophagy Induction for Maintaining Cardiac Homeostasis During Caloric Restriction
  1429. Abstract C67: Investigating PI3K/mTOR inhibition in a mouse model of colorectal cancer mutant for both Apc and Pten.
  1430. mTOR inhibition promotes autophagy that reduces chemosensitivity and is partially restored by chloroquine
  1431. Lymphoma Resulting From β-Catenin Stabilization are Sensitive to mTOR Inhibition: A Unit on Cancer and the Immune System.
  1432. mTOR inhibition hampers cell viability in selected human medullary thyroid carcinoma primary cultures
  1433. Combination of a PI3K/mTOR inhibitor and a MEK inhibitor at suboptimal dose significantly inhibits growth of lung adenocarcinoma tumors in KrasG12D-LSL mice
  1434. miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1
  1435. Enhanced therapeutic efficacy of transarterial chemoembolisation treatment in hepatocelluar carcinoma (HCC) by mTOR inhibitor RAD001: implication for a novel …
  1436. A novel flow cytometry based assay for therapeutic monitoring of mTOR-inhibitor induced immunosuppression after heart transplantation
  1437. SORAFENIB PLUS MTOR-INHIBITOR COMBINATION THERAPY FOR TREATMENT OF RECURRENT HEPATOCELLULAR CARCINOMA AFTER LIVER …
  1438. Grapefruit Juice Increases Bioavailability of mTOR Inhibitor; Turning a Problem with Oral Therapies into an Advantage
  1439. mTOR inhibition blocks tumor growth and pleural fluid accumulation in experimental murine mesothelioma
  1440. Role of Rapamycin as mTOR inhibitor in vitro and its use in the treatment of recurrent hepatitis C after liver transplantation
  1441. mTOR-Inhibitors and CMV Infection after Solid Organ Transplantation-Is CMV Prophylaxis Still Necessary?: 2146
  1442. mTOR Inhibitors Reduce Cerebral Vasospasm in a Subarachnoid Double‐Hemorrhage Canine Model
  1443. P073. Dermatological follow-up of patients with non melanoma skin cancer after solid organ transplantation switched to an mTOR inhibitor
  1444. The Significance of mTOR Inhibitor, Everolimus in TGF-β-Induced Regulatory T cells from Cord Blood
  1445. Germline single nucleotide polymorphisms influence survival status in patients with stage IV renal cell carcinoma receiving VEGF or mTOR inhibitor therapy
  1446. Anti-Proliferative Actions of the mTOR Inhibitor Temsirolimus in Primary Human Retinal Pigmentepithelium (RPE) and Vascular Endothelial Cells
  1447. Diffusion-weighted Magnetic Resonance Imaging of Response to PI3-Kinase/mTOR Inhibition Studied in Human Ovarian Cancer Xenografts
  1448. Cucurbitacin B as a direct mTOR inhibitor synergizes with methotrexate for treatment of human osteosarcoma
  1449. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer
  1450. Abstract B58: The ATP-competitive mammalian target of rapamycin (mTOR) inhibitors suppress proliferation and induce apoptosis in the acquired rapamycin resistant …
  1451. NVP-BEZ235, a dual PI3K/mTOR inhibitor, may be effective for ovarian clear cell carcinoma cells
  1452. Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors.
  1453. Effects of two classes of immunosuppressive agents, mTOR inhibitors vs. calcineurin inhibitors, on the generation and function of human alloreactive T helper cells …
  1454. Adverse events associated with mTOR inhibition: Results from the A2310 study comparing everolimus and mmf in de novo heart transplant recipients
  1455. Investigation of the role of chondroitin sulfate proteoglycan in causing treatment resistance in melanoma to PI3k/mTOR inhibition.
  1456. Predictive Value of Time to Best Response for Efficacy MTOR Inhibitors (MTORI) in Metastatic Renal Cell Carcinoma (MRCC) Patients (PTS)
  1457. mTOR inhibition as a therapeutic strategy in tuberous sclerosis or sporadic lymphangioleiomyomatosis
  1458. Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure–activity relationships of a series of quinoline and …
  1459. Baicalein induces tumor suppression in triple negative breast cancer by mTOR inhibition mediated through DDIT4 expression
  1460. Targeting PI3K/mTOR inhibitor induced survival programs abrogates resistance to cell death in ECM-attached cancer cells
  1461. Effect of PIK3CA and KRAS mutations on sensitivity to ATP-competitive mTOR inhibitors in a primary xenograft model of colorectal carcinoma.
  1462. Combination treatment with hypoxia-activated prodrug TH-302 and the mTOR inhibitor everolimus results in enhanced antitumor efficacy in preclinical models
  1463. mTOR-Inhibitor-Attributed Events: Review of 2-Year Safety Data in Heart Transplant Recipients Receiving Everolimus Vs MMF in the Randomised Multi-Centre 2310 …
  1464. Abstract MS1-3: Clinical Development of mTOR Inhibitors in Breast Cancer
  1465. Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation
  1466. Abstract LB-124: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s …
  1467. Phase I Trial of the mTor Inhibitor Rapamycin in Combination with Short-course Radiotherapy in Operable Rectal Cancer
  1468. Effect of the Combined Administration of mTOR Inhibitor and Dopamine or Somatostatin Analogues in a Human Bronchial Neuroendocrine Cell Line.
  1469. The ATP-competitive mTOR inhibitor Torin2 enhances sensitivity of the ALK F1174L mutation to crizotinib in neuroblastoma
  1470. … Ribosome Entry Site-Medaited Expression of VEGF Rescues HS Sultan Tumor Cells From Mammalian Target of Rapamycin (mTOR)-Inhibitors Induced Apoptosis in …
  1471. Targeted PI3K/mTOR inhibition impairs tumor cell motility and bone metastatic outgrowth via modulation of p27
  1472. NVP-BEZ235, a dual PI3K/mTOR inhibitor, suppress tumorigenicity of ovarian clear cell carcinoma cells.
  1473. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.
  1474. An endogenous mTOR inhibitor, PRAS40, is upregulated in lung cancer and contributes to tumor cell invasion and chemoresistance
  1475. Interim results of a phase II study of the mTOR inhibitor everolimus in patients with pretreated metastatic gastric and esophageal adenocarcinoma.
  1476. Brief Report: A Phase II” Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an …
  1477. Risk of rash and stomatitis with everolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.
  1478. A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer
  1479. ImmunoPET Imaging of VEGF Response To mTOR Inhibition With 64Cu-Radiolabeled Bevacizumab
  1480. The mTOR-‐inhibitor Rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response
  1481. mTOR Inhibition and Hepatic Artery Thrombosis inde NovoLiver Transplant Recipients-Mitigation Strategy with Everolimus: 12 Month Results from Study H2304: 1563
  1482. Effects of two classes of immunosuppressive agents, mTOR inhibitors vs. calcineurin inhibitors, on the generation and function of human alloreactive T helper …
  1483. Observation of Morphology and Proliferative Density for Cashmere Goat Fetal Fibroblasts after mTOR Inhibition with Optical Microscope Cell Imaging
  1484. Metastasis after mTOR inhibition by RAD001 in a neuroendocrine rat tumor model: Combination therapy with 177Lu-DOTA, Tyr3-octreotate
  1485. … toxicity study of the immunosuppressant mTOR inhibitors everolimus and sirolimus in combination with the calcineurin inhibitors cyclosporine and tacrolimus
  1486. … Cyclosporine A with Experimental Ischemia-Reperfusion Injury on Pro-Fibrotic Epithelial-Mesenchymal Transition Is not Reversible by Switching to the mTOR Inhibitor …
  1487. Chronic inhibition of mTOR by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice
  1488. Treatment with the PI3K/mTOR Inhibitor, NVP-BEZ235, Overcomes Resistance to Imatinib in Quiescent or T315I-Mutated Ph+ Leukemia Cells
  1489. Risk of rash and stomatitis with temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.
  1490. Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor …
  1491. The proteasome inhibitor MG-132 induces AIF nuclear translocation through down-regulation of ERK and Akt/mTOR pathway
  1492. … Combinations of a Selective MEK 1/2 Inhibitor (Pimasertib) With PI3K/MTOR Inhibitors or With Multi-Targeted Kinase Inhibitors in Pimasertib-Resistant …
  1493. Mammalian Target of Rapamycin (mTOR) Inhibition Attenuates Angiotensin II-Induced Hypertension and Endothelial Dysfunction
  1494. Inhibitors of Mtor and PI3K Synergistically Block Plasmacytoma Cell Growth
  1495. … a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR …
  1496. Six-Year Survival after Orthotopic Liver Transplantation (OLTtx) UsingDe NovoCombination Treatment of Mtor Inhibitor Everolimus (ERL) with Mycophanolate Sodium …
  1497. Abstract P6-10-05: SU2C Phase 1b Trial of Dual PI3K/mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC)
  1498. Combination of antiangiogenic therapy using the mTOR inhibitor RAD001 (everolimus) and low-dose chemotherapy for locally advanced and/or metastatic pancreatic …
  1499. mTOR inhibition in macrophages of asymptomatic HIV+ persons reverses the decrease in TLR4-mediated TNFα release through prolongation of MAPK …
  1500. Combining whole transcriptome expression with SILAC to investigate mTOR inhibition in cultured baboon fetal proximal tubule cells
  1501. Preclinical studies of the PI3K/mTOR dual inhibitors in endometrial cancer cell lines
  1502. … Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor
  1503. Abstract PR-11: Pharmacogenomics of mTOR inhibitors: A genome-wide association approach of biomarker identification.
  1504. WITHDRAWN: Mammalian target of rapamycin (mTOR) inhibition in polycystic kidney disease (PKD): From bench to bedside
  1505. Activity of a novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 to enhance antitumor activities of gemcitabine and EMAP II in pancreatic cancer.
  1506. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases
  1507. Gemcitabine combined with the MTOR Inhibitor Temsirolimus (CCI-779) in Patients with Inoperable or Metastatic Pancreatic Cancer (He 3/07). A Phase I …
  1508. Abstract LB-201: Prostate cancer stem cells display low mTOR activity and resistance to mTOR inhibitors in hypoxia
  1509. Functional genetic screens to find modulators of sensitivity to inhibitors of the PI3K/mTOR pathway
  1510. Drug Interaction Between Cyclosporine and Mtor Inhibitors in Experimental Model of Chronic Cyclosporine Nephrotoxicity and Pancreatic Islet Dysfunction: 1857
  1511. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian …
  1512. DEPTOR, an mTOR inhibitor, is a novel substrate of SCFαTrCP E3 ubiquitin ligase upon S6K1/RSK1 phosphorylation and regulates survival and autophagy
  1513. … from hR1, a humanized anti-insulin-like growth factor receptor-I monoclonal antibody, are enhanced in renal cell carcinoma and synergistic with an mTOR inhibitor
  1514. Activity of insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic refractory …
  1515. Synergistic Control of Acute GvHD: Effectively Down-Regulating T Cell Proliferation and Cytotoxicity with Combined mTOR Inhibition and CD28: CD80/86 …
  1516. Abstract P4-08-02: Reactivation of oncogenic signaling through mTOR inhibitors-induced feedback adaptations.
  1517. Discovery of GDC-0980, a selective PI3K/mTOR inhibitor in clinical trials
  1518. 145 Novel Immunoassay for Therapeutic Drug Monitoring of mTOR-Inhibitors after Heart and Lung Transplantation
  1519. The mTor inhibitor rapamycin delays xenogeneic acute graft versus host disease (aGVHD) in NOD/SCID/IL2rgnull mice (NSG): impact of regulatory T cells
  1520. Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells
  1521. Sensitivity of gastric cancer cell lines against 2-deoxy-D-glucose is independent of PI3K/mTOR inhibition
  1522. 321 HDAC BLOCKADE COUNTERACTS RESISTANCE DEVELOPMENT CAUSED BY CHRONIC MTOR INHIBITION
  1523. 416 IMPACT OF COMBINED HDAC AND MTOR INHIBITION ON THE INVASIVE POTENTIAL OF PROSTATE CANCER CELLS
  1524. 935 iMPaCt of CoMbined hdaC and Mtor inhibition on the invasive Potential of Prostate CanCer Cells
  1525. Abstract A57: Chondroitin sulfate proteoglycan 4 (CSPG4) Mediates Melanoma Cell Survival During PI3K and mTOR Inhibition
  1526. The mTOR kinase inhibitor, CC214, preferentially blocks the growth of EGFRvIII-activated glioblastomas
  1527. Abstract LB-226: mTOR inhibition by Temsirolimus as second-line treatment for advanced RCC: The Medical optimization of Torisel® (MoTOR) phase II trial by the …
  1528. Treatment effects of the novel mTOR kinase inhibitor AZD8055 in prostate cancer cell models
  1529. Inhibition of mTOR and AKT as a potential strategy for the treatment of basal-like breast cancer
  1530. Abstract B161: PIK3CA mutations H1047R are associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
  1531. Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma
  1532. Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR
  1533. Inhibition of Mammalian Target of Rapamycin (mTOR) Complex 1 and 2 by PP242 Induces G1 Growth Arrest in Pancreatic Ductal Adenocarcinoma and when …
  1534. Abstract P6-11-08: A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative …
  1535. Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors
  1536. Structure–activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6, 5-heterocycles …
  1537. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR
  1538. NVP-BEZ235, a dual inhibitor of phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), is a potent inhibitor of lymphoma cell growth and …
  1539. Inhibition of mTOR promotes dendritic cell activation and survival and enhances therapeutic autologous vaccination in mice (52.4)
  1540. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
  1541. Coordinate autophagy and PI3K/Akt/mTOR pathway inhibition enhances cell death in melanoma
  1542. Therapeutic update in tuberous sclerosis complex: the role of mTOR pathway inhibitors
  1543. Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on …
  1544. Auristatin-based antibody-drug conjugates are synergistic in combination with PI3K-AKT-mTOR pathway inhibitors in hematologic malignancies and carcinoma
  1545. Inhibition of mTOR with everolimus (RAD001) and silencing by vascular endothelial cell growth factor specific siRNA induces additive antitumor activity in …
  1546. Inhibition of Notch and mTOR by nelfinavir as a novel approach for T cell acute lymphoblastic leukemia (T-ALL)
  1547. Combined inhibition of JAK2 and mTOR signaling results in enhanced efficacy in in-vitro and preclinical mouse models of JAK2V617F-driven …
  1548. Docosahexaenoic acid-induced cell death may be related to inhibition of mTOR through AMPK activation and PI3K/Akt inhibition in human non-small cell lung cancer …
  1549. Targeting mTOR by a New Generation of Kinase Inhibitors Sensitizes Leukemia Cells for Chemotherapy Via Suppressing FANCD2 Expression
  1550. Study of mTOR signaling inhibitors as potential treatment for TSC
  1551. … negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial …
  1552. Sirolimus plus MEC chemotherapy has significant activity in high risk AML patients especially those who exhibit in vivo inhibition of the mTOR pathway
  1553. The director’s cut: a genome-wide characterization of active translation of messenger RNA following inhibition of mTOR will transform our view of this signalling …
  1554. RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR
  1555. Inhibitors of phosphatidylinositol 3-kinase and mTOR but not Akt enhance replication of bovine ephemeral fever virus
  1556. … to the BRAF inhibitor GSK2118436, mediated by NRAS or MEK mutation, can be overcome with combinations that inhibit BRAF and MEK, BRAF and PI3K/mTOR, or …
  1557. Correction: inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer’s disease
  1558. Pulsatilla saponin D suppresses angiogenesis and induces apoptosis via inhibition of PI3K/Akt/mTOR signaling pathway in hepatocellular carcinoma
  1559. Growth-Inhibitory Effects of a Class I PI3K Inhibitor GDC-0941 Are Modulated by Hypoxia-Induced mTOR Pathway Activation in Mantle Cell Lymphoma
  1560. … , induces apoptosis, and enhances the antitumor activity of everolimus (RAD001), an inhibitor of mammalian target of rapamycin (mTOR), in mantle cell …
  1561. Mammalian target of rapamycin (mTOR) sigaling pathway involved in the inhibition of silence information regulator1 (Sirt1) on fat deposition of mice.
  1562. Abstract LB-383: Translational studies of the novel prodrug PI3K/mTOR/PIM1 inhibitor SF1126 in DLBCL
  1563. Inhibition of Histone Deacetylases (HDACs) and mTOR Signaling: Novel Strategies Towards the Treatment of Prostate Cancer
  1564. Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer
  1565. Efficacy of INK128, an mTORC1/mTORC2 kinase inhibitor, in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway.
  1566. Tangeretin and its metabolite 4′‐hydroxytetramethoxyflavone attenuate EGF‐stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR …
  1567. Preclinical efficacy of AZD8055, an ATP-competitive mammalian target of rapamycin (mTOR) kinase inhibitor, in vitro in clear cell renal cell carcinoma (RCC)
  1568. Nuclear factor of activated T-cells (NFAT) c3 inhibition of mTOR signaling through induction of REDD1 in human intestinal cells
  1569. Discovery and SAR exploration of a novel series of imidazo [4, 5-b] pyrazin-2-ones as potent and selective mTOR kinase inhibitors
  1570. Erratum to: Inhibition of mTOR in carcinoid tumors
  1571. Design and synthesis of small-molecule inhibitors of two cancer targets: mTor and MDM2/p53
  1572. Abstract B160: PWT33597 promotes apoptosis in tumor cells through balanced dual inhibition of PI3K alpha and mTOR.
  1573. Abstract P6-04-11: Combination of PI3K-AKT-mTOR and MEK-ERK pathway inhibitors overcome acquired resistance to letrozole in ER+ breast cancer models
  1574. Untersuchung der Proliferationshemmung von Brustkrebszellen durch Chloroquin in Kombination mit dem mTOR-Inhibitor Everolimus (RAD001)
  1575. Abstract CN02-02: Dual inhibition of mTOR and IGFR pathways.
  1576. Gezielte molekulare Therapie des Mantelzell-Lymphoms In vitro Wirksamkeit von mTOR-Inhibitor RAD001 und PNP-Inhibitor Forodesin+ dGUO in Mono-und …
  1577. Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor
  1578. mTOR pathway links suppressed autophagy to HDAC inhibitor-induced apoptosis in myeloid leukemia
  1579. Differential effects of mTOR and PI3K inhibition on the phosphorylation of polysome-associated proteins
  1580. The identification of the mTOR-regulated phosphoproteome and a mediator of feedback inhibition to P13K-Akt
  1581. MicroRNA-101 (miR-101) enhances chemosensitivity of pancreatic ductal adenocarcinoma (PDAC) cells by inhibition of MTOR signaling via PRAS40
  1582. Abstract B25: The Effects of PI3K/Akt/mTOR Pathway Inhibitors on a Panel of Non Small Cell Lung Cancer (NSCLC) Cell Lines
  1583. Competitive inhibition of mTOR results in tumor specific radiosensitization
  1584. In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL).
  1585. Abstract A165: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
  1586. Inhibition of Mammalian Target of Rapamycin (mTOR) in Epidermis
  1587. HTLV-1 HBZ activates mTOR signaling pathway via inhibition of GADD34
  1588. Prostate Cancer Radiation Enhancement Through mTOR Pathway Inhibition: The Role of Tumor and Vascular Compartments
  1589. Discovery and optimization of potent and selective benzonaphthyridinone analogs as dual mTOR/ATR small molecular inhibitors for treatment of cancer
  1590. Targeting of endocrine therapy resistance through combined mTOR and histone deacetylase inhibition.
  1591. Abstract PR6: A cooperative molecular response to combined mTOR/HDAC inhibition revealed by transcriptional co-expression analysis
  1592. Tumor regression in a 3-D melanoma model by the dietary flavonoid fisetin is associated with inhibition of Akt/mTOR signaling
  1593. Erprobung einer Kombinationstherapie aus dem Histondeacetylaseinhibitor Valproat und dem mTOR-Inhibitor Temsirolimus für das fortgeschrittene …
  1594. Target-Therapie mit dem mTOR-Inhibitor Temsirolimus (Torisel®)
  1595. Inhibition of the PI3K and mTOR pathways reverses gemcitabine resistance in pancreatic cancer
  1596. Curcumin Potentiates Antitumor Activity of Imatinib via Inhibition of the AKT/mTOR Signaling Pathway and Down-Regulation of Bcr-Abl Gene in Philadelphia …
  1597. Activation of AMP-activated protein kinase (AMPK) enhances Radiosensitization via inhibition of mTOR pathway in Rapamycin-resistant non-small cell lung cancer …
  1598. PIM kinase inhibition blocks activation of mTOR pathway components and enhances rapamycin-mediated tumor growth inhibition in prostate cancers
  1599. Targeting PI3K/mTOR/MAPK pathway in inhibition of cell growth and dissemination of glioblastoma multiforme
  1600. Untersuchung der Proliferationshemmung von Brustkrebszellen durch das Bioflavonoid Quercetin in Kombination mit dem mTOR-Inhibitor Everolimus (RAD001 …
  1601. Ciclopirox induces autophagy through reactive oxygen species-mediated inhibition of mTOR signaling pathway
  1602. Enhancement of Autophagy by Simvastatin through Inhibition of Rac1‐mTOR Signaling Pathway
  1603. Dual Inhibition of mTOR in hepatocellular carcinoma induces tumor regression, return to normal liver gene expression and autophagy
  1604. Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high grade chondrosarcoma
  1605. Nebivolol‐mediated Inhibition of Nutrient Sensor mTOR‐and Inflammatory Marker JAK2‐mediated Signaling in Myocardium: Involvement of Angiotensin II Receptors
  1606. Interrelations between roles of phospholipase C-gamma 1 inhibition, mTOR and glycolytic enzymes in growth and survival of glioblastoma cells
  1607. Inhibition thérapeutique de mTOR dans la polykystose rénale autosomique dominante
  1608. Ex vivo analysis of the mTOR/PI3K & MEK/ERK inhibitors, BEZ235 & AZD6244, alone and in combination in human tumor primary culture micro-spheroids: Exploration …
  1609. … inhibitor, Olaparib with pathway-targeted drug, vandetanib (Caprelsa™) in TNBC: A proof of principle study to determine the role of PI3K-AKT-mTOR or RAS-MAPK …
  1610. The CK2 inhibitor CX-4945 enhances the antitumor activity of EGFR-targeted agents by attenuating signaling in the PI3K/AKT/mTOR pathway
  1611. Abstract LB-20: mTOR kinase inhibition relieves feedback suppression of receptor tyrosine kinase leading to a biphasic regulation of AKT signaling in breast cancer …
  1612. Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors
  1613. P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) as a new therapeutic …
  1614. HM-032, a novel PI3K/mTOR dual inhibitor, is active on K-Ras/Raf mutation tumors through up-regulation of Bim
  1615. Preclinical activity of INK128, a TORC1/2 inhibitor, in triple negative breast cancer: A combination of PARP inhibitor with PI3K-mTOR pathway-targeted inhibitor
  1616. … trägt zur Entstehung der Insulin-induzierten Hepatokarzinogenese bei und lässt sich effektiv durch Gabe des dualen PI3K/mTOR Inhibitors NVP-BEZ235 zurückführen
  1617. Abstract B163: First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on …
  1618. Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancer
  1619. P7170: A potent and oral phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) inhibitor with anti-tumor …
  1620. Etp-47187 a novel potent and efficacious dual inhibitor of phosphoinositide-3-kinases and mTOR
  1621. P3-18-03: In Vitro Potency of mTOR Kinase (TOR1/TOR2) Inhibitor, INK128 in ER+ and HER2 Overexpressing Breast Cancer Cells.
  1622. Steigerung der Apoptoserate durch kombinierte PI3K/mTOR-und Proteasom-Inhibition bei kolorektalen Karzinomzelllinien
  1623. Abstract P6-11-02: Inhibition of mTOR and Fatty Acid Synthase (FASN) overcome acquired resistance to Trastuzumab, Lapatinib and both in HER2+ breast cancer
  1624. Intratumoral delivery of rapamycin: advantages on mTOR pathway inhibition through direct delivery of intratumoral rapamycin in squamous cell carcinomas (초)
  1625. Strategies for the management of adverse events associated with mTOR inhibitors
  1626. Adverse events associated with mTOR inhibitors
  1627. Rapalogs and mTOR inhibitors as anti-aging therapeutics
  1628. mTOR inhibition improves immune function in the elderly
  1629. Differentiating mTOR inhibitors in renal cell carcinoma
  1630. mTOR inhibitors in the treatment of breast cancer
  1631. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques
  1632. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients
  1633. The role of mTOR inhibitors in liver transplantation: reviewing the evidence
  1634. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials
  1635. The pros and the cons of mTOR inhibitors in kidney transplantation
  1636. Metabolic complications with the use of mTOR inhibitors for cancer therapy
  1637. Clinical development of mTOR inhibitors in breast cancer
  1638. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome
  1639. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review
  1640. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy
  1641. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
  1642. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors
  1643. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms
  1644. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis
  1645. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
  1646. mTOR inhibitors as a new therapeutic option for epilepsy
  1647. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
  1648. mTOR inhibition: from aging to autism and beyond
  1649. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation
  1650. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
  1651. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
  1652. Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition
  1653. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
  1654. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
  1655. Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo
  1656. mTOR inhibitors in pediatric kidney transplantation
  1657. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts
  1658. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath …
  1659. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment
  1660. FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
  1661. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
  1662. Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure–response relationships, and clinical outcomes
  1663. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates
  1664. mTOR signaling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target
  1665. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
  1666. TBK1 regulates prostate cancer dormancy through mTOR inhibition
  1667. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy
  1668. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor
  1669. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway
  1670. mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats
  1671. Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition
  1672. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
  1673. mTOR inhibition increases cell viability via autophagy induction during endoplasmic reticulum stress–An experimental and modeling study
  1674. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells
  1675. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma
  1676. From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches
  1677. Prolonged autophagy by MTOR inhibitor leads radioresistant cancer cells into senescence
  1678. Effects of the mTOR inhibitor rapamycin on monocyte-secreted chemokines
  1679. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced …
  1680. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis
  1681. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
  1682. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response
  1683. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic …
  1684. … anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in …
  1685. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy
  1686. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse
  1687. Non‐melanoma skin cancer is reduced after switch of immunosuppression to mTOR‐inhibitors in organ transplant recipients
  1688. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
  1689. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition
  1690. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells
  1691. PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
  1692. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP‐BEZ235 in renal cell carcinoma cells
  1693. Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
  1694. mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA
  1695. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt …
  1696. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
  1697. Novel PI3K and mTOR inhibitor NVP-BEZ235 radiosensitizes breast cancer cell lines under normoxic and hypoxic conditions
  1698. Predicting mTOR inhibitors with a classifier using recursive partitioning and naive Bayesian approaches
  1699. mTOR inhibitors and renal allograft: Yin and Yang
  1700. The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy
  1701. mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis
  1702. Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349
  1703. Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition
  1704. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus
  1705. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer
  1706. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro
  1707. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant …
  1708. Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia
  1709. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3‐kinase inhibitor BEZ235 and the PI3‐kinase inhibitor BKM120 in hepatocellular carcinoma
  1710. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids
  1711. Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions
  1712. mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer
  1713. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical …
  1714. Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors
  1715. Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative …
  1716. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses
  1717. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
  1718. mTOR inhibitors in advanced breast cancer: ready for prime time?
  1719. The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
  1720. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck …
  1721. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells
  1722. The dual PI3K/mTOR inhibitor NVP‐BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial‐lysosomal cross‐talk
  1723. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
  1724. Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer
  1725. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven
  1726. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP‐BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal …
  1727. Inhibition of adipogenesis by oligonol through Akt-mTOR inhibition in 3T3-L1 adipocytes
  1728. Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
  1729. Role of mTOR inhibitor in cholangiocarcinoma cell progression
  1730. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate
  1731. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors
  1732. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer
  1733. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid
  1734. Radiosensitization of glioblastoma cell lines by the dual PI3K and mTOR inhibitor NVP-BEZ235 depends on drug-irradiation schedule
  1735. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment
  1736. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms
  1737. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant …
  1738. Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy
  1739. Optimising the use of mTOR inhibitors in renal transplantation
  1740. mTOR Inhibition ameliorates cognitive and affective deficits caused by Disc1 knockdown in adult-born dentate granule neurons
  1741. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition
  1742. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions
  1743. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer
  1744. Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition
  1745. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and …
  1746. mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
  1747. Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
  1748. mTOR Inhibitors induce cell-cycle arrest and inhibit tumor growth in epstein–barr virus–associated T and natural killer cell lymphoma cells
  1749. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
  1750. The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial–mesenchymal transition induced by hypoxia and TGF-β1
  1751. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1
  1752. Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: results from a large phase III clinical trial program of everolimus …
  1753. The effect of mTOR-inhibition on NF-κB activity in kidney ischemia-reperfusion injury in mice
  1754. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma
  1755. PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats
  1756. mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma
  1757. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition
  1758. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 …
  1759. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen
  1760. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423
  1761. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma
  1762. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines
  1763. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer
  1764. MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1
  1765. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF
  1766. mTOR kinase inhibitors as potential cancer therapeutic drugs
  1767. PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition
  1768. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
  1769. An in silico protocol for identifying mTOR inhibitors from natural products
  1770. Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression
  1771. The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line
  1772. The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis
  1773. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection
  1774. Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer
  1775. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis
  1776. … inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of …
  1777. Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo
  1778. Mammalian target of rapamycin (mTOR) inhibitor‐associated non‐infectious pneumonitis in patients with renal cell cancer: Predictors, management, and outcomes
  1779. The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells
  1780. Foxp3+ T Cells Inhibit Antitumor Immune Memory Modulated by mTOR Inhibition
  1781. Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models
  1782. mTOR inhibitors radiosensitize PTEN‐deficient non‐small‐cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy
  1783. HSP90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer
  1784. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis
  1785. Tetracyclines cause cell stress-dependent ATF4 activation and mTOR inhibition
  1786. Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation
  1787. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy …
  1788. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis
  1789. mTOR inhibition of cardamonin on antiproliferation of A549 cells is involved in a FKBP12 independent fashion
  1790. Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib …
  1791. mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels
  1792. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition
  1793. The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling
  1794. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer
  1795. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications
  1796. Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling
  1797. Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models
  1798. Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis
  1799. Dual PI3K/mTOR inhibitors: does p53 modulate response?
  1800. Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer
  1801. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy
  1802. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice
  1803. The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer
  1804. Effects of mTOR inhibition on normal retinal vascular development in the mouse
  1805. Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment
  1806. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells
  1807. mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death
  1808. Temsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF …
  1809. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
  1810. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis
  1811. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis
  1812. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice
  1813. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors
  1814. mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells
  1815. Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor
  1816. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain …
  1817. mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers
  1818. Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene
  1819. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors
  1820. Adaptation to chronic mTOR inhibition in cancer and in aging
  1821. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors
  1822. Objective monitoring of mTOR inhibitor therapy by three-dimensional facial analysis
  1823. Long‐term mTOR inhibitors administration evokes altered calcium homeostasis and platelet dysfunction in kidney transplant patients
  1824. Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells
  1825. Inhibition of mTOR affects protein stability of OGT
  1826. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype
  1827. Antitumor efficacy of the dual PI3K/mTOR inhibitor PF-04691502 in a human xenograft tumor model derived from colorectal cancer stem cells harboring a …
  1828. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
  1829. Enhanced antitumor activity with combining effect of mTOR inhibition and microtubule stabilization in hepatocellular carcinoma
  1830. Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: in vitro and in vivo
  1831. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas
  1832. Adverse Event Management of mTOR Inhibitors during treatment of hormone receptor–positive advanced breast cancer: considerations for oncologists
  1833. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma
  1834. … expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors
  1835. Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials
  1836. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status
  1837. Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis
  1838. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South …
  1839. mTOR-inhibitors may aggravate chronic hepatitis E
  1840. Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin
  1841. BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition
  1842. Prospective, multicenter study of the Mtor inhibitor everolimus (RAD001) as primary therapy in Waldenstrom’s macroglobulinemia
  1843. Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis
  1844. Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours
  1845. Are calcineurin inhibitors safer than mTOR inhibitors?
  1846. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice
  1847. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors
  1848. Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their …
  1849. Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development
  1850. mTOR inhibitors: changing landscape of endocrine-resistant breast cancer
  1851. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of …
  1852. Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors
  1853. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant
  1854. Use of mTOR inhibitors in the treatment of malignancies
  1855. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer
  1856. Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors
  1857. The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
  1858. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
  1859. Inhibition of mTOR signaling by quercetin in cancer treatment and prevention
  1860. PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
  1861. Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope
  1862. Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics
  1863. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
  1864. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma
  1865. mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open
  1866. Safety and efficacy of BEZ235, a dual PI3-kinase/mTOR inhibitor, in adult patients with relapsed or refractory acute leukemia: results of a phase I study
  1867. Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer
  1868. Final results of a prospective multi-institutional phase II study of everolimus (RAD001), an mTOR inhibitor, in pediatric patients with recurrent or progressive low-grade …
  1869. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
  1870. 18F-FDG is a surrogate marker of therapy response and tumor recovery after drug withdrawal during treatment with a dual PI3K/mTOR inhibitor in a preclinical model …
  1871. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a …
  1872. Rapamycin and mTOR inhibitors probably have therapeutic effects for post-operative cognitive dysfunction
  1873. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma
  1874. Quantitative 31P HR‐MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
  1875. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma
  1876. Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition
  1877. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001
  1878. Recent developments of small molecule PI3K/mTOR dual inhibitors
  1879. 20‐O‐β‐d‐Glucopyranosyl‐20(S)‐Protopanaxadiol Suppresses UV‐Induced MMP‐1 Expression Through AMPK‐Mediated mTOR Inhibition as a Downstream of the …
  1880. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors
  1881. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma
  1882. Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor
  1883. Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin α5–and Integrin β3 …
  1884. Kanser tedavisinde mTOR sinyal yolagi ve mTOR inhibitörleri/mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
  1885. Chemical inhibitors and microRNAs (miRNA) targeting the mammalian target of rapamycin (mTOR) pathway: potential for novel anticancer therapeutics
  1886. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism
  1887. The mTOR inhibitor revolution rolls on
  1888. Effects of Chronic Akt/mTOR Inhibition by Rapamycin on Mechanical Overload–Induced Hypertrophy and Myosin Heavy Chain Transition in Masseter Muscle
  1889. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
  1890. Species difference in glucuronidation formation kinetics with a selective mTOR inhibitor
  1891. Exploring the selectivity of PI3Kα and mTOR inhibitors by 3D-QSAR, molecular dynamics simulations and MM/GBSA binding free energy decomposition
  1892. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients.
  1893. JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition
  1894. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia
  1895. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7, 8-dihydro-5H-thiopyrano [4, 3-d] pyrimidine derivatives as mTOR inhibitors
  1896. Influenza vaccines: mTOR inhibition surprisingly leads to protection
  1897. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR
  1898. Contrasting effects of chronic, systemic treatment with mTOR inhibitors rapamycin and metformin on adult neural progenitors in mice
  1899. Synthesis of 5-substituted-1H-pyrazolo [4, 3-d] pyrimidin-7 (6H)-one analogs and their biological evaluation as anticancer agents: mTOR inhibitors
  1900. The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype
  1901. Reversion of hormone treatment resistance with the addition of an mTOR inhibitor in endometrial stromal sarcoma
  1902. Inhibition of the mTOR pathway: a possible protective role in coronary artery disease
  1903. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells
  1904. Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials
  1905. Neferine from Nelumbo nucifera induces autophagy through the inhibition of PI3K/Akt/mTOR pathway and ROS hyper generation in A549 cells
  1906. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non–small-cell lung cancer
  1907. Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors
  1908. 3D-QSAR and docking studies of 3-Pyridine heterocyclic derivatives as potent PI3K/mTOR inhibitors
  1909. mTOR inhibitors and their role in modern concepts of immunosuppression
  1910. In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
  1911. Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma
  1912. In Silico Investigation of Potential mTOR Inhibitors from Traditional Chinese Medicine for Treatment of Leigh Syndrome
  1913. Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.
  1914. mTOR inhibitor-related pulmonary toxicity; incidence even higher
  1915. Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma
  1916. … women with HR+/HER2–locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.
  1917. Proteinuria associated with mTOR inhibitors after kidney transplant.
  1918. mTOR inhibition in liver transplantation: how to dose for effective/safe CNI reduction?
  1919. mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes
  1920. EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry
  1921. Inhibition of Akt/mTOR attenuates age-related changes in mesenchymal stem cells
  1922. Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation
  1923. Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
  1924. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition
  1925. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells
  1926. Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma
  1927. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer
  1928. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
  1929. Antibody-based depletion of Foxp3+ T cells potentiates antitumor immune memory stimulated by mTOR inhibition
  1930. Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors
  1931. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma
  1932. Preclinical evaluation of the mTOR–PI3K inhibitor BEZ235 in nasopharyngeal cancer models
  1933. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness
  1934. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
  1935. Virtual screening and biochemical evaluation to identify new inhibitors of mammalian target of rapamycin (mTOR)
  1936. … , a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway
  1937. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)
  1938. Painful crural ulcerations and proteinuria as complications after several years of therapy with mTOR inhibitors in the renal allograft recipient: a case report
  1939. Requirement for the eIF4E binding proteins for the synergistic down-regulation of protein synthesis by hypertonic conditions and mTOR inhibition
  1940. The second-generation mTOR kinase inhibitor INK128 exhibits anti-inflammatory activity in lipopolysaccharide-activated RAW 264.7 cells
  1941. Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death
  1942. Inhibitory effect of the CDK4/6 inhibitor, PD 0332991, is enhanced by mTOR inhibition in Non-Small Cell Lung Cancer (NSCLC).
  1943. Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)
  1944. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin
  1945. mTOR inhibitors as primary immunosuppression after heart transplant: confounding factors in clinical trials
  1946. “TRIMing” the patient population to increase the benefit of mTOR inhibition
  1947. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas
  1948. Improvement of quality of life in patients with steroid‐refractory chronic graft‐versus‐host disease treated with the mTOR inhibitor everolimus
  1949. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
  1950. … -independent apoptosis and cell cycle arrest in hematological malignancies and leukemic stem/progenitor cells by inducing ER stress and mTOR inhibition
  1951. Hormone therapy plus mTOR inhibitors in the treatment of endometrial carcinoma
  1952. Kidney transplant recipients receiving mTOR inhibitors experienced twice as many thrombotic events: a single cohort observational study
  1953. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602
  1954. Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle
  1955. Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma‐induced malignant pleural effusion
  1956. Dual Inhibition of PI3K-AKT-mTOR-and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors
  1957. Phase 1b study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with carboplatin (carbo)/paclitaxel (pac)±bevacizumab (bev) and cisplatin (cis) …
  1958. Final results of phase I/II trial of the oral mTOR inhibitor everolimus (RAD001) in combination with bortezomib and rituximab (RVR) in relapsed or refractory …
  1959. Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition
  1960. Amino-functionalized nanoparticles as inhibitors of mTOR and inducers of cell cycle arrest in leukemia cells
  1961. Treatment of muscle invasive urinary bladders tumors: a potential role of the mTOR inhibitors
  1962. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells
  1963. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma
  1964. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
  1965. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
  1966. CNIs to mTOR inhibitors—effects on allosensitization?
  1967. Subependymal giant cell astrocytoma associated with tuberous sclerosis complex-pharmacological treatment using mTOR inhibitors
  1968. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
  1969. Inhibition of PI3K/Akt/mTOR signaling by natural products
  1970. Initial evaluation of novel dual PIM/PI3K and triple PIM/PI3K/mTOR inhibitors in multiple myeloma
  1971. Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes
  1972. … Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitor
  1973. Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC).
  1974. Patient-derived xenografts reveal limits to PI3K/mTOR-and MEK-mediated inhibition of bladder cancer
  1975. The mTOR inhibitors and the skin wound healing.
  1976. Evaluation of subchronic toxicity of GRD081, a dual PI3K/mTOR inhibitor, after 28-day repeated oral administration in Sprague–Dawley rats and beagle dogs
  1977. Can the risk of skin cancer after transplantation be reduced by mTOR Inhibitors?
  1978. Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer
  1979. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro
  1980. AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake
  1981. Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling
  1982. Treating mitochondrial diseases with mTOR inhibitors—a potential treatment for Leigh syndrome?
  1983. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque
  1984. Benzofuran derivatives as a novel class of inhibitors of mTOR signaling
  1985. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor …
  1986. Preserving flow in liver transplant recipients: mTOR inhibitors everolimus and sirolimus are not peas from a pod
  1987. Abstract PD1-6: a randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple …
  1988. BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition
  1989. The PI3K/AKT/MTOR signaling pathway: the role of PI3K and AKT inhibitors in breast cancer
  1990. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma
  1991. Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation
  1992. Mirk/dyrk1B kinase is upregulated following inhibition of mTOR
  1993. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance
  1994. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
  1995. Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients
  1996. Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition
  1997. ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change
  1998. Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.
  1999. Efficacy and mechanisms of the mTOR inhibitor AZD2014 combined with L-asparaginase or JAK2 inhibitor TG101348 in ALL
  2000. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies
  2001. Reversal of acquired resistance to pazopanib in soft tissue sarcoma with addition of an mTOR inhibitor: A case report.
  2002. Difference in adverse-event profiles between mTOR inhibitors, temsirolimus, and everolimus for advanced renal cell carcinoma.
  2003. Influence of the blood-brain barrier on drug distribution and efficacy of PI3K/mTOR inhibitors
  2004. mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia
  2005. GNB1 activating mutations promote myeloid and lymphoid neoplasms targetable by combined PI3K/mTOR inhibition
  2006. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis
  2007. Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy
  2008. A case of male breast cancer for which mTOR inhibitor was effective with advanced renal cancer
  2009. … cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor
  2010. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1
  2011. Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B‐cell lymphoma
  2012. Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/Akt/mTOR/HIF-1 alpha/VEGF pathway
  2013. Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs)
  2014. Abstract LB-260: Combination of Foxp3+ T cells depletion and mTOR inhibitor enhances immune memory and controls cancer growth
  2015. … ) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway–targeted therapy and one prior mTOR inhibitor …
  2016. Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma
  2017. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design
  2018. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer
  2019. Imaging parameters and molecular correlates as predictive markers of treatment response to mTOR inhibition in adults with recurrent low-grade gliomas.
  2020. A combination of dual PI3K-mTOR inhibitor, GDC-0980, with PARP inhibitor plus carboplatin blocked tumor growth of BRCA-competent triple-negative breast cancer …
  2021. Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
  2022. Identification of two novel inhibitors of mTOR signaling pathway based on high content screening
  2023. Exploration of a plucked hair gene signature as a potential pharmacodynamic marker for the dual PI3K/mTOR inhibitor VS-5584.
  2024. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
  2025. Proteasome inhibitors activate autophagy involving inhibition of PI3K-Akt-mTOR pathway as an anti-oxidation defense in human RPE cells
  2026. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor (PNET) metastatic progression
  2027. Risk of serious infection with mTOR inhibitors everolimus and temsirolimus in the treatment of cancer: A meta-analysis of randomized controlled trials.
  2028. Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature
  2029. What Does the Future Hold for PI3K/AKT/mTOR Inhibitors in Breast Cancer?
  2030. Benzofuran derivatives as anticancer inhibitors of mTOR signaling
  2031. Long Term Follow Up ofDe NovoUse of mTOR Inhibitors (mTORi) After Kidney Transplantation.: Abstract# B979
  2032. First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).
  2033. Advancements in mTOR inhibitors for the management of hormone receptor-positive breast cancer
  2034. Merckel cell carcinoma of the skin treated with somatostatin analogue and mTOR inhibitor exhausted after primary surgery, adjuvant radiotherapy and palliative …
  2035. 4′, 6-dihydroxy-4-methoxyisoaurone inhibits the HIF-1α pathway through inhibition of Akt/mTOR/p70S6K/4E-BP1 phosphorylation
  2036. A phase I/II study of mTOR inhibitor temsirolimus in patients with unresectable hepatocellular carcinoma (HCC)
  2037. Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma
  2038. Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling
  2039. Ph II study of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (PNET) after mTOR inhibitor therapy failure: stage I interim results
  2040. Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model
  2041. Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.
  2042. The Impact of Hemi-brain Irradiation on Accumulation of PI3K/mTOR Inhibitors With Limited (GDC-0980) and Robust (GNE-317) Blood–Brain Barrier Penetration
  2043. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series
  2044. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
  2045. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML
  2046. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim …
  2047. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
  2048. Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro
  2049. A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus …
  2050. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF …
  2051. Inhibition of mTOR prevents ROS production initiated by ethidium bromide-induced mitochondrial DNA depletion
  2052. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma
  2053. Abstract CT403: A Phase I study of oral administration of mTOR inhibitor everolimus (E) in association with cisplatin (C) and radiotherapy (R) for the treatment of locally …
  2054. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis
  2055. Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in …
  2056. Perivascular epithelioid cell tumors (PEComas) refractory to mTOR inhibitors
  2057. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway
  2058. New in-capillary electrophoretic kinase assays to evaluate inhibitors of the PI3k/Akt/mTOR signaling pathway
  2059. Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth
  2060. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) …
  2061. Dihydromyricetin induces autophagy in HepG2 cells involved in inhibition of mTOR and regulating its upstream pathways
  2062. Pharmacological inhibition of the mTOR pathway impairs hippocampal development in mice
  2063. Gadd45a suppresses tumor angiogenesis via inhibition of the mTOR/STAT3 protein pathway
  2064. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway
  2065. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR …
  2066. PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of …
  2067. Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition
  2068. Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
  2069. Competitive but not allosteric mTOR kinase inhibition enhances tumor cell radiosensitivity
  2070. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells
  2071. Increased eIF4E phosphorylation prevents response of prostate cancer cells to mTOR inhibitors.
  2072. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling …
  2073. Potential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancer
  2074. Radiation enhancement of head and neck squamous cell carcinoma by the Dual PI3K/mTOR inhibitor PF-05212384
  2075. Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors …
  2076. Inhibition of mTOR kinase via rapamycin blocks persistent predator stress-induced hyperarousal
  2077. Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma …
  2078. … sylvestris (L.) Hoffm. inhibits the growth of breast cancer cells by inhibiting Akt/mTOR signaling, and its apoptotic effects are enhanced by autophagy inhibition
  2079. Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: Association of long-term responses and oncogenomic events.
  2080. Melittin suppresses HIF-1α/VEGF expression through inhibition of ERK and mTOR/p70S6K pathway in human cervical carcinoma cells
  2081. Advances in mTOR Inhibitors
  2082. mTOR inhibitor-associated noninfectious pneumonitis in patients with metastatic renal cell cancer: A single-center experience.
  2083. Tanshinone IIA induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KBM‐5 leukemia cells
  2084. mTOR inhibitor therapy for metastatic sarcomatoid clear cell renal cell carcinoma (ccRCC).
  2085. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells
  2086. … of four active compounds alleviates cerebral ischemia–reperfusion injury in correlation with inhibition of autophagy and modulation of AMPK/mTOR and JNK pathways
  2087. Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors …
  2088. … the response of non-Hodgkin’s lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR …
  2089. Increased phosphorylation of eIF4E induces resistance to treatment with mTOR inhibitors alone or together with AR antagonists in advanced prostate cancer
  2090. SC-31RATIONAL DESIGN OF A PI3-KINASE/mTOR INHIBITOR CYTOTOXIC TO BRAIN CANCER STEM CELLS UNDER HYPOXIA
  2091. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells
  2092. AB98. The study of cell proliferation and apoptosis and autophagy in renal cell carcinoma cells influence by the PI3K/AKT/mTor inhibitor NVP-BEZ235
  2093. Effect of the combination of the dual mTOR/pI3K inhibitor NVP-BEZ235 with gemcitabine on growth inhibition in pancreatic cancer cells in vitro and in vivo.
  2094. Combined BCL-2/XL and mTor inhibition promotes apoptosis in small cell lung cancer
  2095. Abstract A48: Anti-tumor activity of the MEK inhibitor pimasertib in combination with the PI3K/mTOR inhibitor SAR245409 in low-grade serous ovarian cancer
  2096. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis
  2097. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance
  2098. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer
  2099. Autophagy inhibition with monensin enhances cell cycle arrest and apoptosis induced by mTOR or epidermal growth factor receptor inhibitors in lung cancer …
  2100. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways
  2101. mTOR inhibition protects diabetic heart against ischemia/reperfusion injury through STAT3 activation (1078.5)
  2102. Involvement of PI3K-AKT-mTOR pathway in protein kinase CKII inhibition-mediated senescence in human colon cancer cells
  2103. Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells
  2104. LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway
  2105. Effective monotherapy despite intratumor heterogeneity: Clonal convergence within the PI3K pathway and sensitivity to mTOR inhibitors in patients with advanced …
  2106. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2
  2107. Reactivation of cocaine reward memory engages the Akt/GSK3/mTOR signaling pathway and can be disrupted by GSK3 inhibition
  2108. … , a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and …
  2109. … amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)
  2110. Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin
  2111. Synthesis and structure–activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido [2, 3-d] pyrimidine derivatives
  2112. Cdc-like/dual-specificity tyrosine phosphorylation–regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: Implication for Alzheimer’s disease
  2113. Systemic inhibition of mTOR kinase via rapamycin disrupts consolidation and reconsolidation of auditory fear memory
  2114. Abstract B24: Inhibition of mTOR induces multidrug resistance in B-progenitor acute lymphocytic leukemia
  2115. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway
  2116. Pimasertib (Pim) and Sar245409 (Sar)-a Mek and Pi3K/Mtor Inhibitor Combination: a Phase Ib Trial with Expansions in Selected Genotype-Defined Solid …
  2117. Integration of different “-omics” technologies identifies inhibition of the IGF1R-Akt-mTOR signaling cascade involved in the cytotoxic effect of shikonin against …
  2118. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma
  2119. Inhibition of hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector
  2120. Inhibition of mTOR and HIF pathways diminishes chondro-osteogenesis and cell proliferation in chondroblastoma
  2121. Dual targeting of JAK2 signaling with a type II JAK2 inhibitor and of mTOR with a TOR kinase inhibitor induces apoptosis in CRLF2-rearranged Ph-like acute …
  2122. mTOR inhibition increases learning/memory (684.16)
  2123. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy
  2124. Research on mTOR inhibitors used in radio-sensitization
  2125. New insights into mTOR inhibitors: spotlight on tolerability
  2126. Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide …
  2127. Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells
  2128. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in …
  2129. How to Maximize the Potential of mTOR Inhibitors in Breast Cancer–More Questions than Answers
  2130. Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis.
  2131. The Evaluation of Dual PI3K/mTOR Inhibitors as a Superior Alternative to mTOR Inhibitors in Pre-B Acute Lymphoblastic Leukaemia
  2132. Managing mTOR Inhibitor Side Effects in Breast Cancer
  2133. Inhibition of ovarian cancer cell proliferation by Pien Tze Huang via the AKT‑mTOR pathway
  2134. mTOR inhibition in MDR acute myeloid leukemia.
  2135. … Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplantation: A Single Centre Experience Renal Transplantasyonda Kalsinörin İnhibitörlerinden mTOR
  2136. Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR signaling
  2137. Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.
  2138. Hypothalamic nesfatin-1/NUCB2 knockdown augments hepatic gluconeogenesis that is correlated with inhibition of mTOR-STAT3 signaling pathway in rats
  2139. mTOR Inhibitors in Liver Transplantation
  2140. Targeting the insulin-like growth factor 1 (IGF1R) and insulin (IR) receptor with a dual IGF1R/IR inhibitor, OSI-906, to potentiate mTOR inhibitor effects in experimental …
  2141. mTOR Inhibition Enhances the Efficacy of Aurora Inhibitors Liu et al. Page 1326
  2142. Ascofuranone suppresses EGF-induced HIF-1α protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells
  2143. A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced …
  2144. Expression of mTOR in breast cancer and the effect of mTOR inhibitor on the cell prolofera-tion and apoptosis of breast cancer cells
  2145. Upregulation of HIF-1α protein induces mitochondrial autophagy in primary cortical cell cultures through the inhibition of the mTOR pathway
  2146. … pathway activation mapping guided biomarker development to identify optimal combinations of MEK inhibitor with PI3K/mTOR pathway inhibitors for the treatment of …
  2147. Imidazopyrazine derivatives as inhibitors of mTOR
  2148. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model
  2149. Inhibition of protein synthesis or mTOR in the basolateral amygdala blocks retrieval-induced memory strengthening
  2150. Reply to “mTOR inhibitor-related pulmonary toxicity; incidence even higher”
  2151. Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic …
  2152. mTOR inhibitors protect from apoptosis in B-ALL cells treated with chemotherapeutic drugs
  2153. Successful treatment of four patients with severe hyperinsulinaemic hypoglycaemia with a novel therapy using mTOR inhibitor
  2154. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
  2155. Clinical pharmacokinetics and pharmacodynamics of mTOR inhibitors in renal transplantation
  2156. The Effect and Tolerability of MTOR Inhibitors for Metastatic Renal Cell Carcinoma
  2157. mTOR Inhibition and Tuberous Sclerosis Prevention
  2158. Role of mTOR Inhibitors in Heart Transplant Immunosuppressive Regimens
  2159. Discovery of Novel Quinazolinone Based mTOR Inhibitors Endowed with Antifibrotic Properties
  2160. Characterization of mTOR Inhibition and Autophagy Inhibition in Non-Small Cell Lung Cancer
  2161. The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR …
  2162. Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model
  2163. Primary resistance to ATP-competitive mTOR inhibitors for the treatment of solid tumors
  2164. Risk of Metabolic Complications in Kidney Transplantation After Conversion From Calcineurin Inhibitor to mTOR Inhibitor: A Systematic Review and Meta-Analysis …
  2165. Beneficial Effect of Mtor Inhibitors on Inflammation in Human Neutrophils
  2166. Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells
  2167. There is a correlation between interleukin-1beta and endothelial dysfunction in patients with mTOR inhibitor-eluting stent implantation
  2168. In vitro and in vivo tumor cell radiosensitization by the competitive mTOR inhibitor INK128.
  2169. Natural killer cell maturation is blocked by mTOR inhibition in C57Bl/6 mice
  2170. mTOR inhibition, AKT proteins and chronic kidney disease
  2171. Effects of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 on HCC
  2172. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models…
  2173. Determinants of acquired resistance to PI3K/mTOR inhibition in cells refractory to EGFR inhibition.
  2174. Penta-O-galloyl-β-d-glucose Suppresses EGF-Induced eIF3i Expression through Inhibition of the PI3K/AKT/mTOR Pathway in Prostate Cancer Cells
  2175. Pathway convergent evolution underscores treatment response to MTOR inhibitors in kidney cancers.
  2176. AB110. Efficacy and safety of mTOR inhibitor in the treatment of renal cell cancer: a meta-analysis
  2177. The mTOR inhibitor RAD001 exhibited more efficacy against ovarian cancer ascites after pharmacologic inhibition of Mirk kinase
  2178. NEWS FROM THE AAN ANNUAL MEETING: Should mTOR Inhibitors Replace Surgery as the First-Line Treatment of Tuberous Sclerosis-SEGA?
  2179. 13, 14‑bis (cis‑3, 5‑dimethyl‑1‑piperazinyl)‑β‑elemene, a novel β‑elemene derivative, shows potent antitumor activities via inhibition of mTOR in human breast …
  2180. Risk of serious anemia with mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
  2181. Combination HDACi and mTOR inhibitor therapy in poor-risk de novo and refractory elderly patients with AML.
  2182. mTOR Inhibitors in Pediatric Heart Transplantation: Do the Potential Benefits Outweigh the Risks, Clues from the ISHLT Registry
  2183. Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
  2184. Inhibition of compensatory survival and proliferative pathway activation induced by mTOR inhibition in renal cell carcinoma
  2185. Incidence of mucositis in patients treated with mTOR inhibitor-based regimens and correlation to treatment response.
  2186. Combination of mTOR Inhibitor and Calcineurin Inhibitor in EBV-positive and EBV-negative B-lymphocytes
  2187. The dual PI3K/mTOR inhibitor VS-5584 preferentially targets cancer stem cells in vitro and in vivo.
  2188. A Dual PI3K-mTOR Inhibitor Induced Cardiac Hypertrophy in Mice
  2189. Use of a mouse model of constitutive mTOR inhibition to identify molecular modulators of acquired resistance.
  2190. Biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors.
  2191. A Dual PI3K-mTOR Inhibitor Induced Hyperglycemia and Increased Insulin Signals in the Heart
  2192. Dual inhibition of PI3K and mTOR shows preferential antileukemic activity in MLL-rearranged AML
  2193. Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
  2194. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma …
  2195. Incidence and risk of stomatitis to mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
  2196. mTOR inhibition leads to decrease of breast cancer progression in vitro via cytoskeleton remodeling
  2197. HTLV-1 HBZ positively regulates the mTOR signaling pathway via inhibition of GADD34 activity in the cytoplasm
  2198. Inactivation of mTor arrests bovine oocytes in the metaphase‐I stage, despite reversible inhibition of 4E‐BP1 phosphorylation
  2199. MTOR Inhibitor MLN0128 has Antitumor Efficacy in Cell Lines With Intrinsic and Acquired Rapamycin-Resistance.
  2200. Sunitinib-resistant ccRCC cell lines subjected to TKI/mTOR inhibitors as a model for sequence therapy
  2201. Abstract A068: Targeting Akt reactivation following mTOR inhibition in breast cancer treatment
  2202. In vitro and in vivo effects of the mTOR inhibitors everolimus (EVE) and temsirolimus (TEM).
  2203. Dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with AKT inhibitor MK2206 in esophageal carcinoma cells
  2204. GAS5 lncRNA Modulates the Action of mTOR Inhibitors in Prostate Cancer Cells
  2205. Testing the effects of Hsp90 inhibitor and mToR inhibitor on HPIV3 and RSV replication in lung epithelial cells
  2206. mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids
  2207. mTOR inhibitor MLN0128 Has antitumor efficacy in cell lines with intrinsic and acquired rapamycin resistance in vitro and in vivo.
  2208. Conversion of calcineurin inhibitors by mTOR inhibitors contributes to the treatment of intraepithelial neoplasms in the cervix in women with renal …
  2209. First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium.
  2210. mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression
  2211. Mechanism underlying pancreatic cancer cell resistance to mTOR inhibitor RAD001 via c-Raf/ERK1/2 activation
  2212. THERAPEUTIC EFFICACY OF COMBINATION OF MTOR INHIBITORS AND AMPK ACTIVATORS IN NON-SMALL CELL LUNG CANCER.
  2213. Does the mTOR inhibitor everolimus influence the course of epilepsy in children with tuberous sclerosis complex?
  2214. Reduction of fat mass with the mTOR inhibitor, sirolimus, in humans: from transplantation to lipodystrophies
  2215. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds
  2216. Everolimus-retrospective analysis of therapy with mTor-inhibitors of 38 patients after pediatric HTX
  2217. Effects of two mTOR inhibitors on in-vitro models of GH-secreting pituitary adenomas
  2218. Abstract LB-359: Inhibition of DNA repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a novel radiosensitization strategy for glioblastoma.
  2219. Metabolic Re-Programming in Notch-Activated T-ALL By mTOR Inhibitor AZD2014 Combined with L-Asparaginase
  2220. Double mutation of KRAS and PIK3CA affects the efficacy of NVP-BEZ235, a dual PI3K/mTOR inhibitor, in regulating the PI3K/mTOR pathway in colorectal cancer.
  2221. The Role of Autophagy and Translation Initiation Factors in Overcoming Resistance to mTOR Inhibitors in Prostate Cancer
  2222. CLK/DYRK kinases inhibitor Leucettine L41 induces mTOR-dependent autophagy. Implication for Alzheimers’ disease
  2223. The role of mTOR inhibitors in the prevention of organ rejection in adult liver transplant patients: a focus on everolimus
  2224. Medical Management with mTOR Inhibitors vs. Surgical Resection: Comparison of Clinical Outcomes for Subependymal Giant Cell Astrocytoma (SEGA) in Tuberous …
  2225. Multifactorial mechanisms of resistance to the aminopeptidase inhibitor prodrug CHR2863 provoke marked sensitization to the mTOR inhibitor rapamycin
  2226. Risk of pneumonitis with mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus.
  2227. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and the tumor development in vivo
  2228. Cancer stem cell-selected patient-derived xenograft models with sensitivity to FAK and Pan-PI3K/mTOR inhibitors.
  2229. mTOR inhibition is required for conversion of invariant NKT cells into immunosuppressive regulatory cells.
  2230. Long-term resistance to PI3K/mTOR inhibition requires increased expression of c-myc and YAP.
  2231. Hsp90 inhibitor AUY922 abrogates mTOR inhibitor AZD8055-induced up-regulation of HER2/HER3 and potentiates antiproliferative activity in human breast cancer …
  2232. Dual mTOR inhibition demonstrates antiproliferative and chemosensitizing effects in chemoresistant high-grade papillary serous ovarian cancer
  2233. Abstract P5-11-06: Combination of insulin-like growth factor 1 receptor and PI3K/mTOR inhibition in triple-negative breast cancers
  2234. Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients
  2235. mTOR Inhibitors Everolimus and Sirolimus Influence Leukocyte Migration After Ischemia.: Abstract# C2080
  2236. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase
  2237. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma
  2238. The novel PI3K/mTOR dual inhibitor PQR309 in pre-clinical lymphoma models: Demonstration of anti-tumor activity as single agent and in combination and …
  2239. BEZ235, a selective PI3k/mTOR inhibitor, enhances the therapeutic efficacy of doxorubicin in pancreatic cancer (655.7)
  2240. The Dual PI3K/mTOR Inhibitor PF-04691502 Induces Substantial Apoptosis in Chronic Lymphocytic Leukemia Cells in Vitro and Prolongs Survival in the Eµ …
  2241. Different patterns of Akt and ERK feedback activation in response to allosteric and active-site mTOR inhibitors in comparison to metformin in pancreatic cancer cells.
  2242. Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma.
  2243. Monitoring of glioblastoma response to a dual PI3K/mTOR inhibitor using hyperpolarized 13C MRSI and 1H MRS
  2244. Effects of novel PI3K/mTOR inhibitors BKM120 and BEZ235 in comparison to everolimus in Head & Neck Squamous cell carcinomas (HNSCC).
  2245. Lumen LPS inhibits HCO3− absorption in the medullary thick ascending limb through TLR4-PI3K-Akt-mTOR-dependent inhibition of basolateral Na+/H+ exchange
  2246. The Impact of mTOR Inhibition on Evolution of Renal Function and Urinary Protein Excretion-24 Months Data from 719 De Novo LTx Recipients.: Abstract# O-78
  2247. Polycystic Kidney Disease: Literature Review on the Mechanism of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Reduction of Cyst Growth in Patients …
  2248. mTOR Inhibition by Rapamycin Alleviates Mitochondrial Disease in the Ndufs4-Mouse Model of Leigh Syndrome
  2249. A62 LUNG FIBROSIS: FIBROBLAST BIOLOGY: The Effect Of Mtor Inhibition On Fibrotic Function Of Systemic Scleroderma-Derived Mesenchymal Cells
  2250. PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with 1 rapamycin in rats 2
  2251. 73. Neurobehavioral consequences of acute mTOR inhibition
  2252. Effects of mTOR Inhibition On IR/IGF-1R Signalling in PIK3CA-Mutated, Tamoxifen Resistant Breast Cancer
  2253. Characterization of BK viral responses to the dual-PI3K/MTOR inhibitor dactolisib (NVP BEZ-235) in a renal cell culture model
  2254. … activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant …
  2255. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423
  2256. Abstract A15: HDAC6 inhibitor C1A abrogates the recruitment of the autophagic machinery and synergizes with proteasome, src kinase, and PI3K-mTOR inhibition.
  2257. Evaluation of novel combinations of PI3K-mTOR inhibitors with dacomitinib (dac) or chemotherapy in PTEN-deficient genomically characterized patient-derived tumor …
  2258. Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors.
  2259. MTOR KINASE INHIBITORS AND APOPTOSIS IN GLIOBLASTOMA
  2260. FDG is a surrogate marker of therapy response and tumor recovery after drug withdrawal during treatment with a dual PI3K/mTOR inhibitor in a preclinical model of …
  2261. Combined Treatment of the PI3k/mTOR Inhibitor BEZ235 With Doxorubicin Does Not Increase Cardiotoxicity While Improving Efficacy in Breast Cancer Cells
  2262. T-Cell Transcriptome Analysis Reveals the Mechanisms Controlling Synergy Between Costimulation Blockade and mTOR Inhibition during Graft Versus Host …
  2263. … COMPARISON IN FLANK VERSUS ORTHOTOPIC MODELS AND COMPARISON OF BRAIN PENETRANT VERSUS IMPENETRANT PI3K/MTOR INHIBITORS
  2264. Physiologically based pharmacokinetic model and correlative in vitro assessment of metabolism-based interaction between Everolimus and PI3K/mTOR inhibitor …
  2265. Intracerebroventricular administration of ouabain, a Na/K-ATPase inhibitor, activates mTOR signal pathways and protein translation in the rat frontal cortex
  2266. Impact of mTOR inhibition on expression of immune regulatory molecules by circulating dendritic cells and regulatory T cells in stable liver transplant patients
  2267. Molecularly-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER2-Targeted Therapy, mTOR Inhibitor and Antiangiogenic Therapy
  2268. Predicting sensitivity to PI3K/mTOR inhibition in asbestos-induced malignant mesothelioma models Ian Powley1, Sara Galavotti1, Xiao-Ming Sun1
  2269. Abstract A63: NVP-BEZ235, a dual PI3K/mTOR inhibitor, elicits an alternate route for induction of cell death in PTEN null prostate cancer cells.
  2270. A subset of non-small cell lung cancers with wild-type EGFR are sensitized to Erlotinib (EGFR TKI) by mTOR inhibition.
  2271. Next-generation sequencing (NGS) of serum microRNA in hepatocellular carcinoma (HCC) patients treated with sorafenib and an mTOR inhibitor.
  2272. Stem Cell‐Based Combination Therapies for Cancer: Systemic Delivery of a PI3K/mTOR Inhibitor (PI‐103) and Stem Cell‐Mediated Delivery of TRAIL in Brain Tumors
  2273. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances dexamethasone induced apoptosis in models of T-cell ALL with PTEN dysfunction and hyperactivated PI3K/Akt …
  2274. Final Results and Biomarker Correlation of a Phase II Study of the MTOR Inhibitor Everolimus in Patients with Pre-Treated Metastatic Esophagus, Gastro-Esophageal …
  2275. … cancer cells to ABT888 in the presence of carboplatin by impairing DNA-damage repair: A proof of concept combination of PI3K/mTOR inhibitor with PARP inhibitor.
  2276. Induction Of Apoptosis By The Dual PI3K/Mtor Inhibitor NVP-BEZ235 Is Impaired By a Profound G1/G0 Arrest In Acute Leukemia Which Can Be Overcome By …
  2277. 158 PRE-CLINICAL TRIAL OF A NEW DUAL MTOR INHIBITOR: INK128 FOR RENAL CELL CARCINOMA
  2278. Abstract LB-36: JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for co-targeting these pathways in metastatic breast cancer.
  2279. Review of research on dual PI3K-mTOR small molecular inhibitors
  2280. Abstract A166: A Phase I pharmacokinetic/pharmacodynamic (PK/PD) study of the sachet formulation of the oral dual PI3K-mTOR inhibitor BEZ235 given twice daily …
  2281. Abstract C267: Sequential combination of the novel allosteric MEK1/2 inhibitor BAY 86-9766 (RDEA119) with the mTOR inhibitor rapamycin decelerates relapse of …
  2282. 4EVER: The Impact of mTOR Inhibition on Bone Health in Postmenopausal Women With Hormone Receptor Positive (HR+) Advanced Breast Cancer Treated …
  2283. Synergistic Control of Acute GvHD: Effectively Down-Regulating T Cell Proliferation and Cytotoxicity with Combined mTOR Inhibition and CD28: CD80/86 …
  2284. Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
  2285. MP24-14 METABOLIC SHIFT UNDER HYPOXIC ENVIRONMENT CAUSES RESISTANCE TO MTOR INHIBITOR IN HUMAN CASTRATION RESISTANT PROSTATE …
  2286. Abstract LB-224: mTOR inhibition can overcome cetuximab resistance in head and neck cancer.
  2287. DR-08 MSK1/β-CATENIN SIGNALING MEDIATES RESISTANCE TO PI3K/mTOR INHIBITORS IN GLIOBLASTOMA
  2288. PI3K inhibition potentiates ABT-737 induced apoptosis in colorectal cancer cells independent of MCL1 downregulation or AKT/mTOR inhibition.
  2289. 297 Adverse Event Management of mTOR Inhibitors During Treatment of Hormone ReceptorePositive Advanced Breast Cancer: Considerations for Oncologists
  2290. Abstract LB-314: Preclinical investigation of antitumor effects of dual PI3K/mTOR inhibitor PF-04691502 in human xenograft and murine Pten/Tgfbr1 deficient head …
  2291. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program
  2292. MP35-17 COMBINATION OF MTOR INHIBITION AND CD4 DEPLETION GENERATES ANTITUMOR IMMUNITY
  2293. Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway
  2294. Identification of novel 7-amino-5-methyl-1, 6-naphthyridin-2 (1H)-one derivatives as potent PI3K/mTOR dual inhibitors
  2295. Thrombospondin-1 Is a Key Mediator of mTOR Inhibitor-Associated Induction of T and B Lymphocyte Regulatory Phenotype in Kidney Transplanted Patients.: Abstract …
  2296. DHA2, a synthesized derivative of bisbibenzyl, exerts antitumor activity against ovarian cancer through inhibition of XIAP and Akt/mTOR pathway
  2297. Inhibition of the mammalian Target of Rapamycin (mTOR) does not alter nitric oxide or superoxide levels in human skin
  2298. Antiproliferative effects of PI3K-mTOR pathway inhibitors alone or in combination with MEK inhibitor GSK1120212 in pancreatic cancer cell lines are not correlated …
  2299. Preclinical efficacy of GNE-317, a dual PI3K/mTOR inhibitor, with or without bevacizumab in EGFR and/or PTEN-mutated glioblastoma multiforme
  2300. mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer
  2301. Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma
  2302. Dual inhibition of the androgen receptor and PI-3K/mTor pathways has significant antitumor activity in castrate-resistant prostate cancer
  2303. Dual mTOR/PI3K inhibitors induce ERK pathway overactivation in pancreatic cell lines: Rationale for combinatory therapy
  2304. B58 EXPERIMENTAL MODELS OF PULMONARY HYPERTENSION II: Inhibition Of Mtor By Rapamycin Blocks Systemic Angiogenesis
  2305. Combination efficacy of mTOR and MEK inhibitor in malignant pleural mesothelioma (MPM).
  2306. Neferine from Nelumbo nucifera induces autophagy through the inhibition of PI3K/Akt/mTOR pathway and ROS hyper generation in A549 cells.
  2307. Abstract P6-06-32: 4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) …
  2308. Abstract A283: PI3K/Akt/mTOR dual inhibitors have an advantage over single inhibitors in overcoming prostate cancer radioresistance.
  2309. An evaluation of molecular changes in non-small cell lung cancer (NSCLC) cell lines with acquired resistance to NVP-BEZ235, a novel P13K/mTOR dual inhibitor
  2310. SPR965: an oral PI3K/mTOR C1/C2 inhibitor for the treatment of solid tumors
  2311. Benzofuran derivatives as a novel class of mTOR signaling inhibitors
  2312. Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal …
  2313. Inhibition of mTOR Kinase and Cancer Treatment
  2314. Evidence that chronic inhibition of the mammalian Target of Rapamycin (mTOR) reduces skin blood flow in humans
  2315. Inhibition of mTOR signaling induces cumulus expansion and stimulates meiotic maturation of oocytes in mice
  2316. Combined inhibition of mTOR and AKT activity induces potent apoptosis in epithelial ovarian cancer cells.
  2317. … , O’-acac)(γ-acac)(DMS)] Alters SH-SY5Y Cell Migration and Invasion by the Inhibition of Na+/H+ Exchanger Isoform 1 Occurring through a PKC-ε/ERK/mTOR …
  2318. Inhibition of mTOR Pathway and Induction of Autophagy Block Lymphoma Cell Growth: Role of AMPK Activation
  2319. MLN0128, a second-generation mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML
  2320. Effect of inhibition of the PI3K/Akt/mTOR pathway on AR splicing and downstream targets.
  2321. mTOR or VEGFR inhibition—get the order right
  2322. Integral role of the PI3K-AKT-mTOR pathway in DDR-mediated antitumor actions of PARP inhibitor in triple-negative breast carcinogenesis
  2323. PI3K/mTOR dual inhibitor PF-5212384 inhibits aberrant NF-kB activation and exhibits activity in combination with MEK inhibitor PD-325901 and docetaxel in human …
  2324. Inhibition of the PI3K/mTOR pathway potentiates irradiation effects in paediatric glioblastoma inducing metabolic alterations detected by MRS.
  2325. Dopamine-induced regulation and deregulation of the catabolism of cyclic ADP-ribose, an intrinsic mTOR signal inhibitor, during development in the rodent striatum
  2326. Abstract A165: Antitumor activity of mTOR kinase inhibitor CC-223 in a mouse model of prostate cancer.
  2327. adaptive capabilities of the pi3k/akt/mtor pathway in acute myeloid leukemia revealed by the use of selective inhibitors
  2328. Correction: AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake
  2329. Inhibition of PI3K/mTOR by BEZ235 dramatically potentiates panobinostat-induced lethality in diffuse large B-cell lymphoma through multiple mechanisms
  2330. Abstract PD1-8: Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
  2331. Abstract number 14: mTOR complex inhibition as a novel therapeutic strategy in high grade papillary serous ovarian cancer
  2332. Defining optimal combinations of pi3k/akt/mtor and ras/raf/mapk pathway inhibitors for use in endometrial cancer
  2333. Inhibition of mTOR Pathway Reduces Senescence of Corneal Epithelial Cells in Culture.
  2334. Identifying a mechanism of acquired resistance to the combined inhibition of PI3K/mTOR and MEK in colorectal carcinoma
  2335. Inhibition of mTOR in Neuroendocrine Neoplasms of the Digestive Tract
  2336. Effect of evodiagenine mediates photocytotoxicity on human breast cancer cells MDA-MB-231 through inhibition of PI3K/AKT/mTOR and activation of p38 pathways
  2337. Systems Biology Approach for Targeted Therapy of Liver Cancer P13k/Akt/Mtor Pathway Inhibitors: An Ally or Rival for Sorafenib
  2338. Roles of selective inhibition of PI3K/Akt/mTOR signaling pathway on rabbit primary macrophage autophagy and possible pechnism
  2339. Dual mTOR/HDAC Inhibition: Preclinical Development of a Novel Breast Cancer Therapy
  2340. Kawain, a kavalactone, inhibits urinary bladder carcinogenesis in the UPII-mutant Ha-ras transgenic model and associated with inhibition of the mTOR pathway.
  2341. … Mutations in the IL7-Receptor Signaling Pathway in T-Cell Acute Lymphoblastic Leukemia Respond to Combined Inhibition of MEK/ERK and PI3K/AKT/mTOR …
  2342. … evaluation of molecular changes in non-small cell lung cancer (NSCLC) cell lines with acquired resistance to NVP-BEZ235, a novel PI3K/mTOR dual inhibitor
  2343. The rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML
  2344. Dual PI3K/Akt/mTOR Pathway Inhibitor Potentiate Cytarabine Cytotoxicity For Acute Myeloid Leukemia
  2345. Anti-proliferative Activity of NVP-BEZ235, a Dual Inhibitor of PI3K and mTOR, in Colorectal Cancer Cells
  2346. Pitavastatin regulates mTOR Complex 1 signaling through inhibition of Rheb in T cells
  2347. A systems pharmacogenomic approach to identify synergistic molecular mechanisms of combined mTOR/HDAC inhibition.
  2348. A Novel and Highly Selective Dual PI3K/mTOR Kinase Inhibitor VS-5584, Shows Promising Therapeutic Potential For The Treatment Of Multiple Myeloma
  2349. … cardiac hypoxiareoxygenation injury by Suppressed Autophagy and Reduced Cell Death via inhibition of the activation of AMPK-mTOR signalling pathway in rat …
  2350. INHIBITION OF mTOR KINASE AFFECTS ASTROCYTES GFAP mRNA EXPRESSION IN IN VITRO CONDITIONS
  2351. Cell Growth Inhibition of Her2 Positive Trastuzumab Resistant Gastric Cancer Cell Lines By Combined Inhibition of Pi3K/Akt/Mtor and Mapk
  2352. Sorafenib Suppresses Translation in Desmoid Tumors via Inhibition of mTOR Signaling
  2353. Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
  2354. Combined Use of a PI3K-mTOR Dual Inhibitor and Doxorubicin Induced Cardiac Hypertrophy and Early Death in Mice
  2355. The mTOR Kinase Inhibitor AZD-2014 Effectively Reverses XPO1/CRM1 Antagonist KPT-185–induced Glycolysis/Gluconeogenesis, Enhancing Antitumor …
  2356. Research Article Integration of Different ”-omics”Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of …
  2357. A systems approach to understand the molecular synergy of combined mTOR/histone deacetylase (HDAC) inhibition in the treatment of cancer
  2358. Multimodality Imaging End-Points on mTOR and HSP Inhibition in Pancreatic Cancer: A Pre-Clinical PET/MRI/MRS Study
  2359. Rapamycin, an inhibitor of mTOR signaling pathway, reverses lithium‐induced cell proliferation in renal collecting ducts
  2360. Lapatinib Reduced Cardiac Hypertrophy Induced By Combined Use Of A Pi3k-mtor Dual Inhibitor And Doxorubicin
  2361. Combating lapatinib resistance of HER2 positive breast cancer cells by combined inhibition of mTOR and autophagy.
  2362. Cationic polystyrene nanosphere induces autophagy through inhibition of the Akt/mTOR and activation of the AMPK signaling pathways in macrophage and epithelial …
  2363. Targeting PI3K and mTOR with BEZ235, a dual inhibitor, is efficacious in trastuzumab refractory and HER2+/PIK3CA-mutated breast cancer models
  2364. Inhibition of mTOR attenuates tumor lactate production & enhances cisplatin/radiation induced immune mediated clearance of HPV-positive head & neck squamous …
  2365. Retraction: PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and …
  2366. EFFECTS OF SMALL MOLECULE INHIBITORS TARGETING PI3K, EGFR, IGF-1R, MTOR, SMAD3 AND MEK IN TUBE FORMATION AND 3-D SPHEROID …
  2367. 335 Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
  2368. NVP-BYL719, a novel PI3K-alpha selective inhibitor, overcomes acquired erlotinib resistance via upregulation of the PI3K/Akt/mTOR pathway in pancreatic ductal …
  2369. … distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined RAS/RAF/MEK/ERK and PI3K/PTEN/AKT/mTOR pathway inhibition
  2370. … : Lumen LPS inhibits HCO3− absorption in the medullary thick ascending limb through TLR4-PI3K-Akt-mTOR-dependent inhibition of basolateral Na+/H+ …
  2371. AB0276 Methotrexate therapy monitoring by MTOR, autophagy-related ULK1, caspase 3, CDK-inhibitor p21, TNF alpha, and osteoclast-specific cathepsin K and …
  2372. AB0529 Rituximab therapy monitoring by mtor, autophagy-related ULK1, caspase 3, CDK-inhibitor P21, TNF alpha, and osteoclast-specific cathepsin K and …
  2373. Abstract B274: Discovery and characterization of a highly selective inhibitor of B-RAF, PI3K, and mTOR kinases with antitumor activity in B-RAF and B-RAF/PI3K …
  2374. Proteomic analysis of effects of MEK inhibition with BAY86-9766 on LKB1/AMPK and mTOR pathway in lung cancer cell lines.
  2375. … mutations in 3 patients with estrogen receptor-positive breast cancer with responses to treatment with combination aromatase and PI3K/AKT/mTOR pathway inhibition …
  2376. Omega-3 polyunsaturated fatty acids induce apoptotic and autophagic cell death through inhibition of Akt/mTOR pathway in human oral cancer cells
  2377. Chemopreventive effect of omega-3 fatty acid, EPA, in non-small cell lung cancer through formation of PGE3 and inhibition of PI3kinase/mTOR pathways.
  2378. Design and discovery of PWT33597 (VDC-597), a dual inhibitor of PI3-kinase alpha and mTOR
  2379. … 2030: Slide Session; K-LG-01: Lower GI Tract; The Inhibition of MDSC and M2 Macrophage by Metformin is Mediated by AMPK-mTOR and Cholesterole Metabolism …
  2380. BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway.
  2381. … FACTOR-1 RECEPTOR (IGF-1R) SIGNAL TRANSDUCTION PATHWAYS WITH INHIBITORS OF IGF-1R, EGFR, PI3K, MEK, AND MTOR IN BREAST CANCER …
  2382. mTOR inhibitors in cancer therapy
  2383. PI3K/Akt/mTOR inhibitors in breast cancer
  2384. mTOR inhibitors and diabetes
  2385. mTOR inhibitors at a glance
  2386. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
  2387. Gerosuppression by pan-mTOR inhibitors
  2388. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
  2389. The therapeutic potential of mTOR inhibitors in breast cancer
  2390. Role of mTOR inhibitors in kidney disease
  2391. Potential therapeutic effects of mTOR inhibition in atherosclerosis
  2392. mTOR inhibition in epilepsy: rationale and clinical perspectives
  2393. New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation
  2394. Cellular and molecular effects of the mTOR inhibitor everolimus
  2395. Safety of mTOR inhibitors in adult solid organ transplantation
  2396. Role of mTOR inhibitors in epilepsy treatment
  2397. SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells
  2398. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review
  2399. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment
  2400. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
  2401. mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy
  2402. mTOR inhibitor therapy: does it prevent HCC recurrence after liver transplantation?
  2403. The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions
  2404. Management of side effects of mTOR inhibitors in tuberous sclerosis patients
  2405. mTOR inhibitors in children: current indications and future directions in neurology
  2406. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice
  2407. mTOR inhibitors effects on regulatory T cells and on dendritic cells
  2408. Reversal of phenotypes of cellular senescence by pan-mTOR inhibition
  2409. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
  2410. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex
  2411. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients
  2412. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast …
  2413. Muscle wasting associated with the long-term use of mTOR inhibitors
  2414. Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells
  2415. Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells
  2416. Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition
  2417. mTOR inhibitor‐induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm
  2418. Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration
  2419. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review
  2420. Place of mTOR inhibitors in management of BKV infection after kidney transplantation
  2421. mTOR inhibitors for the treatment of severe congenital hyperinsulinism: perspectives on limited therapeutic success
  2422. mTOR inhibitors in urinary bladder cancer
  2423. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC
  2424. Is mTOR inhibitor good enough for treatment all tumors in TSC patients?
  2425. Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?
  2426. Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays
  2427. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition
  2428. Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria‐related disorders
  2429. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors
  2430. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)
  2431. Mutant HRAS as novel target for MEK and mTOR inhibitors
  2432. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
  2433. Inhibition of autophagy increases proliferation inhibition and apoptosis induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in breast cancer cells.
  2434. mTOR inhibition rescues osteopenia in mice with systemic sclerosis
  2435. A novel curcumin analog binds to and activates TFEB in vitro and in vivo independent of MTOR inhibition
  2436. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia
  2437. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex
  2438. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
  2439. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
  2440. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology
  2441. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells
  2442. Treatment of advanced malignant uterine perivascular epithelioid cell tumor with mTOR inhibitors: single-institution experience and review of the literature
  2443. Radiation enhancement of head and neck squamous cell carcinoma by the dual PI3K/mTOR inhibitor PF-05212384
  2444. The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy
  2445. Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
  2446. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma
  2447. Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner
  2448. … alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
  2449. Dual mTOR inhibition is required to prevent TGF-β-mediated fibrosis: implications for scleroderma
  2450. Practical considerations for the use of mTOR inhibitors
  2451. Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling
  2452. A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth
  2453. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
  2454. PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
  2455. Review of PI3K/mTOR inhibitors entering clinical trials to treat triple negative breast cancers
  2456. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation
  2457. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
  2458. Therapeutic potential of mTOR inhibitors for targeting cancer stem cells
  2459. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
  2460. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway …
  2461. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade …
  2462. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth
  2463. Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2
  2464. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance
  2465. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC
  2466. Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells
  2467. A phase I/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia
  2468. NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
  2469. New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft‐versus‐host disease
  2470. Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions
  2471. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
  2472. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer
  2473. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice
  2474. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
  2475. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
  2476. Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma
  2477. MR studies of glioblastoma models treated with dual PI3K/mTOR inhibitor and temozolomide: metabolic changes are associated with enhanced survival
  2478. Modulation of glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235
  2479. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
  2480. ERK and p38 MAPK activities determine sensitivity to PI3K/mTOR inhibition via regulation of MYC and YAP
  2481. Targeting focal adhesion kinase and resistance to mTOR inhibition in pancreatic neuroendocrine tumors
  2482. Predictive factors of response to mTOR inhibitors in neuroendocrine tumours
  2483. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
  2484. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients
  2485. eCF309: a potent, selective and cell-permeable mTOR inhibitor
  2486. Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial
  2487. Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
  2488. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with …
  2489. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell …
  2490. Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial
  2491. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition
  2492. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth
  2493. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
  2494. A novel covalent mTOR inhibitor, DHM25, shows in vivo antitumor activity against triple-negative breast cancer cells
  2495. mTOR Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease
  2496. Age-related neurodegeneration prevention through mTOR inhibition: potential mechanisms and remaining questions
  2497. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
  2498. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas
  2499. The role of 18F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor
  2500. MEK inhibitor PD-0325901 overcomes resistance to PI3K/mTOR inhibitor PF-5212384 and potentiates antitumor effects in human head and neck squamous cell …
  2501. 3D-QSAR, molecular dynamics simulations and molecular docking studies of benzoxazepine moiety as mTOR inhibitor for the treatment of lung cancer
  2502. Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: a systematic review
  2503. Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex—a comprehensive review of the literature
  2504. Oscillatory mTOR inhibition and Treg increase in kidney transplantation
  2505. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a …
  2506. Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1/2 inhibitors in cultured breast cancer cell lines
  2507. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts
  2508. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas
  2509. mTOR inhibitors in cancer: what can we learn from exceptional responses?
  2510. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
  2511. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
  2512. Calcineurin and mTOR inhibitors have opposing effects on regulatory T cells while reducing regulatory B cell populations in kidney transplant recipients
  2513. Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma
  2514. Molecular pathways: increased susceptibility to infection is a complication of mTOR inhibitor use in cancer therapy
  2515. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating …
  2516. Dual PI3K-and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of …
  2517. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and …
  2518. Rapamycin Loaded Solid Lipid Nanoparticles as a New Tool to Deliver mTOR Inhibitors: Formulation and in Vitro Characterization
  2519. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
  2520. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid
  2521. Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors
  2522. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer
  2523. Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling
  2524. mTOR inhibitors for management of encapsulating peritoneal sclerosis: a review of literatures
  2525. Celastrus orbiculatus extract triggers apoptosis and autophagy via PI3K/Akt/mTOR inhibition in human colorectal cancer cells
  2526. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
  2527. A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors
  2528. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
  2529. Silencing Nrf2 impairs glioma cell proliferation via AMPK-activated mTOR inhibition
  2530. mTOR inhibition attenuates dextran sulfate sodium-induced colitis by suppressing T cell proliferation and balancing TH1/TH17/Treg profile
  2531. Risk of metabolic complications in patients with solid tumors treated with mTOR inhibitors: meta-analysis
  2532. mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model
  2533. Dual-modal imaging-guided theranostic nanocarriers based on indocyanine green and mTOR inhibitor rapamycin
  2534. Potential molecular targeted therapeutics: role of PI3-K/Akt/mTOR inhibition in cancer
  2535. Immunosuppressive minimization with mTOR inhibitors and belatacept
  2536. The AMPK agonist PT1 and mTOR inhibitor 3HOI-BA-01 protect cardiomyocytes after ischemia through induction of autophagy
  2537. mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α
  2538. Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated
  2539. High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 …
  2540. MSK1-mediated β-catenin phosphorylation confers resistance to PI3K/mTOR inhibitors in glioblastoma
  2541. Future perspectives for mTOR inhibitors in renal cell cancer treatment
  2542. Successful everolimus treatment of kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: clinical efficacy and adverse effects of mTOR inhibitor …
  2543. Bivalent mTOR inhibitors—the next generation
  2544. mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration
  2545. Cytotoxic properties of a DEPTOR-mTOR inhibitor in multiple myeloma cells
  2546. siRNA-mediated knockdown of the mTOR inhibitor RTP801 promotes retinal ganglion cell survival and axon elongation by direct and indirect mechanisms
  2547. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
  2548. β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
  2549. Assessing metabolic changes in response to mTOR inhibition in a mantle cell lymphoma xenograft model using acidoCEST MRI
  2550. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
  2551. Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive …
  2552. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1
  2553. mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo
  2554. Rapamycin-Mediated mTOR Inhibition Reverses Drug Resistance to Adriamycin in Colon Cancer Cells.
  2555. The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis …
  2556. Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models
  2557. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma
  2558. Antiinflammatory activity of a novel folic acid targeted conjugate of the mTOR inhibitor everolimus
  2559. Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer
  2560. A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I
  2561. Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
  2562. Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 …
  2563. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
  2564. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa
  2565. Dual PI-3 kinase/mTOR inhibition impairs autophagy flux and induces cell death independent of apoptosis and necroptosis
  2566. Abrogation of autophagy by chloroquine alone or in combination with mTOR inhibitors induces apoptosis in neuroendocrine tumor cells
  2567. mTOR inhibition curbs colorectal cancer
  2568. Phase II study of dual phosphoinositol‐3‐kinase (PI 3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ 235 in patients with locally advanced or metastatic …
  2569. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness
  2570. Enhanced antitumor activity of an anti-5T4 antibody–drug conjugate in combination with PI3K/mTOR inhibitors or taxanes
  2571. Mechanistic target of rapamycin (mTOR) inhibition synergizes with reduced internal ribosome entry site (IRES)-mediated translation of cyclin D1 and c-MYC …
  2572. CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model
  2573. Effects of mTOR inhibitors in prevention of abdominal adhesions
  2574. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase …
  2575. Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
  2576. Higher risk of infections with PI3K–AKT–mTOR pathway inhibitors in patients with advanced solid tumors on phase I clinical trials
  2577. … small GTPase DIRAS3 in human white adipose progenitor cells, which negatively regulates adipogenesis and activates autophagy via Akt–mTOR inhibition
  2578. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
  2579. … induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid …
  2580. Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions
  2581. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel
  2582. Differentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor
  2583. Differential reponses of hematopoietic stem and progenitor cells to mTOR inhibition
  2584. mTOR inhibition for cancer therapy: past, present and future
  2585. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
  2586. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity
  2587. mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
  2588. FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition
  2589. Stomatitis associated with use of mTOR inhibitors: implications for patients with invasive breast cancer
  2590. Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation–experiences from a prospective, clinical …
  2591. Proteomic analysis of mTOR inhibition-mediated phosphorylation changes in ribosomal proteins and eukaryotic translation initiation factors
  2592. Long‑lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review
  2593. Safety of mTOR inhibitors in breast cancer
  2594. Hypoxia increases IGFBP-1 phosphorylation mediated by mTOR inhibition
  2595. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of …
  2596. 1 T moderate intensity static magnetic field affects Akt/mTOR pathway and increases the antitumor efficacy of mTOR inhibitors in CNE-2Z cells
  2597. Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma
  2598. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer
  2599. Procyanidins, from Castanea mollissima Bl. shell, induces autophagy following apoptosis associated with PI3K/AKT/mTOR inhibition in HepG2 cells
  2600. Inhibition of mTOR induces a paused pluripotent state
  2601. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus
  2602. Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell
  2603. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological …
  2604. Anandamide suppresses proinflammatory T cell responses in vitro through type-1 cannabinoid receptor–mediated mTOR inhibition in human keratinocytes
  2605. Dose‐level response rates of mTOR inhibition in tuberous sclerosis complex related subependymal giant cell astrocytoma
  2606. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma
  2607. Phase Ib trial of the PI 3K/mTOR inhibitor voxtalisib (SAR 245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell …
  2608. Inhibition of mTOR by apigenin in UVB-irradiated keratinocytes: A new implication of skin cancer prevention
  2609. Activation of both the calpain and ubiquitin-proteasome systems contributes to septic cardiomyopathy through dystrophin loss/disruption and mTOR inhibition
  2610. mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells
  2611. Compensatory increase of transglutaminase 2 is responsible for resistance to mTOR inhibitor treatment
  2612. Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer
  2613. Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.
  2614. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal …
  2615. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression
  2616. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis
  2617. Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma
  2618. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma
  2619. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor
  2620. mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat
  2621. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.
  2622. Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor
  2623. Differential effects of PI3K and dual PI3K/mTOR inhibition in rat prolactin-secreting pituitary tumors
  2624. mTOR inhibition per se induces nuclear localization of FOXP3 and conversion of invariant NKT (iNKT) cells into immunosuppressive regulatory iNKT cells
  2625. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
  2626. mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response
  2627. The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
  2628. A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
  2629. Role of mTOR inhibitors in growth hormone-producing pituitary adenomas harboring different FGFR4 genotypes
  2630. Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cells
  2631. A novel quinoline based second-generation mTOR inhibitor that induces apoptosis and disrupts PI3K-Akt-mTOR signaling in human leukemia HL-60 cells
  2632. Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non–small-cell Lung Cancer
  2633. Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
  2634. Conversion to mTOR-inhibitors with calcineurin inhibitor elimination or minimization reduces urinary polyomavirus BK load in kidney transplant recipients
  2635. Intensified antineoplastic effect by combining an HDAC‐inhibitor, an mTOR‐inhibitor and low dosed interferon alpha in prostate cancer cells
  2636. The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration
  2637. mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience
  2638. Blockage of autophagy rescues the dual PI3K/mTOR inhibitor BEZ235-induced growth inhibition of colorectal cancer cells
  2639. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
  2640. Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells
  2641. An mTOR‐inhibitor‐based protocol and calcineurin inhibitor (CNI)‐free treatment in kidney transplant recipients from donors after cardiac death: good renal function …
  2642. BEZ235 (PIK3/mTOR inhibitor) overcomes pazopanib resistance in patient-derived refractory soft tissue sarcoma cells
  2643. Loss of tuberous sclerosis complex 2 (TSC2) as a predictive biomarker of response to mTOR inhibitor treatment in patients with hepatocellular carcinoma
  2644. Impact of mTOR inhibitors on cancer development in kidney transplantation recipients: a population-based study
  2645. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling
  2646. mTOR inhibition: reduced insulin secretion and sensitivity in a rat model of metabolic syndrome
  2647. Pro-apoptotic activity of ruxolitinib alone and in combination with hydroxyurea, busulphan, and PI3K/mTOR inhibitors in JAK2-positive human cell lines
  2648. Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells
  2649. … mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition
  2650. Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany
  2651. A Practical, Protecting-Group-Free Synthesis of a PI3K/mTOR Inhibitor
  2652. Characterization of LY3023414, a novel PI3K/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth
  2653. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
  2654. Medication-related osteonecrosis of the jaw with the mTOR inhibitor everolimus in a patient with estrogen-receptor positive breast cancer: a case report
  2655. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers
  2656. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer
  2657. mTOR inhibition attenuates glucose deprivation-induced death in photoreceptors via suppressing a mitochondria-dependent apoptotic pathway
  2658. mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer
  2659. REDD2-mediated inhibition of mTOR promotes dendrite retraction induced by axonal injury
  2660. A dose-escalation (DE) study with expansion evaluating safety, pharmacokinetics and efficacy of the novel, balanced PI3K/mTOR inhibitor PQR309 in patients …
  2661. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
  2662. … evaluation and docking studies of novel 2-substituted-4-morpholino-7, 8-dihydro-5H-thiopyrano [4, 3-d] pyrimidine derivatives as dual PI3Kα/mTOR inhibitors
  2663. Stents coated with mammalian target of rapamycin inhibitors (mTOR) appear to be the best choice in patients with antiphospholipid syndrome and myocardial …
  2664. Incidence and risk of rash to mTOR inhibitors in cancer patients–a meta-analysis of randomized controlled trials
  2665. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin …
  2666. Activity of pan-class I isoform PI3K/mTOR Inhibitor PF-05212384 in combination with crizotinib in ovarian cancer xenografts and PDX
  2667. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl) quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents
  2668. Structure-based grafting and identification of kinase–inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma
  2669. Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials
  2670. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors
  2671. mTOR inhibition suppresses posttransplant alloantibody production through direct inhibition of alloprimed B cells and sparing of CD8+ antibody-suppressing …
  2672. Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture
  2673. Inhibition of mTOR reduces lipotoxic cell death in primary macrophages through an autophagy-independent mechanism
  2674. Monitoring of CD8 (+) T-cell activity in mTOR inhibitor-treated cancer patients for successful immunotherapy
  2675. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells
  2676. Differentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor
  2677. mTOR inhibition by rapamycin increases ceramide synthesis by promoting transforming growth factor‐β1/Smad signaling in the skin
  2678. mTOR inhibition beyond rapalogs
  2679. Streptococcus pneumoniae Induces Autophagy through the Inhibition of the PI3K-I/Akt/mTOR Pathway and ROS Hypergeneration in A549 Cells
  2680. Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
  2681. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
  2682. PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
  2683. A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
  2684. Novel quinoline-derived mTOR inhibitors with remarkable enzymatic and cellular activities: design, synthesis and biological evaluation
  2685. A dual PI3K/mTOR inhibitor as potential therapeutic option for vulvar cancer
  2686. The imidazo [1, 2-a] pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors
  2687. PI3 kinase/mTOR inhibition increases sensitivity of ER positive breast cancers to CDK4/6 inhibition by blocking cell cycle re-entry driven by cyclinD1 and inducing …
  2688. Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers
  2689. Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution
  2690. Inhibition of the mechanistic target of rapamycin (mTOR)–rapamycin and beyond
  2691. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
  2692. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
  2693. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
  2694. … and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition …
  2695. PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability
  2696. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer
  2697. Conversion from calcineurin inhibitors to mTOR inhibitors stabilizes diabetic and hypertensive nephropathy after liver transplant
  2698. … /AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor
  2699. Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma
  2700. Current use of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas and epilepsy in patients with TSC
  2701. PQR309: structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor
  2702. mTOR Inhibitors in the Treatment of Cancer
  2703. mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside
  2704. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro
  2705. Efficacy and safety of sirolimus (mTOR inhibitor) in two patients with diazoxide-unresponsive hyperinsulinemic hypoglycemia
  2706. … with HR+/HER2–locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment.
  2707. Inhibitors of mTOR in aging and cancer
  2708. Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation
  2709. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines
  2710. Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors.
  2711. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease
  2712. mTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy
  2713. Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition
  2714. Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro
  2715. Anticancer mammalian target of rapamycin (mTOR) signaling pathway inhibitors: current status, challenges and future prospects in management of epilepsy
  2716. … tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
  2717. Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
  2718. Inhibition of AMP-activated protein kinase alleviates focal cerebral ischemia injury in mice: Interference with mTOR and autophagy
  2719. A dual PI3K/AKT/mTOR signaling inhibitor miR-99a suppresses endometrial carcinoma
  2720. Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma
  2721. Doubling down on mTOR inhibition: Harnessing ZEBRA for insights
  2722. PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer
  2723. Combination of mTOR inhibitors augments potency while activating PI3K signaling in pituitary tumors
  2724. Omipalisib (GSK458), a Novel Pan-PI3K/mTOR Inhibitor, Exhibits In Vitro Anti-Lymphoma Activity in Chemotherapy-Sensitive and-Resistant Models of Burkitt …
  2725. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate
  2726. Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression
  2727. Docosahexaenoic acid induces cell death in human non-small cell lung cancer cells by repressing mTOR via AMPK activation and PI3K/Akt inhibition
  2728. bULKing up mTOR inhibition
  2729. mTOR inhibition in diffuse large B-cell lymphoma: new hope?
  2730. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents
  2731. Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate
  2732. Resistance mechanisms to mTOR inhibition in renal cancer
  2733. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600
  2734. The role of mTOR inhibitors in solid organ transplantation
  2735. Crosstalk between Ca2+ signaling and mitochondrial H2O2 is required for rotenone inhibition of mTOR signaling pathway leading to neuronal apoptosis
  2736. Inhibition of mTOR pathway restrains astrocyte proliferation, migration and production of inflammatory mediators after oxygen–glucose deprivation and reoxygenation
  2737. Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells
  2738. Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
  2739. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma
  2740. Activation of the PI3K/mTOR pathway following PARP inhibition in small cell lung cancer
  2741. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human acute lymphoblastic leukemia
  2742. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid …
  2743. Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).
  2744. MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma
  2745. A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid …
  2746. … Protein from Ganoderma microsporum Induces Pro-Death Autophagy through Akt-mTOR-p70S6K Pathway Inhibition in Multidrug Resistant Lung Cancer …
  2747. A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell …
  2748. Early initiation of mTOR inhibitors in children with heart transplantation: a propensity-based registry analysis
  2749. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
  2750. Synergistic effects between mTOR complex 1/2 and glycolysis inhibitors in non-small-cell lung carcinoma cells
  2751. FAK and PI3K/mTOR inhibitors target cancer stem cells: Implications for SCLC treatment strategies
  2752. The role of mTOR inhibitors in breast cancer
  2753. Drug sensitivity research of mTOR inhibitor on breast cancer stem cells
  2754. Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study.
  2755. α-Solanine induces ROS-mediated autophagy through activation of endoplasmic reticulum stress and inhibition of Akt/mTOR pathway
  2756. mTOR inhibition in T-cell lymphoma: a path (way) forward
  2757. Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt
  2758. Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells
  2759. Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside
  2760. mTOR kinase inhibitors enhance efficacy of TKIs in preclinical models of Ph-like B-ALL
  2761. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways
  2762. Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells
  2763. Optimization of a series of triazole containing mammalian target of rapamycin (mTOR) kinase inhibitors and the discovery of CC-115
  2764. The mTOR kinase inhibitor INK128 blunts migration of cultured retinal pigment epithelial cells
  2765. Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia
  2766. The dual PI3K/mTOR inhibitor PQR309 has synergistic activity with other targeted agents in diffuse large B cell lymphomas
  2767. A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  2768. Rapamycin inhibition of mTOR reduces levels of the Na+/H+ exchanger 3 in intestines of mice and humans, leading to diarrhea
  2769. Upstream and downstream co-inhibition of mitogen-activated protein kinase and PI3K/Akt/mTOR pathways in pancreatic ductal adenocarcinoma
  2770. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells
  2771. 4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells
  2772. Phase Ib trial of the mTOR inhibitor everolimus given in combination with multiagent chemotherapy in relapsed acute lymphoblastic leukemia
  2773. pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
  2774. Potential role of vitamin D in restoring sensitivity to mTOR inhibitors in hepatocellular carcinoma (HCC): 1, 25 (OH) vitamin D (VITD) reverts everolimus (EVE) …
  2775. Somatostatin agonist and mTOR inhibitors as potential radioprotectors or radiosensitizers in neuroendocrine tumor cells
  2776. Commentary: mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia
  2777. Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients
  2778. Inhibition of mTOR pathway by rapamycin reduces brain damage in rats subjected to transient forebrain ischemia
  2779. Neuroprotective effects of DAHP and Triptolide in focal cerebral ischemia via apoptosis inhibition and PI3K/Akt/mTOR pathway activation
  2780. The role of PI3K/AKT/mTOR inhibitors in the treatment of hematological malignancies
  2781. A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
  2782. Polyphyllin VII induces an autophagic cell death by activation of the JNK pathway and inhibition of PI3K/AKT/mTOR pathway in HepG2 cells
  2783. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy
  2784. PI 3K/Akt/mTOR pathway dual inhibitor BEZ 235 suppresses the stemness of colon cancer stem cells
  2785. Cell panel profiling reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors
  2786. A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches
  2787. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
  2788. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells
  2789. Structure–activity relationships study of mTOR kinase inhibition using QSAR and structure-based drug design approaches
  2790. Subependymal giant cell astrocytoma in pediatric patients with tuberous sclerosis complex treated with mTOR inhibitors: One center experience.
  2791. Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling
  2792. Factors influencing the CNS distribution of a novel PI3K/mTOR inhibitor GSK2126458: implications for overcoming resistance with combination therapy for …
  2793. Current management of mTOR inhibitor-associated stomatitis
  2794. Comment on “mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT …
  2795. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic …
  2796. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical …
  2797. Abstract A123: Preclinical evaluation of dual mTOR inhibitor, AZD2014, in prostate cancer
  2798. The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
  2799. Inhibition of mTOR suppresses human gallbladder carcinoma cell proliferation and enhances the cytotoxicity of 5-fluorouracil by downregulating MDR1 …
  2800. Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling
  2801. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors
  2802. Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathway
  2803. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
  2804. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway
  2805. mTOR inhibitor interactions with azole antifungals
  2806. In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway
  2807. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma
  2808. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model
  2809. Inhibition of aerobic glycolysis represses Akt/mTOR/HIF-1α axis and restores tamoxifen sensitivity in antiestrogen-resistant breast cancer cells
  2810. Inhibition of Notch signaling promotes the adipogenic differentiation of mesenchymal stem cells through autophagy activation and PTEN-PI3K/AKT/mTOR …
  2811. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell
  2812. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
  2813. A group of novel HIF‐1α inhibitors, glyceollins, blocks HIF‐1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding
  2814. Salidroside induces apoptosis and autophagy in human colorectal cancer cells through inhibition of PI3K/Akt/mTOR pathway
  2815. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma
  2816. Synergistic targeted inhibition of MEK and dual PI 3k/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical …
  2817. Andrographolide analogue induces apoptosis and autophagy mediated cell death in U937 cells by inhibition of PI3K/Akt/mTOR pathway
  2818. Inhibition of mTOR improves the impairment of acidification in autophagic vesicles caused by hepatic steatosis
  2819. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway
  2820. Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309
  2821. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells
  2822. Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic …
  2823. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer
  2824. Triggering PIK3CA mutations in PI3K/Akt/mTOR axis: exploration of newer inhibitors and rational preventive strategies
  2825. Oxamate-mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: Involvement of the Akt–mTOR signaling pathway
  2826. … Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
  2827. Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223
  2828. 161P Discovery of novel 1, 3, 5-triazine-thiourea based dual PI3K/mTOR inhibitor against non-small cell lung cancer (NSCLC)
  2829. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition-a Warburg-reversing effect
  2830. The Role of mTOR Inhibitors and PI3K Pathway Blockade in Renal Cell Cancer
  2831. PI3K-Akt-mTOR signal inhibition affects expression of genes related to endoplasmic reticulum stress
  2832. Inhibition of mTOR by Rapamycin Results in Auditory Hair Cell Damage and Decreased Spiral Ganglion Neuron Outgrowth and Neurite Formation In Vitro
  2833. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells
  2834. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical …
  2835. Probucol inhibits neural cell apoptosis via inhibition of mTOR signaling pathway after spinal cord injury
  2836. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein–Barr virus positive and negative Burkitt lymphoma cells
  2837. Long-term follow-up of de novo use of mTOR and calcineurin inhibitors after kidney transplantation
  2838. 8-Chloroadenosine sensitivity in renal cell carcinoma is associated with AMPK activation and mTOR pathway inhibition
  2839. mTOR inhibitors preserve fertility in a murine model: a novel pharmacologic approach to fertility preservation during gonadotoxic chemotherapy
  2840. Cognitive and functional outcomes after a trial of an mTOR inhibitor in an adolescent with neuropsychiatric sequelae of TSC
  2841. The’enablers’: Inhibitors of mTOR, PI3K and CDK that prolong endocrine sensitivity
  2842. Che‐1‐induced inhibition of mTOR pathway enables stress‐induced autophagy
  2843. … inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK …
  2844. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid …
  2845. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
  2846. Carnosic acid induces autophagic cell death through inhibition of the Akt/mTOR pathway in human hepatoma cells
  2847. Inhibition of mTOR activity in diabetes mellitus reduces proteinuria but not renal accumulation of hyaluronan
  2848. Enhanced anti-tumor activity of an Auristatin-based antibody-drug conjugate in combination with PI3K/mTOR inhibitors or taxanes: Translational implications and …
  2849. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells
  2850. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation
  2851. Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells
  2852. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
  2853. Novel mTOR inhibitor MLN0128 inhibits imatinib-resistant GIST more potently than rapalogues by abrogating AKT and 4EBP1 activation
  2854. G9a Inhibition Induces Autophagic Cell Death via AMPK/mTOR Pathway in Bladder Transitional Cell Carcinoma
  2855. Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells
  2856. Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma
  2857. Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration …
  2858. NOTCH1 inactivating mutation mediates sensitivity to PI3K/mTOR inhibitors in head and neck squamous cell carcinoma
  2859. P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway
  2860. MTOR inhibition favors the differentiation of human in vitro-induced regulatory T cell through selective protein synthesis
  2861. The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT–mTOR signaling pathway
  2862. A dual PI3K/mTOR inhibitor, PI-103, cooperates with TRAIL in laryngeal squamous carcinoma cells in vitro
  2863. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells
  2864. Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.
  2865. Anticancer activity of the mTOR inhibitor (everolimus) and dual mTORC1/mTORC2 Inhibitor (AZD2014) on mouse lymphocytic leukemia both in vitro and in vivo
  2866. Dual PI3K/mTOR inhibition as a treatment strategy for PIK3CA and APC mutant colorectal cancers
  2867. In silico prediction of the clinical response to the mTOR inhibitor everolimus using a Boolean model: validation from a cohort of the SHIVA trial
  2868. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
  2869. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
  2870. … agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK …
  2871. Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts
  2872. FGFR4 Polymorphism as Molecular Determinant of the Efficacy of mTOR Inhibitors In GH-Secreting Pituitary Adenomas
  2873. Hyperphosphatemia induces protective autophagy in endothelial cells through the inhibition of Akt/mTOR signaling
  2874. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
  2875. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer
  2876. Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin
  2877. Novel pan-PIM/pan-PI3K/mTOR inhibitors are highly active in preclinical models of pancreatic ductal adenocarcinoma
  2878. p53 inhibition provides a pivotal protective effect against ischemia-reperfusion injury in vitro via mTOR signaling
  2879. Potent efficacy of combined PI3K/mTOR and JAK or SRC/ABL inhibition in Philadelphia chromosome-like acute lymphoblastic leukemia
  2880. Fucoxanthin activates apoptosis via inhibition of PI3K/Akt/mTOR pathway and suppresses invasion and migration by restriction of p38-MMP-2/9 pathway in human …
  2881. Inhibition of mTOR signaling protects photoreceptor cells against serum deprivation by reducing oxidative stress and inducing G2/M cell cycle arrest
  2882. Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
  2883. The involvement of mutual inhibition of ERK and mTOR in PLCγ1-mediated MMP-13 expression in human osteoarthritis chondrocytes
  2884. … and improves immuno-regulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR …
  2885. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
  2886. Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR inhibitor in patients with metastatic renal cell …
  2887. Abstract A48: Phase I study of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR, VEGFR, RET) in children, adolescents, and …
  2888. FP-208, a novel mTOR inhibitor with potent antitumor activities
  2889. CXCR2 inhibition in human pluripotent stem cells induces predominant differentiation to mesoderm and endoderm through repression of mTOR, β-catenin, and …
  2890. Comparative effectiveness of first-line (1st) VEGF TKI followed by second-line (2nd) therapy with either a VEGF TKI or an mTOR inhibitor in patients (pts) with …
  2891. ATPS-94THIRD GENERATION mTOR INHIBITORS IN GLIOBLASTOMA
  2892. … Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human …
  2893. Predictive Biomarkers of Response to mTOR Inhibitors
  2894. Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway
  2895. mTOR inhibition in breast cancer
  2896. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice
  2897. Correction: mTOR Inhibition Attenuates Dextran Sulfate Sodium-Induced Colitis by Suppressing T Cell Proliferation and Balancing TH1/TH17/Treg Profile
  2898. Fascaplysin induces caspase mediated crosstalk between apoptosis and autophagy through the inhibition of PI3K/AKT/mTOR signaling cascade in human leukemia …
  2899. Muscle wasting in fasting requires activation of NF-κB and inhibition of AKT/mechanistic target of rapamycin (mTOR) by the protein acetylase, GCN5
  2900. Unfolded protein response promotes doxorubicin-induced nonsmall cell lung cancer cells apoptosis via the mTOR pathway inhibition
  2901. Final results of the pharmacodynamic (PD) data of PQR309-001, a first-in-human trial of a combined PI3K/mTOR inhibitor in advanced solid tumors
  2902. Research progress of mTOR inhibitors in the treatment of breast cancer
  2903. Small molecule inhibition of miR-544 biogenesis disrupts adaptive responses to hypoxia by modulating ATM-mTOR signaling
  2904. … leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL …
  2905. Effects of metformin and a mammalian target of rapamycin (mTOR) ATP-competitive inhibitor on targeted metabolomics in pancreatic cancer cell line
  2906. PI3K/AKT/mTOR Inhibitors in Breast Cancer
  2907. … -containing inositol 5-phosphatase (SHIP2) inhibition ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK/mTOR …
  2908. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137
  2909. A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG‑1 dependent on …
  2910. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in …
  2911. Primary cross-resistance to BRAFV600E-, MEK1/2-and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway …
  2912. Aspirin-triggered resolvin D1 inhibits TGF-β1-induced EMT through the inhibition of the mTOR pathway by reducing the expression of PKM2 and is closely …
  2913. Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR
  2914. Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer
  2915. Combined targeting of JAK2 with a type II JAK2 inhibitor and mTOR with a TOR kinase inhibitor constitutes synthetic activity in JAK2-driven Ph-like acute …
  2916. A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks
  2917. Derivatives containing both coumarin and benzimidazole potently induce caspase-dependent apoptosis of cancer cells through inhibition of PI3K-AKT-mTOR …
  2918. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia
  2919. Rational combinations of mTOR inhibitors as anticancer strategies
  2920. mTOR inhibitors in cancer therapy [version 1; peer review: 3
  2921. … of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-кB/mTOR …
  2922. mTOR inhibitors in liver transplantation for HCC
  2923. Down-regulation of Homer1b/c protects against chemically induced seizures through inhibition of mTOR signaling
  2924. Solanum nigrum Suppress Angiogenesis-Mediated Tumor Growth Through Inhibition of the AKT/mTOR Pathway
  2925. … via the AMPK/mTOR pathway in CNE-2 human nasopharyngeal carcinoma cells following ionizing radiation, while inhibition of autophagy contributes to the …
  2926. Discovery of a 6-(pyridin-3-yl) benzo [d] thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors
  2927. Role of mTOR inhibition in triple-negative breast cancer
  2928. Abstract IA16: Mechanisms of resistance to mTOR inhibitors in leukemia and lymphoma
  2929. transplantation symposia: mTOR-inhibition: what have we learned and how so we best apply the learning
  2930. Malignant PEComas: a rare sarcoma responding to mTOR inhibitors
  2931. New Indications of mTOR Inhibitors in Rare Tumors
  2932. Quinones derived from polychlorinated biphenyls induce ROS-dependent autophagy by evoking an autophagic flux and inhibition of mTOR/p70S6k
  2933. Mtor inhibitors responsiveness associates with Akt/Mtor pathway activation in pancreatic neuroendocrine tumors
  2934. Effect of mTOR inhibitors on the risk of cancer development after kidney transplantation in Chinese population
  2935. Proceedings of the 13th international transplantation symposia: mTOR-inhibition: what have we learned and how so we best apply the learning
  2936. The Role of mTOR Inhibitors in Neuroendocrine Tumors
  2937. Effects of mTOR Inhibition on Immunosenescence in the Elderly
  2938. Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2
  2939. SP833 MTOR INHIBITORS IN RENAL TRANSPLANTATION: A FIFTEEN YEAR, SINGLE-CENTER EXPERIENCE
  2940. The inhibition of microRNA-128 on IGF-1-activating mTOR signaling involves in temozolomide-induced glioma cell apoptotic death
  2941. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes
  2942. Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation
  2943. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemia …
  2944. Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review
  2945. Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
  2946. Loss of muscle mass associated with the long term use of mTOR inhibitors
  2947. Cinnamtannin D1 from Rhododendron formosanum Induces Autophagy via the Inhibition of Akt/mTOR and Activation of ERK1/2 in Non-Small-Cell Lung Carcinoma …
  2948. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas
  2949. mTOR Inhibition Per Se Induces Nuclear
  2950. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
  2951. Diabetes-accelerated experimental osteoarthritis is prevented by MTOR inhibition
  2952. Transcriptional Effects of mTOR Inhibitors on Vascular Smooth Muscle Cells
  2953. Application of mTOR inhibitor everolimus for the treatment of renal cell carcinoma
  2954. Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway
  2955. Research Article Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition
  2956. Prediction and Optimization of the Therapeutic Effect of mTOR Inhibitors in Aggressive B-Cell Lymphomas
  2957. Correction: eCF309: a potent, selective and cell-permeable mTOR inhibitor
  2958. mTOR Inhibition remodels extracellular matrix components of human osteoarthritic cartilage
  2959. Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K/Akt-mTOR pathway
  2960. Characterization of MicroRNA Expression during the Development of Resistance to a mTOR-Inhibitor in renal cell carcinoma
  2961. Abstract IA25: Autophagy: A potentially druggable resistance mechanism to PI3K/mTOR inhibitors
  2962. Is It Time to Use De Novo mTOR Inhibitors Posttransplant?
  2963. MEK inhibition sensitizes precursor B-cell acute lymphoblastic leukemia (B-ALL) cells to dexamethasone through modulation of mTOR activity and stimulation …
  2964. Direct evidence of target inhibition with anti-VEGF, EGFR, and mTOR therapies in a clinical model of wound healing
  2965. Progress of research on mTOR inhibitor in endocrine and HER 2 targeted therapy resistance in breast cancer
  2966. PI3-kinase, Akt, and mTOR Inhibitors in RCC
  2967. Abstract B33: Understanding resistance mechanisms to PI3K/mTOR inhibitors in ovarian cancer model systems
  2968. mTOR inhibitors effects on regulatory T cells and on dendritic cells
  2969. L-Glutamate deficiency can trigger proliferation inhibition via down regulation of the mTOR/S6K1 pathway in pig intestinal epithelial cells
  2970. Abstract IA28: PI3K and mTOR inhibitors in lymphoid malignancies: Clinical data
  2971. Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells
  2972. Differential cell cycle control protein profiles characterise bronchial carcinoids sensitive to mTOR inhibitors
  2973. Norepinephrine transporter as a predictive marker of response to PI3K/mTOR inhibition in phaeochromocytoma
  2974. Abstract A45: In depth molecular characterization of novel PI3K-mTOR inhibitor resistant NSCLC cell lines
  2975. Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold
  2976. B7-H4-mediated immunoresistance is supressed by PI3K/Akt/mTOR pathway inhibitors
  2977. … of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast …
  2978. Ribavirin inhibits the activity of mTOR/eIF4E, ERK/Mnk1/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl …
  2979. Safety and Efficacy of Radiation Therapy Concurrent With VEGF and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
  2980. … kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR …
  2981. The role of mTOR inhibitors in targeting a putative cancer stem cell-like population in esophageal cancer.
  2982. Downregulation of RGS10 induces PI3K/mTOR inhibitor resistance by Ras activation in glioblastoma
  2983. Cell-specific regulation of immediate early gene BZLF1 in Epstein-Barr virus under mTOR inhibition
  2984. Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309
  2985. Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245709) in Tumor Models with Diverse Genetic Alterations Impacting the PI3K Pathway
  2986. New Treatment Options in Gynecologic Malignancy The PI3K/AKT/mTOR Inhibitor in Gynecologic Malignancy
  2987. SP097 PATHOLOGICAL FINDINGS OF PROTOCOL BIOPSY IN KIDNEY TRANSPLANT RECIPIENTS USING MTOR INHIBITOR
  2988. L10 Two novel mtor and PI3K/mTOR inhibitors induce autophagy and reduce the amount of aggregated mutant huntingtin in cell models of HD
  2989. Blockade of mTOR pathway inhibition in the neointimal hyperplasia and promoting macrophage autophagy—Effect of statin-eluting stents to reduce in-stent restenosis
  2990. Chronic mTOR Inhibition by Rapamycin and Diabetes: What is the Role of Mitochondria?
  2991. G115 (P) Use of mTOR inhibitors in children with tuberous sclerosis complex for renal angiomyolipomatosis–does it have secondary benefits on seizures and …
  2992. Genomic analysis of PI3K/AKT/mTOR pathway in mesothelioma and treatment of mesothelioma cell lines in vitro using PI3K/mTOR inhibitor PKI-587
  2993. β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
  2994. Abstract PR01: Adaptive resistance of patient-derived ovarian cancer cells to PI3K/mTOR inhibition
  2995. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
  2996. The Evolving Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in Renal Cell Carcinoma
  2997. Inhibition of mTOR enhances radiosensitivity of lung cancer cells and protects normal lung cells against radiation
  2998. Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) inhibitors in patients with renal cell carcinoma.
  2999. Abstract A117: An integrated phosphoproteomic approach to dissect the mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
  3000. Dual P13K/mTOR Inhibition in Combination With Radiation in a Murine Model of Head and Neck Squamous Cell Carcinoma
  3001. Inhibition of mTOR promotes hyperthermia sensitivity in SMMC-7721 human hepatocellular carcinoma cell line
  3002. Mechanisms of transcriptional regulation of FOXO3 by cofactors upon PI3K/AKT/mTOR inhibition
  3003. Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids
  3004. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
  3005. Abstract A56: A dual PI3K-mTOR inhibitor induced cardiac hypertrophy in mice: Role of the insulin signaling
  3006. β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
  3007. Abstract B46: Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent AKT reactivation
  3008. Radiosensitization of bladder cancer cells by the mTOR inhibitor, RAD001: a novel strategy for treatment
  3009. Abstract B03: Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
  3010. Abstract A34: Therapeutic potential of the novel mTOR inhibitor Torin-2 to overcome AKT reactivation in B-precursor acute lymphoblastic leukemia (B-pre ALL).
  3011. CCAAT/enhancer binding protein beta facilitates castrate-resistant prostate cancer cell growth and sensitivity to mTOR inhibitors
  3012. The ATP-Competitive mTOR Inhibitor AZD8055 Reduces Cell Proliferation and Tumour Load in Chronic Lymphocytic Leukaemia
  3013. ID: 74: Interleukin-6 globally influences stress-signaling by reducing the expression of the mTOR-Inhibitor REDD1 in a STAT3-dependent manner
  3014. mTOR Inhibitors Ameliorate Ischemia-Reperfusion Injury through Endothelin-A Modulation and Reduction of Free Radical Production
  3015. Inhibition of the PI3K/AKT/mTOR pathway leads to down-regulation of c-Myc and overcomes resistance to ATRA in acute myeloid leukemia
  3016. In vivo molecular imaging of the impact of mTOR inhibition on hypoxia signaling in mouse tumor model
  3017. Correlation of decreased pS6 expression under MEK inhibitor (MEKi) with response to MEKi alone or combined with PI3K-mTOR inhibitor (PI3Ki-mTORi) in pancreatic …
  3018. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
  3019. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
  3020. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway
  3021. Cytotoxic activity of the novel dual PI3K/mTOR inhibitor NVP-BGT226 in both normoxic and hypoxic hepatocarcinoma cells
  3022. Increased phosphorylation of eIF4E induces resistance to treatment with mTOR inhibitors alone or together with AR antagonists in advanced prostate cancer
  3023. Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by …
  3024. Loss of Tuberous Sclerosis Complex 2 (TSC2) Confers Sensitivity to mTOR Inhibitor Everolimus in Hepatocellular Carcinoma
  3025. Norepinephrine transporter (NET) as a predictive marker of response to PI3K/mTOR inhibition in pheochromocytoma
  3026. Proliferation inhibition and autophagy induction of PI3K/mTOR inhibitor NVP-BEZ235 in human breast cancer cells
  3027. Ligustrazine suppresses the growth of HRPC cells through the inhibition of cap-dependent translation via both the mTOR and the MEK/ERK pathways
  3028. The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene …
  3029. Abstract C199: PI3K/AKT/mTOR inhibitors enhance the anti-tumor activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in FGF-dependent breast cancer models
  3030. Drug-related pneumonitis during mTOR inhibitor therapy in patients with neuroendocrine tumors: A radiographic pattern-based approach
  3031. Abstract P5-07-07: Combination of IGF1R/FAK inhibition and PI3K/mTOR inhibition in triple-negative breast cancers
  3032. … /mTOR inhibition in cancer models using dual dissociative TORC1/TORC2 (P529), single dissociative TORC1 (rapalogs) and catalytic inhibitors (PI3K/Akt, PI3K/mTOR …
  3033. Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC).
  3034. Abstract B193: Ibrutinib potentiates the effects of mTOR inhibitors and pazopanib in renal cell carcinoma in vitro and in vivo
  3035. mTOR Inhibition With Rapamycin Mitigates Radiation-Induced Pulmonary Fibrosis in a Murine Model
  3036. Testing ER-Beta Agonist Synergy with B7-H1 and mTOR Inhibitors as Novel and Effective Treatments for Ovarian Cancer
  3037. Abstract A67: The mTOR inhibitor, everolimus, enhances the cytotoxicity of pseudomonas-based immunotoxins: Mechanistic insights
  3038. The mammalian target of rapamycin (mTOR) inhibitor rapamycin improves postoperative cognitive dysfunction (POCD)
  3039. Everolimus as Targeted mTOR Inhibition in Neonates and Infants with Tuberous Sclerosis
  3040. Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions
  3041. EPT-17PHASE I STUDY OF BRAF INHIBITOR (VEMURAFENIB) IN COMBINATION WITH THE MTOR INHIBITOR (EVEROLIMUS) IN BRAFV600E POSITIVE …
  3042. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
  3043. Treatment of PIK3CA and APC mutant colorectal cancers with dual PI3K/mTOR inhibition.
  3044. The activity of HDAC and mTOR inhibitors in three dimensional in-vitro model of BRCA-2 mutated breast cancer cell line.
  3045. The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration [Retraction]
  3046. Combination of Metformin and a Dual mTOR Inhibitor Shows Enhanced Inhibitory Effects on Cell Proliferation of Glioblastoma Cells
  3047. A Phase I dose-escalation study of the BRAF inhibitor vemurafenib in combination with the MTOR inhibitor everolimus in subjects with advanced cancer
  3048. The Oral Mtor Inhibitor Everolimus in Relapsed and Refractory Hodgkin Lymphoma-Compassionate Use in 8 Centers in Brazil
  3049. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia
  3050. INAUGURAL ARTICLE by a Recently Elected Academy Member: mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as …
  3051. The dual mTOR inhibitor, AZD2014, and castration increase intra-tumoral immune cell infiltration and anti-tumour activity in a genetically engineered mouse model of …
  3052. Discovery and Process Development of Class I PI3K and Class I PI3K/mTOR Inhibitors GDC-0941 and GDC-0980
  3053. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
  3054. Preclinical data supporting the flavone baicalein as a novel mTOR inhibitor with potent activity against endometrial cancer cells
  3055. OOTR-N006: mTOR inhibition with everolimus in invasive breast cancer patients after pre-operative use of anthracycline and/or taxane-based chemotherapy.
  3056. OP53–2462: The role of mTOR inhibitors in TSC associated epilepsy
  3057. Abstract PR09: Single cell phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in …
  3058. Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma …
  3059. T-Cell Transcriptome Analysis Reveals the Mechanisms Controlling Synergy Between Costimulation Blockade and mTOR Inhibition during GVHD Prevention
  3060. Abstract B11: A dual PI3K/mTOR inhibitor, BEZ235 blocks tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment
  3061. Defining the Role of Autophagy Kinase ULK1 Signaling in Therapeutic Response of Tuberous Sclerosis Complex to mTOR Inhibitors
  3062. p21 WAF1/Cip1-mediated radiosensitization of bladder cancer cells by mTOR inhibitor, RAD001 disrupts the balance between autophagy and apoptosis
  3063. Abstract PR03: The Hippo pathway effector YAP1 contributes to escape from proliferation arrest under chronic PI3K/mTOR inhibition
  3064. Pneumocystis Jirovecii pneumonia (PJP) in metastatic breast cancer (MBC) patients (pts) treated with mTOR inhibitor everolimus (EVE) and exemestane (AI).
  3065. Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus
  3066. … : HCC Recurrence after Liver Transplantation; Preventive Treatment for HCC Recurrence after Liver Transplantation: Role of mTOR Inhibitor and Adjuvant Treatment
  3067. The impact of cetuximab plus AKT-or mTOR-inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.
  3068. FP018 MTOR INHIBITORS PROMOTE AUTOPHAGIC NOT APOPTOTIC CELL DEATH IN PROXIMAL TUBULAR RENAL CELLS, VIA P75NTR ACTIVATION
  3069. Combinatorial Testing of an ERK Inhibitor, SCH-772984 with PI3K/AKT/mTOR Inhibitors in Melanoma
  3070. The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators …
  3071. Dual-Modal Imaging-Guided Theranostic Nanocarriers Based on Indocyanine Green and mTOR Inhibitor Rapamycin
  3072. Abstract P3-05-06: Evolution of genomic alterations on endocrine therapy and mTOR inhibition in estrogen receptor (ER)-positive breast cancer
  3073. … -based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc …
  3074. Abstract CT052: A phase I dose escalation trial of vemurafenib in combination with the mTOR inhibitor everolimus for melanoma and non-melanoma cancers with a …
  3075. … enumeration and characterization has predictive and prognostic implications in patients with metastatic breast cancer treated with exemestane plus the mTOR inhibitor …
  3076. Dual PI3K/mTOR inhibition with BEZ235 augments the therapeutic efficacy of doxorubicin in cancer without influencing cardiac function
  3077. Knock-in of Dnmt3a R878H Recapitulates Human Acute Myeloid Leukemia Harboring DNMT3A Mutation and Is Highly Responsive to mTOR Inhibitor …
  3078. Robust differentiation of human embryonic stem cells into definitive endoderm using Activin A coupled with mTOR inhibition.
  3079. CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway
  3080. A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 …
  3081. Targeting Rac-Gtpases Reverses Stroma-Induced Resistance to Notch and mTOR-Inhibition in Acute T-Cell Leukemia
  3082. Complete Inhibition of STAT5 Phosphorylation Is Achieved By Combination of JAK1/2 and PI3K/mTOR Inhibitors in in Vitro and In Vivo MPN Models
  3083. Mcl-1-mediated resistance to ABT-263 is combated by mTOR inhibition in luminal breast cancers
  3084. Abstract B07: Mcl-1-mediated resistance to ABT-263 is combated by mTOR inhibition in luminal breast cancers
  3085. AB0061 MTOR Inhibition by Rapamycin is Associated with Downregulation of Pro-Infammatory Cytokine TNFα, and Genes Involved in Bone Resoption (MMP-9 and …
  3086. Anti CD20 Radioimmunotherapy and mTOR Inhibition in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Relapsed/Refractory B Cell …
  3087. Abstract LB-040: mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction upon 4E-BP1 dephosphorylation
  3088. Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid …
  3089. Addition of mTOR inhibition to HER2 blockade results in improved antitumor activity in a preclinical model of uterine serous carcinoma with HER2 gene amplification …
  3090. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors
  3091. Response to Comment on “mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive …
  3092. Autophagy and mTOR inhibition as mechanisms for combatting chemoresistance to standard chemotherapy: Final results of a phase I study of infusional …
  3093. Fisetin suppresses lipid accumulation in mouse adipocytic 3T3-L1 cells by repressing GLUT4-mediated glucose uptake through inhibition of mTOR-C/EBPα signaling
  3094. Research progress of small molecule inhibitors targeting PI3K-Akt-mTOR pathway
  3095. MB-20EVALUATING THE ONCOGENIC POTENTIAL OF TSC1/2 MUTATIONS AND EFFICACY OF MTOR INHIBITORS IN HIGH RISK PEDIATRIC …
  3096. Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.
  3097. EPN-26ONCOLOGY DRUG SCREEN IDENTIFIES EPENDYMOMA-SELECTIVE POTENCY OF 5-FU ANALOGS AND mTOR INHIBITORS
  3098. Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.
  3099. VS-5584, a dual PI3K/mTOR inhibitor, demonstrates robust activity in pre-clinical models of SCLC with the inhibition of both cancer stem cells and bulk tumor cells
  3100. Abstract A15: Dual inhibition of the PI3K-mTOR signaling in combination with HER2 inhibitor is necessary for maximal antitumor activity in HER2+ breast cancer cells
  3101. D23 PEDIATRIC RARE DISEASES AND LUNG DEVELOPMENT: A Phase 2 Clinical Trial Assessing Efficacy And Safety Of The Mtor Inhibitor Sirolimus In The …
  3102. DPP IV inhibitor suppresses STZ-induced islets injury dependent on activation of the IGFR/Akt/mTOR signaling pathways by GLP-1 in monkeys
  3103. Phosphatidylinositol 3-kinase (PI3K) and mTOR inhibitors demonstrate broad efficacy and synergy in head and neck cancer cell lines and patient-derived xenografts
  3104. Abstract A34: GDC-0980, a dual PI3K/mTOR inhibitor, selectively inhibits NF2 mutant malignant mesothelioma (MM) cells and inhibits TOR signaling without activating …
  3105. CLINICAL PHARMACOKINETICS AND BRAIN PENETRATION OF GDC-0084, AN ORAL PI3K/mTOR INHIBITOR, IN PATIENTS WITH HIGH-GRADE GLIOMA.
  3106. Approaches to mTOR pathway inhibition in acute leukemic cell lines
  3107. Abstract B09: Targeting the anti-apoptotic protein Mcl-1 with the mTOR inhibitor RAD001 sensitizes luminal breast cancers to the Bcl-2/Bcl-xL inhibitor ABT-263
  3108. Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax
  3109. Abstract B53: Effects of metformin and ATP-competitive inhibitor of mTOR on targeted-metabolomic profile in HPAF-II pancreatic cancer cell lines
  3110. Abstract P3-06-04: 4EVER: The impact of mTOR inhibition on bone health in postmenopausal women with hormone receptor positive (HR+) advanced breast cancer …
  3111. ATPS-46 Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
  3112. Integrative drug sensitivity analysis of PI3K/mTOR pathway inhibitors in Head and Neck Squamous Cell Carcinoma (HNSCC)
  3113. … -3 promotes proprioceptive axon regeneration when combined with activation of the mTor intrinsic growth pathway but not with reduction of myelin extrinsic inhibitors
  3114. Lysine-specific demethylase 1 (LSD1) inhibitor S2101 induces autophagy via the AKT/mTOR pathway in SKOV3 ovarian cancer cells
  3115. Advances in inhibitors of PI3K/Akt/mTOR pathway in treatment of advanced breast cancer
  3116. MP88-09 PRECLINICAL MODEL OF DUAL-SPECIFIC, MTOR COMPLEX 1 (TORC1) AND MTOR COMPLEX 2 (TORC2) INHIBITORS FOR BLADDER CANCER …
  3117. Abstract A109: Dual mTOR/PI3K inhibitors induce compensatory MEK/ERK activation in human pancreatic cancer cells: A mechanism contributing to drug resistance
  3118. Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro
  3119. Topical mTOR (mechanistic target of rapamycin) inhibitor therapy in facial angiofibroma
  3120. Abstract P6-02-01: Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors
  3121. … triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with …
  3122. Inhibition of mTOR induces chemoresistance in B-cell acute lymphoblastic leukemia
  3123. Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer
  3124. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent
  3125. … exerts antiproliferative effect and downregulates vegf signaling in caco‐2 human colon carcinoma cell line through a selective ppar‐α‐dependent inhibition of akt/mtor …
  3126. Abstract B57: Effects of MEK inhibition alone or in combination with PI3K-mTOR pathway inhibitors in pancreatic ductal adenocarcinoma in vitro and on an innovative …
  3127. Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in …
  3128. Inhibition of 11β-Hydroxysteroid dehydrogenase type II suppresses lung carcinogenesis by blocking tumor COX-2 expression as well as the ERK and mTOR …
  3129. The combination of GDC-0980, a PI3K/mTOR kinase inhibitor and BAY-86-9766, a MEK inhibitor is able to induce cell growth inhibition of HER2 positive Trastuzumab …
  3130. Abstract A53: Dual inhibition of mTOR in hepatocellular carcinoma: Autophagy friend or foe?
  3131. Involvement of mTOR in type 2 CRF receptor inhibition of insulin signaling in muscle cells
  3132. Abstract A16: DDR-mediated antitumor actions of PARP inhibitor: Can PI3K-mTOR pathway inhibitor be combined with PARP inhibitor in TNBT?
  3133. Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway
  3134. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells
  3135. Inhibition of TK better than MTOR
  3136. … derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR/p70s6k signaling pathway
  3137. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways
  3138. The discovery and process chemistry development of GDC-0084, a brain penetrating inhibitor of PI3K and mTOR
  3139. MTOR kinase inhibition results in oocyte loss characterized by empty follicles in human ovarian cortical strips cultured in…
  3140. Identification of a novel long intergenic noncoding RNA-LINC00936, with significant impact on multiple myeloma cell growth via mtor pathway inhibition
  3141. A cocktail of specific inhibitors of HER-2, PI3K, and mTOR radiosensitises human breast cancer cells
  3142. Management of Advanced Endometrial Cancer and Inhibitors of the PI3K/AKT/mTOR Pathway
  3143. Comparative cancer cell line profiling differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors
  3144. PI3K/Akt/mTOR pathway inhibition in chemotherapy-sensitive and-resistant models of Burkitt Lymphoma
  3145. Inhibition of DNA nanotube-conjugated mTOR siRNA on the growth of pulmonary arterial smooth muscle cells
  3146. Design and development of novel mTOR and SRC family kinase inhibitors via a phenotypic drug discovery approach
  3147. Abstract A35: Proteomic and transcriptional profiling reveal differential responses to combined MEK and PI3K-mTOR network inhibition in basal-like and mesenchymal …
  3148. Mechanisms of resistance to PBK-Akt-mTOR signaling pathway inhibitors
  3149. TARGETED INHIBITION OF PI3K, MTOR, AND IGF1R FOR THE TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
  3150. Abstract B59: Dual mTOR kinase inhibitor reverses rapamycin resistance in prostate cancer cells
  3151. Analysis of mTOR Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.
  3152. Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple …
  3153. Inhibition of mTOR Signaling Protects Against Myocardial Reperfusion Injury, Acute Myocardial Infarction
  3154. Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors.
  3155. Dual inhibition of the PI3K/mTOR and MAPK pathways in Non-Hodgkin Lymphoma
  3156. Effect of PI3K inhibitor LY294002 combined with RAD001, a mTOR specificity inhibitor, on proliferation and apoptosis of triple-negative breast cancer cell lines MDA …
  3157. … chromosome positive acute lymphoblastic leukemia cells are also resistant to ABL inhibitors, which can be overcome by targeting the PI3K/AKT/mTOR …
  3158. Cranberry proanthocyanidins induce autophagic cell death via ROS generation and inhibition of AKT/mTOR/MAPK signaling pathways in esophageal …
  3159. Inhibition of mTOR as Antiangiogenic Strategy in Multiple Myeloma
  3160. Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination
  3161. Abstract B50: Targeting KRASG12D colorectal cancer with combined inhibition of PI3K/mTOR and MAPK signaling
  3162. Research Article Inhibition of mTOR by Rapamycin Results in Auditory Hair Cell Damage and Decreased Spiral Ganglion Neuron Outgrowth and Neurite …
  3163. Dual mTOR kinase inhibitor overcomes rapamycin resistance in vitro
  3164. Metformin Sensitizes Glucose Starved Microvascular Endothelial Cells to Death by Inhibition of the mTOR Pathway and Autophagy
  3165. Targeting glioblastoma and its stem cells using novel small molecule inhibitors of the mTOR pathway
  3166. HG-121THE EFFECTS OF MTOR COMPLEX 1/2 INHIBITION ON DIFFUSE INTRINSIC PONTINE GLIOMA CELLS
  3167. Abstract A36: Combined inhibition of PI3K isoforms and mTOR kinase is critical for cancer stem cell inhibition by VS-5584
  3168. Dual targeting of PI3K/mTOR leads to MEK/ERK over-activation in leiomyosarcoma through suppression of mTORC2 inhibition
  3169. … 08 SYNERGISTIC ANTICANCER EFFECT OF COMBINATION TREATMENT WITH MEK INHIBITOR AND PI3K/MTOR DUAL INHIBITOR IN CASTRATION-RESISTANT …
  3170. Targeting therapy-resistant gastric and esophageal cancers with mTOR ATP site inhibitors
  3171. A Novel Approach to QTc Studies: Assessing Cardiac Safety of the mTOR Kinase Inhibitor CC-223 within the Dose-Escalation/Expansion Study
  3172. MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR …
  3173. Evaluation of small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 for their radiomodulatory effects in human breast cancer cell lines
  3174. Inhibition of mTOR Increases the Severity of Lung Inflammation in Mice Infected With Influenza A Virus
  3175. Abstract B02: mTOR/S6K pathway-dependent metabolic reprogramming in cancer cells mediates resistance to glycolytic inhibitors
  3176. Protein phosphatase 4 regulates cell survival and responses to PI3K/AKT/mTOR pathway inhibitors in breast cancer cell lines
  3177. CHLOROQUINE DOES NOT CANCEL E1A+ cHa-Ras TRANSFORMANTS’DEATH INDUCED BY mTOR KINASE INHIBITOR pp242..
  3178. … A41: Automated immunohistochemistry of phosphobiomarkers: Case study of MTOR (MLN0128) and PI3Kα (MLN1117) investigational inhibitors, single agent and in …
  3179. mTOR signaling pathway for regulating inhibition of 1, 25 dihydroxyvitamin D3 on Hep-2 cells proliferation in laryngeal carcinoma
  3180. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
  3181. mTOR Pathway Inhibition Prevents Neuroinflammation and Neuronal Death in a Mouse Model of Spinal Cord Injury
  3182. Genetic and pharmacologic inhibition of mTOR delays mortality due to thymc lymphoma formation in mice and is associated with decreases in cell cycle proteins
  3183. Effect of Rapamycin as an Inhibitor of the mTOR Cell Cycle Entry Complex on the Selective Lysis of Human Leukemia Cells Lines in Vitro Using 20 kHz Pulsed Low …
  3184. … suppresses systemic autoimmunity in Roquinsan/San mice through inhibition of B cell differentiation into plasma cells VIA AMPK/MTOR/Stat3 Pathway Regulation
  3185. Inhibition of the PI3K/AKT/mTOR pathway in a murine model attenuates primordial follicle depletion during gonadotoxic chemotherapy
  3186. Evaluation of the effect of selected Pl3K/Akt/mTOR and RAF/MEK/ERK pathways inhibitors on proliferation and apoptosis in human H295R adrenocortical …
  3187. Glutamine PET to Predict Response to Dual Pharmacological Inhibition of BRAFV600E and PI3K/mTOR Pathway Activity in vivo.
  3188. … derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR …
  3189. … VARIANT-TARGETED COMBINATION THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER USING EPI-002 AND A PI3K/MTOR DUAL INHIBITOR
  3190. Cell-based screening identifies gene expression signature correlated with sensitivity to PI3K-mTOR dual inhibitor BEZ235
  3191. Biomarker analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/RAD001
  3192. Sequential treatment of HCC cells with PI3K/Akt/mTOR pathway inhibitors prior to sorafenib attenuates cancer stem cell population
  3193. Paclitaxel exerts anticancer bioactivity on SGC7901 human gastric adenocarcinoma cell line through inhibition of Akt/mTOR signaling pathway
  3194. Fibroblast-induced switching to the invasive phenotype and PI3K-mTOR signaling protects melanoma cells from BRAF inhibitors
  3195. Metformin Mediated Inhibition of the mTOR Pathway Promotes Death in Glucose Starved Micro-Vascular Endothelial Cells
  3196. Abstract P6-07-01: Anti-tumor efficacy of PI3K-mTOR pathway inhibitors in combination with PARP inhibitor plus carboplatin in BRCA1-competent TNBC, beyond …
  3197. 133P The mTOR kinase inhibitor AZD-2014 enhances the antitumor effects of XPO1 antagonist KPT-185 in mantle cell lymphoma
  3198. GDC-0980, a novel PI3K/mTOR kinase inhibitor, is effective in HER2 positive gastric cancer (GC) cell lines resistant to Trastuzumab
  3199. Inhibition of mTOR signaling by everolimus has concurrent anti-tumor and bone-protective effects in murine osteolytic cancer models
  3200. Peer review report 1 on “P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway”
  3201. Pharmacological Inhibition Of Mtor Kinase Activity Reverses Sugen/hypoxia-Induced Pulmonary Hypertension, Right Ventricular Hypertrophy, And Improves Heart …
  3202. PTPS-22 Dual mTOR kinase inhibitor (MLN0128) markedly induces growth suppression and apoptosis in diffuse intrinsic pontine glioma cell lines
  3203. mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies
  3204. … Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors
  3205. … changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-κB or the PI3K/mTOR …
  3206. Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia
  3207. Abstract LB-C22: Acquired resistance to the cMET inhibitor savolitinib in lung cancer models through EGFR/mTOR/MYC deregulation and adoption of PIM signaling
  3208. A66 PH: MOLECULES, CELLS AND ANIMAL MODELS: Pharmacological Inhibition Of Mtor Kinase Activity Reverses Sugen/hypoxia-Induced Pulmonary Hypertension …
  3209. The energy sensor AMP-activated protein kinase (AMPK) signals neuronal death in glaucoma through inhibition of the mammalian target of rapamycin (mTOR).
  3210. MP92-14 INHIBITION OF MTOR/AKT PATHWAY ENHANCES CELL DEATH VIA AUTOPHAGY IN RENAL CELL CARCINOMA
  3211. Targeted inhibition of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) sensitizes pancreatic cancer cells to doxorubicin without exacerbating …
  3212. Abstract B107: Targeting PI3K and mTOR with GDC-0980, a dual inhibitor, is efficacious in trastuzumab refractory and HER2+/PIK3CA-mutated breast cancer models
  3213. … : [Pt(O,O’-acac)(γ-acac)(DMS)] Alters SH-SY5Y Cell Migration and Invasion by the Inhibition of Na+/H+ Exchanger Isoform 1 Occurring through a PKC-ε/ERK/mTOR …
  3214. Peer review report 2 on “P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway”
  3215. Cancer and mTOR inhibitors in transplant recipients
  3216. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
  3217. mTOR inhibitor therapy and metabolic consequences: where do we stand?
  3218. mTOR inhibition role in cellular mechanisms
  3219. The therapeutic potential of PI3K/Akt/mTOR inhibitors in breast cancer: rational and progress
  3220. The role of mTOR inhibitors in the management of viral infections: a review of current literature
  3221. mTOR inhibition and kidney diseases
  3222. mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis
  3223. Therapeutic use of mTOR inhibitors in renal diseases: advances, drawbacks, and challenges
  3224. Clinical development of mTor inhibitors for renal cancer
  3225. Deptor: not only a mTOR inhibitor
  3226. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
  3227. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
  3228. Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review
  3229. MTOR inhibitor-based combination therapies for pancreatic cancer
  3230. mTOR inhibitors in castration-resistant prostate cancer: a systematic review
  3231. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
  3232. PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy
  3233. Recent advances and challenges of mTOR inhibitors use in the treatment of patients with tuberous sclerosis complex
  3234. Evolving significance and future relevance of anti-angiogenic activity of mTOR inhibitors in cancer therapy
  3235. Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
  3236. Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis
  3237. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid …
  3238. … the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with …
  3239. … for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition
  3240. mTOR inhibition and cardiovascular diseases: cardiac hypertrophy
  3241. mTOR inhibition and clinical transplantation: heart
  3242. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
  3243. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
  3244. mTOR inhibition rejuvenates the aging gingival fibroblasts through alleviating oxidative stress
  3245. Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
  3246. Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
  3247. Disruption of peroxisome function leads to metabolic stress, mTOR inhibition, and lethality in liver cancer cells
  3248. mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2
  3249. A novel mTOR inhibitor; anthracimycin for the treatment of human hepatocellular carcinoma
  3250. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer
  3251. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients
  3252. Additive cytotoxic effects of radiation and mTOR inhibitors in a cervical cancer cell line
  3253. Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers
  3254. Emerging perspectives on mTOR inhibitor‐associated pneumonitis in breast cancer
  3255. A multi-arm phase I study of the PI3K/mTOR inhibitors PF-04691502 and gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in …
  3256. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)
  3257. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma
  3258. Selective effects of mTOR inhibitor sirolimus on naïve and CMV-specific T cells extending its applicable range beyond immunosuppression
  3259. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition
  3260. Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition
  3261. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor
  3262. Discovery and development of ATP-competitive mTOR inhibitors using computational approaches
  3263. Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression
  3264. Exploiting radiation-induced signaling to increase the susceptibility of resistant cancer cells to targeted drugs: AKT and mTOR inhibitors as an example
  3265. mTOR inhibition and clinical transplantation: pancreas and islet
  3266. The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in …
  3267. Phase I trial of the mTOR inhibitor everolimus in combination with multi‐agent chemotherapy in relapsed childhood acute lymphoblastic leukemia
  3268. A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer
  3269. The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma
  3270. RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition
  3271. Protection by mTOR inhibition on zymosan-induced systemic inflammatory response and oxidative/nitrosative stress: contribution of mTOR/MEK1/ERK1/2/IKKβ/IκB-α …
  3272. CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128
  3273. mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus
  3274. MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
  3275. NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with …
  3276. Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms
  3277. CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
  3278. The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous …
  3279. Low-dose controlled release of mTOR inhibitors maintains T cell plasticity and promotes central memory T cells
  3280. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer
  3281. Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR inhibition in primary human acute myeloid leukemia cells is associated with altered cell metabolism
  3282. Anti-cancer effects of radix Angelica sinensis (Danggui) and N-butylidenephthalide on gastric cancer: Implications for REDD1 activation and mTOR inhibition
  3283. Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition
  3284. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation
  3285. mTOR inhibition in glioblastoma: requiem for a dream?
  3286. … in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor …
  3287. Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma
  3288. The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
  3289. … inhibits cell growth and pro-inflammatory response in IL-1β-stimulated fibroblast-like synoviocytes by enhancement of autophagy via PI3K/AKT/mTOR inhibition
  3290. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells
  3291. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma
  3292. Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis
  3293. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells
  3294. Everolimus as an mTOR inhibitor suppresses endometriotic implants: an experimental rat study
  3295. Adeno-associated viral vector-mediated mTOR inhibition by short hairpin RNA suppresses laser-induced choroidal neovascularization
  3296. The dual PI3K/mToR inhibitor omipalisib/GSK2126458 inhibits clonogenic growth in oncogenically-transformed cells from neurocutaneous melanocytosis
  3297. Impact on autophagy and ultraviolet B induced responses of treatment with the MTOR inhibitors rapamycin, everolimus, torin 1, and pp242 in human …
  3298. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity
  3299. mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease …
  3300. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
  3301. mTOR inhibition via displacement of phosphatidic acid induces enhanced cytotoxicity specifically in cancer cells
  3302. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8
  3303. PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
  3304. Multinuclear NMR and MRI reveal an early metabolic response to mTOR inhibition in sarcoma
  3305. Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of rapamycin binding site
  3306. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors
  3307. Early LC3 lipidation induced by d-limonene does not rely on mTOR inhibition, ERK activation and ROS production and it is associated with reduced clonogenic …
  3308. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
  3309. On the pathogenesis of mTOR inhibitor‐associated stomatitis (mIAS)—studies using an organotypic model of the oral mucosa
  3310. Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
  3311. mTor inhibitors for the treatment of endometriosis
  3312. Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity
  3313. Improved Fetal Hemoglobin With mTOR Inhibitor–Based Immunosuppression in a Kidney Transplant Recipient With Sickle Cell Disease
  3314. Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
  3315. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
  3316. Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen
  3317. Highly selective, potent, and oral mTOR inhibitor for treatment of cancer as autophagy inducer
  3318. … atovaquone selectively increases chemosensitivity in retinoblastoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition
  3319. Two mTOR inhibitors, rapamycin and Torin 1, differentially regulate iron-induced generation of mitochondrial ROS
  3320. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis
  3321. Neuroimaging biomarkers of mTOR inhibition on vascular and metabolic functions in aging brain and Alzheimer’s disease
  3322. mTOR inhibition mitigates molecular and biochemical alterations of vigabatrin-induced visual field toxicity in mice
  3323. Interleukin-1β is associated with coronary endothelial dysfunction in patients with mTOR-inhibitor-eluting stent implantation
  3324. mTOR inhibition and clinical transplantation: kidney
  3325. The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus
  3326. mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma cells in vitro
  3327. PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4
  3328. Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
  3329. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma
  3330. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
  3331. A review of mTOR pathway inhibitors in gynecologic cancer
  3332. The return of the mTOR inhibitors: getting it right in patients after cardiac transplantation
  3333. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with …
  3334. Expert opinion on the metabolic complications of mTOR inhibitors
  3335. mTOR inhibitors for treatment of low-risk prostate cancer
  3336. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
  3337. Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide‑induced autophagic death of U251 glioma cells
  3338. Effects of mTOR inhibition on cardiac and adipose tissue pathology and glucose metabolism in rats with metabolic syndrome
  3339. Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer
  3340. mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
  3341. Gemcitabine combined with the mTOR inhibitor temsirolimus in patients with locally advanced or metastatic pancreatic cancer. A hellenic cooperative oncology group …
  3342. Invasive pulmonary aspergillosis mimicking organizing pneumonia after mTOR inhibitor therapy: A case report
  3343. Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
  3344. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC)
  3345. Potential natural mTOR inhibitors screened by in silico approach and suppress hepatic stellate cells activation
  3346. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study
  3347. The impact of cetuximab plus AKT-or mTOR-inhibitor in a patient-derived colon cancer cell model with wild-type RAS and PIK3CA mutation
  3348. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced …
  3349. Effect of dual mTOR inhibitor on TGFβ1-induced fibrosis in primary human urethral scar fibroblasts
  3350. Triggering of eryptosis, the suicidal erythrocyte death by mammalian target of rapamycin (mTOR) inhibitor temsirolimus
  3351. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
  3352. … carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors
  3353. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and …
  3354. Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma
  3355. Intermittent mTOR inhibition reverses kidney aging in old rats
  3356. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1
  3357. Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors
  3358. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors
  3359. Immunosuppression with mTOR inhibitors prevents the development of donor‐specific antibodies after liver transplant
  3360. The role of endothelial colony forming cells in kidney cancer’s pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review
  3361. The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
  3362. … -1, 3, 5-triazin-2-yl)-4-(trifluoromethyl) pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate …
  3363. Nanosecond pulsed electric fields enhance the anti-tumour effects of the mTOR inhibitor everolimus against melanoma
  3364. Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells
  3365. Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
  3366. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.
  3367. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
  3368. Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients
  3369. The influence of mTOR inhibitors on the incidence of CMV infection in high‐risk donor positive–recipient negative (D+/R−) kidney transplant recipients
  3370. Controlled release of second generation mTOR inhibitors to restrain inflammation in primary immune cells
  3371. Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor
  3372. Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells
  3373. The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cell functions, critical for re-endothelialisation after percutaneous …
  3374. Therapeutic relevance of mTOR inhibition in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism
  3375. Evidence of the immunomodulatory role of dual PI 3K/mTOR inhibitors in transplantation: an experimental study in mice
  3376. Calcineurin and mtor inhibitor–free post-transplantation cyclophosphamide and bortezomib combination for graft-versus-host disease prevention after …
  3377. Discovery of an orally bioavailable dual PI3K/mTOR inhibitor based on sulfonyl-substituted morpholinopyrimidines
  3378. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions
  3379. Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition
  3380. Critical analysis of graft loss and death in kidney transplant recipients treated with mTOR inhibitors
  3381. Presurgical administration of mTOR inhibitors in patients with large subependymal giant cell astrocytoma associated with tuberous sclerosis complex
  3382. Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
  3383. mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines
  3384. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro
  3385. Renal cell carcinoma associated with Xp11. 2 translocation/TFE3 gene-fusion: a long response to mammalian target of rapamycin (mTOR) inhibitors
  3386. MANTA-a randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor …
  3387. A system to identify inhibitors of mTOR signaling using high-resolution growth analysis in Saccharomyces cerevisiae
  3388. Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition
  3389. Recent advances in targeting mTOR signaling pathway using small molecule inhibitors
  3390. Phosphoramide mustard induces autophagy markers and mTOR inhibition prevents follicle loss due to phosphoramide mustard exposure
  3391. High incidence of ovarian cysts in women receiving mTOR inhibitors after renal transplantation
  3392. VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute …
  3393. HIF is not essential for suppression of experimental tumor growth by mTOR inhibition
  3394. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma
  3395. HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
  3396. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis
  3397. The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes
  3398. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic …
  3399. Overcoming palbociclib resistance by combined treatment with PI3K/AKT/mTOR inhibitors in mesothelioma cells
  3400. Potential targets’ analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas—an ENITEC Group Initiative
  3401. Synergistically suppressive effects on colorectal cancer cells by combination of mTOR inhibitor and glycolysis inhibitor, Oxamate
  3402. Pharmacological inhibition of mTOR kinase reverses right ventricle remodeling and improves right ventricle structure and function in rats
  3403. Drug repurposing: Targeting mTOR inhibitors for anticancer activity
  3404. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts
  3405. The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+/-mice through suppression of cell proliferation and induction …
  3406. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment
  3407. Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis
  3408. 3D-QSAR, virtual screening, docking and design of dual PI3K/mTOR inhibitors with enhanced antiproliferative activity
  3409. Design, synthesis, and biological evaluation of imidazo [1, 2-b] pyridazine derivatives as mTOR inhibitors
  3410. Is there a role for mTOR inhibitors in renal transplantation?
  3411. Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures
  3412. Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
  3413. Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation
  3414. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
  3415. Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition
  3416. Cancer and mTOR inhibitors in kidney transplantation recipients
  3417. Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling
  3418. Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives
  3419. Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials
  3420. Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
  3421. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia
  3422. Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma
  3423. PI3K–mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models
  3424. G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer
  3425. Discovery of pyridopyrimidinones as potent and orally active dual inhibitors of PI3K/mTOR
  3426. mTOR signalling pathway-protein expression in post-transplant cutaneous squamous-cell carcinomas before and after conversion to mTOR-inhibitors
  3427. Inhibition of mTOR complexes protects cancer cells from glutamine starvation induced cell death by restoring Akt stability
  3428. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer
  3429. Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
  3430. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1
  3431. Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia
  3432. Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report
  3433. Inhibition of the mTOR pathway in abdominal aortic aneurysm: implications of smooth muscle cell contractile phenotype, inflammation, and aneurysm expansion
  3434. … synthesis, cytotoxicity evaluation and docking studies of 1, 2, 4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors
  3435. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: Clinical evidence and current challenges
  3436. New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation
  3437. Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis
  3438. FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor
  3439. OTUB1 protein suppresses mTOR complex 1 (mTORC1) activity by deubiquitinating the mTORC1 inhibitor DEPTOR
  3440. Abstract GS2-07: MANTA-A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in …
  3441. Inhibition of the AKT/mTOR pathway augments the anticancer effects of sorafenib in thyroid cancer
  3442. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and …
  3443. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
  3444. Consensus scoring model for the molecular docking study of mTOR kinase inhibitor
  3445. Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
  3446. Effects of resveratrol, lovastatin and the mTOR-inhibitor RAD-001 on insulin-induced genomic damage in vitro
  3447. mTOR (mechanistic target of rapamycin) inhibition decreases mechanosignaling, collagen accumulation, and stiffening of the thoracic aorta in elastin-deficient mice
  3448. The mTOR kinase inhibitor everolimus synergistically enhances the anti‐tumor effect of the Bruton’s tyrosine kinase (BTK) inhibitor PLS‐123 on Mantle cell lymphoma
  3449. Beneficial effects of resveratrol-mediated inhibition of the mTOR pathway in spinal cord injury
  3450. mTOR inhibition subdues milk disorder caused by maternal VLDLR loss
  3451. Breast cancer patients have increased risk of developing mTOR inhibitor‐associated stomatitis
  3452. mTOR inhibition by everolimus does not impair closure of punch biopsy wounds in renal transplant patients
  3453. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma
  3454. Effects of mTOR Inhibitor Rapamycin on Burkitt’s Lymphoma Cells
  3455. The long journey of mtor inhibitors and the long path that is still ahead
  3456. Potent Anticancer and mTOR Inhibitor Activities of Some Synthesized Linear and Macrocyclic Pyridine Derivatives
  3457. hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells
  3458. Phase 2 trial of single agent gedatolisib (PF-05212384), a dual PI3K/mTOR inhibitor, for adverse prognosis and relapse/refractory AML: clinical and …
  3459. Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities
  3460. mTOR masters monocyte development in bone marrow by decreasing the inhibition of STAT5 on IRF8
  3461. Streptomyces sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines
  3462. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
  3463. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
  3464. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease
  3465. Anti-proliferative effect of metformin on a feline injection site sarcoma cell line independent of Mtor inhibition
  3466. Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR
  3467. Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors
  3468. GSK458 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in T Cell lymphomas as a single agent and in combination therapy
  3469. Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer
  3470. Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes
  3471. Evaluation of quantitative changes in regulatory T cells in peripheral blood of kidney transplant recipients with skin cancer after conversion to mTOR inhibitors
  3472. Combined inhibition of PI3Kβ and mTOR inhibits growth of PTEN-null tumors
  3473. Effect of confounding factors on a phospho-flow assay of ribosomal S6 protein for therapeutic drug monitoring of the mTOR-inhibitor everolimus in heart transplanted …
  3474. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance
  3475. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication
  3476. Acid suspends the circadian clock in hypoxia through inhibition of mTOR
  3477. mTOR inhibitors in uterine and extra-uterine malignant PEComas: a multicenter international case series retrospective analysis
  3478. mTOR and HDAC inhibitors converge on the TXNIP/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors
  3479. Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation
  3480. Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells
  3481. SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway
  3482. Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer
  3483. Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor–positive breast cancer
  3484. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia
  3485. Effect and mechanism of inhibition of PI3K/Akt/mTOR signal pathway on chronic neuropathic pain and spinal microglia in a rat model of chronic constriction …
  3486. In vivo evaluation of the synergic effect of metformin and mTOR inhibitors on the endothelial healing of drug-eluting stents in diabetic patients
  3487. c‑Myc promotes cholangiocarcinoma cells to overcome contact inhibition via the mTOR pathway
  3488. The role of antioxidant proteins in improvement of autism core symptoms in two patients with tuberous sclerosis treated with mTOR inhibitor everolimus
  3489. NLRC3 mediated PI3K-mTOR inhibition takes a toll on colon cancer
  3490. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition
  3491. Design, synthesis and biological evaluation of novel 3H-imidazole [4, 5-b] pyridine derivatives as selective mTOR inhibitors
  3492. Glycolysis inhibition via mTOR suppression is a key step in cardamonin-induced autophagy in SKOV3 cells
  3493. Tetrandrine, an activator of autophagy, induces autophagic cell death via PKC-α inhibition and mTOR-dependent mechanisms
  3494. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1
  3495. mTOR Inhibition for Transplantation: More May Not Be Better
  3496. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
  3497. PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium
  3498. Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
  3499. Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight
  3500. Correction to: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
  3501. PI3K/mTOR dual inhibitor, LY3023414, demonstrates potent antitumor efficacy against esophageal adenocarcinoma in a rat model
  3502. Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition
  3503. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma
  3504. Design, synthesis, and biological evaluation of dimorpholine substituted thienopyrimidines as potential class I PI3K/mTOR dual inhibitors
  3505. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
  3506. Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer
  3507. UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism
  3508. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer
  3509. Evaluating the effectiveness of MAPK, AKT, and mTOR inhibitors in reducing proliferation in cellular models of papillary and follicular thyroid cancer
  3510. The macrolide toxin mycolactone promotes bim-dependent apoptosis in Buruli ulcer through inhibition of mTOR
  3511. Clinical Outcomes after switch to mTOR inhibitors in kidney transplant recipients
  3512. Maternal folate deficiency causes inhibition of mTOR signaling, down-regulation of placental amino acid transporters and fetal growth restriction in mice
  3513. Efficiency of an mTOR inhibitor in Kasabach-Merritt phenomenon with indolent tufted angioma: a case report
  3514. Preserving Treg Function: Beyond mTOR Inhibitors
  3515. Inhibition of mTOR signaling pathway delays follicle formation in mice
  3516. Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy of articular chondrocytes and attenuates inflammatory response in rats with osteoarthritis
  3517. mTOR inhibition decreases mechanosignaling, collagen accumulation, and stiffening of the thoracic aorta in elastin-deficient mice
  3518. Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: safety and survival
  3519. Inhibition of mTOR pathway decreases the expression of pre‐meiotic and meiotic markers throughout postnatal development and in adult testes in mice
  3520. DIPG-29. Preclinical efficacy of combined ACVR1 and PI3K/mTOR inhibition in diffuse intrinsic pontine glioma (DIPG)
  3521. Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition
  3522. Neuroprotective strategy in retinal degeneration: suppressing ER stress-induced cell death via inhibition of the mTOR signal
  3523. mTOR Inhibition to Prevent Posttransplant Malignancies—Don’t Stop Believin’
  3524. Inhibition of human lung cancer cell proliferation and survival by post-exercise serum is associated with the inhibition of Akt, mTOR, p70 S6K, and Erk1/2
  3525. Combined inhibition of autophagy with mTOR inhibitor to enhance cell death in renal cell carcinoma.
  3526. ROS promote Ox-LDL-induced platelet activation by up-regulating autophagy through the inhibition of the PI3K/AKT/mTOR pathway
  3527. Natural cyclopeptide RA-XII, a new autophagy inhibitor, suppresses protective autophagy for enhancing apoptosis through AMPK/mTOR/P70S6K pathways in HepG2 …
  3528. The mTOR kinase inhibitor CZ415 inhibits human papillary thyroid carcinoma cell growth
  3529. A pharmacokinetic–pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055
  3530. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of …
  3531. HDAC inhibition counteracts metastatic re-activation of prostate cancer cells induced by chronic mTOR suppression
  3532. … characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
  3533. Inhibition of autophagy via activation of PI3K/Akt/mTOR pathway contributes to the protection of hesperidin against myocardial ischemia/reperfusion injury
  3534. … -tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular …
  3535. Inhibition of the PI3K-Akt-mTOR signaling pathway in T lymphocytes in patients with active tuberculosis
  3536. Interaction between mTOR pathway inhibition and autophagy induction attenuates adriamycin-induced vascular smooth muscle cell senescence through decreased …
  3537. Inhibition of Akt/mTOR/p70S6K signaling activity with Huangkui capsule alleviates the early glomerular pathological changes in diabetic nephropathy
  3538. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
  3539. Experience of Using mTOR Inhibitor in Lung Transplant at Recipients With Lymphangioleiomyomatosis
  3540. Cap-independent translation ensures mTOR expression and function upon protein synthesis inhibition
  3541. PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis
  3542. Pharmacological inhibition of O-GlcNAcase enhances autophagy in brain through an mTOR-independent pathway
  3543. Correction: the dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
  3544. Exploring the effects and effectors of mTOR inhibition in oncolysis and TOP mRNA translation
  3545. MEDU-44. TARGETING SHH SIGNALING VIA PI3K/MTOR INHIBITION IN MEDULLOBLASTOMA AND EWING SARCOMA
  3546. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma
  3547. Inhibition of mast cell function and proliferation by mTOR activator MHY1485
  3548. Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma
  3549. Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib
  3550. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia
  3551. Leucine can modulate the expression of proteins related to protein degradation signalling under mTOR inhibition in C2C12 cells
  3552. PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy
  3553. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway
  3554. microvascular integrity can be preserved by anti-platelet therapy and in combination with mTOR inhibitor
  3555. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network
  3556. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma
  3557. mTOR inhibition prolongs reproductive longevity in a murine model of physiologic ovarian aging
  3558. Matrine induces Akt/mTOR signalling inhibition‐mediated autophagy and apoptosis in acute myeloid leukaemia cells
  3559. Activated cMyc/PIM kinase promotes resistance to PI3K/mTOR inhibition in NSCLC
  3560. Inhibition of mammalian target of rapamycin (mTOR) signaling in the insular cortex alleviates neuropathic pain after peripheral nerve injury
  3561. Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis
  3562. 20 (S)-Protopanaxadiol-induced apoptosis in MCF-7 breast cancer cell line through the inhibition of PI3K/AKT/mTOR signaling pathway
  3563. Cooperative targets of combined mTOR/HDAC inhibition promote MYC degradation
  3564. QSAR modeling and structure based virtual screening of new PI3K/mTOR inhibitors as potential anticancer agents
  3565. QSAR modeling and structure based virtual screening of new PI3K/mTOR inhibitors as potential anticancer agents
  3566. Brg1 aggravates airway inflammation in asthma via inhibition of the PI3K/Akt/mTOR pathway
  3567. How Readily Available Are mTOR Inhibitors?
  3568. Omipalisib (GSK458), a dual an-PI3K/mTOR inhibitor, exhibits in vitro and in vivo activity in chemotherapy-sensitive and-resistant models of Burkitt lymphoma
  3569. Gax suppresses chemerin/CMKLR1‐induced preadipocyte biofunctions through the inhibition of Akt/mTOR and ERK signaling pathways
  3570. Inhibition of autophagy promotes salinomycin-induced apoptosis via reactive oxygen species-mediated PI3K/AKT/mTOR and ERK/p38 MAPK-dependent signaling in …
  3571. Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients.
  3572. Inhibition of mTOR signaling confers protection against cerebral ischemic injury in acute hyperglycemic rats
  3573. mTOR kinase inhibition effectively decreases progression of a subset of neuroendocrine tumors that progress on rapalog therapy and delays cardiac impairment
  3574. CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study
  3575. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415
  3576. AdipoRon, an adiponectin receptor agonist, attenuates PDGF-induced VSMC proliferation through inhibition of mTOR signaling independent of AMPK: Implications …
  3577. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells
  3578. Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fibrosis through inhibition of autophagy and activation of mTOR.
  3579. Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
  3580. The novel mTOR complex 1/2 inhibitor P529 inhibits human lung myofibroblast differentiation
  3581. Synthesis and biological activity of imidazo [4, 5-c] quinoline derivatives as PI3K/mTOR inhibitors
  3582. Luteolin reduces migration of human glioblastoma cell lines via inhibition of the p‑IGF‑1R/PI3K/AKT/mTOR signaling pathway
  3583. Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass …
  3584. mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition
  3585. Sex-specific dimorphism in cellular stress response upon mTOR inhibition revealed by podocyte specific RNA sequencing
  3586. Inhibition of Prostate Cancer DU-145 Cells Proliferation by Anthopleura anjunae Oligopeptide (YVPGP) via PI3K/AKT/mTOR Signaling Pathway
  3587. A first-in-human phase 1 study of LY3023414, an oral PI3K/mTOR dual inhibitor, in patients with advanced cancer
  3588. Gambogic acid improves non-small cell lung cancer progression by inhibition of mTOR signaling pathway
  3589. mTOR Inhibitors Maintain low levels of immune activation, immune senescence and EBV load in kidney transplant patients
  3590. Lycium barbarum polysaccharide protects diabetic peripheral neuropathy by enhancing autophagy via mTOR/p70S6K inhibition in Streptozotocin-induced diabetic …
  3591. Silibinin induced human glioblastoma cell apoptosis concomitant with autophagy through simultaneous inhibition of mTOR and YAP
  3592. Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent
  3593. Curcumin suppresses epithelial–mesenchymal transition of renal tubular epithelial cells through the inhibition of Akt/mTOR pathway
  3594. An iridium (III) complex as potent anticancer agent induces apoptosis and autophagy in B16 cells through inhibition of the AKT/mTOR pathway
  3595. PI3K/mTOR pathway inhibition induces Aurora B mediated cell death in NOTCH1 mutant head and neck squamous (HNSCC) cells
  3596. Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like …
  3597. Effects of endoplasmic reticulum stress on autophagy and apoptosis of human leukemia cells via inhibition of the PI3K/AKT/mTOR signaling pathway
  3598. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib
  3599. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR …
  3600. Synergistic anti-proliferative effects of mTOR and MEK inhibitors in high-grade chondrosarcoma cell line OUMS-27
  3601. The SIRT1 inhibitor EX-527 suppresses mTOR activation and alleviates acute lung injury in mice with endotoxiemia
  3602. … Elevated MTORC1 signature in B cells from sjÖgren’s syndrome patients correlates with B cell hyperactivity that is abrogated by MTOR inhibition: a novel therapeutic …
  3603. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR
  3604. The Coefficient of Variability is the Same in the mTOR-inhibitors?
  3605. Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway
  3606. Design, Synthesis and biological evaluation of novel phenylsulfonylurea derivatives as PI3K/mTOR dual inhibitors
  3607. Inhibition of the mTOR pathway exerts cardioprotective effects partly through autophagy in CLP rats
  3608. Inhibition of PI3K/AKt/mTOR signaling pathway protects against d-galactosamine/lipopolysaccharide-induced acute liver failure by chaperone-mediated autophagy in …
  3609. Anti-inflammatory effect of lovastatin is mediated via the modulation of NF-κB and inhibition of HDAC1 and the PI3K/Akt/mTOR pathway in RAW264. 7 …
  3610. Inhibition of Gli1‑mediated prostate cancer cell proliferation by inhibiting the mTOR/S6K1 signaling pathway
  3611. Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition
  3612. Dioscin ameliorates cardiac hypertrophy through inhibition of the MAPK and Akt/GSK3β/mTOR pathways
  3613. Discovery, Process Development, and Scale-Up of a Benzoxazepine-Containing mTor Inhibitor
  3614. Nutmeg extract increases skeletal muscle mass in aging rats partly via IGF1-AKT-mTOR pathway and inhibition of autophagy
  3615. Discovery of novel 1, 3, 5-triazine-thiozolidine (DDDL-251) based dual PI3K/mTOR inhibitor against breast cancer
  3616. Identification of NOTCH1 inactivating mutation as a therapeutic vulnerability to PI3K/mTOR pathway inhibition in head and neck squamous cell carcinoma (HNSCC)
  3617. Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation
  3618. Deoxypodophyllotoxin induces cytoprotective autophagy against apoptosis via inhibition of PI3K/AKT/mTOR pathway in osteosarcoma U2OS cells
  3619. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
  3620. PO-505 Targeting PIM kinase to overcome resistance to PI3K-mTOR inhibition in NSCLC
  3621. Triptolide suppresses glomerular mesangial cell proliferation in diabetic nephropathy is associated with inhibition of PDK1/Akt/mTOR pathway
  3622. Circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2-metastatic breast cancer
  3623. The protective effects of Κ-opioid receptor stimulation in hypoxic pulmonary hypertension involve inhibition of autophagy through the AMPK-MTOR pathway
  3624. Inhibition of miR-20 promotes proliferation and autophagy in articular chondrocytes by PI3K/AKT/mTOR signaling pathway
  3625. Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant
  3626. Notoginsenoside R1 attenuates glucose-induced podocyte injury via the inhibition of apoptosis and the activation of autophagy through the PI3K/Akt/mTOR …
  3627. Inhibition of ghrelin o-acyltransferase attenuated lipotoxicity by inducing autophagy via AMPK–mTOR pathway
  3628. EB-3D a novel choline kinase inhibitor induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells
  3629. Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells
  3630. Inhibition of mTOR/S6K1/4E-BP1 signaling by nutraceutical SIRT1 modulators
  3631. Bigelovin, a sesquiterpene lactone, suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS …
  3632. Metformin plus caloric restriction show anti-epileptic effects mediated by mTOR pathway inhibition
  3633. Design, synthesis, and docking studies of new Torin2 analogs as potential ATR/mTOR kinase inhibitors
  3634. Anti-fibrosis effect for Hirsutella sinensis mycelium based on inhibition of mTOR p70S6K phosphorylation
  3635. Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP …
  3636. mTOR inhibitors in kidney transplantation
  3637. STK25-induced inhibition of aerobic glycolysis via GOLPH3-mTOR pathway suppresses cell proliferation in colorectal cancer
  3638. miR-21 inhibitors modulate biological functions of gastric cancer cells via PTEN/PI3K/mTOR pathway
  3639. mTOR inhibitors in epilepsy management: from bench to bedside
  3640. Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex …
  3641. Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations
  3642. Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction
  3643. Dietary α-mangostin provides protective effects against acetaminophen-induced hepatotoxicity in mice via Akt/mTOR-mediated inhibition of autophagy and apoptosis
  3644. Research progress of mTOR inhibitors for anti-atherosclerosis
  3645. Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
  3646. Pharmacological inhibition of 2-arachidonoilglycerol hydrolysis enhances memory consolidation in rats through CB2 receptor activation and mTOR signaling …
  3647. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
  3648. Abstract IA25: Third-generation inhibitors of mTOR
  3649. mTOR Inhibitor-Corticoid Combination Therapy For Multiple Sclerosis
  3650. Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma …
  3651. … companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
  3652. Early Conversion to mTOR Inhibitors Prevents Kidney Function Better Than Late Conversion
  3653. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 …
  3654. Role of mTOR inhibitors in solid organ transplantation
  3655. PI3kinase/mTOR Inhibition Alters Global Metabolism in IPF Patients: Exploratory Biomarker Analysis from a Phase I Proof of Mechanism Study
  3656. Inhibition of Rac1 ameliorates neuronal oxidative stress damage via reducing Bcl-2/Rac1 complex formation in mitochondria through PI3K/Akt/mTOR pathway
  3657. Companion diagnostic for predicting the efficacy of mTOR inhibitor in neuroendocrine tumor
  3658. mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents
  3659. Multitargeted kinase inhibition (AEE788) alleviates mTOR inhibitor drug resistance in triple-negative breast cancer
  3660. Therapy monitoring of mTOR-inhibitors using 3D reconstruction of SEGA volume, DTI and SVS
  3661. Chemical identification of a sulfated glucan from Antrodia cinnamomea and its anti-cancer functions via inhibition of EGFR and mTOR activity
  3662. Globularifolin exerts anticancer effects on glioma U87 cells through inhibition of Akt/mTOR and MEK/ERK signaling pathways in vitro and inhibits tumor growth in vivo
  3663. Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells
  3664. Docosahexaenoic Acid Attenuated Experimental Chronic Colitis in Interleukin 10–Deficient Mice by Enhancing Autophagy Through Inhibition of the mTOR Pathway
  3665. Early use of mTOR inhibitors and risk of Cytomegalovirus infection in liver transplant patients
  3666. … effects in human kidney tumor cells mediated via mitochondrial mediated apoptosis, inhibition of cell migration and invasion and targeting PI3K/AKT/mTOR …
  3667. Effect of sirolimus on arteriosclerosis induced by advanced glycation end products via inhibition of the ILK/mTOR pathway in kidney transplantation recipients
  3668. Kavalactone yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway
  3669. Anticancer activity of cucurbitacin-A in ovarian cancer cell line SKOV3 involves cell cycle arrest, apoptosis and inhibition of mTOR/PI3K/Akt signaling pathway
  3670. Inhibition of MMP-2 expression enhances the antitumor effect of sorafenib in hepatocellular carcinoma by suppressing the PI3K/AKT/mTOR pathway
  3671. The pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
  3672. Abstract A49: Transcription factor upregulation after mTOR inhibition by Torin1 induces growth factor receptor expression
  3673. Lymphatically directed MAPK/PI3K/mTOR inhibitor for treatment of cancer growth and metastasis
  3674. CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
  3675. Efficacy of the ERK inhibitor LY3214996 and the PI3K/mTOR inhibitor LY3023414 in patient-derived RAS-mutant NSCLC models
  3676. Safety of mTOR Inhibitors in Infants with Tuberous Sclerosis Complex (TSC): Multicenter Clinical Experience (S35. 003)
  3677. KLF15 protects against isoproterenol-induced cardiac hypertrophy via regulation of cell death and inhibition of Akt/mTOR signaling
  3678. Mechanisms of secondary resistance to dual PI3K/mTOR inhibition in sarcomas with complex genetics
  3679. SP757 COMBINATION OF CALCINEURIN INHIBITORS AND MTOR INHIBITORS FOLLOWING KIDNEY TRANSPLANTATION IN COMPARISON WITH …
  3680. Understanding the biochemical alterations in cancer cells chronically treated with PI3K/mTOR inhibitors
  3681. An anti‐cancer drug candidate OSI‐027 and its analog as inhibitors of mTOR: computational insights into the inhibitory mechanisms
  3682. Controlled release of mTOR inhibitors to enhance CD8+ T cell memory
  3683. … activity of caffeic acid n‑butyl ester against A431 skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling …
  3684. DIPG-61. HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT SYNERGIZES WITH DUAL MTOR INHIBITOR TAK228 TO POTENTIATE KILLING OF DIPG CELLS
  3685. Combined PI3 K/mTOR Inhibition and Transcriptional Repression in Head and Neck Carcinoma
  3686. mTOR Inhibitors Enhance Antitumor Activity of Liver Resident NK Cells
  3687. Qianlie Xiaozheng decoction induces autophagy in human prostate cancer cells via inhibition of the Akt/mTOR pathway
  3688. Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma
  3689. Vitamin D increases glucocorticosteroid efficacy via mTOR-inhibition in Multiple Sclerosis (P3. 392)
  3690. Effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibitor in non-small-cell lung cancer
  3691. Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite
  3692. Pediatric relapsed acute lymphoblastic leukemia patients display enrichment of the PI3K/mTOR pathway and respond to the dual PI3K/mTOR inhibitor PKI-587
  3693. Immunotherapy and mTOR inhibitors a new perspective in the treatment of advanced and metastatic urothelial carcinomas.
  3694. … Immunosuppression on Mineral Metabolism One Year after Kidney Transplantation: Differences Between a Mycophenolate-Based Regimen Versus an mTOR Inhibitor …
  3695. Use of Antiepileptic Drugs among Patients with Tuberous Sclerosis Complex Related Epilepsy who Initiated an Oral mTOR Inhibitor (P6. 277)
  3696. Clinical efficacy of mTOR inhibitor for Kaposiform hemangioendotheliomas with Kasabach-Merritt phenomenon
  3697. SP769 RITUXIMAB AND MTOR INHIBITORS IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER. IS PROGNOSIS CHANGING?
  3698. Consequences of mTOR inhibition on epileptogenesis and neuroprotection in lithium-pilocarpine model of epilepsy in rats
  3699. Effect of dibutyltin dilaurate on triglyceride metabolism through the inhibition of the MTOR pathway in human HL7702 liver cells
  3700. Microvascular Loss in Experimental Murine Tracheal Transplantation can be Prevented by Anti-Platelet Therapy and in Combination with mTOR Inhibitor
  3701. Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
  3702. differential effects of linsitinib and mtoR inhibitors on cell migration and proliferation of pancreatic neuroendocrine tumor cells
  3703. Role of the Early Association of a mTOR Inhibitor and Tacrolimus in BK Polyomavirus Infection in Kidney Transplant Recipients
  3704. Abstract P525: Mtor Inhibitor Everolimus Decreases Aortic Sensitivity To Phenylephrine In Normotensive Rats
  3705. Abstract NTOC-110: UNEXPECTED ROLES FOR KDM4A: PROTEIN SYNTHESIS AND MTOR INHIBITOR SENSITIVITY
  3706. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
  3707. Abstract B22: Increased phosphorylation of eIF4E induces resistance to treatment with mTOR inhibitors together with AR antagonists in advanced prostate cancer
  3708. Inhibition of mTOR pathway by rapamycin decreases P-glycoprotein expression and spontaneous seizures in pharmacoresistant epilepsy
  3709. Pain-relieving effects of the mTOR inhibitor in the anterior cingulate cortex of neuropathic rats
  3710. Radio sensitizing effect of double PI3K/mTOR inhibitor NVPBEZ235 on Hela cells of cervical cancer
  3711. Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with …
  3712. OP-MTOR INHIBITOR-ASSOCIATED STOMATITIS (MIAS) INDUCED BY EVEROLIMUS IN ADVANCED BREAST CANCER PATIENT-CASE REPORT
  3713. CD44 positive and sorafenib resistant hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128
  3714. Phosphodiesterase-3 Inhibitor Regulates Endothelial Autophagy and Re-Endothelialization in Experimental Models of a First-Generation mTOR Inhibitor-Eluting Stent
  3715. Precision Assessment of on-and Off-Target Effects of mTOR Kinase Inhibitors in a Mouse Model
  3716. … of Immunosuppression on Metabolic Outcomes One Year after Kidney Transplantation: The Role of Mycophenolate and mTOR Inhibitors on Lipid Metabolism and …
  3717. MP83-02 OVERCOMING PI3K/MTOR INHIBITOR RESISTANCE BY PIM1 INHIBITOR THROUGH REGULATION OF TYROSINE KINASE EXPRESSION.
  3718. Cuprizone model of demyelination in the presence of mTOR inhibitor rapamycin
  3719. Abstract B153: CDK4/6 inhibitor synergizes with mTOR inhibitor to suppress cholangiocarcinoma pathogenesis
  3720. … on isoproterenol-induced myocardial injury in high-fat-fed rats involves modulation of PI3K/Akt/mTOR signaling pathway and inhibition of apoptosis: comparison to …
  3721. A drug screening assay identifies mTOR inhibitors and SERMs as novel radiosensitizers for head and neck cancer
  3722. BENEFICIAL EFFECTS OF THE MTOR INHIBITOR EVEROLIMUS IN PATIENTS WITH ADVANCED MEDULLARY THYROID CARCINOMA; SUB-GROUP …
  3723. … liver stem cell-derived extracellular vesicles enhance cancer stem cell sensitivity to tyrosine kinase inhibitors through Akt/mTOR/PTEN combined modulation
  3724. mTOR inhibitor augments the antitumor effect of p53-expressing oncolytic adenovirus in human neuroblastoma cells
  3725. … 5, 8′-coupled naphthylisoquinoline alkaloid, eliminates the tolerance of cancer cells to nutrition starvation by inhibition of the Akt/mTOR/autophagy signaling pathway
  3726. Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition
  3727. Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway
  3728. … effects of resveratrol on transforming growth factor β1-induced fibrogenesis in primary human lung fibroblasts through autophagy induction via Akt/mTOR inhibition
  3729. TEMSIROLIMUS IS A CANDIDATE OF THE OPTIMAL MTOR INHIBITOR FOR PROTECTING HUMAN INTERVERTEBRAL DISC NUCLEUS PULPOSUS CELLS: 6
  3730. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells
  3731. … Mutational Burden and Alterations to DNA Damage Repair Genes are Associated With Poor Prognosis and Sensitivity to PI3K-mTOR Inhibitors in Multiple Myeloma
  3732. Arsenic trioxide sensitizes glioma stem cells to brain penetrant PI3K and mTOR inhibitor GDC-0084
  3733. Assessing Impaired Oatp1b1-and Oatp1b3-Mediated Transport by Mtor Inhibitors, Multi-Kinase Inhibitor Vemurafenib and by Protein Kinase C Activation
  3734. … shows preferential cytotoxicity to acidity-tolerant prostate carcinoma PC-3 cells through ROS-mediated mitochondrial damage and the inhibition of PI3K/Akt/mTOR …
  3735. Xanthohumol induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI3K/Akt/mTOR-kinase in human gastric cancer cells
  3736. UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA‑MB‑231 cells
  3737. Inhibition of PI 3K‐Akt‐mTOR signal pathway dismissed the stimulation of glucose on goose liver cell growth
  3738. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma
  3739. Anti-angiogenic efficacy of Bevacizumab alone and in combination with a dual PI3K/mTOR inhibitor in an orthotopic model of malignant glioma: A multimodal neuro …
  3740. … resistance to an emibetuzumab analogue in MET-amplified gastric xenografts can be overcome by a MET-targeting antibody mixture or PIK3CA/AKT/mTOR inhibition
  3741. Increased mTORC1 activation in salivary gland B cells and T cells from Sjögren’s syndrome patients: mTOR inhibition as a novel therapeutic strategy to halt …
  3742. Eicosapentaenoic acid abolishes inhibition of insulin-induced mTOR phosphorylation by LPS via PTP1B downregulation in skeletal muscle
  3743. Mutations in TSC1/TSC2 genes are prevalent in sporadic renal angiomyolipoma and insulinoma tumors, supporting their responsiveness to mTOR inhibitors
  3744. Down‐Regulation of OATP1B1‐Mediated Transport by Mammalian Target of Rapamycin (mTOR) Inhibitors Everolimus and Sirolimus: Potential Mechanism and …
  3745. Targeting Rac-GTPases reverses stroma-induced resistance to notch and mtor-inhibition in T-cell acute lymphoblastic leukemia
  3746. EXTH-51. PI3K/mTOR INHIBITION LEADS TO REDUCTION IN 2HG PRODUCTION AND CELL PROLIFERATION IN IDH1 MUTANT CELLS
  3747. P. 039 mTOR inhibitors as a new therapeutic strategy in treatment resistant epilepsy in hemimegalencephaly: a case report
  3748. Whole exome sequencing identifies mTOR and KEAP1 as potential targets for radiosensitization of HNSCC cells refractory to EGFR and β1 integrin inhibition
  3749. Proteomics and Network Analyses Reveal Inhibition of Akt‐mTOR Signaling in CD4+ T Cells by Mycobacterium tuberculosis Mannose‐Capped Lipoarabinomannan
  3750. Abstract CT161: Clinical study of PD-1 inhibitor with mTOR inhibitor for relapsed and refractory brain tumors
  3751. … 3 study of buparlisib (BKM120)+ fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2-ABC after progression on an mTOR inhibitor
  3752. CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5‐FU‐induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway
  3753. Abstract LB-A08: Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells
  3754. Abstract LB-A08: Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells
  3755. Dual inhibitory effects of novel naringenin analogue in tobacco-carcinogen induced lung cancer via inhibition of PI3K/Akt/mTOR pathway
  3756. MP88-14 CANCER STEM CELL FEATURE CAN INDUCE RESISTANCE TO MTOR INHIBITORS VIA THE NOTCH PATHWAY IN RENAL CELL CARCINOMAS
  3757. … and bioinformatics pipeline identifies microenvironment-derived FGF2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER+ breast …
  3758. Curcumin suppresses the progression of laryngeal squamous cell carcinoma through the upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway
  3759. Active fraction (HS7) from Taiwanofungus camphoratus inhibits AKT-mTOR, ERK and STAT3 pathways and induces CDK inhibitors in CL1-0 human lung …
  3760. Effect of HER3 dimer feedback upregulation via PI3K-AKT-mTOR pathway inhibition on androgen receptor (AR) stabilization in metastatic prostate cancer.
  3761. Renal Cell Carcinoma Associated With Xp11. 2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors.
  3762. In silico discovery of a small molecule suppressing lung carcinoma A549 cells proliferation and inducing autophagy via mTOR pathway inhibition
  3763. EXTH-35. IN VIVO 1H MRS DETECTS REDUCED 2HG PRODUCTION IN IDH1 MUTANT GLIOMAS TREATED WITH A DUAL PI3K/MTOR INHIBITOR
  3764. Low frequency magnetic fields induce autophagy-associated cell death in lung cancer through miR-486-mediated inhibition of Akt/mTOR signaling pathway
  3765. P3. 02c-010 Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC: Topic: Targeted Therapy
  3766. Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted …
  3767. P2. 06-009 Combined PKCi and mTOR Inhibition in Advanced or Recurrent Lung Cancer, Preliminary Report of an Ongoing Phase I/II Trial: Topic: Phase I/II Trials
  3768. Snail reduces the antitumor efficacy of mTOR kinase inhibitors by transcriptional repression of 4E-BP1
  3769. Effect of inhibitors (PP242), PKI402 and (MTOR) in their combination with MEK cytometry on cancer cell cells
  3770. A cyclometalated iridium (III) complex induces apoptosis and autophagy through inhibition of the PI3K/AKT/mTOR pathway
  3771. Inhibitors Targeting IGF‐1r and mTOR Induce Synergistic Cell Growth Inhibition and Enhance Apoptotic Activity in Cancer Cell Lines
  3772. Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3. 1 and inhibition of AKT/mTOR signaling
  3773. Inhibition of Rabies Virus by 1,2,3,4,6-Penta-O-galloyl-β-d-Glucose Involves mTOR-Dependent Autophagy
  3774. Design and synthesis of alkyl substituted pyridino [2, 3-D] pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent …
  3775. Development of novel 1, 2, 4-triazole-thiol derivatives as dual PI3K/mTOR inhibitor against the non-small cell lung cancer (NSCLC)
  3776. Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer
  3777. Telmisartan induces osteosarcoma cells growth inhibition and apoptosis via suppressing mTOR pathway
  3778. Cyclic ADP-ribose as an endogenous inhibitor of the mTOR pathway downstream of dopamine receptors in the mouse striatum
  3779. Catalpol prevents denervated muscular atrophy related to the inhibition of autophagy and reduces BAX/BCL2 ratio via mTOR pathway
  3780. CSIG-26. MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA
  3781. Discovery of a series of N-(5-(quinolin-6-yl) pyridin-3-yl) benzenesulfonamides as PI3K/mTOR dual inhibitors
  3782. Inhibition of tissue transglutaminase attenuates lipopolysaccharide-induced inflammation in glial cells through AKT/mTOR signal pathway
  3783. Combined 3D-QSAR and Molecular Docking Study on benzo [h][1, 6] naphthyridin-2 (1H)-one Analogues as mTOR Inhibitors.
  3784. … of metformin, an antidiabetic drug, against ovarian cancer cells involves inhibition of cysteine-rich 61 (cyr61)/Akt/mammalian target of rapamycin (mTOR) …
  3785. CSIG-29. THE DUAL PI3K/mTOR-PATHWAY INHIBITOR GDC-0084 ACHIEVES ANTITUMOR ACTIVITY IN BREAST CANCER BRAIN METASTASES IN VITRO AND …
  3786. Inhibition of mTOR signaling pathway by aqueous extract of Siberian ginseng
  3787. PI3K/AKT/mTOR pathway inhibition sensitizes ovarian cancer cells to anti-estrogen therapy
  3788. Abstract PD4-04: combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long term growth inhibition in estrogen receptor …
  3789. Inhibition of mTOR signalling: a potential anti-aging drug strategy
  3790. Antifibrotic effect of rapamycin, an inhibitor of mTOR pathway, on the TGF-β2 induced proliferation of human tenon fibroblasts
  3791. Pharmacological Inhibition Of Mtor Kinase Selectively Suppresses Rv-Specific Activation Of Mtorc1 Signaling, Reverses Rv Remodeling And Improves Rv Morphology …
  3792. Essential signaling in NF2 loss-related tumours: The therapeutic potential of CRL4DCAF1 and mTOR combined inhibition
  3793. Advances in Cardiovascular Geroscience: Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive …
  3794. Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR
  3795. Effect of PI3K/Akt/mTOR signal pathway-mediated N822K mutation on apoptosis induced by c-KIT inhibitor in AML cells
  3796. PO-233 Chemoresistant NSCLC cells are hypersensitive to metabolic drugs due to mTOR-mediated inhibition of autophagy
  3797. EIF4E Phosphorylation as a Mechanism of Resistance To mTOR and Androgen Receptor Inhibition in Advanced Prostate Cancer
  3798. Bornyl cis-4-Hydroxycinnamate Suppresses Cell Metastasis of Melanoma through FAK/PI3K/Akt/mTOR and MAPK Signaling Pathways and Inhibition of the Epithelial …
  3799. … of novel cardamonin analogues and identification of a highly active Cu (II)-cardamonin complex that inhibits migration and induces apoptosis via inhibition of mTOR …
  3800. Effects of PI3K/AKT/mtor And VEGFR Pathway Inhibitors on Liver Cancer Stem Cells and Bioactivities of Novel Pyrazolic Chalcone Derivatives on Liver Cancer
  3801. Inhibition of laryngeal cancer cell activity by pterostilbene via modulating AKT/mTOR signal pathway and related mechanisms
  3802. … , Taiwanofungus camphoratus (Agaricomycetes), Induces Protective Autophagy in SPCA-1 Cells through AMPK Inhibition-Independent Blockade of the Akt/mTOR …
  3803. Inhibition of Endothelial mTOR Drives Hematopoietic Stem Cell Aging
  3804. MAPkinase and PI3K/mTOR pathways inhibition in conjunctival melanoma
  3805. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR
  3806. Combined Inhibition of mTOR and BTK Signaling Is Required for Optimal Long Term Growth Inhibition in DLBCL Models
  3807. Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
  3808. Mechanisms resistance analysis of inhibitors involved in the PI3K/Akt/mTOR pathway in vitro and in cftDNA collected from patients with breast tumors
  3809. The effect of selective tyrosine kinase inhibitors on the expression of HIF1α and mTOR in p16-positive and-negative squamous cell carcinoma (HNSCC)
  3810. Discovery and evaluation of WX047, a potent and oral active phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitor
  3811. Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation
  3812. … PRETEND WE’RE MARRIED: THE RIGHT VENTRICLE AND THE PULMONARY VASCULATURE: Pharmacological Inhibition Of Mtor Kinase Selectively Suppresses …
  3813. Combined inhibition of MEK and mTOR pathways is effective in NRAS Q61K mutant small cell lung cancer
  3814. Characterization of a Novel Mouse Model for Angiosarcoma in Which Combined Inhibition of mTOR and MEK Results in Tumor Suppression
  3815. Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation
  3816. mTOR-and tyrosine kinase inhibitors reduce AKT-and IGF-R expression in squamous cell carcinoma (HNSCC), dependent on p16 status
  3817. Advances in childhood T-cell acute lymphoblastic leukemia and inhibitors targeting PI3K-Akt-mTOR signaling pathway
  3818. The Investigation of mTOR, JAK/STAT and Hedgehog pathways inhibitor effect on hematological cancer cell lines proliferation
  3819. Abstract B175: Rational combination of mTOR and Aurora kinase A inhibition in preclinical models of triple-negative breast cancer
  3820. Oxidative Stress Induces Autophagy through Inhibition of mTOR in Corneal Epithelial Cells
  3821. Antitumor effect by inhibition of PI3K/AKT/mTOR and RAS/MAPK pathways in human oral squamous cell carcinoma cells
  3822. Epi-magnolin suppresses EGF-induced neoplastic cell transformation by inhibition of Akt/mTOR signaling pathway in JBC Cl41 cells
  3823. PLGA-PEG nanoparticles for targeted delivery of an mTOR/PI3kinase inhibitor, NVP-BEZ235, to inflamed endothelium
  3824. A dual mTOR-PI3K inhibitor DCB-HDG2-57 with Hedgehog signaling pathway antagonist activity
  3825. Effects of Emodin against Renal Tubular Epithelial Cell Fibrosis via the Inhibition of Akt/mTOR Signal Pathway
  3826. Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer when combined to PARP inhibition
  3827. Fibroblast-Mediated Resistance to BRAF Inhibition in Metastatic Melanoma-Effect of drugs targeting PI3K/AKT/mTOR signaling pathway
  3828. Inhibition of Upper Small Intestinal mTOR Lowers Plasma Glucose Levels by Inhibiting Hepatic Glucose Production
  3829. Modulation of MEK/ERK and mTOR pathways by Na+‐K+‐ATPase and AMPK inhibitors in ovarian cancer cells
  3830. Effect of silencing Notch1 gene on proliferation, apoptosis and Akt/mTOR pathyway inhibition in clear cell renal cell carcinoma
  3831. Synergistic effect of alectinib and everolimus on anaplastic large cell lymphoma cells via ALK-mTOR pathway inhibition
  3832. Inhibition of mammalian target of rapamycin (mTOR) signaling in the anterior cingulate cortex alleviates neuropathic pain
  3833. Inhibition of mTOR Signaling Reduces Mesenchymal Cell Migration To Sites Of Injury And Eliminates Heterotopic Ossification In A Mouse Model
  3834. Phosphorylated mTOR by signaling through EphB3 confers resistance to a selective FGFR inhibitor in SNU-16 gastric cancer cells
  3835. Pharmacological Inhibition of mTOR and ERK1/2 Resulted in Attenuated Protein Synthesis Rates in Differentiated C2C12 Myoblasts in a Similar Fashion to in vivo …
  3836. Ribonuclease inhibitor interacts with integrin-linked kinase and inhibits bladder cancer growth in vitro and in vivo through ILK/AKT/mTOR pathway
  3837. Activation of WNT/b-catenin signaling results in resistance to PI3K/mTOR dual inhibitor in co-existing KRAS and PIK3CA mutant colorectal cancer cells
  3838. Lysosome membrane permeabilization and disruption of mTOR-lysosome interaction are associated with the inhibition of lung cancer cell proliferation by a …
  3839. Neuropathic Pain Relieving in Rats by the Inhibition of Monomer of Lamiophlomis Rotata on AKT-mTOR Signaling Pathway in Spinal Dorsal Horn
  3840. Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid …
  3841. Correction: Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation
  3842. Antibody targeting PDZ domain of TIP-1 induces proliferation arrest through AKT/mTOR signaling inhibition in lung cancer and glioblastoma
  3843. Hedgehog inhibition impaired platinum response in high-grade serous ovarian cancer harboring high hedgehog ligand expression and mTOR pathway activation.
  3844. Inhibition of Inositol hexakisphosphate Kinase 1 (IP6K1) Does Not Increase Akt or mTOR Activity in vitro.
  3845. Soluble epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid, represses human aortic smooth muscle cell proliferation and migration …
  3846. Abstract PD4-08: a microenvironment secretome screen reveals FGF2 as a mediator of resistance to anti-estrogens and PI3K/mTOR pathway inhibitors in ER+ breast …
  3847. … and Undifferentiated Pleomorphic Sarcoma Sensitive to Mammalian Target of Rapamycin (mTOR) and Insulin-Like Growth Factor 1 (IGF1) Receptor Inhibitors
  3848. … harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid …
  3849. Abated microRNA-21 attenuates high glucose-induced autophagy inhibition in rat mesangial cells by PTEN/Akt/mTOR pathway
  3850. … -Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway
  3851. Research progress of mTOR inhibitors
  3852. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
  3853. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
  3854. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy
  3855. Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors
  3856. Mechanisms of resistance to mTOR inhibitors
  3857. Exploring mTOR inhibition as treatment for mitochondrial disease
  3858. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives
  3859. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
  3860. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
  3861. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation
  3862. Revisiting mTOR inhibitors as anticancer agents
  3863. Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma?
  3864. Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas)
  3865. Immunoregulation with mTOR inhibitors to prevent COVID‐19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines
  3866. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age–a multicenter retrospective study
  3867. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers
  3868. mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19
  3869. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors
  3870. mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases
  3871. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth
  3872. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
  3873. Novel mTOR inhibitor enhances the sensitivity of hepatocellular carcinoma cells to molecular targeting agents
  3874. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
  3875. mTOR inhibitors in advanced biliary tract cancers
  3876. Inhaled biguanides and mTOR inhibition for influenza and coronavirus
  3877. Phytochemicals as PI3K/Akt/mTOR inhibitors and their role in breast cancer treatment
  3878. A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
  3879. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
  3880. Autophagy inhibition to augment mTOR inhibition: a phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma
  3881. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition
  3882. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors
  3883. Synergistic anti-tumor effect of mTOR inhibitors with irinotecan on colon cancer cells
  3884. Second generation mTOR inhibitors as a double-edged sword in malignant glioma treatment
  3885. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition
  3886. mTOR inhibitor everolimus in regulatory T cell expansion for clinical application in transplantation
  3887. mTOR inhibitor everolimus reduces invasiveness of melanoma cells
  3888. High sensitivity of circulating tumor cells derived from a colorectal cancer patient for dual inhibition with AKT and mTOR inhibitors
  3889. 4E-BP1 is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer
  3890. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
  3891. Addition of antiestrogen treatment in patients with malignant PEComa progressing to mTOR inhibitors
  3892. Pharmacodynamic monitoring of mTOR inhibitors
  3893. Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
  3894. Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation
  3895. First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma
  3896. TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1
  3897. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells
  3898. Overexpression of ABCB1 transporter confers resistance to mTOR inhibitor WYE-354 in cancer cells
  3899. Pain-relieving effects of mTOR inhibitor in the anterior cingulate cortex of neuropathic rats
  3900. Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
  3901. Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors
  3902. In silico analyses and cytotoxicity study of asiaticoside and asiatic acid from malaysian plant as potential mTOR inhibitors
  3903. A molecular sub-cluster of colon cancer cells with low VDR expression is sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment
  3904. mTOR inhibitors as a new therapeutic strategy in treatment resistant epilepsy in hemimegalencephaly: a case report
  3905. Extracellular acidosis and mTOR inhibition drive the differentiation of human monocyte-derived dendritic cells
  3906. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy
  3907. Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
  3908. Dual-mTOR inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity
  3909. Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
  3910. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma
  3911. Investigating the Role of Everolimus in mTOR Inhibition and Autophagy Promotion as a Potential Host-Directed Therapeutic Target in Mycobacterium tuberculosis …
  3912. Macropinocytosis renders a subset of pancreatic tumor cells resistant to mTOR inhibition
  3913. Synergistic effects of combination therapy with AKT and mTOR inhibitors on bladder cancer cells
  3914. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
  3915. PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
  3916. Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma
  3917. mTOR inhibitor INK128 attenuates systemic lupus erythematosus by regulating inflammation-induced CD11b+ Gr1+ cells
  3918. mTOR inhibition by metformin impacts monosodium urate crystal–induced inflammation and cell death in gout: a prelude to a new add-on therapy?
  3919. Individual response to mTOR inhibition in delaying replicative senescence of mesenchymal stromal cells
  3920. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic …
  3921. Effects of mTOR inhibitors on neuropathic pain revealed by optical imaging of the insular cortex in rats
  3922. Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors
  3923. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer
  3924. Discovery and SAR of novel disubstituted quinazolines as dual PI3Kalpha/mTOR inhibitors targeting breast cancer
  3925. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma …
  3926. Hyperpolarized MRI visualizes Warburg effects and predicts treatment response to mTOR inhibitors in patient-derived ccRCC xenograft models
  3927. Virtual screening and optimization of novel mTOR inhibitors for radiosensitization of hepatocellular carcinoma
  3928. Use of human induced pluripotent stem cells and kidney organoids to develop a cysteamine/mTOR inhibition combination therapy for cystinosis
  3929. Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104
  3930. mTOR inhibitors in pediatric liver transplant recipients
  3931. Eribulin synergistically increases anti-tumor activity of an mTOR inhibitor by inhibiting pAKT/pS6K/pS6 in triple negative breast cancer
  3932. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
  3933. A conformational restriction strategy for the identification of a highly selective pyrimido-pyrrolo-oxazine mTOR inhibitor
  3934. A phase I trial of IGF-1R inhibitor cixutumumab and mTOR inhibitor temsirolimus in metastatic castration-resistant prostate cancer
  3935. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70
  3936. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
  3937. Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD
  3938. Dual PI3K/mTOR inhibitor NVP-BEZ235 enhances radiosensitivity of head and neck squamous cell carcinoma (HNSCC) cell lines due to suppressed double-strand …
  3939. mTOR inhibitor INK128 attenuates dextran sodium sulfate‐induced colitis by promotion of MDSCs on Treg cell expansion
  3940. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver …
  3941. Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus
  3942. Metformin ameliorates experimental diabetic periodontitis independently of mammalian target of rapamycin (mTOR) inhibition by reducing NIMA‐related kinase 7 …
  3943. The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non–small cell lung cancer
  3944. Use of de novo mTOR inhibitors in hypersensitized kidney transplant recipients: experience from clinical practice
  3945. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
  3946. Chronic sulforaphane administration inhibits resistance to the mTOR-inhibitor everolimus in bladder cancer cells
  3947. Phenotyping an adult zebrafish lamp2 cardiomyopathy model identifies mTOR inhibition as a candidate therapy
  3948. Functional effects of cuprizone-induced demyelination in the presence of the mTOR-inhibitor rapamycin
  3949. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines
  3950. Using SMOTE to deal with class-imbalance problem in bioactivity data to predict mTOR inhibitors
  3951. Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit
  3952. Radiosensitising cancer using phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT) or mammalian target of rapamycin (mTOR) inhibitors
  3953. … , Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of …
  3954. RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma
  3955. Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system
  3956. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators
  3957. The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma
  3958. Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma
  3959. Effects of neddylation and mTOR inhibition in acute myelogenous leukemia
  3960. The mTOR inhibitor rapamycin prevents general anesthesia-induced changes in synaptic transmission and mitochondrial respiration in late postnatal mice
  3961. Long-term follow-up of mTOR inhibition for Erdheim-Chester disease
  3962. mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
  3963. Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice
  3964. Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
  3965. Sex-dependent lifespan extension of ApcMin/+ FAP mice by chronic mTOR inhibition
  3966. Electroacupuncture upregulated ghrelin in rats with functional dyspepsia via AMPK/TSC2/Rheb-mediated mTOR inhibition
  3967. The RNA helicase DHX33 is required for cancer cell proliferation in human glioblastoma and confers resistance to PI3K/mTOR inhibition
  3968. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell …
  3969. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles
  3970. UV damage induces G3BP1-dependent stress granule formation that is not driven by mTOR inhibition-mediated translation arrest
  3971. Autophagy, lysosome dysfunction and mTOR inhibition in MNU-induced photoreceptor cell damage
  3972. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors
  3973. Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis
  3974. Combined treatment with MEK and mTOR inhibitors is effective in in vitro and in vivo models of hepatocellular carcinoma
  3975. PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth in vitro and in vivo
  3976. Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells
  3977. Long‐term treatment with the mTOR inhibitor rapamycin has minor effect on clinical laboratory markers in middle‐aged marmosets
  3978. mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers
  3979. Comparing the effects of the mTOR inhibitors azithromycin and rapamycin on in vitro expanded regulatory T cells
  3980. Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma
  3981. A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor
  3982. The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation
  3983. Artesunate targets oral tongue squamous cell carcinoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition
  3984. mTOR inhibitor use in head and neck squamous cell carcinoma: a meta‐analysis on survival, tumor response, and toxicity
  3985. High‐throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto) antibody production by human plasma cells
  3986. Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
  3987. mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development
  3988. Combining PI3K/Akt/mTOR inhibition with chemotherapy
  3989. Early adjuvant medication with the mTOR inhibitor sirolimus in a preterm neonate with compressive cystic lymphatic malformation
  3990. Gemcitabine and selected mTOR inhibitors in uterine sarcomas and carcinosarcoma cells-an isobolographic analysis
  3991. Haprolid inhibits tumor growth of hepatocellular carcinoma through Rb/E2F and Akt/mTOR inhibition
  3992. Impact of minor structural modifications on properties of a series of mTOR inhibitors
  3993. Anti‑proliferative effect of cardamonin on mTOR inhibitor‑resistant cancer cells
  3994. Mtor inhibition leads to src-mediated egfr internalisation and degradation in glioma cells
  3995. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma
  3996. mTOR inhibitors can enhance the anti-tumor effects of DNA vaccines through modulating dendritic cell function in the tumor microenvironment
  3997. Immune activation, immune senescence and levels of Epstein Barr Virus in kidney transplant patients: Impact of mTOR inhibitors
  3998. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following …
  3999. Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration‐resistant prostate cancer
  4000. Visualizing DC morphology and T cell motility to characterize DC-T cell encounters in mouse lymph nodes under mTOR inhibition
  4001. Behavioral conditioning of anti-proliferative and immunosuppressive properties of the mTOR inhibitor rapamycin
  4002. Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP‑BEZ235 in combination with cisplatin on drug‑resistant non‑small cell lung cancer cell
  4003. Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia
  4004. Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt …
  4005. … carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated …
  4006. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)
  4007. mTOR inhibitor therapy diminishes circulating CD8+ CD28− effector memory T cells and improves allograft inflammation in belatacept-refractory renal allograft …
  4008. Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors
  4009. Discovery of a brain-penetrant ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR) for CNS disorders
  4010. A multimodal treatment of carbon ions irradiation, miRNA-34 and mTOR inhibitor specifically control high-grade chondrosarcoma cancer stem cells
  4011. Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis
  4012. Topical Application of a Dual PI3K/mTOR Inhibitor Prevents Anal Carcinogenesis in an HPV Mouse Model of Anal Cancer
  4013. Potential therapeutic effect of curcumin, a natural mTOR inhibitor, in tuberous sclerosis complex
  4014. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells
  4015. ABI-009 (nab-Sirolimus) improves tumor accumulation and antitumor activity over oral mTOR inhibitors
  4016. A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed/refractory Richter’s transformation and de novo diffuse …
  4017. Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of …
  4018. IRF-1 mediates the suppressive effects of mTOR inhibition on arterial endothelium
  4019. Recent advances of mTOR inhibitors use in autosomal dominant polycystic kidney disease: is the road still open?
  4020. COVID‐19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use of mTOR inhibitors
  4021. A novel molecular mechanism of IKKε-mediated Akt/mTOR inhibition in the Cardiomyocyte autophagy after myocardial infarction
  4022. Practical synthesis of vistusertib (AZD2014), an ATP competitive mTOR inhibitor
  4023. Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer
  4024. Mammalian target of rapamycin (mTOR) inhibitors and skin cancer risk in nonrenal solid organ transplant recipients: systematic review and meta‐analysis
  4025. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a …
  4026. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor
  4027. Management of mTOR inhibitors oral mucositis: current state of knowledge
  4028. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges
  4029. Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled …
  4030. Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene
  4031. Curcumin analog, WZ37, promotes G2/M arrest and apoptosis of HNSCC cells through Akt/mTOR inhibition
  4032. The effects of different mTOR inhibitors in EGFR inhibitor resistant colon carcinoma cells
  4033. Combined anti‐CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors
  4034. VicTORia: A randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line …
  4035. Horizontal combination of MEK and PI3K/mTOR inhibition in BRAF mutant tumor cells with or without concomitant PI3K pathway mutations
  4036. Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus
  4037. Long-term redistribution of peripheral lymphocyte subpopulations after switching from calcineurin to mTOR inhibitors in kidney transplant recipients
  4038. Low-level ionizing radiation induces selective killing of HIV-1-infected cells with reversal of cytokine induction using mTOR inhibitors
  4039. mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model
  4040. … )-6-((R)-3-methylmorpholino)-1, 3, 5-triazin-2-yl) pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of …
  4041. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer
  4042. ATHENA: wisdom and warfare in defining the role of de novo mTOR inhibition in kidney transplantation
  4043. Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers
  4044. UV damage induces G3BP1-dependent stress granule formation that is not driven by translation arrest via mTOR inhibition
  4045. Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma
  4046. Rational discovery of a highly novel and selective mTOR inhibitor
  4047. Preclinical evidence for targeting PI3K/mTOR signaling with dual-inhibitors as a therapeutic strategy against cutaneous T-cell lymphoma
  4048. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition
  4049. Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu] Lu-DOTA-TATE in Lewis rats
  4050. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
  4051. 18 mTOR Inhibitors: Sirolimus and Everolimus
  4052. Inhibition of gastric cancer cell growth by a PI3K-mTOR dual inhibitor GSK1059615
  4053. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: a natural experiment
  4054. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1, 3, 5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors
  4055. 2, 6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo
  4056. Brain-Restricted mTOR Inhibition with Binary Pharmacology
  4057. A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines
  4058. Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma …
  4059. Rapamycin-mediated mTOR inhibition impairs silencing of sex chromosomes and the pachytene piRNA pathway in the mouse testis
  4060. Anti‐tumor effects of PIM/PI 3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
  4061. Manganese-enhanced MRI depicts a reduction in brain responses to nociception upon mTOR inhibition in chronic pain rats
  4062. Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway
  4063. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
  4064. Preventive Role of mTOR Inhibitor in Post–Kidney Transplant Urothelial Carcinoma
  4065. Combination effect of Notch1 and PI3K/AKT/mTOR signaling pathways inhibitors on T-ALL cell lines
  4066. Repurposing potential of riluzole as an ITAF inhibitor in mTOR therapy resistant glioblastoma
  4067. Inhibition of mTOR signaling and clinical activity of rapamycin in head and neck cancer in a window of opportunity trial
  4068. Therapeutic Enhancement of Verteporfin‐mediated Photodynamic Therapy by mTOR Inhibitors
  4069. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
  4070. Effect of mTOR inhibitors during CMV disease in kidney transplant recipients: Results of a pilot retrospective study
  4071. Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and …
  4072. Eosinophilic fasciitis triggered by nivolumab: a remarkable efficacy of the mTOR inhibitor sirolimus
  4073. FUS contributes to mTOR-dependent inhibition of translation
  4074. Inhibition of mTOR alleviates early brain injury after subarachnoid hemorrhage via relieving excessive mitochondrial fission
  4075. Inhibition of mTOR by rapamycin aggravates corneal epithelial stem cell deficiency by upregulating inflammatory response
  4076. mTOR inhibitor therapy for tuberous sclerosis complex: longitudinal study of muscle mass determined by abdominal cross-sectional imaging with CT and MRI
  4077. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma
  4078. Topical delivery of mTOR inhibitor halts scarring
  4079. Effects of mTOR inhibitor, everolimus, on proliferation, autophagy and temozolomide sensitivity of glioma cells
  4080. Regulation of autophagy in chick skeletal muscle: effect of mTOR inhibition
  4081. Accelerated regression of cardiac rhabdomyoma by mTOR inhibitors in a neonate with heart failure: A case report
  4082. PI3K/mTOR pathway inhibition: opportunities in oncology and rare genetic diseases
  4083. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
  4084. Inhibition of mTOR suppresses IFNα production and the STING pathway in monocytes from systemic lupus erythematosus patients
  4085. Combination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer
  4086. Activated mTOR signaling pathway in myofibers with inherited metabolic defect might be an evidence for mTOR inhibition therapies
  4087. Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: strategy for non-small cell lung cancer with mutant RAS gene
  4088. Exploring molecular descriptors and fingerprints to predict mTOR kinase inhibitors using machine learning techniques
  4089. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis
  4090. mTOR‐Inhibitor‐Based Immunosuppression Following Liver Transplantation for Hereditary Hemorrhagic Telangiectasia
  4091. Abstract P5-13-02: neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 …
  4092. Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with …
  4093. Lipopolysaccharide promotes lung fibroblast proliferation through autophagy inhibition via activation of the PI3K-Akt-mTOR pathway
  4094. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models
  4095. Exploration of markers of synergistic lethality of PARP and PI3K-akt-mTOR inhibitors in women’s cancers
  4096. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and …
  4097. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
  4098. CD4+ T cell activation and concomitant mTOR metabolic inhibition can ablate microbiota-specific memory cells and prevent colitis
  4099. Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) …
  4100. Advancement on clinical application of mTOR inhibitors in gastrointestinal cancers
  4101. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling
  4102. PI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells
  4103. Pharmacological inhibition of mTOR attenuates replicative cell senescence and improves cellular function via regulating the STAT3-PIM1 axis in human …
  4104. Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production
  4105. Laser-assisted delivery of topical rapamycin: mTOR inhibition for Birt–Hogg–Dube syndrome
  4106. Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in …
  4107. Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors
  4108. … ‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors
  4109. ABI-009, nab-sirolimus, an mTOR inhibitor with high lung accumulation in preclinical models is active in patients with severe pulmonary arterial hypertension
  4110. Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer
  4111. The Use of Geroprotective Agents (mTOR Inhibitors) in the Treatment of Cancer Patients
  4112. Patients with severe pulmonary arterial hypertension treated with ABI-009, nab-sirolimus, an mTOR inhibitor: Interim results from a phase 1 clinical trial
  4113. Conjunctival melanoma targeted therapy: MAPK and PI3K/mTOR pathways inhibition
  4114. CTNI-27. first-in-pediatrics phase I study of GDC-0084 (PAXALISIB), a CNS-penetrant PI3K/mTOR inhibitor, in newly diagnosed diffuse intrinsic pontine glioma (DIPG) …
  4115. Overcoming Endocrine Resistance in Breast Cancer: mTOR Inhibitors and New Drugs
  4116. Inhibition of mTOR signaling enhances maturation of cardiomyocytes derived from human-induced pluripotent stem cells via p53-induced quiescence
  4117. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis
  4118. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
  4119. The use of mTOR inhibitors is associated with improved survival in lung transplant recipients
  4120. Beta-catenin mutations in hepatocellular cancer, tumor cell metabolism, and the response of these tumors to mTOR inhibition.
  4121. Combined inhibition of FGFR and mTOR pathways is effective in suppressing ovarian cancer
  4122. mTOR inhibitors for the management of difficult lymphangioma in adults
  4123. Transient inhibition of mTOR in human pluripotent stem cells enables robust formation of mouse-human chimeric embryos
  4124. Role of mTOR and VEGFR inhibition in prevention of metastatic tumor growth in the spine
  4125. mTOR inhibitor sirolimus negatively impacts in vitro fertilization outcomes
  4126. First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy
  4127. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway
  4128. Continuation of mTOR Inhibition in LAM Patients Listed for Lung Transplant is Safe
  4129. Abstract CT205: Phase 2 study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) …
  4130. A genome-scale CRISPR screen identifies the ERBB and mTOR signaling networks as key determinants of response to PI3K inhibition in pancreatic cancer
  4131. Inhibition of mTOR via an AAV-delivered shRNA tested in a rat OIR model as a potential antiangiogenic gene therapy
  4132. Inhibition of mTOR delayed but could not prevent experimental collapsing focal segmental glomerulosclerosis
  4133. Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers
  4134. Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches
  4135. The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway
  4136. Nanoparticles induce autophagy via mTOR pathway inhibition and reactive oxygen species generation
  4137. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells
  4138. Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy
  4139. Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition
  4140. Retraction Note: HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
  4141. Inhibition of mTOR in head and neck cancer cells alters endothelial cell morphology in a paracrine fashion
  4142. Calycosin induces apoptosis in adenocarcinoma HT 29 cells by inducing cytotoxic autophagy mediated by SIRT 1/AMPK‐induced inhibition of Akt/mTOR
  4143. Durable response to mTOR inhibition in a patient with relapsing papillary tumor of the pineal region
  4144. Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth
  4145. Phase 2a study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) given to glioblastoma (GBM) …
  4146. Virtual screening of naphthoquinone analogs for potent inhibitors against the cancer‐signaling PI3K/AKT/mTOR pathway
  4147. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth
  4148. p53-Mediated PI3K/AKT/mTOR Pathway Played a Role in PtoxDpt-Induced EMT Inhibition in Liver Cancer Cell Lines
  4149. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
  4150. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker …
  4151. miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in …
  4152. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer …
  4153. Correction to: Electroacupuncture Upregulated Ghrelin in Rats with Functional Dyspepsia via AMPK/TSC2/Rheb‑Mediated mTOR Inhibition
  4154. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors
  4155. Casticin-induced inhibition of cell growth and survival are mediated through the dual modulation of Akt/mTOR signaling cascade
  4156. Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
  4157. Pharmacological treatment of Autoimmune Polyendocrine Syndrome type I with Rapamycin, a mTOR inhibitor
  4158. In silico Analysis and Molecular Docking Studies of Novel 4-Amino-3-(Isoquinolin-4-yl)-1H-Pyrazolo [3, 4-d] Pyrimidine Derivatives as Dual PI3-K/mTOR Inhibitors
  4159. Stomatitis in mTOR inhibitors treatment and other targeted cancer therapy, possibilities of infl uencing it, and the use of local corticotherapy.
  4160. Novel Dual mTOR Inhibitor/AMPK Activator Mitigates Doxorubicin Cardiotoxicity and Potentiates Its Chemotherapeutic Efficacy Against Triple Negative Breast Cancer
  4161. Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial‐lysosomal crosstalk
  4162. ROS-dependent inhibition of the PI3K/Akt/mTOR signaling is required for Oroxylin A to exert anti-inflammatory activity in liver fibrosis
  4163. Alpha‐lipoic acid inhibits lung cancer growth via mTOR‐mediated autophagy inhibition
  4164. Inhibition of the glutamine transporter SNAT1 confers neuroprotection in mice by modulating the mTOR-autophagy system
  4165. The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
  4166. Bupivacaine inhibits angiogenesis through oxidative stress‐dependent inhibition of Akt/mTOR and activation of AMPK
  4167. Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway
  4168. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells
  4169. PSORI-CM02 ameliorates psoriasis in vivo and in vitro by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway
  4170. Inhibition of the PI3K-AKT-mTOR pathway suppresses the adipocyte-mediated proliferation and migration of breast cancer cells
  4171. Dual-inhibition of mTOR and Bcl-2 enhances the anti-tumor effect of Everolimus against renal cell carcinoma in vitro and in vivo
  4172. Investigating the use of mTOR inhibitors in Tuberous Sclerosis Complex
  4173. Thioredoxin‐interacting protein deficiency alleviates phenotypic alterations of podocytes via inhibition of mTOR activation in diabetic nephropathy
  4174. Dexmedetomidine protects against lipopolysaccharide-induced acute kidney injury by enhancing autophagy through inhibition of the PI3K/AKT/mTOR …
  4175. Characterization of Anti-Neovascularization Activity and Ocular Pharmacokinetics of PI3K/mTOR Inhibitor GNE-947
  4176. mTOR inhibitors vs calcineurin inhibitors: A Catch‐22—preventing nephrotoxicity or acute allograft rejection after heart transplantation
  4177. Dual mTOR/DNA-PK inhibitor CC-115 induces cell death in melanoma cells and has radiosensitizing potential
  4178. The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human …
  4179. Enhanced inflammatory response mediated by parenchymal cells associates with resistance towards mTOR inhibition
  4180. DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects
  4181. Discovery of 3-oxabicyclo [4.1. 0] heptane, a non-nitrogen containing morpholine isostere, and its application in novel inhibitors of the PI3K-AKT-mTOR pathway
  4182. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease
  4183. Cardamonin induces G2/M phase arrest and apoptosis through inhibition of NF-κB and mTOR pathways in ovarian cancer
  4184. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway
  4185. Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer
  4186. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor
  4187. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma
  4188. Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa
  4189. Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K/AKT/mTOR pathway and inhibition of topoisomerase II: in vitro …
  4190. Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models
  4191. Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors
  4192. Targeting mTOR: up-to-date mTOR inhibitors.
  4193. Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling
  4194. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt …
  4195. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
  4196. Bisperoxovanadium mediates neuronal protection through inhibition of PTEN and activation of PI3K/AKT-mTOR signaling after traumatic spinal injuries
  4197. Combination Therapy with a PI3K/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein–Barr Virus-Infected Gastric …
  4198. Discovery and development of SPR519 as a potent, selective, and orally bioavailable inhibitor of PI3Kα and mTOR kinases for the treatment of solid tumors
  4199. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells
  4200. … and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and …
  4201. ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway
  4202. Neuroprotective effect of ginkgetin in experimental cerebral ischemia/reperfusion via apoptosis inhibition and PI3K/Akt/mTOR signaling pathway activation
  4203. Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy and relieves hyperalgesia in diabetic rats
  4204. Synergistic antitumor effects of combined treatment with hsp90 inhibitor and pi3k/mtor dual inhibitor in cisplatin-resistant human bladder cancer cells
  4205. AMP‐kinase inhibitor dorsomorphin reduces the proliferation and migration behavior of colorectal cancer cells by targeting the AKT/mTOR pathway
  4206. DRAM1 regulates autophagy and cell proliferation via inhibition of the phosphoinositide 3-kinase-Akt-mTOR-ribosomal protein S6 pathway
  4207. Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve …
  4208. BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K/mTOR dual inhibitor VS-5584
  4209. Akt/mTOR-mediated autophagy confers resistance to BET inhibitor JQ1 in ovarian cancer
  4210. Piperlonguminine and piperine analogues as TrxR inhibitors that promote ROS and autophagy and regulate p38 and Akt/mTOR signaling
  4211. Synthesis and validation of [18F] mBPET-1, a fluorine-18 labelled mTOR inhibitor derivative based on a benzofuran backbone
  4212. Inhibition of autophagy attenuated intestinal injury after intestinal I/R via mTOR signaling
  4213. Real-Life Experience With mTOR Inhibitors Treatment After Liver Transplantation
  4214. mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
  4215. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway
  4216. Repurposing of mTOR complex inhibitors attenuates MCL-1 and sensitizes to PARP inhibition
  4217. mTOR inhibitor INK128 promotes diabetic wound healing by regulating MDSCs
  4218. INTERIM RESULTS OF PHASE 2 STUDY TO EVALUATE PI3K/MTOR INHIBITOR PAXALISIB (GDC-0084) GIVEN TO NEWLY DIAGNOSED GLIOBLASTOMA …
  4219. The vicious cycle between ferritinophagy and ROS production triggered EMT inhibition of gastric cancer cells was through p53/AKT/mTor pathway
  4220. Epigallocatechin gallate suppresses premature senescence of preadipocytes by inhibition of PI3K/Akt/mTOR pathway and induces senescent cell death by regulation …
  4221. Inhibition of PHLPP1 ameliorates cardiac dysfunction via activation of the PI3K/Akt/mTOR signalling pathway in diabetic cardiomyopathy
  4222. MTOR INHIBITORS ENHANCE ANTITUMOR ACTIVITY OF LIVER NATURAL KILLER CELLS IN MICE
  4223. … Rb3 provides protective effects against cisplatin‐induced nephrotoxicity via regulation of AMPK‐/mTOR‐mediated autophagy and inhibition of apoptosis in vitro and …
  4224. In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei
  4225. Bee venom and its peptide component melittin suppress growth and migration of melanoma cells via inhibition of PI3K/AKT/mTOR and MAPK pathways
  4226. The synergistic effect of an ATP-competitive inhibitor of mtor and metformin on pancreatic tumor growth
  4227. Renin-angiotensin system inhibitor attenuates oxidative stress induced human coronary artery endothelial cell dysfunction via the PI3K/AKT/mTOR pathway
  4228. Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD‑1 colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway
  4229. mTOR inhibition in primary neurons and the developing brain represses transcription of cholesterol biosynthesis genes and alters cholesterol levels
  4230. Allosteric and ATP-competitive inhibitors of mTOR effectively suppress tumor progression-associated epithelial-mesenchymal transition in the kidneys of …
  4231. Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1< alpha> signaling pathway
  4232. Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR
  4233. … suppress doxorubicin-induced cardiotoxicity via inhibition of oxidative stress, MAP kinase activation, NF-κB pathway, PI3K/Akt/mTOR impairment, and cardiac …
  4234. Dual inhibition of autophagy and PI3K/AKT/MTOR pathway as a therapeutic strategy in head and neck squamous cell carcinoma
  4235. Use of human iPSCs and kidney organoids to develop a cysteamine/mTOR inhibition combination therapy to treat cystinosis
  4236. Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway
  4237. A new SIRT1 inhibitor, MHY2245, induces autophagy and inhibits energy metabolism via PKM2/mTOR pathway in human ovarian cancer cells
  4238. The Role of mTOR Inhibitors in Breast Cancer Treatment
  4239. Effect of PI3K/mTOR signal pathway inhibitor XL765 on human leukemic KG-1 cells
  4240. mTOR inhibitor Treats Autistic-like Behaviors in Tsc2+/-rats but not following Developmental Status Epilepticus
  4241. mTOR inhibition in the treatment of resistant breast cancer
  4242. Enhanced skeletal muscle insulin sensitivity after acute resistance-type exercise is upregulated by rapamycin-sensitive mTOR complex 1 inhibition
  4243. ACTR-64. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/mTOR INHIBITOR GDC-0084 IN GBM …
  4244. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition
  4245. TGFβ Causes Postoperative Natural Killer Cell Paralysis Through mTOR Inhibition
  4246. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
  4247. Inhibition of decidual IGF-1 signaling in response to hypoxia and leucine deprivation is mediated by mTOR and AAR pathways and increased IGFBP-1 …
  4248. Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor
  4249. Inhibition of PLK4 might enhance the anti‐tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway
  4250. Geroprotective drugs-mTOR inhibitors in the treatment of cancer patients.
  4251. mTOR signalling in cancer-Is there a role for mTOR inhibitors in current anti-cancer therapies?
  4252. Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway
  4253. Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells
  4254. Vanillic acid suppresses HIF-1α expression via inhibition of mTOR/p70S6K/4E-BP1 and Raf/MEK/ERK pathways in human colon cancer HCT116 cells
  4255. KDM1A and mTOR inhibition is a novel therapeutic combination for the treatment of endometrial cancer
  4256. Berberine attenuates cardiac hypertrophy through inhibition of mTOR signaling pathway
  4257. Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway
  4258. Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer
  4259. APLNR is involved in ATRA‐induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K‐Akt‐mTOR signaling
  4260. Targeting the PI3K/mTOR pathway augments CHK1 inhibitor–induced replication stress and antitumor activity in high-grade serous ovarian cancer
  4261. Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells
  4262. Structure-based design and biological evaluation of novel mTOR inhibitors as potential anti-cervical agents.
  4263. Attenuation of free fatty acid (FFA)-induced skeletal muscle cell insulin resistance by resveratrol is linked to activation of AMPK and inhibition of mTOR and p70 S6K
  4264. MSTN attenuates cardiac hypertrophy through inhibition of excessive cardiac autophagy by blocking AMPK/mTOR and miR-128/PPARγ/NF-κB
  4265. Inhibition of CD133 overcomes cisplatin resistance through inhibiting PI3K/AKT/mTOR signaling pathway and autophagy in CD133-positive gastric cancer cells
  4266. Long non-coding RNA MALAT1 enhances the apoptosis of cardiomyocytes through autophagy inhibition by regulating TSC2-mTOR signaling
  4267. Safety and Efficacy of mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex under 2 Years of Age
  4268. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells
  4269. Inhibition of dipeptidyl peptidase-4 accelerates epithelial–mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis
  4270. Cytotoxic and antiproliferative effects of β-mangostin on rat C6 glioma cells depend on oxidative stress induction via PI3K/AKT/mTOR pathway inhibition
  4271. Retracted: GABARAP promotes bone marrow mesenchymal stem cells‐based the osteoarthritis cartilage regeneration through the inhibition of PI3K/AKT/mTOR …
  4272. TREATMENT OF B-CELL LYMPHOMAS AS CHARACTERISED BY MTOR INHIBITORS
  4273. … stem cell-derived exosomal miRNA-29c decreases cardiac ischemia/reperfusion injury through inhibition of excessive autophagy via the PTEN/Akt/mTOR signaling …
  4274. Sequential or concomitant inhibition of cyclin-dependent kinase 4/6 before mTOR pathway in hormone-positive HER2 negative breast cancer: biological …
  4275. Inhibition of HIF1A-AS1 promoted starvation-induced hepatocellular carcinoma cell apoptosis by reducing HIF-1α/mTOR-mediated autophagy
  4276. Combining the mTOR Inhibitor Everolimus and Gemcitabine in Relapsed/Refractory Peripheral T-Cell Lymphomas
  4277. Doxorubicin‐induces NFAT/Fas/FasL cardiac apoptosis in rats through activation of calcineurin and P38 MAPK and inhibition of mTOR signalling pathways
  4278. mTOR inhibitor enhances anti-tumor effect of BET bromodomain inhibitor in small cell lung cancer
  4279. Dual inhibition of BRAF and mTOR in BRAFV600E-mutant pediatric, adolescent, and young adult brain tumors
  4280. Rapamycin suppresses postnatal muscle hypertrophy induced by myostatin-inhibition accompanied by transcriptional suppression of the Akt/mTOR pathway
  4281. Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway
  4282. PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome
  4283. Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism
  4284. Tanc2-dependent direct and regulated mTOR inhibition balances mTORC1/2 signaling in developing mouse and human neurons
  4285. Simultaneous inhibition of atypical protein kinase‑C and mTOR impedes bladder cancer cell progression
  4286. HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment
  4287. Improvement of cerebral ischemia/reperfusion injury by daucosterol palmitate-induced neuronal apoptosis inhibition via PI3K/Akt/mTOR signaling pathway
  4288. MECHANISMS OF NEUROPROTECTION BY MTOR INHIBITORS
  4289. mTOR inhibitors in combination regimens guided by encyclopedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers
  4290. Fate of Pediatric Renal Angiomyolipoma During mTOR Inhibitor Treatment in Tuberous Sclerosis Complex
  4291. 18572 Relevant skin exposure after topical application of the pan-PI3K/mTOR inhibitor bimiralisib
  4292. … contribute to the DMAMCL-induced inhibition of glioma cell proliferation by regulating the ROS/MAPK signaling pathway and suppressing the Akt/mTOR …
  4293. Synergistic activity of magnolin combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma cells via targeting PI3K-AKT/mTOR and ERK MAPK …
  4294. Abstract IA04: Stroma-driven resistance to PI3K/mTOR inhibition
  4295. Oral mucositis:’In Vitro’model and systematic review of treatment with natural mTOR inhibitors
  4296. Pharmacological inhibition of O-GlcNAc transferase promotes mTOR-dependent autophagy in rat cortical neurons
  4297. Novel Delivery of Mtor Inhibitor to Glioblastoma Cells
  4298. Metabolic modulation combined with mTOR pathway inhibition may overcame cutaneous melanoma resistance to MAPK inhibitors treatment
  4299. … and rapamycin attenuate isoflurane-induced cognitive impairment through inhibition of neuroinflammation by suppressing the mTOR signaling in the …
  4300. A study on the protective mechanism of mTOR inhibitor Everolimus on brain injury after epilepsy
  4301. Triclosan induces PC12 cells injury is accompanied by inhibition of AKT/mTOR and activation of p38 pathway
  4302. Expanding the use of mtor inhibitors to high-risk kidney transplant recipients
  4303. Opposite Effects of the Triple Target (DNA-PK/PI3K/mTOR) Inhibitor PI-103 on the Radiation Sensitivity of Glioblastoma Cell Lines MO59K and MO59J Differing in …
  4304. Hif-Mediated suppression of DEPTOR confers resistance to mTOR kinase inhibition in renal cancer
  4305. Genetic Analysis of PI3k and mTOR Inhibition in U87mg Glioblastoma Cell Line
  4306. Yangxinkang tablet protects against cardiac dysfunction and remodelling after myocardial infarction in rats through inhibition of AMPK/mTOR-mediated autophagy
  4307. Exploring mTOR Inhibition as Treatment for Mitochondrial Disease (P4. 6-060)
  4308. … sirolimus reduces organic anion-transporting polypeptide (OATP) 1B1-and 1B3-mediated transport independently of mTOR kinase inhibition: implication in assessing …
  4309. Safety and efficacy of mTOR inhibitors following intestine and multivisceral transplantation
  4310. Discovery and preclinical characterization of PQR626: A potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of tuberous sclerosis complex
  4311. DDIS-33. SELECTIVE AND COMPLETE INHIBITION OF mTORC1 BY BI-STERIC mTOR INHIBITORS DRIVES THERAPEUTIC RESPONSE IN GLIOBLASTOMA
  4312. P1761 SIDE EFFECTS OF MTOR INHIBITORS DEPEND ON THE BASELINE METABOLIC STATUS OF KIDNEY TRANSPLANT RECIPIENTS
  4313. α7-Nicotinic acetylcholine receptor antagonist QND7 suppresses non-small cell lung cancer cell proliferation and migration via inhibition of Akt/mTOR signaling
  4314. The effect of mTOR inhibitor rapamycin on a dietary Drosophila melanogaster model of calcium oxalate nephrolithiasis
  4315. Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute
  4316. Manganese-enhanced MRI depicts a reduction in brain response to nociception by mTOR inhibition in chronic pain rats
  4317. P1752 THE ROLE OF MTOR INHIBITORS ON CARDIOVASCULAR AGING IN RENAL TRANSPLANT PATIENTS WITH CHRONIC GRAFT DYSFUNCTION
  4318. … effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis
  4319. Artesunate protects against surgery-induced knee arthrofibrosis by activating Beclin-1-mediated autophagy via inhibition of mTOR signaling
  4320. Response of mTOR inhibitor associated with mutation of FBXW7 gene identified by comprehensive genomic profiling in cervical squamous cell carcinoma supports …
  4321. MTOR INHIBITION ENHANCES HUMAN REGULATORY T CELL FUNCTION THROUGH INDUCTION OF A METABOLICALLY-CONTROLLED SOLUBLE FACTOR
  4322. … membrane permeabilization and disruption of the molecular target of rapamycin (mTOR)-lysosome interaction are associated with the inhibition of lung cancer cell …
  4323. Timosaponin A‑III induces autophagy of T‑cell acute lymphoblastic leukemia Jurkat cells via inhibition of the PI3K/Akt/mTOR pathway
  4324. Fibroblast growth factor 21 stimulates pancreatic islet autophagy via inhibition of AMPK-mTOR signaling
  4325. Carrier-free small-molecule drug nanoassembly elicits chemoimmunotherapy via co-inhibition of PD-L1/mTOR
  4326. … inhibition enhances Matrine derivative MASM induced apoptosis in cancer cells via a mechanism involving reactive oxygen species-mediated PI3K/Akt/mTOR …
  4327. The VEGFR and mTOR inhibitors for treatment of advanced renal cell carcinoma: an economic analysis.
  4328. Feasibility of mTOR inhibitor for the treatment of Fuchs endothelial corneal dystrophy
  4329. … Electroacupuncture Ameliorates D-Galactose-Induced Alzheimer’s Disease-Like Pathology and Memory Deficits Probably via Inhibition of GSK3β/mTOR …
  4330. mTOR inhibitor and VEGFR inhibitor combination therapy regress a doxorubicin resistant osteosarcoma in a patient-derived orthotopic xenograft model and in vivo …
  4331. Outcomes after Early Initiation of mTOR-Inhibitors in Adult Cardiac Transplant Recipients
  4332. mTOR Inhibitor in Combination with Cyclosporine as Primary Maintenance Immunosuppression in Combined Kidney/Pancreas Transplant Recipients
  4333. Inhibition of p-mTOR represses transcription of PS1 and Notch 1-signaling
  4334. Abstract A26: mTOR inhibition promotes differentiation of human regulatory T cells via privileged mRNA translation
  4335. Novel Pineal Germinoma Model Demonstrates Sensitivity to MTOR Inhibition
  4336. Combined mTOR inhibition and chemotherapy as an effective strategy to treat KRAS-mutant lung cancer
  4337. Teaching an Old Dog New Tricks: Introducing a Hypothetical Mechanism of Synergy Between Metformin and New Generation mTOR Inhibitors in the Fight Against …
  4338. Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines
  4339. ErbB activation and heterodimerisation is responsible for resistance upon PI3K-mTOR inhibition in metastatic prostate cancer
  4340. … chloride-induced memory loss and hippocampal apoptosis by increased intracellular glutathione stores and activation of PTEN/AMPK induced inhibition of Akt/mTOR …
  4341. Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers
  4342. RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM
  4343. Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
  4344. Down‐regulation of lncRNA OGFRP1 induces autophagy and growth inhibition by AKT/mTOR signaling pathway in HCAECs
  4345. Mammalian Target of Rapamycin (mTOR) Inhibitor Induced Pulmonary Alveolar Proteinosis
  4346. SP775 PERIPHERAL LYMPHOCYTE CHANGES IN RENAL ALLOGRAFT RECIPIENTS AFTER CONVERSION TO mTOR INHIBITORS
  4347. GSK458, a novel oral dual PI3K/mTOR Inhibitor, is effective in preclinical model of T-cell lymphoma alone and in combination therapies
  4348. Hydrogen-rich saline ameliorated LPS-induced acute lung injury via autophagy inhibition through the ROS/AMPK/mTOR pathway in mice
  4349. mTOR Inhibition Delays Hepatoblastoma Growth in a Relevant Mouse Model
  4350. Harnessing WYE-132 as an inhibitor of the mTOR signaling enriches the cytotoxicity effect of vinblastine in B16F10 melanoma cancer cells
  4351. Analyses of PTEN gene aberrations and evaluation of the therapeutic potential of mTOR inhibitor in HPV negative cervical carcinoma
  4352. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway
  4353. Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer
  4354. A conjugated mTOR/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery
  4355. Impact of ER stress and PI3K-AKT-mTOR inhibitors on NIS glycosylation and subcellular localization in thyroid cell lines
  4356. mTOR Inhibitor rapamycin can reverses the combination antiretroviral therapy induced central nervous system disorder
  4357. … of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
  4358. Feasibility of pre-operative mTOR inhibitor Sirolimus in children and young adults with desmoid tumor
  4359. PI3K/mTOR and topoisomerase inhibitors with potential activity against SARS-CoV-2 infection
  4360. SP779 DIFFERENT EFFECTS ON TRANSITIONAL B LYMPHOCYTES AFTER CONVERSION TO mTOR INHIBITORS OR STEROID WITHDRAWAL IN RENAL …
  4361. Abstract B14: Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC
  4362. PP242, mTOR inhibitor, decreases phenylephrine‐induced vascular contractility in hypertensive and normotensive arteries
  4363. Novel Dual MTOR Inhibitors/AMPK Activators Attenuate Doxorubicin-Induced Cardiotoxicity
  4364. P1. 15-02 Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
  4365. CUDC‑907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2
  4366. mTOR inhibition promotes LPS‐induced acute lung injury by inducing endothelial hyperpermeability
  4367. Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: safety and survival
  4368. mTor inhibitor GDC-0349 improves ASO induced SAMMSON knock down resulting in enhanced anti-tumor efficacy in uveal melanoma
  4369. … metabolism, encourages crosstalk between autophagy and apoptosis in lung carcinoma cells by use of an AMPK inhibition-independent blockade of the Akt/mTOR …
  4370. … )-6-morpholino-1, 3, 5-triazin-2-yl) pyridin-2-amine (PQR530), a potent, orally bioavailable, and brain-penetrable dual inhibitor of class I PI3K and mTOR kinase
  4371. Combined autophagy and mTOR inhibition reduces cells proliferation and induces apoptosis in a lung carcinoid in-vitro model
  4372. Isoparvifuran isolated from Dalbergia odorifera attenuates H2O2-induced senescence of BJ cells through SIRT1 activation and AKT/mTOR pathway inhibition
  4373. Novel Duel Mtor Inhibitors/AMPK Activators Improve Therapeutic Efficacy of Doxorubicin and Ameliorate Its Associated Cardiotoxicity in Mice
  4374. Synthesis and syntehtic process optimization of mTOR protein inhibitor Torin2
  4375. The Ca channel antagonist Verapamil exerts a protective effect against the negative actions of the mTOR inhibitor everolimus on ovarian follicle preservation
  4376. Protosappanin‐A and oleanolic acid protect injured podocytes from apoptosis through inhibition of AKT‐mTOR signaling
  4377. The PI3K/mTOR dual inhibitor PF-04691502 shows antitumor activity in Sezary cells and in a xenograft mouse model
  4378. … TRANSPLANT PATIENTS HARBOR NEUTROPHILS SECRETING B-CELL ACTIVATING FACTOR (BAFF) WHICH CAN BE SUPPRESSED BY MTOR INHIBITORS
  4379. PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED …
  4380. First-in-human Phase I study to evaluate the brain-penetrant dual PI3K and mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade …
  4381. P2. 48: Safety and efficacy of mTOR inhibitors following intestine and multivisceral transplantation
  4382. Caffeine potentiates ethanol-induced neurotoxicity through mTOR/p70S6K/4E-BP1 inhibition in SH-SY5Y cells
  4383. MP70-01 EARLY APPLICATION OF MTOR INHIBITORS REDUCE VASCULAR INFLAMMATORY RESPONSE AFTER ISCHEMIA-REPERFUSION INJURY
  4384. Corrigendum to” The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)”[Cancer Lett. 392 (1)(2017) 9 …
  4385. MicroRNA-6071 suppresses glioblastoma progression through the inhibition of PI3K/AKT/mTOR pathway by binding to ULBP2
  4386. Manganese-enhanced magnetic resonance study on a reduction in brain responses to nociception by mTOR inhibition in chronic pain rats
  4387. … pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR …
  4388. PE-253: The Use of mTOR Inhibitors in Pediatric Liver Transplant Recipients: First Experience in a University Medical Center
  4389. Correction: mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development
  4390. Isoferulic acid inhibits human leukemia cell growth through induction of G2/M‑phase arrest and inhibition of Akt/mTOR signaling
  4391. Phosphorylation of PRAS40 contributes to the activation of the PI3K/AKT/mTOR signaling pathway and the inhibition of autophagy following status epilepticus …
  4392. A novel STAT3 inhibitor YHO-1701 inhibits ovarian and endometrial cancer cell growth, with augmented cytotoxicity in combination with an mTOR inhibitor
  4393. Hypoxia-induced downregulation of SRC-3 suppresses trophoblastic invasion and migration through inhibition of the AKT/mTOR pathway: implications for the …
  4394. Rab1A knockdown represses proliferation and promotes apoptosis in gastric cancer cells by inhibition of mTOR/p70S6K pathway
  4395. Abstract A27: The relationship between aspirin and cancer via its inhibition of mTOR pathway
  4396. … acute liver injury by promoting liver‐resident macrophage NLRP 3 inflammasome activation via the inhibition of AMPK/mTOR‐mediated autophagy induction
  4397. A SYSTEM TO IDENTIFY INHIBITORS OF MTOR SIGNALING USING HIGH-RESOLUTION GROWTH ANALYSIS IN S. CEREVISIAE
  4398. Inhibition of mTOR signaling enhances trabectedin activity in soft tissue sarcoma
  4399. Inhibition of mitochondrial autophagy protects donor lungs for lung transplantation against ischaemia‐reperfusion injury in rats via the mTOR pathway
  4400. Epithelial cells expressed IL-33 to promote degranulation of mast cells through inhibition on ST2/PI3K/mTOR-mediated autophagy in allergic rhinitis
  4401. An mTor-based immunosuppression reduces the antiviral efficacy of NS3/4A and NS5A inhibitors for HCV genotype 1b treatment in vitro
  4402. Inhibition of nasopharyngeal carcinoma by beta-lapachone occurs by targeting the mammalian target of rapamycin (mTOR)/PI3K/AKT pathway, reactive …
  4403. THER-34. MEK BLOCKADE SYNERGISTICALLY INCREASES THE ANTI-TUMOR EFFECTS OF mTOR INHIBITION IN GLIOMAS
  4404. Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor
  4405. Transcriptome profiling of tolerogenic dendritic cells conditioned with dual mTOR kinase inhibitor, AZD8055
  4406. Current status of PI3K/AKT/mTOR pathway and its inhibitors in breast cancer
  4407. Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
  4408. Interferon‐γ‐induced HLA Class II expression on endothelial cells is decreased by inhibition of mTOR and HMG‐CoA reductase
  4409. Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway
  4410. mTOR pathway components dictate cell response to Src inhibitors in prostate cancer cells
  4411. HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways
  4412. The regulation and mechanism of a dual PI3K/mTOR signaling inhibitor in hemangioma vascular endothelial cells in vitro
  4413. … of THP-1 leukemia cells infected with cytomegalovirus to anti-tumor antibiotic doxorubicin and restoration of the sensitivity by inhibitors of the PI3K/AKT/mTOR …
  4414. Systemic lupus erythematosus: PKCA is an inhibition pathway for mTOR by the active ingredient of green tea
  4415. Glycogen synthase kinase 3-β inhibition induces lymphangiogenesis through β-catenin-dependent and mTOR-independent pathways
  4416. … , synthesis and biological evaluation of thieno [3, 2-d] pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition
  4417. The effect of combined PI3K/mTOR and ERK inhibition in monolayer, three-dimensional and in vivo ovarian cancer models.
  4418. Activation of autophagy during farnesyl pyrophosphate synthase inhibition is mediated through PI3K/AKT/mTOR signaling
  4419. Flavonoids from Apios americana Medikus Leaves Protect RAW264.7 Cells against Inflammation via Inhibition of MAPKs, Akt-mTOR Pathways, and Nfr2 …
  4420. … Protein Kinase IV (CaMKIV) limits ER stress and improves insulin sensitivity through inhibition of autophagy via the mTOR/CREB signaling pathway
  4421. Inhibition of PI3K/mTOR pathways with GDC-0980 in pediatric leukemia: Impact on abnormal FLT-3 activity and cooperation with intracellular signaling targets
  4422. … of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2-metastatic breast cancer treated with everolimus (mTOR inhibitor).
  4423. Knockdown of inhibitor of differentiation 1 suppresses proliferation and induces apoptosis by inactivating PI3K/Akt/mTOR signaling in hemangioma-derived …
  4424. … A375 human malignant melanoma cells through apoptosis induction, DNA damage, cell invasion inhibition and downregulation of the mTOR/PI3K/Akt signalling …
  4425. … vesicles derived from M2 bone marrow-derived macrophages attenuate apoptosis and promote motor function recovery via inhibition of mTOR in spinal cord …
  4426. Combined mTOR/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors.
  4427. … , a Pan-Pim kinase inhibitor, has anti-growth effect on 93T449 human liposarcoma cells via control of the expression and phosphorylation of Pim-3, mTOR, 4EBP-1, S6 …
  4428. … cardioprotection against hypoxia/reoxygenation‐induced apoptosis in human cardiomyocytes via inhibition of PTEN and BCL2L11 and modulation of AKT/mTOR …
  4429. Abstract B19: Susceptibility of NOTCH1 mutant head and neck squamous carcinoma to PI3K/mTOR pathway inhibition via PDK1
  4430. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
  4431. 2-(2-(2, 4-dioxopentan-3-ylidene) hydrazineyl) benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma
  4432. Novel 4-Acrylamido-Quinoline Derivatives as Potent PI3K/mTOR Dual Inhibitors: The Design, Synthesis, and in vitro and in vivo Biological Evaluation
  4433. A study of zederone for the inhibition on ovarian cancer cell proliferation through mTOR/p70s6K signalling pathway
  4434. Murrayanine exerts antiproliferative effects on human oral cancer cells through inhibition of AKT/mTOR and Raf/MEK/ERK signalling pathways In vitro and …
  4435. Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans
  4436. Inhibition of peiminine on invasion and migration of human lung cancer A549 cells by decreasing epithelial-mesenchymal transition process via PI3K/Akt/mTOR …
  4437. Inhibition of mammalian target of rapamycin (mTOR) improves neurobehavioral deficit and modulates inflammatory response after traumatic brain injury
  4438. Abstract P6-18-13: Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer
  4439. mTOR Signal Pathway Inhibition Promote the Cytotoxicity of Chemotherapy on SHI-1 Cells
  4440. Inhibition of p-mTOR represses PS1 transcription by reducing p-JNK
  4441. RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation …
  4442. Abstract B11: mTOR pathway inhibition induces GPNMB expression and sensitizes breast cancer cells to an antibody-drug conjugate targeting GPNMB
  4443. … is mediated via inhibition of cell migration and invasion, and suppression of phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of rapamycin (mTOR …
  4444. Overexpression of ribonuclease inhibitor induces autophagy in human colorectal cancer cells via the Akt/mTOR/ULK1 pathway
  4445. Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway
  4446. PDK1 inhibitor GSK-470 exhibits potent anticancer activity in a pheochromocytoma PC12 cell tumor model via Akt/mTOR pathway
  4447. Inhibition of nasopharyngeal cells mediated via G2/M cell cycle arrest, blocking PI3K/AKT/mTOR signalling pathway and suppression of cell migration and …
  4448. Investigation of enhanced antitumor effects via co-inhibition of Wnt/β-catenin and PI3K/Akt/mTOR signaling pathways in human gastric cancer.
  4449. In Silico Approach for Identification of PI3K/mTOR Dual Inhibitors for Multiple Myeloma Treatment
  4450. Inhibition of MEK5 suppresses TDP-43 toxicity via the mTOR-independent activation of the autophagy-lysosome pathway
  4451. PDK1 drives susceptibility of NOTCH1 mutant head and neck squamous carcinoma to PI3K/mTOR pathway inhibition
  4452. Impact of Neuroinflammatory and mTOR Signaling Inhibition following Flurothyl Seizures on the Acute Development of Autistic-like Behavior in C57BL/6 Mice
  4453. Synergistic Cytotoxic Effect of a Novel mTOR/PI3K Dual Inhibitor PF-04691502 and Radiation Therapy on Neuroendocrine Tumor Cells
  4454. Pharmacological inhibition of mTOR attenuates replicative cell senescence and improves cellular function via regulating the STAT3-PIM1 axis in human cardiac …
  4455. … penetration, anti-tumor activity, and survival of ABI-009 (nab-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition
  4456. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
  4457. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
  4458. CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A …
  4459. Discovery of Hesperidin Based Novel AMPK/mTOR Kinase Inhibitor against Colorectal Cancer Cells.
  4460. Microcytic anemia associated with mTOR or calcineurin inhibition: An unusual situation after allogeneic hematopoietic stem cell transplantation
  4461. Altered Glutamine Metabolism Exposes EMT Derived Mesenchymal Cells to PI3K/Akt/mTOR Pathway Inhibition
  4462. Combination of mTOR kinase inhibitors with Src inhibitors in PTEN-mt prostate cancer cells
  4463. Identification of predictive biomarkers of response for mTOR pathway inhibitors in renal cell carcinoma
  4464. … via mitochondrial-mediated apoptosis, inhibition of cell migration, invasion suppression, and mammalian target of rapamycin (mTOR)-TOR/PI3K/AKT …
  4465. … , a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) …
  4466. Progress of targeting PI3K-AKT-mTOR signaling pathway inhibitors in treatment of triple-negative breast cancer
  4467. E2F2 inhibition induces autophagy to impair metastasis via the PI3K/Akt/mTOR pathway in gastric cancer
  4468. Effect of novel mTOR-PI3K dual inhibitors on neuroendocrine tumor cell proliferation and apoptosis
  4469. Maf1 suppresses hepatocarcinogenesis in mice through inhibition of Akt-mTOR signaling
  4470. Corrigendum to” ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway”[Cancer Lett. 454 …
  4471. SNX-2112, an Hsp90 inhibitor, suppresses cervical cancer cells proliferation, migration, and invasion by inhibiting the Akt/mTOR signaling pathway
  4472. The Inhibition of EV71 Virus-Induced Apoptosis by ZVAD Through ROS and mTOR Pathway
  4473. P11. 45 Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma …
  4474. CK2 inhibitor CX4945 shows strong in vivo synergistic anti-leukemia activity with rapamycin in B-ALL due to enhanced ikaros mediated repression of mtor …
  4475. Eriodictyol modulates glioma cell autophagy and apoptosis by inhibition of PI3K/Akt/mTOR signaling pathway
  4476. Inhibition of mTOR during a postnatal critical sensitive window rescues deficits in GABAergic PV cell connectivity and social behavior caused by loss of TSC1
  4477. Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum]
  4478. Resistance to Cisplatin in NSCLC is Related to Autophagy Induced by PI3K/AKT/mTOR Signaling Pathway Inhibition
  4479. Cardiac glycoside Cerberin exerts anticancer activity by PI3K/AKT/mTOR signal transduction inhibition.
  4480. 30P Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung …
  4481. Inhibition of hepatitis B virus replication by FAM176A via activation of PI3K-AKT-mTOR signaling pathway
  4482. Abstract B02: Combined inhibition of mTOR and Src family kinases enhances treatment effects in prostate cancer cells
  4483. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and could suppress EMT process through PI3K/Akt/mTOR signaling …
  4484. Effect of lithium chloride on AKT-mTOR signal pathway in osteoblasts after estrogen receptor inhibition
  4485. … TRANSITION AND AUTOPHAGY IN ANTITUMORAL RESPONSE OF MELANOMA CELL LINES TO TARGET INHIBITION OF MEK AND mTOR KINASES
  4486. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition
  4487. Retraction: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
  4488. BRMS1 performs an anti-tumor effect on renal cell carcinoma via inhibition of PI3K/AKT/mTOR signaling pathway.
  4489. … inhibition of Atypical Protein Kinase-C and mTOR impedes bladder canSimultaneous inhibition of atypical protein kinase-C and mTOR impedes bladder cancer cell …
  4490. Abstract B33: Targeting PI3K/mTOR signaling with potent, selective and orally-available small-molecule inhibitors of eIF4E
  4491. CXCR4 Blockade Enhances The Sensitivity Of Osteosarcoma To Doxorubicin By Inducing Autophagic Cell Death Via PI3K-Akt-Mtor Pathway Inhibition
  4492. PI3K/mTOR and topoisomerase inhibitors with potential activity against SARS-CoV-2 infection (preprint)
  4493. Investigation of enhanced antitumor effects via co-inhibition of Wnt/β-catenin and PI3K/Akt/mTOR signaling pathways in human gastric cancer
  4494. Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells
  4495. … TRANSITION AND AUTOPHAGY IN ANTITUMORAL RESPONSE OF MELANOMA CELL LINES TO TARGET INHIBITION OF MEK AND mTOR KINASES
  4496. Combination of hemiasterlin derivative (R)(S)(S)-BF65 and PI3K/mTOR dual inhibitor NVP-BEZ235 as a new strategy to inhibit ovarian cancer growth and metastasis
  4497. Discovery of 4-phenyl-2H-benzo [b][1, 4] oxazin-3 (4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors
  4498. Combined Pharmacologic Inhibition of MEK-ERK and PI3K/mTOR Signaling in Glioblastoma Models Enhances Therapeutic Antitumor Activity (P2. 6-023)
  4499. … LIVER-RESIDENT MACROPHAGE NLRP3 INFLAMMASOME ACTIVATION VIA THE INHIBITION OF AMPK/MTOR-MEDIATED AUTOPHAGY INDUCTION
  4500. … receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR …
  4501. Inhibition of the mTOR and MAPK pathways suppresses growth, induces apoptosis, and decreases vascularity in pediatric low grade glioma
  4502. Abstract P3-14-02: Upper extremity edema in the at-risk arm among patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer
  4503. Combined inhibition of mTOR and PIKKs exploits replicative and checkpoint vulnerabilities to induce death of PI3K-activated triple-negative breast cancer …
  4504. CC-115, a dual mTOR/DNA-PK inhibitor in clinical trial, is a substrate of ABCG2, a risk factor for CC-115 resistance
  4505. Inhibition of mTOR-Akt-ULK1 signaling pathway and activation of autophagy by TNFAIP8 in metastasis of gastric cancer
  4506. Correction to Discovery of 3-Oxabicyclo [4.1. 0] heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR …
  4507. Pharmacological Inhibition of Nemo-like Kinase Rescues mTOR-Mediated Translation and Primes Progenitors for Leucine-Stimulated Erythroid Expansion in …
  4508. Abstract P6-21-08: Synergistic anti-cancer activity of cyclin-dependent kinase 4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing …
  4509. FXR activation impairs liver progenitor cell‐driven liver regeneration by enhancing PTEN‐dependent inhibition of AKT‐mTOR axis
  4510. Calcium/calmodulin-dependent Protein Kinase IV Limits ER stress and Insulin Resistance through Inhibition of Autophagy in Adipocytes by mTOR/CREB Signaling
  4511. MP51-06 SMYD3 INHIBITION INDUCES PROTECTIVE AUTOPHAGY IN BLADDER CANCER VIA MTOR PATHWAY
  4512. … potentiates paclitaxel and gemcitabine mediated antitumor effects against pancreatic cancer via inhibition of prosurvival PI3k/AKT/mTOR and ERK pathways
  4513. … of effectiveness of targeted drugs of RAS and PI3K pathways in TNBC: Testing a combination of MEK 1/2 inhibitor with mTOR kinase inhibitor or AKT inhibitor
  4514. Triptolide Suppresses Glomerular Mesangial Cell Proliferation in Diabetic Nephropathy Is Associated with Inhibition of PDK1/Akt/mTOR Pathway: Erratum
  4515. 1015-INHIBITION OF ENDOTHELIAL MTOR DRIVES HEMATOPOIETIC STEM CELL AGING
  4516. Inhibition of Long Non-Coding RNA LOC100996425 Suppresses the Proliferation, Migration and Promotes Apoptosis of Prostate Cancer Cells Through the AMPK …
  4517. Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
  4518. Induction of apoptosis in SGC-7901 cells by ruthenium (II) complexes through ROS-mediated lysosome–mitochondria dysfunction and inhibition of PI3K/AKT/mTOR …
  4519. 3182–PHARMACOLOGICAL INHIBITION OF NEMO-LIKE KINASE RESCUES MTOR-MEDIATED TRANSLATION AND ERYTHROPOIESIS IN PRE-CLINICAL …
  4520. ARID1a as a marker of prognosis and increased sensitivity to CDK4/6, mTOR 1/2 and Src homology region 2 phosphatase (SHP 1/2) inhibitors in breast cancer (BC).
  4521. Overview of research into mTOR inhibitors
  4522. Recent advances and limitations of mTOR inhibitors in the treatment of cancer
  4523. Combining mTOR inhibitors and T cell-based immunotherapies in cancer treatment
  4524. The role of mTOR inhibitors in hematologic disease: from bench to bedside
  4525. mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses
  4526. Recent advances in dual PI3K/mTOR inhibitors for tumour treatment
  4527. Perfect match: mTOR inhibitors and tuberous sclerosis complex
  4528. Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
  4529. Brain-restricted mTOR inhibition with binary pharmacology
  4530. Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015–2021)
  4531. mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression
  4532. mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters
  4533. A patent review of mTOR inhibitors for cancer therapy (2011–2020)
  4534. p53-mediated AKT and mTOR inhibition requires RFX7 and DDIT4 and depends on nutrient abundance
  4535. A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19
  4536. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer …
  4537. The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages
  4538. mTOR inhibitor INK128 promotes wound healing by regulating MDSCs
  4539. mTOR inhibitors improve both humoral and cellular response to SARS‐CoV‐2 messenger RNA BNT16b2 vaccine in kidney transplant recipients
  4540. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction
  4541. Targeting the biology of aging with mTOR inhibitors
  4542. Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition
  4543. mTOR inhibition: a double-edged sword in patients with COVID-19?
  4544. Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells
  4545. Can we use mTOR inhibitors for COVID-19 therapy?
  4546. Mechanistic target of rapamycin (mTOR) inhibitors
  4547. Preclinical evaluation and phase Ib study of prexasertib, a CHK1 inhibitor, and samotolisib (LY3023414), a dual PI3K/mTOR inhibitor
  4548. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 positive feedback loop induces cell cycle arrest by dual PI3K/mTOR inhibitor PQR309 in endometrial cancer cell …
  4549. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma
  4550. Treatment of cardiac rhabdomyomas with mtor inhibitors in children with tuberous sclerosis complex—a systematic review
  4551. Unbiased evaluation of rapamycin’s specificity as an mTOR inhibitor
  4552. RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition
  4553. Pharmacologic activation of autophagy without direct mTOR inhibition as a therapeutic strategy for treating dry macular degeneration
  4554. Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy
  4555. A theoretical insight in interactions of some chemical compounds as mTOR inhibitors
  4556. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: Phase 2b and phase 3 randomised trials
  4557. mTOR inhibition as a novel gene therapeutic strategy for diabetic retinopathy
  4558. Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin
  4559. Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
  4560. Novel dual PI3K/mTOR inhibitor, apitolisib (GDC-0980), inhibits growth and induces apoptosis in human glioblastoma cells
  4561. Therapeutic role of mTOR inhibitors in control of SARS-CoV-2 viral replication
  4562. mTOR inhibition impairs extinction memory reconsolidation
  4563. Deficiency in the treatment description of mTOR inhibitor resistance in medulloblastoma, a systematic review
  4564. mTOR inhibitor use is associated with a favorable outcome of COVID-19 in patients of kidney transplant: Results of a retrospective study
  4565. An amino acid-defined diet impairs tumour growth in mice by promoting endoplasmic reticulum stress and mTOR inhibition
  4566. Upfront treatment with mTOR inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience
  4567. mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells
  4568. Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment
  4569. mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus
  4570. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex—An update
  4571. The putative role of mTOR inhibitors in non-tuberous sclerosis complex-related epilepsy
  4572. mTOR inhibitors prevent CMV infection through the restoration of functional αβ and γδ T cells in kidney transplantation
  4573. Evaluating targeted therapies in ovarian cancer metabolism: novel role for PCSK9 and second generation mTOR inhibitors
  4574. mTOR inhibition ablates cisplatin-resistant salivary gland cancer stem cells
  4575. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches
  4576. mTOR inhibition and T-DM1 in HER2-positive breast cancer
  4577. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations
  4578. mTOR inhibition with Sirolimus in multiple system atrophy: a randomized, double‐blind, placebo‐controlled futility trial and 1‐year biomarker longitudinal analysis
  4579. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
  4580. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells
  4581. mTOR inhibitors potentially reduce TGF-β2-induced fibrogenic changes in trabecular meshwork cells
  4582. Transcriptomic repositioning analysis identifies mTOR inhibitor as potential therapy for epidermolysis bullosa simplex
  4583. mTOR inhibitor improves testosterone-induced myocardial hypertrophy in hypertensive rats
  4584. TFEB Overexpression, Not mTOR Inhibition, Ameliorates RagCS75Y Cardiomyopathy
  4585. Mtor inhibitors associated with higher cardiovascular adverse events—A large population database analysis
  4586. … the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma?–ie Strategies to Revert Resistance to mTOR Inhibitors
  4587. The 40S-LARP1 complex reprograms the cellular translatome upon mTOR inhibition to preserve the protein synthetic capacity
  4588. Inhibitors of the PI3K/Akt/mTOR pathway in prostate cancer chemoprevention and intervention
  4589. The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
  4590. mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
  4591. Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
  4592. mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS‐CoV‐2 mRNA vaccines in solid organ transplant …
  4593. mTOR inhibition prevents angiotensin II–induced aortic rupture and pseudoaneurysm but promotes dissection in Apoe-deficient mice
  4594. Real life experience with mTOR-inhibitors after lung transplantation
  4595. Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an …
  4596. Targeting the tumor microenvironment through mTOR inhibition and chemotherapy as induction therapy for locally advanced head and neck squamous cell …
  4597. Biodegradable stent with mTOR inhibitor-eluting reduces progression of ureteral stricture
  4598. Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons
  4599. Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors
  4600. VEGFR inhibitors for uterine metastatic perivascular epithelioid tumors (PEComa) resistant to mTOR inhibitors. a case report and review of literature
  4601. Arctigenin triggers apoptosis and autophagy via PI3K/Akt/mTOR inhibition in PC-3M cells
  4602. … mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition
  4603. Discovery of the First Raptor (Regulatory-Associated Protein of mTOR) Inhibitor as a New Type of Antiadipogenic Agent
  4604. The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation
  4605. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor− Positive Recurrent or Metastatic Endometrial …
  4606. mTOR-inhibition and COVID-19 in kidney transplant recipients: focus on pulmonary fibrosis
  4607. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis
  4608. Evaluation of a dual PI3K/mTOR inhibitor PF-04691502 against bladder cancer cells
  4609. Low temperature and mTOR inhibition favor stem cell maintenance in human keratinocyte cultures
  4610. The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review
  4611. Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain
  4612. PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition
  4613. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and-Positive HNSCC Cell …
  4614. Effect of mTOR inhibitors on sodium taurocholate cotransporting polypeptide (NTCP) function in vitro
  4615. … docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and …
  4616. Medical Aspects of mTOR Inhibition in Kidney Transplantation
  4617. Improvement of PD-1 blockade efficacy and elimination of immune-related gastrointestinal adverse effect by mTOR inhibitor
  4618. Cardamonin suppresses pro-tumor function of macrophages by decreasing M2 polarization on ovarian cancer cells via mTOR inhibition
  4619. mTOR inhibition promotes pneumonitis through inducing endothelial contraction and hyperpermeability
  4620. New insights into mTOR inhibition: understanding the mechanisms and their importance
  4621. Mtor inhibition via rapamycin treatment partially reverts the deficit in energy metabolism caused by fh loss in rpe cells
  4622. mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death
  4623. Bioactive PI3-kinase/Akt/mTOR inhibitors in targeted lung cancer therapy
  4624. mTOR inhibition attenuates cTfh cell dysregulation and chronic T-cell activation in multilineage immune cytopenias
  4625. Sarcoidosis incidence after mTOR inhibitor treatment
  4626. Connectivity map analysis indicates PI3K/Akt/mTOR inhibitors as potential anti-hypoxia drugs in neuroblastoma
  4627. Pan-mTOR inhibitors sensitize the senolytic activity of navitoclax via mTORC2 inhibition-mediated apoptotic signaling
  4628. mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction
  4629. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and …
  4630. The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings
  4631. Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
  4632. mTOR inhibition by TAK‐228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models
  4633. The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry
  4634. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex
  4635. Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA …
  4636. Targeting ganglioneuromas with mTOR inhibitors
  4637. Real-life experience of mTOR inhibitors in liver transplant recipients in a region where living donation is predominant
  4638. MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor
  4639. Evidence that C/EBP-β LAP Increases Fat Metabolism and Protects Against Diet-Induced Obesity in Response to mTOR Inhibition
  4640. Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma
  4641. mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation
  4642. Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells
  4643. mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in patients with juvenile polyposis of infancy with PTEN-BMPR1A deletion
  4644. Anisomycin inhibits angiogenesis, growth, and survival of triple-negative breast cancer through mitochondrial dysfunction, AMPK activation, and mTOR inhibition
  4645. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
  4646. In silico development of new PET radiopharmaceuticals from mTOR inhibitors
  4647. Disarming the Old Foe. Restoring T-Cell Immune Function with mTor-Inhibitors to Tackle Cytomegalovirus Infection
  4648. The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
  4649. Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex
  4650. Effects of mTOR inhibitor–related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients
  4651. The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients …
  4652. NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)
  4653. Compound library screening for synergistic drug combinations: mTOR inhibitor and proteasome inhibitor effective against osteosarcoma cells
  4654. Phosphoproteome profiling revealed the importance of mTOR inhibition on CDK1 activation to further regulate cell cycle progression
  4655. Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy
  4656. AI-Predicted mTOR Inhibitor Reduces Cancer Cell Proliferation and Extends the Lifespan of C. elegans
  4657. DHW-221, a dual PI3K/mTOR inhibitor, overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and akt-mediated FOXO3a Nuclear …
  4658. Subependymal giant-cell astrocytoma: A surgical review in the modern era of mTOR inhibitors
  4659. The PI3K/mTOR inhibitor ompalisib suppresses nonhomologous end joining and sensitizes cancer cells to radio-and chemotherapy
  4660. CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated …
  4661. CAVEAT mTOR: You’ve heard about the benefits of using mTOR inhibitors, here are some of the risks
  4662. TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review
  4663. Fibroblast-Induced Paradoxical PI3K pathway activation in PTEN-competent colorectal cancer: implications for therapeutic PI3K/mTOR Inhibition
  4664. A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant
  4665. Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K/mTOR inhibitor and resists HIF-1α …
  4666. The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats
  4667. mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3-and Blimp-1-mediated BCL-2 upregulation
  4668. Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative …
  4669. m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition
  4670. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
  4671. Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor rapamycin
  4672. mTOR inhibitors and risk of ovarian cysts: a systematic review and meta-analysis
  4673. EMT-derived alterations in glutamine metabolism sensitize mesenchymal breast cells to mTOR inhibition
  4674. Dual targeting of melanoma translation by MNK/eIF4E and PI3K/mTOR inhibitors
  4675. Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients
  4676. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility
  4677. Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age
  4678. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
  4679. Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
  4680. Inhibition of mTOR signaling protects human glioma cells from hypoxia-induced cell death in an autophagy-independent manner
  4681. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma
  4682. SPR965, a dual PI3K/mTOR inhibitor, as a targeted therapy in ovarian cancer
  4683. The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid …
  4684. Treatment by PI3K/mTOR Inhibitor BEZ235 Combined with TLR-7/8 Agonist Interfere with Immune Evasion Mechanisms of WEHI-3 Mouse Leukemia Cells
  4685. Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
  4686. Combination of CDK4/6 and mTOR inhibitors suppressed doxorubicin-resistant osteosarcoma in a patient-derived orthotopic xenograft mouse model: a translatable …
  4687. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines
  4688. Biomimetic polyphenol-coated nanoparticles by Co-assembly of mTOR inhibitor and photosensitizer for synergistic chemo-photothermal therapy
  4689. Role of natural mTOR inhibitors in treatment of diabetes mellitus
  4690. Lactotransferrin downregulation serves as a potential predictor for the therapeutic effectiveness of mtor inhibitors in the metastatic clear cell renal cell …
  4691. Conversion to mTOR Inhibitor to Reduce the Incidence of Cytomegalovirus Recurrence in Kidney Transplant Recipients Receiving Preemptive Treatment: A …
  4692. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein–Barr virus–associated post …
  4693. mTOR Inhibition Is Effective against Growth, Survival and Migration, but Not against Microglia Activation in Preclinical Glioma Models
  4694. mTOR inhibitors as radiosensitizers in neuroendocrine neoplasms
  4695. Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study
  4696. The Role of Green Tea Catechin Epigallocatechin Gallate (EGCG) and Mammalian Target of Rapamycin (mTOR) Inhibitor PP242 (Torkinib) in the Treatment …
  4697. Tetrahydroquinoline: an efficient scaffold as mTOR inhibitor for the treatment of lung cancer
  4698. Drug Repurposing Reveals mTOR Inhibition as a Promising Strategy for Epidermolysis Bullosa Simplex
  4699. A Combination therapy using an mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells and …
  4700. Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis
  4701. Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database
  4702. PI3Kinase/AKT/mTOR Pathway in Breast Cancer; Pathogenesis and Prevention with mTOR Inhibitors
  4703. … after lung transplantation–a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
  4704. Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability
  4705. The combination of Trametinib, a MEK inhibitor, and temsirolimus, an mTOR inhibitor, radiosensitizes lung cancer cells
  4706. mTOR inhibition improves the formation of functional T cell memory following COVID-19 vaccination of kidney transplant recipients
  4707. The incidence of cytomegalovirus and BK polyomavirus infections in kidney transplant patients receiving mTOR inhibitors: A systematic review and meta‐analysis
  4708. HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models
  4709. HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53
  4710. Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells
  4711. The case for the therapeutic use of mechanistic/mammalian target of rapamycin (mTOR) inhibitors in xenotransplantation
  4712. mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4+CD57+ T Cells In Vivo and In Vitro
  4713. … and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAFV600E mutant …
  4714. Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor
  4715. Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells
  4716. Conversion to mTOR-Inhibitors Plus IV Immunoglobulins in Kidney-Transplant Recipients with BKV Infection: A Retrospective Comparative Study
  4717. mTOR inhibition as a possible pharmacological target in the management of systemic inflammatory response and associated neuroinflammation by …
  4718. Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
  4719. Oxadiazol-based mTOR inhibitors with potent antiproliferative activities: synthetic and computational modeling
  4720. As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression
  4721. mTOR inhibition increases transcription factor E3 (TFE3) activity and modulates programmed death-ligand 1 (PD-L1) expression in translocation renal cell …
  4722. Jabło nska, E.; Cechowska-Pasko, M. Novel dual PI3K/mTOR inhibitor, Apitolisib (GDC-0980), inhibits growth and induces apoptosis in human glioblastoma …
  4723. Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation
  4724. Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors
  4725. Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients
  4726. Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish
  4727. Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational …
  4728. Mtor inhibition by INK128 extends functions of the ovary reconstituted from germline stem cells in aging and premature aging mice
  4729. STAT3 polymorphism associates with mTOR inhibitor-induced interstitial lung disease in patients with renal cell carcinoma
  4730. Association of HLA mismatch and MTOR inhibitor regimens with malignancy and mortality after kidney transplantation
  4731. Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and …
  4732. BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate …
  4733. PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors
  4734. Inhibition of the PI3K/mTOR pathway in breast cancer to enhance response to immune checkpoint inhibitors in breast cancer
  4735. Validated HPLC‐UV method for quantification of paxalisib, a pan PI3K and mTOR inhibitor in mouse plasma: Application to a pharmacokinetic study in mice
  4736. … anti‑HLA class I antibodies on the immunological properties of human glomerular endothelial cells and their modification by mTOR inhibition or GCN2 kinase …
  4737. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy
  4738. Preventive Effect of Combined Zingiber officinale and Terminalia chebula against DMBA-Induced Breast Cancer Rats via mTOR Inhibition
  4739. PI3K/mTOR inhibition prevents anal cancer in mice with established low-grade anal dysplasia
  4740. Structural Aspects of mTOR Inhibitors: Search for Potential Compounds
  4741. Design, synthesis and pharmacological evaluation of 2-arylurea-1, 3, 5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy
  4742. Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
  4743. The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury
  4744. PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model
  4745. Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma
  4746. Analysis of serum lipid parameters predicting lipid metabolic disorders in TSC‐AML patients with treatment of mTOR inhibitors
  4747. Discovery of 2-Methyl-2-(4-(2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-naphtho[1,2-d]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor …
  4748. The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in …
  4749. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
  4750. Minimal mitochondrial respiration is required to prevent cell death by inhibition of mTOR signaling in CoQ-deficient cells
  4751. Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe …
  4752. Clinical validation of a liquid chromatography-tandem mass spectrometry method for the quantification of calcineurin and mTOR inhibitors in dried matrix on …
  4753. Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive …
  4754. Marine-derived natural products as ATP-competitive mTOR kinase inhibitors for cancer therapeutics
  4755. Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review
  4756. Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation
  4757. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the …
  4758. Enterovirus 71 induces autophagy in mice via mTOR inhibition and ERK pathway activation
  4759. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer
  4760. Inhibition of mTOR in bovine monocyte derived macrophages and dendritic cells provides a potential mechanism for postpartum immune dysfunction in dairy …
  4761. Geniposide protection against Aβ1-42 toxicity correlates with mTOR inhibition and enhancement of autophagy
  4762. Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
  4763. Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual …
  4764. A Mechanistic Target of Rapamycin (mTOR) Inhibitor, Everolimus Safely Ameliorated Lupus Nephritis in a Patient Complicated with Tuberous Sclerosis.
  4765. Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
  4766. Systemic Delivery of a Dual PI3K/mTOR Inhibitor More Effective than Topical Delivery in Preventing Anal Carcinogenesis in an HPV Transgenic Mouse Model
  4767. nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access …
  4768. mTOR inhibition prevents coronary artery remodeling in a murine model of Kawasaki disease.
  4769. Randomized Trial of Early mTOR Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction.
  4770. The New PI3K/mTOR Inhibitor GNE-477 Inhibits the Malignant Behavior of Human Glioblastoma Cells
  4771. The impact of mTOR inhibitors in the regression of left ventricular hypertrophy in elderly kidney transplant recipients
  4772. PI3K/Akt/mTOR pathways inhibitors with potential prospects in non-small-cell lung cancer
  4773. In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines
  4774. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells
  4775. … comparison of clinical outcomes for subependymal giant cell astrocytomas treated with laser interstitial thermal therapy, open surgical resection, and mTOR inhibitors
  4776. Effective disease control after combinatorial treatment with a PD-1 antibody and an mTOR inhibitor for recurrent ovarian clear cell carcinomas: a case report and …
  4777. Clinical trials of mTOR inhibitors to boost immunity to viral infection in older adults
  4778. The effects of Pi3k/Akt/Mtor signaling pathway inhibitors on the expression of immune checkpoint ligands in acute myeloid leukemia cell line
  4779. … activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
  4780. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy
  4781. Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma
  4782. Inhibition of MTOR signaling impairs rat embryo organogenesis by affecting folate availability
  4783. Pseudomonas aeruginosa survives in epithelia by ExoS‐mediated inhibition of autophagy and mTOR
  4784. How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?
  4785. mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis E Screening in …
  4786. The anti-non-small cell lung cancer cell activity by a mTOR kinase inhibitor PQR620
  4787. Cutaneous Adnexal Carcinoma with Apocrine Differentiation: A Challenging Diagnosis and Personalized Treatment with mTOR Inhibitor in a Very Rare …
  4788. Mammalian target of rapamycin (mTOR) inhibitors in dermatology
  4789. Repurposing HDAC and mTOR inhibitors for pancreatic cancer.
  4790. 17P Exploiting the immune-modulatory effects of PI3K/mTOR inhibitors to enhance response to immune-checkpoint blockade in uterine leiomyosarcoma
  4791. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
  4792. An insight on PI3K/AKT/MTOR inhibitors in cancer: Opportunity and translational perspectives
  4793. PI3K/AKT/mTOR and TLR4/MyD88/NF-κB signaling inhibitors attenuate pathological mechanisms of allergic asthma
  4794. Uterine perivascular epithelioid tumors (PEComas) with lung metastasis showed good responses to mTOR and VEGFR inhibitors: A case report
  4795. Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients
  4796. How do mTOR inhibitors fit in the relapsed acute lymphoblastic leukemia treatment landscape?
  4797. Bcl-2, JAK and mTOR Inhibitors
  4798. Growth of Angiomyolipomas in Patients with Tuberous Sclerosis Complex Treated with mTOR Inhibitor Differs by Indication for Treatment (P8-13.003)
  4799. The mTOR-inhibitor everolimus reduces hypervolemia in patients with primary aldosteronism.
  4800. mTOR Inhibition Suppresses Salinomycin-Induced Ferroptosis in Breast Cancer Stem Cells by Ironing Out Mitochondrial Dysfunctions
  4801. Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction
  4802. Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid …
  4803. Oral mTOR Inhibition Limits And Reduces Actinic Keratosis And Cutaneous Squamous Cell Carcinoma In A UVB-Induced Mouse Model
  4804. mTOR inhibitor induces non-apoptotic, autophagy dependent cell death (ADCD) in TP53 mutant HNSCC
  4805. Immunomodulatory properties of PI3K/AKT/mTOR and MAPK/MEK/ERK inhibition augment response to immune checkpoint blockade in melanoma and triple-negative …
  4806. mTOR inhibitor treatment in patients with tuberous sclerosis Complex is associated with specific changes in microRNA Serum profile
  4807. Searching for new mTOR kinase inhibitors: Analysis of binding sites and validation of docking protocols
  4808. Comprehensive Evaluation of the Specificity of Rapamycin as an mTOR Inhibitor
  4809. Enhancing plant-derived smart nano inhibitor in targeting mammalian target of rapamycin (mTOR) in breast cancer using Curcuma longa-derived compound …
  4810. Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism
  4811. Design, synthesis and biological evaluation of novel 9-methyl-9H-purine and thieno [3, 2-d] pyrimidine derivatives as potent mTOR inhibitors
  4812. KRAS G12C mutated NSCLC and bladder cancer xenografts treated with sotorasib and adagrasib in combination with mTOR inhibitors show improved antitumor …
  4813. An mTOR feedback loop mediates the ‘flare'(‘rebound’) response to MET tyrosine kinase inhibition
  4814. P422: Omipalisib, a dual PI3K/MTOR inhibitor, targets mitochondria and impairs oxidative phosphorylation in acute myeloid leukemia
  4815. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
  4816. PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling
  4817. Design and development of Tetrahydro-Quinoline derivatives as dual mTOR-C1/C2 inhibitors for the treatment of lung cancer
  4818. Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions
  4819. Inhibition of mTOR decreases insoluble proteins burden by reducing translation in C. elegans
  4820. Molecularly targeted radiation therapy using mTOR inhibition for the management of malignant perivascular epithelioid cell tumor (PEComa): a case report …
  4821. Combination of mTOR inhibitor PP242 and AMPK activator metformin exerts enhanced inhibitory effects on colorectal carcinoma cells in vitro by blocking multiple …
  4822. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model
  4823. mTOR Inhibition via Low-dose, Pulsed Rapamycin with Intraovarian Condensed Platelet Cytokines: An Individualized Protocol to Recover Diminished Reserve
  4824. Expanding the horizons of mTOR inhibitors for treating subependymal giant cell astrocytomas with obstructive hydrocephalus
  4825. Plant-based mTOR inhibitors for the treatment of Parkinson’s Disease.
  4826. Comprehensive Evaluation of Rapamycin’s Specificity as an mTOR Inhibitor
  4827. Discovery of novel 1, 3, 5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR
  4828. Exploiting the Regulation of Apoptosis to Improve Therapeutic Responses of Tumors to mTOR Inhibitors
  4829. Transcriptomic-Based in silico Drug Screening Reveals Dual PI3K/mTOR Inhibitors Overcome Cabozantinib-Resistance of FLT3-ITD AML Cells
  4830. # 4364 LEUCOPENIA AFTER KIDNEY TRANSPLANTATION: SWITCHING MYCOPHENOLATE TO MTOR INHIBITOR APPEARS SAFE AND FEASIBLE TO REDUCE …
  4831. Combined inhibition of Akt and mTOR is effective against non-Hodgkin lymphomas
  4832. MTOR Inhibition Alters miRNA Profile in Cultured Bone Marrow Mesenchymal Stem Cells
  4833. 314.2: MTOR Inhibitors Promote Highly Functional T Cell Immunity in Kidney Transplant Recipients Vaccinated Against COVID-19
  4834. Immunosuppressive Effects and Potent Anti-tumor Efficacy of mTOR Inhibitor Everolimus in Breast Tumor-bearing Mice
  4835. Author Correction: Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons
  4836. mTOR inhibitor-independent Autophagy Activator Ameliorates Cellular Tauopathy and Prionopathy Neurodegeneration Phenotypes
  4837. 420.3: The Use of mTOR Inhibitors Is Associated With Reduced Mortality Among Kidney Transplant Patients Developing COVID-19
  4838. Synergy of MALT1 and mTOR inhibition in DLBCL
  4839. Immunological results of long-term use of mammalian target of rapamycin (Mtor) inhibitors and its effects on renal graft functions
  4840. mTOR inhibitors in a patient with lupus nephritis; why not?
  4841. Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor
  4842. … -122-5p inhibitor abolishes angiotensin II–mediated loss of autophagy and promotion of apoptosis in rat cardiofibroblasts by modulation of the apelin-AMPK-mTOR …
  4843. Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway
  4844. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma
  4845. Current status of mTOR inhibition in cancer therapy
  4846. Mediation of Anti-Keloid Effects of mTOR Inhibitors by Autophagy-Independent Machinery
  4847. AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung …
  4848. Systemic actions of sglt2 inhibition on chronic mtor activation as a shared pathogenic mechanism between alzheimer’s disease and diabetes
  4849. Impact of mTOR Inhibitor Conversion Protocol on Renal Function in Cardiac Transplant Recipients
  4850. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer
  4851. Pneumocystis jirovecii Pneumonia and Use of mTOR Inhibitors in Kidney Transplantation
  4852. Using mTOR Inhibitor Nanoimmunotherapy to Induce Cardiac Allograft Tolerance in Non-Human Primates
  4853. Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells
  4854. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers
  4855. mTOR Inhibitor-Induced Transient Acantholytic Dermatitis.
  4856. Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and rewires the microenvironment toward an immune-suppressive state
  4857. E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer
  4858. MAPK AND AKT/MTOR INHIBITION IMPROVES CHILDHOOD RASOPATHY-ASSOCIATED CARDIOMYOPATHY
  4859. Fleeting Efficacy of mTOR Inhibitors in RCC Produces the Need for Unique Combinations
  4860. Systematic review of mTOR inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures
  4861. Combination mTOR and SHP2 inhibitor treatment of lymphatic malformation endothelial cells
  4862. Inhibition of the PI3K/AKT/mTOR signaling promotes an M1 macrophage switch by repressing the ATF3-CXCL8 axis in Ewing sarcoma
  4863. Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells
  4864. Stress granules affect the dual PI3K/mTOR inhibitor response by regulating the mitochondrial unfolded protein response
  4865. MAPK and mTOR Inhibition Improves Childhood RASopathy-Associated Hypertrophic Cardiomyopathy
  4866. VS-5584, a PI3K/mTOR dual inhibitor, exerts antitumor effects on neuroblastomas in vitro and in vivo
  4867. Corrigendum to “mTOR inhibition and p53 activation, microRNAs: the possible therapy against pandemic COVID-19”[Gene Rep. 20 (2020) 100765]
  4868. 20P Tissue agnostic application of mTOR inhibitors for the management of therapy-refractory solid tumors
  4869. Artemisinin inhibits the migration and invasion in uveal melanoma via inhibition of the PI3K/AKT/mTOR signaling pathway
  4870. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
  4871. Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor
  4872. Celastrol inhibits rheumatoid arthritis by inducing autophagy via inhibition of the PI3K/AKT/mTOR signaling pathway
  4873. Inhibition of mTOR by temsirolimus overcomes radio‐resistance in nasopharyngeal carcinoma
  4874. Synergistic inhibition of drug-resistant colon cancer growth with PI3K/mTOR dual inhibitor BEZ235 and nano-emulsioned paclitaxel via reducing multidrug resistance …
  4875. Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors
  4876. Abstract P138: nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and …
  4877. Paxalisib. PI3K/mTOR inhibitor, Treatment of gliomas
  4878. A preclinical investigation of GBM-N019 as a potential inhibitor of glioblastoma via exosomal mTOR/CDK6/STAT3 signaling
  4879. Novel mTOR inhibitors: Promising therapeutic interventions in oral cancer therapy
  4880. HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD
  4881. Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2-d]Pyrimidine Series as Novel PI3K/mTOR Inhibitors
  4882. Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.
  4883. Familial uterine leiomyoma-associated germline oncogenic mutant VEGFR1 is sensitive to mTOR inhibitor
  4884. Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells
  4885. Cryptotanshinone, a novel PDK 4 inhibitor, suppresses bladder cancer cell invasiveness via the mTOR/β‑catenin/N‑cadherin axis
  4886. Predictive value of EGFR-PI3K-AKT-mTOR-pathway inhibitor biomarkers for head and neck squamous cell carcinoma: a systematic review
  4887. Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway
  4888. mTOR inhibition and T-DM1 in HER2-positive breast cancer
  4889. PS-B02-10: MTOR INHIBITOR IMPROVES TESTOSTERONE-INDUCED MYOCARDIAL HYPERTROPHY IN HYPERTENSIVE RATS
  4890. Discovery of Novel Mammalian target of rapamycin (mTOR) Inhibitors by Support Vector Machine
  4891. … glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK–mTOR signaling pathway–mediated …
  4892. ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
  4893. Ponatinib, lestaurtinib, and mTOR/PI3K inhibitors are promising repurposing candidates against Entamoeba histolytica
  4894. mTOR inhibition alleviates CD8+ T-cell senescence in activated phosphoinositide 3-kinase δ syndrome 2 patients
  4895. RNF43 G659fs is an oncogenic mutation in colorectal cancer and sensitizes tumor cells to PI3K/mTOR inhibition
  4896. Inhibition of mTOR signaling by genetic removal of p70 S6 kinase 1 increases anxiety-like behavior in mice
  4897. Four-octyl itaconate improves osteoarthritis by enhancing autophagy in chondrocytes via PI3K/AKT/mTOR signalling pathway inhibition
  4898. AUTOPHAGY ACTIVATION IN BREAST CANCER CELLS IN VITRO AFTER THE TREATMENT WITH PI3K/AKT/MTOR INHIBITORS
  4899. Exploring the Link Between Mtor Inhibitors and Interstitial Lung Diseases: A Disproportionality Analysis Using Fda Adverse Event Reporting System Database
  4900. Deubiquitinase USP9X loss Sensitizes Cancer Cells to mTOR Inhibitors through p62 Dysregulation
  4901. 207P Comparison of CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors in the second-line treatment of hormone receptor-positive, HER2-negative …
  4902. Molecular docking of potential inhibitors with the mTOR protein
  4903. Inhibition of NLRP3 inflammasome activation and pyroptosis in macrophages by taraxasterol is associated with its regulation on mTOR signaling
  4904. Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer …
  4905. Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA-and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
  4906. New amino acid Schiff bases as anticancer agents via potential mitochondrial complex I-associated hexokinase inhibition and targeting AMP-protein kinases/mTOR …
  4907. Structure-Based Virtual Screening Towards The Discovery of Usnic Acid Derivatives as Novel mTOR Inhibitor to Treat Breast Cancer
  4908. Correction to: Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database
  4909. Combining neratinib with CDK4/6, mTOR, and MEK inhibitors in models of HER2-positive cancer
  4910. Mechanism of mTOR inhibitors mediated DDP resistance in pancreatic cancer through the mTOR pathway
  4911. Inhibition of PI3K/AKT/mTOR signalling pathway activates autophagy and suppresses peritoneal fibrosis in the process of peritoneal dialysis
  4912. Newer generation mTOR inhibition represents effective therapeutic strategy for BRAF-mutant melanoma
  4913. Erianthridin suppresses non-small-cell lung cancer cell metastasis through inhibition of Akt/mTOR/p70S6K signaling pathway
  4914. RAMS11 promotes CRC through mTOR-dependent inhibition of autophagy, suppression of apoptosis, and promotion of epithelial-mesenchymal transition
  4915. Very-low-protein diets lead to reduced food intake and weight loss, linked to inhibition of hypothalamic mTOR signaling, in mice
  4916. Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
  4917. mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors
  4918. Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
  4919. Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer
  4920. Bimiralisib. Phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) inhibitor, Treatment of solid tumors, Treatment of lymphoma
  4921. YQFM alleviated cardiac hypertrophy by apoptosis inhibition and autophagy regulation via PI3K/AKT/mTOR pathway
  4922. Characteristics, predictors and outcomes of early mTOR inhibitor use after heart transplantation: insights from the UNOS database
  4923. The anti-proliferative effect of PI3K/mTOR and ERK inhibition in monolayer and three-dimensional ovarian cancer cell models
  4924. TEOA promotes autophagic cell death via ros-mediated inhibition of mtor/p70s6k signaling pathway in pancreatic cancer cells
  4925. Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC
  4926. The effects of mTOR inhibition in ischemic stroke
  4927. Cell Signaling Analysis of Metastatic Triple Negative Breast Cancer Following Dual PI3K/mTOR Inhibitor (PIKTOR)
  4928. Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia
  4929. Sulfamethizole attenuates poloxamer 407‐induced atherosclerotic neointima formation via inhibition of mTOR in C57BL/6 mice
  4930. Myricetin induces apoptosis and autophagy in human gastric cancer cells through inhibition of the PI3K/Akt/mTOR pathway
  4931. INVESTIGATING THE IMPACT OF mTOR INHIBITOR TREATMENT ON TRANSGENERATIONAL OFFSPRING HEALTH AND FERTILITY
  4932. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition
  4933. Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive …
  4934. mTOR inhibition attenuates chemosensitivity through induction of a persister state
  4935. p53 inhibition protects against neuronal ischemia/reperfusion injury by the p53/PRAS40/mTOR pathway
  4936. Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling
  4937. Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity
  4938. Bipartite binding and partial inhibition links DEPTOR and mTOR in a mutually antagonistic embrace
  4939. Oroxin B alleviates osteoarthritis through anti-inflammation and inhibition of PI3K/AKT/mTOR signaling pathway and enhancement of autophagy
  4940. … -down induced tau hyperphosphorylation at Thr181, Ser199, Thr231, Ser262, Ser396 epitopes and inhibition of autophagy by overactivation of GSK3β/mTOR …
  4941. HDAC inhibitor cowanin extracted from G. fusca induces apoptosis and autophagy via inhibition of the PI3K/Akt/mTOR pathways in Jurkat cells
  4942. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia
  4943. REVIEW ON APPLICABILITY OF mTOR INHIBITOR DOCKING SCORE ANALYSIS METHODS IN DRUG DEVELOPMENT OF LUNG CANCER
  4944. Tacrolimus inhibits insulin release and promotes apoptosis of Min6 cells through the inhibition of the PI3K/Akt/mTOR pathway
  4945. The glucosylceramide synthase inhibitor PDMP causes lysosomal lipid accumulation and mTOR inactivation
  4946. Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy
  4947. Cardiac-specific Trim44 knockout in rat attenuates isoproterenol-induced cardiac remodeling via inhibition of AKT/mTOR pathway
  4948. Combined xCT and mTOR Inhibition as a New Therapeutic Option for Pancreatic Adenocarcinoma
  4949. Malignancies and Pediatric Liver Transplantation: Promising Management with the mTOR-inhibitor Everolimus
  4950. Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for the treatment of peripheral T cell lymphoma.
  4951. Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity
  4952. SMER28 attenuates PI3K/mTOR signaling by direct inhibition of PI3K p110 delta
  4953. Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS …
  4954. Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors
  4955. Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway
  4956. … ischemia/reperfusion injury‑induced damage to the blood‑brain barrier in hyperglycemia through PI3K/AKT/mTOR pathway‑mediated autophagy inhibition
  4957. Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways
  4958. eIF4A1 inhibitor suppresses hyperactive mTOR-associated tumors by inducing necroptosis and G2/M arrest
  4959. Abstract PR009: RNF43 G659fs is an oncogenic and immune-modulating colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition
  4960. RAC3 Inhibition Induces Autophagy to Impair Metastasis in Bladder Cancer Cells via the PI3K/AKT/mTOR Pathway
  4961. ST8SIA1 inhibition sensitizes triple negative breast cancer to chemotherapy via suppressing Wnt/β-catenin and FAK/Akt/mTOR
  4962. P-256 Fibroblast-induced paradoxical PI3K pathway activation in colorectal cancer: Role of PTEN and potential implications for PI3K/mTOR inhibition
  4963. Selenite Induces Cell Cycle Arrest and Apoptosis via Reactive Oxygen Species-Dependent Inhibition of the AKT/mTOR Pathway in Thyroid Cancer
  4964. BNIP3 contributes to silibinin-induced DNA double strand breaks in glioma cells via inhibition of mTOR
  4965. Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.
  4966. Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
  4967. Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway
  4968. Apoptotic effect of compound K in hepatocellular carcinoma cells via inhibition of glycolysis and Akt/mTOR/c‐Myc signaling
  4969. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
  4970. Pharmacological inhibition of the PI3K/PTEN/Akt and mTOR signalling pathways limits follicle activation induced by ovarian cryopreservation and in vitro …
  4971. Effect of MTOR Inhibitor Combined with Photodynamic Therapy on the Regulation of Cancer Stem Cells through Reactive Oxygen Species
  4972. Putative dual inhibitors of mTOR and RET kinase from natural products: Pharmacophore-based hierarchical virtual screening
  4973. Mammalian Target of Rapamycin (mTOR) Inhibitor Improves Local Immune Microenvironment and Reduces Seizures via Increasing miR-211 Level in Rat Brain
  4974. Early Use of mTOR Inhibitors in Tuberous Sclerosis: Current State and Plan for a Prospective Clinical Trial of Early Prophylactic mTOR Inhibitor Treatment (PROTECT)
  4975. Global mapping of protein and lipid network driven by mtor inhibition in oa cartilage
  4976. Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β …
  4977. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways
  4978. Uranium induces kidney cells apoptosis via reactive oxygen species generation, endoplasmic reticulum stress and inhibition of PI3K/AKT/mTOR signaling in culture
  4979. Exosomes derived from M2 macrophages exert a therapeutic effect via inhibition of the PI3K/AKT/mTOR pathway in rats with knee osteoarthritic
  4980. … attenuated oxygen and glucose deprivation/reperfusion-induced PC12ácell injury through inhibition of apoptosis and autophagy by activating the PI3K/AKT/mTOR …
  4981. Glutathione peroxidase 4 inhibition induces ferroptosis and mTOR pathway suppression in thyroid cancer
  4982. Anti-angiogenic properties of rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via inhibition of the mTOR pathway
  4983. An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth
  4984. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances
  4985. Design, synthesis and molecular docking of novel substituted azepines as inhibitors of PI3K/Akt/TSC2/mTOR signaling pathway in colorectal carcinoma
  4986. Efficacy of Dual PI3K/mTOR Inhibitor Combined With Autophagy Suppression Against Laryngeal Squamous Cell Carcinoma
  4987. Co-administration of mTor Inhibitors and Carbamazepine May Lead to Ineffectiveness of Therapy: A Case Report of a 24-year-old Man
  4988. DHODH inhibition exerts synergistic therapeutic effect with cisplatin to induce ferroptosis in cervical cancer through regulating mTOR pathway
  4989. Acquired sensitivity to ONC201/TIC10 in ER+ breast cancer progressing on the mTOR inhibitor everolimus
  4990. Binding site hotspot map of PI3Kα and mTOR in the presence of selective and dual ATP-competitive inhibitors
  4991. Inhibition of mTOR signaling by rapamycin protects photoreceptors from degeneration in rd1 mice
  4992. Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism
  4993. RapaBlock, a Novel Drug that Prevents the On-Target–Off-Tissue Effects of mTOR Inhibition
  4994. Neuroprotective effect of chrysophanol as a PI3K/AKT/mTOR signaling inhibitor in an experimental model of autologous blood-induced intracerebral hemorrhage
  4995. Discovery of Novel Hybrids of mTOR Inhibitor and NO Donor as Potential Anti-Tumor Therapeutics
  4996. Dual inhibitor of ACVR1 and MEK 1/2 E6201 and PI3K/mTOR inhibitor paxalisib synergistically inhibit cell growth in DMG
  4997. Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational …
  4998. Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma
  4999. Overcoming adaptive resistance in AML by synergistically targeting FOXO3A-GNG7-mTOR axis with FOXO3A inhibitor Gardenoside and rapamycin
  5000. Activation of AMPK/mTOR-driven autophagy and inhibition of NLRP3 inflammasome by saxagliptin ameliorate ethanol-induced gastric mucosal damage
  5001. mTOR signaling inhibition decreases lysosome migration and impairs the success of Trypanosoma cruzi infection and replication in cardiomyocytes
  5002. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway
  5003. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
  5004. … a novel GLUT1 inhibitor and cisplatin synergistically inhibits breast cancer cell growth by enhancing the DNA damaging effect and modulating the Akt/mTOR …
  5005. mTOR inhibition decreases angiotensin II-induced steroidogenesis in HAC15 human adrenocortical carcinoma cells.
  5006. … regimen of carbamazepine and imipramine exhibits synergism against grandmal epilepsy in rats: Inhibition of pro-inflammatory cytokines and PI3K/Akt/mTOR …
  5007. Inhibition of ANGPT2 activates autophagy during hypertrophic scar formation via PI3K/AKT/mTOR pathway
  5008. Utilizing Catalytic mTOR Inhibition in Preclinical Models of Huntington Disease
  5009. … photobiomodulation against hydrogen peroxide-induced oxidative damage by promoting autophagy through inhibition of PI3K/AKT/mTOR pathway in MC3T3 …
  5010. Hepatitis E viral infection regulates estrogen signaling pathways: Inhibition of the cAMPK–PKA–CREB and PI3K–AKT–mTOR signaling pathways
  5011. Compression stress induces nucleus pulposus cell autophagy by inhibition of the PI3K/AKT/mTOR pathway and activation of the JNK pathway
  5012. PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and …
  5013. Qingyihuaji Formula promotes apoptosis and autophagy through inhibition of MAPK/ERK and PI3K/Akt/mTOR signaling pathway on pancreatic cancer in vivo and in …
  5014. Inhibition of PI3K/Akt/mTOR pathway by ammonium chloride induced apoptosis and autophagy in MAC-T cell
  5015. Sclerostin aggravates insulin signaling in skeletal muscle and hepatic steatosis via upregulation of ER stress by mTOR‐mediated inhibition of autophagy under …
  5016. Design, synthesis, characterization and pharmacological evaluation of mTOR inhibitors for anticancer activity
  5017. … profiling and protein analysis reveal suppression of the C-Myc oncogene and inhibition JAK/STAT and PI3K/AKT/mTOR signaling by thymoquinone in acute …
  5018. Orf virus induces complete autophagy to promote viral replication via inhibition of AKT/mTOR and activation of the ERK1/2/mTOR signalling pathway in OFTu …
  5019. IL-38 prevents induction of trained immunity by inhibition of mTOR signaling
  5020. Natural prenylated xanthones as potential inhibitors of PI3k/Akt/mTOR pathway in triple negative breast cancer cells
  5021. Effectiveness and durability of benefit of mTOR inhibitors (mTORi) in a real-world cohort of metastatic prostate cancer (mPCA) patients with PI3K pathway alterations.
  5022. PMON171 DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Pituitary Neuroendocrine Tumoral Cells
  5023. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition
  5024. mTOR inhibition enhances delivery and activity of antisense oligonucleotides in uveal melanoma cells
  5025. Atractylenolide III alleviates the apoptosis through inhibition of autophagy by the mTOR-dependent pathway in alveolar macrophages of human silicosis
  5026. Impact of PI3K/mTOR inhibitors on the development of taxane resistance
  5027. Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties
  5028. MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer
  5029. Change Specifically Responses To Mtor Inhibition Based On Brain Of N. Guentheri
  5030. Synthesis and antitumor evaluation of menthone-derived pyrimidine-urea compounds as potential PI3K/Akt/mTOR signaling pathway inhibitor
  5031. Novel Specific Pyruvate Kinase M2 Inhibitor, Compound 3h, Induces Apoptosis and Autophagy through Suppressing Akt/mTOR Signaling Pathway in LNCaP Cells
  5032. POS-791 Metabolic complications of mTOR inhibitors in kidney transplantation: a tunisian multicenter study
  5033. … to combat doxorubicin-induced toxicity via inactivation of PI3K/AKT/mTOR signaling mediated ROS-dependent apoptosis and autophagic flux inhibition in MCF-7 …
  5034. Alpinia katsumadai Hayata induces growth inhibition and autophagy‑related apoptosis by regulating the AMPK and Akt/mTOR/p70S6K signaling pathways in …
  5035. Pulmonary toxicity of mTOR inhibitors in kidney transplantation: A single-center experience
  5036. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy …
  5037. Targeting inhibition of accumulation and function of myeloid-derived suppressor cells by artemisinin via PI3K/AKT, mTOR, and MAPK pathways enhances anti …
  5038. … -08-21: Development of novel inhibitors of the serum/glucocorticoid induced kinase (SGK) family to address limitations of AKT/PI3K/mTOR inhibitors in breast cancer
  5039. Abstract A016: Selective delivery of fibroblast activation protein conjugated dual phosphoinositide 3-kinase–AKT Kinase-mTOR inhibitor associated with decreased …
  5040. … eradication of colon cancer cells harboring PI3K and/or MAPK pathway mutations in 3D culture by combined PI3K/AKT/mTOR pathway and MEK inhibition
  5041. Zingerone suppresses cell proliferation via inducing cellular apoptosis and inhibition of the PI3K/AKT/mTOR signaling pathway in human prostate cancer PC‐3 cells
  5042. Tortured by mTOR Inhibitors? A Case of Pneumocystis Pneumonia Originally Diagnosed as mTOR Pneumonitis
  5043. POS-792 Evolution of proteinuria after introduction of mTOR inhibitors in kidney transplant patients: a Tunisian multicenter study
  5044. The eIF4A inhibitor silvestrol blocks the growth of human glioblastoma cells by inhibiting AKT/mTOR and ERK1/2 signaling pathway
  5045. Real-world experience of mTOR inhibitors in liver transplant recipients in a region where living donation is predominant
  5046. Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach
  5047. FOXD1-mTOR signaling pathway on oral squamous cell carcinoma and its inhibition by rosemary extract (invitro-study)
  5048. Shuangshen granules attenuate lung metastasis by modulating bone marrow differentiation through mTOR signalling inhibition
  5049. SGLT2 inhibition mitigates perturbations in nephron segment-specific metabolic transcripts and mTOR pathway activity in kidneys of young persons with type 2 …
  5050. Depletion of glioma stem cells by synergistic inhibition of mTOR and c-Myc with a biological camouflaged cascade brain-targeting nanosystem
  5051. … and vernonioside e from Vernonia amygdalina delile. Leaves as inhibitor of epidermal growth factor receptor (egfr) and mammalian target of rapamycin (mTOR)
  5052. … to” Design, synthesis and pharmacological evaluation of 2-arylurea-1, 3, 5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy” …
  5053. Spatial transcriptomics analysis of co-targeted PIM and PI3 K/mTOR in multikinase inhibitor and single kinase inhibitor combination-treated patient-derived prostate …
  5054. … responses induced by polychlorinated bisphenol intoxication in rats via activation of the mTOR signaling pathway mediating inhibition of apoptosis, inflammation, and …
  5055. Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer
  5056. Combination Therapy With Pde5-mtor Inhibitors Attenuates Cardiotoxicity While Enhancing Cancer Cell Death Following Treatment With Doxorubicin and Human …
  5057. P86. 14 Next-Generation Sequencing Guided the Gene Mutations Associated with mTOR-Inhibitors in Chinese Lung Cancer Patients
  5058. Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK …
  5059. Inhibition of ATF4-mediated elevation of both autophagy and AKT/mTOR was involved in antitumorigenic activity of curcumin
  5060. PI3K/AKT/mTOR signalling inhibitor chrysophanol ameliorates neurobehavioural and neurochemical defects in propionic acid-induced experimental model of autism …
  5061. Dual Ampk Activator/mtor Inhibitor Improves Metabolic Parameters in T2d Mice and Protects Cardiomyocytes Against Ischemic Injury
  5062. Effect of mTOR inhibition in a 3D in vitro model of alveolar epithelium and epithelial regeneration
  5063. … kinase inhibitor (Fasudil) suppresses TGF-β mediated autophagy in urethra fibroblasts to attenuate traumatic urethral stricture (TUS) through re-activating Akt/mTOR …
  5064. Ticagrelor ameliorates bleomycin-induced pulmonary fibrosis in rats by the inhibition of TGF-Β1/Smad3 and PI3K/AKT/MTOR pathways
  5065. Sophoridine Derivatives Induce Apoptosis and Autophagy to Suppress the Growth of Triple‐Negative Breast Cancer through Inhibition of mTOR Signaling
  5066. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition
  5067. REGRESSION OF INTIMAL HYPERPLASIA USING MTOR INHIBITORS AFTER HEART TRANSPLANTATION
  5068. mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsu ciency but not following developmental status epilepticus
  5069. mTOR Inhibition Abrogates Human Mammary Stem Cells and Early Breast Cancer Progression Markers
  5070. mTOR Inhibitor Therapy for Epilepsy Secondary to Tuberous Sclerosis
  5071. Fucoxanthin prevents cell growth and induces apoptosis in endometrial cancer HEC‐1A cells by the inhibition of the PI3K/Akt/mTOR pathway
  5072. The acute transcriptional responses to dietary methionine restriction are triggered by inhibition of ternary complex formation and linked to Erk1/2, mTOR, and …
  5073. Apelin-13 increases functional connexin-43 through autophagy inhibition via AKT/mTOR Pathway in the non-myocytic cell population of the heart
  5074. Synergistic effect of CXCR5+ CD8+ TAb-supp cell therapy and mTOR inhibition (but not calcineurin inhibition) in suppressing alloantibody following kidney transplant …
  5075. Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancer
  5076. AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axis
  5077. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF …
  5078. Development of TAT-fused mTOR Inhibitor Binding Proteins for the Treatment of Breast Cancer
  5079. COX-2/sEH dual inhibitor alleviates hepatocyte senescence in NAFLD mice by restoring autophagy through Sirt1/PI3K/AKT/mTOR
  5080. … and Validation of a Robust Genomic Classifier for High-Risk Sporadic Type 2 Papillary Renal Cell Carcinoma: Support More Accurate Utilization of mTOR inhibitors
  5081. Idebenone-Activating Autophagic Degradation of α-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson’s Disease: A …
  5082. AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo
  5083. Liquiritigenin exerts the anti-cancer role in oral cancer via inducing autophagy-related apoptosis through PI3K/AKT/mTOR pathway inhibition in vitro and in vivo
  5084. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants Part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and …
  5085. Inhibition of PI3K/Akt/mTOR signaling by NDRG2 contributes to neuronal apoptosis and autophagy in ischemic stroke
  5086. The effect of mTOR activation and PTEN inhibition on human primordial follicle activation in ovarian tissue culture
  5087. PD43-03 MCT INHIBITION SYNERGIZES WITH TYROSINE KINASE AND MTOR INHIBITOR TREATMENT IN RENAL CELL CARCINOMA
  5088. Brain penetrant HDAC and PI3K/mTOR inhibitors synergize to induce DIPG cell death
  5089. Mtor Inhibition Decreases Ligand-induced Mineralocorticoid Receptor Activation
  5090. SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway
  5091. mTOR inhibition represses transcription of cholesterol biosynthesis genes and alters cholesterol levels in primary neurons and in the developing brain
  5092. … to invasive lobular carcinoma and mixed ductal/lobular treated with endocrine therapy in combination with CDK4/6 inhibitors, mTOR inhibitor, or PI3K inhibitor.
  5093. Colistin-induced pulmonary toxicity involves the activation of NOX4/TGF-β/mtROS pathway and the inhibition of Akt/mTOR pathway
  5094. Abstract P036: Trial in progress: Combination of the dual RAF/MEK inhibitor VS-6766 with the mTOR inhibitor everolimus with expansion in patients with KRAS mutant …
  5095. mTOR pathway inhibition stimulates pharmacologically induced nonsense suppression
  5096. Nimbolide-encapsulated PLGA nanoparticles induces mesenchymal-to-epithelial transition by dual inhibition of AKT and mTOR in pancreatic cancer stem cells
  5097. Design, synthesis, and biological evaluation of novel dual inhibitors of heat shock protein 90/mammalian target of rapamycin (Hsp90/mTOR) against bladder cancer …
  5098. Extended-Release Tacrolimus and mTOR Inhibitor-Based Immunosuppressive Regimen in Living Donor Kidney Transplantation: A Single-Center Retrospective …
  5099. Impact of Age, Menopause and mTOR Inhibitor Use on Spontaneous Pneumothoraces in Lymphangioleiomyomatosis
  5100. Low-dose mTOR inhibitor alleviates RPE cellular senescence and pro-inflammation induced by accumulation of cytosolic nuclear DNA fragments
  5101. The positive feedback exerted by mtor inhibitor everolimus in pituitary neuroendocrine tumoral cells is reverted by cabergoline co-treatment
  5102. Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
  5103. Astragaloside IV protects from PM2. 5-induced lung injury by regulating autophagy via inhibition of PI3K/Akt/mTOR signaling in vivo and in vitro
  5104. Mtor Inhibition Prolongs Survival and Improves Contractile Function after Onset of Lamin A/C Mutation Cardiomyopathy
  5105. Anticancer effects of morusin in prostate cancer via inhibition of Akt/mTOR signaling pathway
  5106. Anticancer effects of the HDAC inhibitor, 3β, 6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways
  5107. Growth inhibition and suppression of the mTOR and Wnt/β‐catenin pathways in T‐acute lymphoblastic leukemia by rapamycin and MYCN depletion
  5108. Amifostine attenuates bleomycin-induced pulmonary fibrosis in mice through inhibition of the PI3K/Akt/mTOR signaling pathway
  5109. P15. 06: Distinct FOXP3 Gene Expression in the Peripheral Blood And Inside Renal Allografts Is Associated With Use of MTOR Inhibitors and Extended Criteria Kidney …
  5110. PD24-08 SEQUENTIAL USAGE OF MTOR INHIBITOR FOLLOWED BY IMMUNOTHERAPIES FOR CABOZANTINIB-RESISTANT METASTATIC CLEAR CELL RENAL …
  5111. Gomisin N attenuated cerebral ischemia-reperfusion injury through inhibition of autophagy by activating the PI3K/AKT/mTOR pathway
  5112. Xanthohumol alleviates oxidative stress and impaired autophagy in experimental severe acute pancreatitis through inhibition of AKT/mTOR
  5113. CD5-mediated mTOR inhibition on T cells through binding of soluble CEACAM1
  5114. … differential expression status of endogenous PTEN helps in KSHV oncogenesis and acts as the key determinant for the sensitivity of mTOR inhibitors which induce a …
  5115. … ‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum …
  5116. Anisomycin sensitizes non‐small‐cell lung cancer cells to chemotherapeutic agents and epidermal growth factor receptor inhibitor via suppressing PI3K/Akt/mTOR
  5117. … antitumor evaluation of (aryl) methyl-amine derivatives of dehydroabietic acid-based B ring-fused-thiazole as potential PI3K/AKT/mTOR signaling pathway inhibitors
  5118. Dieckol exerts anticancer activity in human osteosarcoma (MG-63) cells through the inhibition of PI3K/AKT/mTOR signaling pathway
  5119. Dual inhibition of autophagy and PI3K/mTOR pathway as a potential therapeutic strategy against laryngeal squamous cell carcinoma
  5120. PDE4 inhibitor eliminates breast cancer stem cells via noncanonical activation of mTOR
  5121. Bifidobacterium infantis Promotes Foxp3 Expression in Colon Cells via PD-L1-Mediated Inhibition of the PI3K-Akt-mTOR Signaling Pathway
  5122. Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitors suitable for the treatment of CNS disorders
  5123. Insulin‑like growth factor 1 promotes neurological functional recovery after spinal cord injury through inhibition of autophagy via the PI3K/Akt/mTOR signaling …
  5124. Tomentosin inhibits cell proliferation and induces apoptosis in MOLT‐4 leukemia cancer cells through the inhibition of mTOR/PI3K/Akt signaling pathway
  5125. Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR‐138‐5p and activation of AKT/mTOR signaling pathway
  5126. PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
  5127. Synthesis and evaluation of [18F] mIpoPET-1, a fluorine-18 labelled mTOR inhibitor derivative based on an imidazo [4, 5-b] pyrazin-2-one backbone.
  5128. Inhibition of SRSF3 alleviates proliferation and migration of gastric cancer cells by regulating the PI3K/AKT/mTOR signalling pathway
  5129. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo …
  5130. Lycopene prevents oxygen-glucose deprivation-induced autophagic death in SH-SY5Y cells via inhibition of the oxidative stress-activated AMPK/mTOR …
  5131. Inhibition of Connexin 43 reverses ox-LDL-mediated inhibition of autophagy in VSMC by inhibiting the PI3K/Akt/mTOR signaling pathway
  5132. CHARACTERISTICS, PREDICTORS AND OUTCOMES OF EARLY MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITOR USE AFTER HEART …
  5133. Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling
  5134. Potential new therapy of Rapalink-1, a new generation mTOR inhibitor, against sunitinib-resistant renal cell carcinoma.
  5135. Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K/AKT/mTOR signaling pathways
  5136. Abstract P5-08-15: Overcoming mTOR inhibitor resistance by targeting the lysosomal deregulation
  5137. First, second, and third generation mTOR pathways inhibitors for treatment of glioblastoma
  5138. … Attenuates Myocardial Hypertrophy and Fibrosis in Pressure Overload-Induced Mice Involving mTOR and TGF-β1/Smad Signaling Pathway Inhibition
  5139. ATL1 inhibits the proliferation and invasion of trophoblast cells via inhibition of the mTOR signaling pathway
  5140. … -5-(3-(pyridin-4-yl)-1H-pyrazolo [3, 4-b] pyridin-5-yl) pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of …
  5141. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway
  5142. Alkali exposure induces autophagy through activation of the MAPKpathway by ROS and inhibition of mTOR in Eriocheir sinensis
  5143. Targeting CDK4/6 inhibitor resistance in relapsed RB-proficient osteosarcoma patient-derived xenografts via PI3 Kinase/mTOR inhibition
  5144. … cell death induced by the quinoline derivative 2‐(6‐methoxynaphthalen‐2‐yl) quinolin‐4‐amine in pancreatic cancer cells is via ER stress and inhibition of Akt/mTOR …
  5145. Xanthatin suppresses proliferation and tumorigenicity of glioma cells through autophagy inhibition via activation of the PI3K‐Akt–mTOR pathway
  5146. LncRNA RHPN1‐AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR‐7‐5p/EGFR/PI3K/AKT/mTOR signaling pathway
  5147. Endogenous Aβ induces osteoporosis through an mTOR-dependent inhibition of autophagy in bone marrow mesenchymal stem cells (BMSCs)
  5148. Inhibition of PI3K/mTOR/KATP channel blunts sodium thiosulphate preconditioning mediated cardioprotection against ischemia–reperfusion injury
  5149. … , a novel phosphatidylinositol 3-kinase inhibitor, inhibits colorectal carcinoma cell proliferation and suppresses angiogenesis by attenuating PI3K/AKT/mTOR …
  5150. Nicorandil mitigates amiodarone‐induced pulmonary toxicity and fibrosis in association with the inhibition of lung TGF‐β1/PI3K/Akt1‐p/mTOR axis in rats
  5151. Down regulation of fatty acid synthase via inhibition of PI3K/AKT/mTOR in ovarian cancer cell line by novel organoselenium pseudopeptide
  5152. Abstract PO-094: Gα13 loss in KPC mouse model promotes well-differentiated pancreatic tumors that are susceptible to mTOR inhibition
  5153. LSC-2021-Effect of mTOR inhibition in a 3D in vitro model of alveolar epithelium and epithelial regeneration
  5154. Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells
  5155. Neddylation inhibition reduces liver steatosis in MAFLD mice models by promoting hepatic fatty acid oxidation via DEPTOR-mTOR axis
  5156. The Potent Anti-Tumor Effects of Rhodiola Drinking Are Associated with the Inhibition of the mTOR Pathway and Modification of Tumor Metabolism in the UPII …
  5157. Inhibition of NF-κB might enhance the protective role of roflupram on SH-SY5Y cells under amyloid β stimulation via PI3K/AKT/mTOR signaling pathway
  5158. … -01: Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
  5159. Effect of 2-deoxyglucose-mediated inhibition of glycolysis on the regulation of mTOR signaling and protein synthesis before and after high-intensity muscle contraction
  5160. Abstract P1-10-06: Effect of aging and mTOR inhibition on human mammary stem cells and early breast cancer progression markers
  5161. Rehmanniae Radix-Induced apoptosis via inhibition of PI3K/AKT/mTOR signaling pathways in human hepatocellular carcinoma cell lines SMMC-7721
  5162. … like activity in mice by a mechanism involving receptor potentiation but not neurotransmitter reuptake inhibition. Correlation with mTOR intracellular pathway activation
  5163. Investigation of mTOR, JAK/STAT, and Hedgehog pathways inhibitor effect on the proliferation of haematological cancer cell lines
  5164. MicroRNA‑223‑induced inhibition of the FBXW7 gene affects the proliferation and apoptosis of colorectal cancer cells via the Notch and Akt/mTOR pathways
  5165. Abstract P102: Inhibition Of Mtor Decreases Angiotensin Ii-induced Steroidogenesis In Hac15 Cells
  5166. Inhibition of autophagy by CRMP2-derived peptide ST2-104 (R9-CBD3) via a CaMKKβ/AMPK/mTOR pathway contributes to ischemic postconditioning …
  5167. The inhibition of centromere protein K causes anticancer effects in breast carcinoma via effects on the FAK/PI3K/AKT/mTOR pathway
  5168. PI3K/mTOR Dual Inhibitor Pictilisib Stably Binds to Site I of Human Serum Albumin as Observed by Computer Simulation, Multispectroscopic, and Microscopic Studies
  5169. Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells
  5170. JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17/Treg cells via regulating the JAK2/STAT3-AKT/mTOR …
  5171. … enhancing potential of piracetam with diethylstilbestrol in prevention of grand-mal seizures in rats: inhibition of PI3K/Akt/mTOR signaling pathway and IL-1ß, IL …
  5172. Facile synthesis of rapamycin-peptide conjugates as mTOR and Akt inhibitors
  5173. Overexpression of Notch2 enhances radiosensitivity via inhibition of the AKT/mTOR signaling pathway in nasopharyngeal carcinoma
  5174. Efficient protocol for the differentiation of kidney podocytes from induced pluripotent stem cells, involving the inhibition of mTOR
  5175. Itaconate attenuates autoimmune hepatitis via PI3K/AKT/mTOR pathway-mediated inhibition of dendritic cell maturation and autophagy
  5176. Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT/mTOR and NF-κB pathway in …
  5177. Inhibition of mTOR by rapamycin does not improve hypoxic pulmonary hypertension-induced right heart failure in old mice
  5178. Neuroblastoma cell death induced by eEF1A2 knockdown is possibly mediated by the inhibition of Akt and mTOR phosphorylation
  5179. … agent, 4′-O-methylgrynullarin from Derris scandens induces PANC-1 human pancreatic cancer cell death under nutrition starvation via inhibition of Akt/mTOR …
  5180. Sinigrin Impedes the Breast Cancer Cell Growth through the Inhibition of PI3K/AKT/MTOR Phosphorylation-Mediated Cell Cycle Arrest
  5181. Abstract P4-01-18: Acquired sensitivity strategies in ER+ breast cancer progressing on CDK4/6 and mTOR inhibitors
  5182. The effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on Immune Evasion Mechanisms of Acute Myeloid Leukemia Cell Line
  5183. … butyrate/polyethylene glycol nanocomposite‐induced apoptosis and cell death in nasopharyngeal cancer (C666‐1) cells through the inhibition of the PI3K/AKT/mTOR …
  5184. … nanoparticles exhibit antibacterial activity and induce reactive oxygen species mediated apoptosis in MCF‐7 breast cancer cells through inhibition of PI3K/Akt/mTOR …
  5185. Inhibition of STX17–SNAP29–VAMP8 complex formation by costunolide sensitizes ovarian cancer cells to cisplatin via the AMPK/mTOR signaling pathway
  5186. Inhibition effects of 7-phloro-eckol from Ecklonia cava on metastasis and angiogenesis induced by hypoxia through regulation of AKT/mTOR and ERK …
  5187. … acid promotes the formation of autophagosomes in MCF-7 breast cancer cells through oxidative stress-induced growth inhibitor 1 mediated activation of AMPK/mTOR …
  5188. Influence of Notch Inhibition on mTOR and Wnt Signaling in Repairing Muscle
  5189. Inhibition of TRIM32 by ibr‐7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway
  5190. Ubiquitously specific protease 4 inhibitor‐Vialinin A attenuates inflammation and fibrosis in S100‐induced hepatitis mice through Rheb/mTOR signalling
  5191. … Chemoprevention: Spotlight on JAK/STAT, VEGF, EGF/EGFR, TRAIL/TRAIL-R, AKT/mTOR and Non-Coding RNAs in the Inhibition of Carcinogenesis and …
  5192. The SGLT2 inhibitor ertugliflozin causes a switch of cardiac substrate utilization leading to reduced cardiac mTOR-signaling, unfolded protein response and apoptosis
  5193. Study on the interaction of two quinazoline derivatives as novel PI3K/mTOR dual inhibitors and anticancer agents to human serum albumin utilizing spectroscopy and …
  5194. … /6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR
  5195. The Exploration of PI3K/Akt/mTOR, JAK/STAT, and Hedgehog pathways inhibitor effect on CALR Del52 cells proliferation
  5196. In vitro Anti-Hantavirus Activity of Protein Kinase Inhibitor 8G1 Targeting AKT/mTOR/eIF4E Signaling Pathway
  5197. Function-oriented synthesis of Imidazo [1, 2-a] pyrazine and Imidazo [1, 2-b] pyridazine derivatives as potent PI3K/mTOR dual inhibitors
  5198. … umbilical-cord-derived mesenchymal stem cells in combination with rapamycin reduce cartilage degradation via inhibition of the AKT/mTOR signaling pathway
  5199. Inhibition of VDAC1 prevents oxidative stress and apoptosis induced by bisphenol A in spermatogonia via AMPK/mTOR signaling pathway
  5200. … /neodymium nanocomposites from Avaram senna flower extract induces apoptosis in gastric cancer ags cell line through inhibition of the PI3K/AKT/mTOR …
  5201. Single cell proteomics of tumor compartments identifies differential kinase activities defining sensitivity to mTOR-PI3-kinase inhibition
  5202. Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of ex vivo treated pediatric T …
  5203. The SGLT2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR-signaling, endoplasmic reticulum stress and …
  5204. … Imidazo[1,2-a]pyridine, Modulates Intracellular Redox State and Causes Akt/mTOR/HIF-1α and MAPK Signaling Inhibition, Promoting Antiproliferative Effect …
  5205. … of tumor necrosis factor-alpha promote human periodontal ligament stem cells osteogenic differentiation by activation of autophagy via inhibition of AKT/mTOR …
  5206. Atractylodin induces oxidative stress‐mediated apoptosis and autophagy in human breast cancer MCF‐7 cells through inhibition of the P13K/Akt/mTOR pathway
  5207. Inhibition of the AKT1/mTOR pathway through SIRT6 over expression downregulated the expression of programmed death-ligand 1 and prolonged overall …
  5208. 1288P Mutations in MTOR pathway and response of immune checkpoint inhibitors
  5209. … [4,5]thieno[2,3‐d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR‐2 inhibition, and down‐regulation of PI3K/AKT/mTOR …
  5210. … cells by inducing mitochondrial mediated apoptosis, G2/M phase cell cycle arrest, inhibition of cell migration and invasion and modulating mTOR/PI3K/AKT signalling …
  5211. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma
  5212. Role of the mTOR Pathway and Autophagy in Mediating PARP Inhibitor Sensitivity in Small Cell Lung Cancer
  5213. Anti-leukemia effects of Omipalisib in Acute Myeloid Leukemia: inhibition of PI3K-AKT-mTOR signaling and suppression of Mitochondrial Biogenesis
  5214. … of a novel glucocorticoid-resistant human B-cell acute lymphoblastic leukemia cell line, with AMPK, mTOR and fatty acid synthesis pathway inhibition
  5215. Inhibition of mTOR protects against skeletal muscle and kidney injury following hindlimb ischemia-reperfusion in rats by regulating MEK1/ERK1/2 activity
  5216. P09. 01 The use of FDA approved JAK, mTOR and Src inhibitors to regulate T cell-bispecific antibody-induced cytokine release while not preventing T cell …
  5217. Inhibition of Oxidative Phosphorylation and Glycolysis Reduces Viability in Multiple Myeloma By Affecting mTOR-Mediated Protein Synthesis
  5218. The Effects of PKI-402 On Breast Tumor Models’ Radiosensitivity via Dual Inhibition of PI3K/mTOR
  5219. … -2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K/AKT/GSK-3β/mTOR …
  5220. … signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors
  5221. Triptolide exhibits anti-inflammatory effects on adipocytes and macrophages by inhibition of AMPK/mTOR pathway
  5222. … Nano Solanine in Chronic Myelogenous Leukemia Cell Line through Attenuation of PI3K/AKT/mTOR Signaling Pathway and Inhibition of hTERT Expression
  5223. Inhibition of APLN suppresses cell proliferation and migration and promotes cell apoptosis in esophageal cancer cells in vitro, through activating PI3K/mTOR …
  5224. Abstract B065: Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate …
  5225. … Mouse Model Ptch1+/−/Tis21KO Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611
  5226. … -steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS (ON) inhibitors in RAS-addicted …
  5227. Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced …
  5228. Network analysis and basic experiments on the inhibition of renal cancer proliferation and migration by alpinetin through PI3K/AKT/mTOR pathway
  5229. 42P Apigenin: An immunomodulatory nutraceutical overriding PD-L1 inhibitors by halting AKT/mTOR pathway in triple-negative breast cancer (TNBC)
  5230. MicroRNA-137-mediated inhibition of lysine-specific demethylase-1 prevents against rheumatoid arthritis in an association with the REST/mTOR axis
  5231. MicroRNA-122 Is More Effective than Rapamycin in Inhibition of Epithelial-mesenchymal Transition and mTOR Signaling Pathway in Triple Negative Breast Cancer
  5232. Anticancer activity of caffeic acid n-butyl ester against A431 skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling …
  5233. Dietary restriction and mTOR and IIS inhibition: the potential to antiaging drug approach
  5234. … hyperactive RAS network signaling identified: dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors
  5235. Inhibition effect of active fraction from clove on PI3K/Akt/mTOR signaling pathway to induce apoptosis of human colon cancer HCT116 cells
  5236. A Brain-Penetrant mTOR Kinase Inhibitor for the Treatment of Neurological Disorders
  5237. … hyperactive RAS network signaling identified: dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors
  5238. Retraction notice to “Globularifolin exerts anticancer effects on glioma U87 cells through inhibition of Akt/mTOR and MEK/ERK signaling pathways in vitro and inhibits …
  5239. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis
  5240. Design and development of novel 1, 2, 3-triazole chalcone derivatives as potential anti-osteosarcoma agents via inhibition of PI3K/Akt/mTOR signaling pathway
  5241. mSWI/SNF interacts with the ribosome and its inhibition/mutations alter translation and sensitize to mTOR/PI3K inhibitors
  5242. AKT/mTOR and MAPK Inhibition Improves Childhood RASopathic Cardiomyopathy
  5243. Rapamycin, mTOR, TNF Inhibition, RA, Longevity and Canadian Content
  5244. miR-183 enhances autophagy of GC cells by targeted inhibition of mTOR
  5245. The UCHL1 Inhibitor LDN-57444 Promotes the Transdifferentiation of Supporting Cells into Hair Cells by Regulating the mTOR Pathway
  5246. Tipifarnib potentiates the antitumor effects of PI3Kα blockade in HNSCC via convergent inhibition of mTOR activity
  5247. RETROPERITONEAL PERIVASCULAR EPITHELIOID CELL NEOPLASM (PECOMA) RESPONSE TO MTOR KINASE INHIBITION. A CASE REPORT WITH …
  5248. Inhibition of mTOR enhances sorafenib-induced activated HSC ferroptosis.
  5249. Runner Up: Incidence of Cutaneous Adverse Events with PI3K-Akt-mTOR Pathway Inhibitors: A Systematic Review and Network Meta-Analysis
  5250. Novel specific PKM2 inhibitor, compound 3h, induces apoptotic and autophagic cell death through Akt/mTOR signaling pathway in prostate cancer cells
  5251. mTOR kinase inhibitor AZD8055 reverses acquired rapamycin resistance in prostate cancer cells
  5252. mTOR signaling pathway-mediated autophagy involved in inhibition of osteoblast differentiation induced by cadmium in human bone marrow mesenchymal stem cells
  5253. … and Enriched Environment Ameliorated Low Protein-Induced Intrauterine Growth Retardation by IGF-1 And mtor Signaling Pathway and Autophagy Inhibition in Rats
  5254. A commentary on” PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern …
  5255. Synergistic Renoprotective Effect of Melatonin and Zileuton by Inhibition of Ferroptosis via the AKT/mTOR/NRF2 Signaling in Kidney Injury and Fibrosis.
  5256. Therapeutic Resistance to FLT3 Inhibition in Acute Myeloid Leukemia Cells Is Driven by a Novel ATM/mTOR Pathway Regulating Oxidative Phosphorylation
  5257. MEK inhibition in combination with PI3K/AKT/MTOR is a promising therapeutic in basal bladder cancer
  5258. Effect of Dunhuang Pingweiwan and Its Decomposed Recipes on Tumor Inhibition and PI3K/Akt/mTOR Pathway in SCG-7901 Gastric Cancer Mice
  5259. Icariin Suppresses Activated Macrophages-Mediated Inflammatory Response Inhibition of mTOR/S6K1 and NF-κB Signaling
  5260. Inhibition of Neuropilin-1 improves non-alcoholic fatty liver disease via PI3K/AKT/mTOR signaling in high-fat-diet induced obese mouse
  5261. Autophagy Inhibition Amplifies Anti-Tumor Immunity Effect of Dinutuximab Beta On Neuroblastoma via the VEGFR/AKT/mTOR and ROS/NF-κB Pathways
  5262. Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity through autophagy inhibition by activating PI3K/Akt/mTOR pathway in glioblastoma
  5263. WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma.
  5264. Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss-driven Tumorigenesis
  5265. Lung cancer growth inhibition and autophagy activation by tetrazole via ERK1/2 up-regulation and mTOR/p70S6K signaling down-regulation
  5266. Erratum to “The Inhibition of Insulin-stimulated Proliferation of Vascular Smooth Muscle Cells by Rosiglitazone Is Mediated by the Akt-mTOR-P70S6K Pathway” by …
  5267. Proton Pump Inhibitors Could Ameliorate Cachexia of Gastric Cancer by Down-regulating Vacuolar H+-ATPases and Disrupting PI3K/AKT/mTOR/HIF-1α/PKM2 …
  5268. O012/# 761 INHIBITION OF PAIN-RELATED MTOR PROTEINS USING DIFFERENTIAL TARGET MULTIPLEXED SCS IN AN ANIMAL NEUROPATHIC PAIN MODEL …
  5269. Cell growth of sunitinib-resistant renal cell carcinoma was inhibited by Shikonin through necroptosis induction and Akt/mTOR signaling inhibition
  5270. Retracted: Inhibition of Nasopharyngeal Carcinoma by Beta-Lapachone Occurs by Targeting the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Pathway …
  5271. … P2-07-05: Activation of the AKT/mTOR signaling pathway is associated with response to the combination of endocrine therapy and CDK4/6 inhibitor in HR+/HER2 …
  5272. … therapy for temozolomide-resistant GBM: identification of temozolomide/small molecule inhibitor combinations that target the MDM2/p53 and PI3K-AKT/mTOR …
  5273. PI3K/AKT/mTOR pathway and CDK4/6 inhibitors efficiently inhibit cell growth of HPV-positive and HPV-negative head and neck squamous cell carcinoma in vitro
  5274. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1-splicing and mTOR/sz-catenin pathways imbalances
  5275. Inhibition of the mToR pathway with everolimus can modulate heat shock genes and ERCC1 gene expression and improves outcomes on serous ovarian cancer in …
  5276. Retraction Note: The PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair …
  5277. Down-regulation of PHLPP1 expression ameliorates high glucose-induced autophagy inhibition and apoptosis promotion of podocytes by activating PI3K/AKT/mTOR …
  5278. … Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT …
  5279. EGFR inhibition in combination with PI3K/AKT/mTOR and/or Bcl-2 inhibition is a promising novel therapeutic approach for inverted sinonasal papillomas and …
  5280. … : Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR …
  5281. Combined inhibition of mTOR and HSP90 potentiates cisplatin antitumor effect and reverts cisplatin resistance in vitro and in vivo models of epithelial ovarian cancer …
  5282. Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in …
  5283. … post-translational modifications implicates DDR and AKT-mTOR signaling in mediating response or primary resistance of ovarian carcinoma cells to PARP1 inhibitors
  5284. … Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) …
  5285. Abstract PS16-18: Inhibition of mTOR signaling by rapamycin abrogates mammary stem/progenitor cell activity in aged mice
  5286. P-444 Presence of pharmacological inhibitors of the PI3K/PTEN/Akt and mTOR signalling pathways during cryopreservation and organotypic cultures of murine …
  5287. Effect of microRNA-221 targeting tissue inhibitor of metalloproteinase-2 to mediate Akt/mTOR signaling pathway on non-small cell lung cancer transplanted tumor …
  5288. Modulation of immune checkpoints on linage HL-60 of acute myeloid leukemia treated with BRD4 inhibitor and mTOR pathway inhibitor
  5289. FTI-277 and GGTI-289 induce apoptosis via inhibition of the Ras/ERK and Ras/mTOR pathway in head and neck carcinoma HEp-2 and HSC-3 cells
  5290. EP16. 03-028 Cancer Cells May be Re-sensitized to Tumor Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway
  5291. … derived from naive and pretreated metastatic patients with high-risk CDK4/6 hyperactivation signatures are sensitive to dual inhibition of CDK4/6 and PI3K/mTOR
  5292. Anti-proliferation effect of polo-like kinase-4 inhibitor in ovarian cancer via AKT/mTOR/p70S6K pathway
  5293. … ) phenyl)-1H-pyrazolo [4, 3-c] pyridin-4 (5H)-one (FMPPP) exhibits anti-proliferative effect on prostate cancer via autophagy induction and mTOR/p70S6K inhibition

Related Posts

Shopping Cart
Scroll to Top